Package: metadat (via r-universe)

October 15, 2026

Version 1.7-2

Date 2026-06-26

Title Meta-Analysis Datasets

Depends R (>= 4.0.0)

Imports utils, tools, mathjaxr

Suggests metafor, numDeriv, BiasedUrn, dfoptim, igraph, ape, testthat, digest, lme4, clubSandwich, meta, netmeta, mvtnorm, gridExtra, rms, bayesmeta, ellipse, metasens, mada

Description A collection of meta-analysis datasets for teaching purposes, illustrating/testing meta-analytic methods, and validating published analyses.

License GPL (>=2)

ByteCompile TRUE

LazyData TRUE

Encoding UTF-8

RdMacros mathjaxr

BuildManual TRUE

URL https://github.com/wviechtb/metadat, https://wviechtb.github.io/metadat/

BugReports https://github.com/wviechtb/metadat/issues

Repository https://wviechtb.r-universe.dev

Date/Publication 2026-07-17 06:46:11 UTC

RemoteUrl https://github.com/wviechtb/metadat

RemoteRef HEAD

RemoteSha 0cb96ce4ff16586a9dbc8a9b0f9bc617538d2738

Contents

metadat-package 4
dat.aloe2013 6
dat.anand1999 8
dat.anker2025 10
dat.assink2016 12
dat.axfors2021 14
dat.bachmann2010 16
dat.bakdash2021 19
dat.baker2009 24
dat.bangertdrowns2004 26
dat.bartos2023 28
dat.baskerville2012 31
dat.bassler2004 33
dat.bauer2002 34
dat.bcg 37
dat.begg1989 39
dat.berkey1998 41
dat.besson2016 43
dat.bonett2010 45
dat.bornmann2007 47
dat.bourassa1996 49
dat.cannon2006 51
dat.chiarito2020 53
dat.cohen1981 56
dat.colditz1994 57
dat.collins1985a 60
dat.collins1985b 62
dat.craft2003 63
dat.crede2010 65
dat.crisafulli2020 67
dat.curtin2002 69
dat.curtis1998 70
dat.dagostino1998 72
dat.damico2009 75
dat.debruin2009 76
dat.demir2022 78
dat.dogliotti2014 79
dat.dong2013 81
dat.dorn2007 83
dat.dumouchel1994 85
dat.egger2001 87
dat.feng2019 89
dat.fine1993 91
dat.franchini2012 93
dat.frank2008 95
dat.furukawa2003 98

dat.gibson2002 99
dat.graves2010 102
dat.greb2008 103
dat.greenland1992 104
dat.gurusamy2011 106
dat.hackshaw1998 108
dat.haeuser2009 110
dat.hahn2001 113
dat.hannum2020 115
dat.hart1999 116
dat.hartmannboyce2018 118
dat.hasselblad1998 120
dat.higgins2008 123
dat.hine1989 124
dat.huber2000 126
dat.ishak2007 128
dat.kalaian1996 130
dat.karner2014 132
dat.kearon1998 134
dat.knapp2017 137
dat.konstantopoulos2011 140
dat.landenberger2005 142
dat.laopaiboon2015 144
dat.lau1992 146
dat.lee2004 147
dat.lehmann2018 149
dat.li2007 151
dat.lim2014 152
dat.linde2005 155
dat.linde2015 157
dat.linde2016 159
dat.lloyd2010 162
dat.lopez2019 163
dat.maire2019 167
dat.mccurdy2020 169
dat.mcdaniel1994 171
dat.meeker2017 174
dat.metap 176
dat.michael2013 178
dat.molloy2014 180
dat.moore1998 182
dat.moura2021 184
dat.nakagawa2007 186
dat.nielweise2007 187
dat.nielweise2008 189
dat.nissen2007 190
dat.normand1999 195
dat.obrien2003 196

dat.pagliaro1992 . . . 199
dat.pignon2000 . . . 201
dat.poole2003 . . . 202
dat.pritz1997 . . . 204
dat.quan2000 . . . 206
dat.raudenbush1985 . . . 208
dat.riley2003 . . . 210
dat.rivera2025 . . . 211
dat.roever2022 . . . 213
dat.senn2013 . . . 216
dat.spooner2002 . . . 220
dat.steurer2006 . . . 222
dat.stowe2010 . . . 223
dat.tannersmith2016 . . . 226
dat.thompson1999 . . . 228
dat.tian2009 . . . 229
dat.ursino2021 . . . 232
dat.vanhowe1999 . . . 235
dat.viechtbauer2021 . . . 237
dat.white2020 . . . 241
dat.woods2010 . . . 243
dat.yusuf1985 . . . 245
datsearch . . . 246

Index **249**

`metadat-package` *Meta-Analysis Datasets for R*

Description

The **metadat** package contains a large collection of meta-analysis datasets. These datasets are useful for teaching purposes, illustrating/testing meta-analytic methods, and validating published analyses.

Browsing and Searching for Datasets

A listing of all datasets in the package can be obtained with `help(package=metadat)`. Each datasets is also tagged with one or multiple concept terms. These concept terms refer to various aspects of a dataset, such as the field/topic of research, the outcome measure used for the analysis, the model(s) used for analyzing the data, and the methods/concepts that can be illustrated with the dataset. The `datsearch` function can be used to search among the existing datasets in the package based on their concept terms or based on a full-text search of their corresponding help files.

You can also read the documentation online at https://wviechtb.github.io/metadat/ (where the output from the example analyses corresponding to each dataset is provided).

Contributing New Datasets

We welcome contributions of new datasets to the package. For each dataset, there must be a citable reference, ideally in a peer-reviewed journal or publication. The general workflow for contributing a new dataset is as follows:

- Install the `metadat` package in R in the usual manner (i.e., `install.packages("metadat")`).
- If you are familiar with Git/GitHub and making pull requests, fork the package repository. Otherwise, download the source version of the package from GitHub and unzip the file to some directory on your computer.
- Place the raw data (in a non-binary format) in the `data-raw` directory. The file should be named `dat.<author><year>.<ext>`, where `<author>` is the last name of the first author of the publication from which the data come, `<year>` is the publication year, and `<ext>` is the file extension (e.g., `.txt`, `.csv`).
- Place a corresponding R script in the `data-raw` directory named `dat.<author><year>.r` that reads in the data, possibly does some data cleaning/processing, and then saves the dataset to the `data` directory (using `save`), with name `dat.<author><year>.rda`.
- Start R, load the `metadat` package (i.e., `library(metadat)`), and then run the `prep_dat` function (either set the working directory to the location of the source package beforehand or use the `pkgdir` argument of the `prep_dat` function to specify the source package location).
- For a new dataset, this should create a boilerplate template for a corresponding help file in the `man` directory, named `dat.<author><year>.Rd`. Edit the help file, adding the title and a short description of the dataset in general, a description of each variable in the dataset, further details on the dataset (e.g., the field of research, how the data was collected, the purpose of the dataset / what it was used for, the effect size or outcome measure used in the analysis, the types of analyses/models that can be illustrated with the dataset), a reference for the source of the dataset, one or multiple concept terms, the name and email address of the contributor of the dataset, and (optionally) example code to illustrate the analysis of the dataset.
- Either make a pull request (if you are familiar with this workflow) or zip up the `dat.<author><year>.<ext>`, `dat.<author><year>.r`, `dat.<author><year>.rda`, and `dat.<author><year>.Rd` files and open up a new issue at GitHub, attaching the zip file.
- If the above makes no sense to you, you can also email one of the package authors with a cleaned, raw data file in `.txt` or `.csv` format, along with a meta-data file (format doesn't matter) that includes the information described above.

Citing the Package

If you use these data, please cite both the **metadat** package (see `citation("metadat")` for the reference) and the original source of the data as given under the help file of a dataset.

Bug/Error Reports

If you think you have found an error in an existing dataset or a bug in the package in general, please go to `https://github.com/wviechtb/metadat/issues` and open up a new issue.

Author(s)

Thomas White, <thomas.white@sydney.edu.au>
Daniel Noble, <daniel.noble@anu.edu.au>
Alistair Senior, <alistair.senior@sydney.edu.au>
W. Kyle Hamilton, <whamilton@ucmerced.edu>
Wolfgang Viechtbauer, <wvb@metafor-project.org>

`dat.aloe2013` *Studies on the Association Between Supervision Quality and Various Outcomes in Social, Mental Health, and Child Welfare Workers*

Description

Results from 5 studies examining the association between various measures of supervision quality and various work-related outcomes in social, mental health, and child welfare workers.

Usage

```
dat.aloe2013
```

Format

The data frame contains the following columns:

study	`character`	study author(s) and year
n	`integer`	sample size
tval	`numeric`	t-statistic for the test of the association/predictor
preds	`integer`	number of predictors included in the regression model
R2	`numeric`	the coefficient of determination (i.e., R-squared value) of the regression model

Details

The dataset is based on studies that used regression models to examine the association between some measure of perceived supervision quality (e.g., the quality of the relationship with one's supervisor) and some work-related outcome (e.g., job satisfaction) in social, mental health, and child welfare workers. The dataset was extracted from Aloe and Thompson (2013), which in turn is a subset of the studies included in the meta-analysis by Mor Barak et al. (2009).

The dataset can be used to illustrate the meta-analysis of regression models, using measures such as the (semi-)partial correlation coefficient. For this, the t-statistic from the regression model for the association (i.e., predictor) of interest was extracted from each regression model (`tval`), as well as the sample size (`n`), the number of predictors included in the regression model (`preds`), and the coefficient of determination (i.e., R-squared value) of the regression model (`R2`). Based on this information, the (semi-)partial correlation coefficient can be computed for each study, as well as its corresponding sampling variance. These values can then be meta-analyzed using standard methods.

Concepts

social work, (semi-)partial correlations, meta-regression

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Aloe, A. M., & Thompson, C. G. (2013). The synthesis of partial effect sizes. *Journal of the Society for Social Work and Research*, **4**(4), 390–405. https://doi.org/10.5243/jsswr.2013.24

References

Mor Barak, M. E., Travis, D. J., Pyun, H., & Xie, B. (2009). The impact of supervision on worker outcomes: A meta-analysis. *Social Service Review*, **83**(1), 3–32. https://doi.org/10.1086/599028

Examples

```
### copy data into 'dat' and examine data
dat <- dat.aloe2013
dat

## Not run:
### load metafor package
suppressPackageStartupMessages(library(metafor))

### compute the partial correlation coefficients and corresponding sampling variances
dat <- escalc(measure="PCOR", ti=tval, ni=n, mi=preds, data=dat)
dat

### random-effects model
res <- rma(yi, vi, data=dat)
res

### mixed-effects meta-regression model examining the relationship between the partial
### correlation coefficients and the number of predictors included in the models
res <- rma(yi, vi, mods = ~ preds, data=dat)
res

### compute the r-to-z transformed partial correlation coefficients and their variances
dat <- escalc(measure="ZPCOR", ti=tval, ni=n, mi=preds, data=dat)
dat

### random-effects model
res <- rma(yi, vi, data=dat)
res

### back-transformation to the partial correlation scale
predict(res, transf=transf.ztor)

### compute the semi-partial correlation coefficients and their variances
```

```
dat <- escalc(measure="SPCOR", ti=tval, ni=n, mi=preds, r2i=R2, data=dat)
dat

### random-effects model
res <- rma(yi, vi, data=dat)
res

## End(Not run)
```

`dat.anand1999` *Studies on the Effectiveness of Oral Anticoagulants in Patients with Coronary Artery Disease*

Description

Results from 34 trials examining the effectiveness of oral anticoagulants in patients with coronary artery disease.

Usage

```
dat.anand1999
```

Format

The data frame contains the following columns:

study	`character`	author(s) or trial name
year	`numeric`	publication year
intensity	`character`	intensity of anticoagulation (low, medium, or high)
asp.t	`numeric`	concomitant use of aspirin in the treatment group (0 = no, 1 = yes)
asp.c	`numeric`	concomitant use of aspirin in the control group (0 = no, 1 = yes)
ai	`numeric`	number of deaths in the treatment group
n1i	`numeric`	number of patients in the treatment group
ci	`numeric`	number of deaths in the control group
n2i	`numeric`	number of patients in the control group

Details

The dataset includes the results from 34 randomized clinical trials that examined the effectiveness of oral anticoagulants in patients with coronary artery disease. The results given here are focused on the total mortality in the treatment versus control groups.

Concepts

medicine, cardiology, odds ratios, Mantel-Haenszel method

Note

Strictly speaking, there are only 31 trials, since Breddin et al. (1980) and ATACS (1990) are multi-arm trials.

According to a correction, `dat.anand1999$ci[29]` should be 1. But then `dat.anand1999$ci[21]` would also have to be 1 (if these data indeed refer to the same control group). This appears contradictory, so this correction was not made.

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Anand, S. S., & Yusuf, S. (1999). Oral anticoagulant therapy in patients with coronary artery disease: A meta-analysis. *Journal of the American Medical Association*, **282**(21), 2058–2067. https://doi.org/10.1001/jama.282.21.2058

Examples

```
### copy data into 'dat' and examine data
dat <- dat.anand1999
dat

## Not run:
### load metafor package
library(metafor)

### High-Intensity OA vs Control
rma.mh(measure="OR", ai=ai, n1i=n1i, ci=ci, n2i=n2i, data=dat,
       subset=(intensity=="high" & asp.t==0 & asp.c==0), digits=2)

### High- or Moderate-Intensity OA vs Aspirin
rma.mh(measure="OR", ai=ai, n1i=n1i, ci=ci, n2i=n2i, data=dat,
       subset=(intensity %in% c("high","moderate") & asp.t==0 & asp.c==1), digits=2)

### Moderate-Intensity OA vs Control
rma.mh(measure="OR", ai=ai, n1i=n1i, ci=ci, n2i=n2i, data=dat,
       subset=(intensity=="moderate" & asp.t==0 & asp.c==0), digits=2)

### High- or Moderate-Intensity OA and Aspirin vs Aspirin
rma.mh(measure="OR", ai=ai, n1i=n1i, ci=ci, n2i=n2i, data=dat,
       subset=(intensity %in% c("high","moderate") & asp.t==1 & asp.c==1), digits=2)

### Low-Intensity OA and Aspirin vs Aspirin
rma.mh(measure="OR", ai=ai, n1i=n1i, ci=ci, n2i=n2i, data=dat,
       subset=(intensity=="low" & asp.t==1 & asp.c==1), digits=2)

## End(Not run)
```

dat.anker2025 *Cardiology Example Data with Subgroup and Interaction Effects*

Description

Treatment effects, overall and in male/female patient subgroups, as well as treatment-by-subgroup interaction effects in six randomized, placebo-controlled trials.

Usage

```
dat.anker2025
```

Format

The data frame contains the following columns:

study	character	study identifier
year	integer	study year
intv.n	integer	number of patients in the intervention group
placebo.n	integer	number of patients in the placebo group
iv.iron	factor	the intravenous (IV) iron formulation investigated
size	factor	study size ("small" or "large", based on total number of patients)
followup	numeric	followup duration (months)
baseline.age	numeric	mean age at baseline (years)
baseline.lvef	numeric	mean *left ventricular ejection fraction (LVEF)* at baseline (%)
baseline.hgb	numeric	mean haemoglobin at baseline (g/dl)
baseline.ft	numeric	mean ferritin at baseline (μg/l)
baseline.tsat	numeric	mean *transferritin saturation (TSAT)* at baseline (%)
total.n	integer	total number of patients
total.logrr	numeric	overall effect (log-RR)
total.se	numeric	standard error of overall effect
female.n	integer	number of female patients
female.logrr	numeric	effect (log-RR) in females
female.se	numeric	standard error of effect in females
male.n	integer	number of male patients
male.logrr	numeric	effect (log-RR) in males
male.se	numeric	standard error of effect in males
sex.logrrr	numeric	treatment-by-subgroup interaction (log-RRR)
sex.se	numeric	standard error of treatment-by-subgroup interaction

Details

Anker et al. (2025) analyzed the effects of intravenous (IV) iron therapy observed in six randomized, placebo-controlled trials. The primary endpoint was a composite of (recurrent) heart failure (HF) hospitalizations and cardiovascular (CV) death, and treatment effects were quantified in terms of risk ratios (RRs). Individual participant data were available for five trials, and analyses were

harmonized to match the analysis of the sixth trial (the Ironman study). Meta-analyses were then performed based on logarithmic RRs (log-RRs).

Besides investigation of the overall effect, it was of interest to what extent male and female patients benefited, and whether effects differed between both patient subgroups. The data set includes effect estimates within each study's male and female subgroups (in terms of log-RRs), as well as estimates of the difference between the subgroups (in terms of logarithmic ratios of RRs (log-RRRs). Technically, the RRRs then constitute treatment-by-subgroup interaction effects.

Concepts

medicine, cardiology, incidence rates

Author(s)

Christian Roever, <christian.roever@med.uni-goettingen.de>

Source

Anker, S. D., Karakas, M., Mentz, R. J., Ponikowski, P., Butler, J., Khan, M. S., Talha, K. M., Kalra, P. R., Hernandez, A. F., Mulder, H., Rockhold, F. W., Placzek, M., Röver, C., Cleland, J. G. F., & Friede, T. (2025). Systematic review and meta-analysis of intravenous iron therapy for patients with heart failure and iron deficiency. Nature Medicine, 31(8), 2640-2646. https://doi.org/10.1038/s41591-025-03671-1

Examples

```
# show data
dat.anker2025
## Not run:
library(bayesmeta)

# specify heterogeneity (tau) prior density (half-normal(0.5))
HN05 <- function(t){dhalfnormal(t, scale=0.5)}

#######################################
#  reproduce primary analysis (Fig.2)
es.primary <- escalc(measure="IRR", yi=total.logrr, sei=total.se,
                     ni=total.n, slab=study, data=dat.anker2025)
bma01 <- bayesmeta(es.primary, tau.prior=HN05)
forestplot(bma01, expo=TRUE, xlog=TRUE,
           xlab="rate ratio (RR)", title="HF hospitalizations / CV mortality")

#######################################
#  reproduce sex interaction analysis
#  (Tab.2, Supplementary Fig.4)
es.sex <- escalc(measure="GEN", yi=sex.logrrr, sei=sex.se,
                 ni=total.n, slab=study, data=dat.anker2025)
bma02 <- bayesmeta(es.sex, tau.prior=HN05)
forestplot(bma02, expo=TRUE, xlog=TRUE,
           xlab="ratio of RRs (RRR)", title="sex interaction (females/males)")

#########################################
```

```
#  reproduce male/female subgroup analyses
#  (Tab.2, Supplementary Fig.12)
es.female <- escalc(measure="IRR", yi=female.logrr, sei=female.se,
                    ni=female.n, slab=study, data=dat.anker2025)
es.male   <- escalc(measure="IRR", yi=male.logrr, sei=male.se,
                    ni=male.n, slab=study, data=dat.anker2025)
bma03a <- bayesmeta(es.female, tau.prior=HN05)
bma03b <- bayesmeta(es.male, tau.prior=HN05)
forestplot(bma03a, expo=TRUE, xlog=TRUE,
           xlab="rate ratio (RR)", title="female subgroup")
forestplot(bma03b, expo=TRUE, xlog=TRUE,
           xlab="rate ratio (RR)", title="male subgroup")

## End(Not run)
```

`dat.assink2016` *Studies on the Association between Recidivism and Mental Health*

Description

Results from 17 studies on the association between recidivism and mental health in delinquent juveniles.

Usage

```
dat.assink2016
```

Format

The data frame contains the following columns:

study	numeric	study id number
esid	numeric	effect size within study id number
id	numeric	row id number
yi	numeric	standardized mean difference
vi	numeric	corresponding sampling variance
pubstatus	numeric	published study (0 = no; 1 = yes)
year	numeric	publication year of the study (approximately mean centered)
deltype	character	type of delinquent behavior in which juveniles could have recidivated (either general, overt, or cov

Details

The studies included in this dataset (which is a subset of the data used in Assink et al., 2015) compared the difference in recidivism between delinquent juveniles with a mental health disorder and a comparison group of juveniles without a mental health disorder. Since studies differed in the way recidivism was defined and assessed, results are given in terms of standardized mean differences, with positive values indicating a higher prevalence of recidivism in the group of juveniles with a mental health disorder.

Multiple effect size estimates could be extracted from most studies (e.g., for different delinquent behaviors in which juveniles could have recidivated), necessitating the use of appropriate models/methods for the analysis. Assink and Wibbelink (2016) illustrate the use of multilevel meta-analysis models for this purpose.

Concepts

psychology, criminology, standardized mean differences, multilevel models, cluster-robust inference

Note

The `year` variable is not constant within study 3, as this study refers to two different publications using the same data.

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Assink, M., & Wibbelink, C. J. M. (2016). Fitting three-level meta-analytic models in R: A step-by-step tutorial. *The Quantitative Methods for Psychology*, **12**(3), 154–174. https://doi.org/10.20982/tqmp.12.3.p154

References

Assink, M., van der Put, C. E., Hoeve, M., de Vries, S. L. A., Stams, G. J. J. M., & Oort, F. J. (2015). Risk factors for persistent delinquent behavior among juveniles: A meta-analytic review. *Clinical Psychology Review*, **42**, 47–61. https://doi.org/10.1016/j.cpr.2015.08.002

Examples

```
### copy data into 'dat' and examine data
dat <- dat.assink2016
head(dat, 9)

## Not run:
### load metafor package
library(metafor)

### fit multilevel model
res <- rma.mv(yi, vi, random = ~ 1 | study/esid, data=dat)
res

### use cluster-robust inference methods
robust(res, cluster=study, clubSandwich=TRUE)

### LRTs for the variance components
res0 <- rma.mv(yi, vi, random = ~ 1 | study/esid, data=dat, sigma2=c(0,NA))
anova(res0, res)
res0 <- rma.mv(yi, vi, random = ~ 1 | study/esid, data=dat, sigma2=c(NA,0))
```

```
anova(res0, res)

### examine some potential moderators via meta-regression
rma.mv(yi, vi, mods = ~ pubstatus, random = ~ 1 | study/esid, data=dat)
rma.mv(yi, vi, mods = ~ year, random = ~ 1 | study/esid, data=dat)
dat$deltype <- relevel(factor(dat$deltype), ref="general")
rma.mv(yi, vi, mods = ~ deltype, random = ~ 1 | study/esid, data=dat)
rma.mv(yi, vi, mods = ~ year + deltype, random = ~ 1 | study/esid, data=dat)

### assume that the effect sizes within studies are correlated with rho=0.6
V <- vcalc(vi, cluster=study, obs=esid, data=dat, rho=0.6)
round(V[dat$study %in% c(1,2), dat$study %in% c(1,2)], 4)

### fit multilevel model using this approximate V matrix
res <- rma.mv(yi, V, random = ~ 1 | study/esid, data=dat)
res

### use cluster-robust inference methods
robust(res, cluster=study, clubSandwich=TRUE)

### use a correlation of 0.7 for effect sizes corresponding to the same type of
### delinquent behavior and a correlation of 0.5 for effect sizes corresponding
### to different types of delinquent behavior
V <- vcalc(vi, cluster=study, type=deltype, obs=esid, data=dat, rho=c(0.7, 0.5))

### fit multilevel model using this approximate V matrix
res <- rma.mv(yi, V, random = ~ 1 | study/esid, data=dat)
res

### use cluster-robust inference methods
robust(res, cluster=study, clubSandwich=TRUE)

## End(Not run)
```

`dat.axfors2021` *Mortality Outcomes with Hydroxychloroquine and Chloroquine in COVID-19 from an International Collaborative Meta-Analysis of Randomized Trials*

Description

Results from 33 trials examining the effectiveness of hydroxychloroquine or chloroquine in patients with COVID-19.

Usage

```
dat.axfors2021
```

Format

The data frame contains the following columns:

id	character	registry number
acronym	character	shortened registry number
patient_setting	character	patient setting
blinding_exact	character	study blinding
high_dose	character	high or low dose of medication
Published	character	publication status
hcq_cq	character	medication type (hcq = hydroxychloroquine or cq = chloroquine)
hcq_arm_event	numeric	number of deaths in the treatment group
hcq_arm_total	numeric	number of patients in the treatment group
control_arm_event	numeric	number of deaths in the control group
control_arm_total	numeric	number of patients in the control group
Control	character	control group type (Standard of Care or Placebo)

Details

The dataset includes the results from 33 published and unpublished randomized clinical trials that examined the effectiveness of hydroxychloroquine or chloroquine in patients with COVID-19. The results given here are focused on the total mortality in the treatment versus control groups.

Concepts

medicine, covid-19, odds ratios

Author(s)

W. Kyle Hamilton <whamilton@ucmerced.edu> https://kylehamilton.com

Source

Axfors, C., Schmitt, A., Janiaud, P., van 't Hooft, J., Moher, D., Goodman, S., ... Hemkens, L. G. (2021, March 9). Hydroxychloroquine and chloroquine for survival in COVID-19: An international collaborative meta-analysis of randomized trials. https://doi.org/10.17605/OSF.IO/QESV4

References

Axfors, C., Schmitt, A. M., Janiaud, P., van't Hooft, J., Abd-Elsalam, S., Abdo, E. F., Abella, B. S., Akram, J., Amaravadi, R. K., Angus, D. C., Arabi, Y. M., Azhar, S., Baden, L. R., Baker, A. W., Belkhir, L., Benfield, T., Berrevoets, M. A. H., Chen, C.-P., Chen, T.-C., ... Hemkens, L. G. (2021). Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nature Communications, 12(1), 2349. https://doi.org/10.1038/s41467-021-22446-z

Examples

```
# copy data into 'dat' and examine data
dat <- dat.axfors2021
```

```
dat

## Not run:
# load metafor package
library(metafor)

# calculate log odds ratios and corresponding sampling variances
dat <- escalc(measure="OR", ai=hcq_arm_event, n1i=hcq_arm_total,
                            ci=control_arm_event, n2i=control_arm_total, data=dat)

# meta-analysis Hydroxychloroquine
res_hcq <- rma(yi, vi, subset=(hcq_cq=="hcq"), slab = id, data=dat)
print(res_hcq, digits=2)

# meta-analysis Chloroquine
res_cq <- rma(yi, vi, subset=(hcq_cq=="cq"), slab = id, data=dat)
print(res_cq, digits=2)

## End(Not run)
```

`dat.bachmann2010` *Studies on Inpatient Rehabilitation for Geriatric Patients*

Description

Results from studies examining inpatient rehabilitation for geriatric patients with respect to various outcomes.

Usage

```
dat.bachmann2010
```

Format

The data frame contains the following columns:

author	`character`	first author of study
year	`numeric`	publication year
country	`numeric`	country where study was conducted
rehabtype	`character`	type of rehabilitation (general / orthopaedic)
lohs1	`numeric`	mean/median length of hospital stay before randomization (days)
lohs2	`numeric`	mean/median length of hospital stay after randomization (days)
mage	`numeric`	mean age of participants
nti	`numeric`	number of participants in the intervention group
nci	`numeric`	number of participants in the control group
multidim	`character`	multidimensional geriatric assessment (yes / no)
assign	`character`	assignment to therapy (yes / no)
meetings	`character`	intervention team meetings for goal setting

fup	character	follow-up after discharge (yes / no)
conc	character	concealment of allocation (yes / no)
blind	character	blinding of outcome assessor (yes / no)
itt	character	intention to treat analysis (yes / no)
outcome	character	outcome variable (function, admission, mortality)
time	character	time of assessment (at discharge, at follow-up)
or	numeric	odds ratio for functional improvement
lb	numeric	lower 95% CI bound for the odds ratio
ub	numeric	upper 95% CI bound for the odds ratio
ai	numeric	number of cases in the intervention group
n1i	numeric	total number of patients in the intervention group
ci	numeric	number of cases in the control group
n2i	numeric	total number of patients in the control group

Details

The meta-analysis by Bachmann et al. (2010) assessed the effects of inpatient rehabilitation specifically designed for geriatric patients compared with usual care on functional status, admissions to nursing homes, and mortality. For outcome functional status, odds ratios with corresponding confidence interval bounds are provided via variables `or`, `lb`, and `ub`. For outcomes admissions to nursing homes and mortality, the number of cases and the group sizes for the intervention and control groups are given via variables `ai`, `n1i`, `ci`, and `n2i`.

Riley et al. (2011) used part of these data in their discussion of prediction intervals in the context of the random-effects model for meta-analysis.

Concepts

medicine, odds ratios, risk ratios

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Bachmann, S., Finger, C., Huss, A., Egger, M., Stuck, A. E., & Clough-Gorr, K. M. (2010). Inpatient rehabilitation specifically designed for geriatric patients: Systematic review and meta-analysis of randomised controlled trials. *British Medical Journal*, **340**, c1718. https://doi.org/10.1136/bmj.c1718

References

Riley, R. D., Higgins, J. P. T., & Deeks, J. J. (2011). Interpretation of random effects meta-analyses. *British Medical Journal*, **342**, d549. https://doi.org/10.1136/bmj.d549

Examples

```
### copy data to 'dat' and examine the data
dat <- dat.bachmann2010
head(dat)
```

```
## Not run:
### load metafor package
library(metafor)

### compute log odds ratios and corresponding sampling variances from the
### reported odds ratios and confidence interval bounds
dat <- conv.wald(or, ci.ub=ub, transf=log, data=dat)

### meta-analyze the effects on functional status at discharge
res <- rma(yi, vi, data=dat, method="DL",
           slab=paste0(author, ", ", year),
           subset=outcome=="function"&time=="discharge")
res
predict(res, transf=exp, digits=2)

### meta-analyze the effects on functional status at follow-up
res <- rma(yi, vi, data=dat, method="DL",
           slab=paste0(author, ", ", year),
           subset=outcome=="function"&time=="followup")
res
predict(res, transf=exp, digits=2)

### compute the PI exactly as in Riley et al. (2011)
predict(res, transf=exp, digits=2, predtype="riley")

### compute log risk ratios and corresponding sampling variances from the
### reported 2x2 table counts
dat <- escalc(measure="RR", ai=ai, n1i=n1i,
                            ci=ci, n2i=n2i,
                            data=dat, drop00=TRUE)

### meta-analyze the effects on admission to nursing homes at discharge
res <- rma(yi, vi, data=dat, method="DL",
           slab=paste0(author, ", ", year),
           subset=outcome=="admission"&time=="discharge")
res
predict(res, transf=exp, digits=2)

### meta-analyze the effects on admission to nursing homes at follow-up
res <- rma(yi, vi, data=dat, method="DL",
           slab=paste0(author, ", ", year),
           subset=outcome=="admission"&time=="followup")
res
predict(res, transf=exp, digits=2)

### meta-analyze the effects on mortality at discharge
res <- rma(yi, vi, data=dat, method="DL",
           slab=paste0(author, ", ", year),
           subset=outcome=="mortality"&time=="discharge")
res
predict(res, transf=exp, digits=2)

### meta-analyze the effects on mortality at follow-up
```

```
res <- rma(yi, vi, data=dat, method="DL",
           slab=paste0(author, ", ", year),
           subset=outcome=="mortality"&time=="followup")
res
predict(res, transf=exp, digits=2)

## End(Not run)
```

`dat.bakdash2021` *Dataset on Situation Awareness and Task Performance Associations*

Description

Results from 77 papers with 678 effects evaluating associations among measures of situation awareness and task performance.

Usage

```
dat.bakdash2021
```

Format

The data frame contains the following columns:

Author	`character`	paper author(s)
Year	`integer`	year of paper publication
Title	`character`	title of paper
DOI	`character`	digital object identifier (DOI)
DTIC.link	`character`	permanent link for Defense Technical Information Collection (DITC) reports; see: `https:/`
SA.measure.type	`character`	type of SA measure
Sample.size	`integer`	reported sample size
Sample.size.stats	`integer`	reported sample size based on reported statistics (this reflects excluded participants)
es.z	`numeric`	z-transformed correlation coefficient; includes ghost results (disclosed and undisclosed non
vi.z	`numeric`	variance for z-transformed correlation (calculated using `Sample.size.stats`, *not* `Sample.`
SampleID	`character`	unique identifier for each experiment/study
Outcome	`integer`	unique value for each effect size

Details

The dataset contains behavioral experiments from 77 papers/79 studies with a total of 678 effects, evaluating associations among measures of situation awareness ("knowing what is going on") and task performance. Examples of situation awareness include knowledge of current vehicle speed in a simulated driving task and location and heading of aircraft in a simulated air traffic control task. Corresponding examples of task performance include "the number of collisions in a simulated driving task" and "subject matter expert rating of conflict management in a simulated air control task" (Bakdash et al. 2021a, p. 2). This dataset and the 'Examples' are a highly simplified version of the data and code in Bakdash et al. (2021b; 2021c). The journal article by Bakdash et al. (2021a) describes the systematic review and meta-analysis in detail.

This dataset is used to illustrate multilevel multivariate meta-analytic models for the overall pooled effect and pooled effects by situation awareness measure. We also adjust meta-analytic models using cluster-robust variance estimation / cluster-robust inference with the `robust` function in *metafor*. Results are shown graphically in a customized forest plot with a prediction interval (estimated plausible range of individual effects). Last, we create a table summarizing the estimated meta-analytic heterogeneity parameters.

The meta-analytic results show most pooled effect sizes in the positive medium range or less. There was also substantial meta-analytic heterogeneity (estimated systematic variance in true effects), nearing the magnitude of the overall pooled effect. We interpret the meta-analytic results as situation awareness typically having limited validity for task performance (i.e., good situation awareness does not tend to have strong probabilistic links with good performance and vice-versa). More formally, measures of situation awareness do not generally and meaningfully capture cognitive processes and other relevant factors underlying task performance.

Run-Time:

The code run-time can be greatly sped-up using a linear algebra library with *R* that makes use of multiple CPU cores. See: https://www.metafor-project.org/doku.php/tips:speeding_up_model_fitting. To measure the run-time, uncomment these three lines: `start.time <- Sys.time()`, `end.time <- Sys.time()`, and `end.time - start.time`. Run-times on Windows 10 x64 with the Intel Math Kernel Library are:

CPU	*Run-Time (Minutes)*
i7-11850H	2.49
i7-4770	5.38

Concepts

psychology, human factors, engineering, correlation coefficients, multilevel models, multivariate models, cluster-robust inference

Author(s)

Jonathan Bakdash, <jonathan.z.bakdash.civ@army.mil>, <jbakdash@gmail.com>
Laura Marusich, <laura.m.cooper20.civ@army.mil>, <lmarusich@gmail.com>

Source

Bakdash, J. Z., Marusich, L. R., Cox, K. R., Geuss, M. N., Zaroukian, E. G., & Morris, K. M. (2021b). The validity of situation awareness for performance: A meta-analysis (Code Ocean Capsule). https://doi.org/10.24433/CO.1682542.v4

Bakdash, J. Z., Marusich, L. R., Cox, K. R., Geuss, M. N., Zaroukian, E. G., & Morris, K. M. (2021c). The validity of situation awareness for performance: A meta-analysis (Systematic Review, Data, and Code). https://doi.org/10.17605/OSF.IO/4K7ZV

References

Bakdash, J. Z., Marusich, L. R., Cox, K. R., Geuss, M. N., Zaroukian, E. G., & Morris, K. M. (2021a). The validity of situation awareness for performance: A meta-analysis. *Theoretical Issues in Ergonomics Science*, 1–24. https://doi.org/10.1080/1463922X.2021.1921310

Supplemental materials: https://www.tandfonline.com/doi/suppl/10.1080/1463922X.2021.1921310/suppl_file/

Examples

```
### copy data into 'dat' and examine data
dat <- dat.bakdash2021
head(dat[c(1,2,6,8:12)])

## Not run:
#start.time <- Sys.time()

### load metafor
library(metafor)

### multilevel meta-analytic model to get the overall pooled effect
res.overall <- rma.mv(es.z, vi.z, mods = ~ 1,
                      random = ~ 1 | SampleID / Outcome,
                      data = dat,
                      test = "t")
res.overall

### get prediction interval
predict(res.overall)

### cluster-robust variance estimation (CRVE) / cluster-robust inference
res.overall.crve <- robust(res.overall, cluster = SampleID)
res.overall.crve

### get prediction interval
res.overall.crve.pred <- predict(res.overall.crve)
res.overall.crve.pred

### multilevel meta-analytic model for SA measures
res.sa <-  rma.mv(es.z, vi.z, mods = ~ 0 + SA.measure.type,
                  random = ~ 1 | SampleID / Outcome,
                  data = dat,
                  test = "t")
res.sa

### cluster-robust variance estimation (CRVE) / cluster-robust inference
res.sa.crve <- robust(res.sa, cluster = SampleID)
res.sa.crve

### profile likelihood plots
par(mfrow=c(2,1))
profile(res.sa.crve, progbar = FALSE)

### format and combine output of meta-analytic models for the forest plot
all.z        <- c(res.sa.crve$beta,            # SA measures
                  res.overall.crve$beta,      # pooled effect for confidence interval (CI)
                  res.overall.crve$beta)      # pooled effect for prediction interval (PI)

all.ci.lower <- c(res.sa.crve$ci.lb,           # SA measures
```

```
                  res.overall.crve.pred$ci.lb, # pooled effect, lower CI
                  res.overall.crve.pred$pi.lb) # pooled effect, lower PI

all.ci.upper <- c(res.sa.crve$ci.ub,           # SA measures
                  res.overall.crve.pred$ci.ub, # pooled effect, upper CI
                  res.overall.crve.pred$pi.ub) # pooled effect, upper PI

### note: there is no p-value for the PI
all.pvals  <- c(res.sa.crve$pval, res.overall.crve$pval)
all.labels <- c(sort(unique(dat$SA.measure.type)), "Overall", "95% Prediction Interval")

### function to round p-values for the forest plot
pvals.round <- function(input) {
  input <- ifelse(input < 0.001, "< 0.001",
           ifelse(input < 0.01, "< 0.01",
           ifelse(input < 0.05 & input >= 0.045, "< 0.05",
           ifelse(round(input, 2) == 1.00, "0.99",
           sprintf("%.2f", round(input, 2))))))}

all.pvals.rounded <- pvals.round(all.pvals)

### forest plot
plot.vals <- data.frame(all.labels, all.z, all.ci.lower, all.ci.upper)

par(mfrow=c(1,1), cex = 1.05)
forest(plot.vals$all.z,
       ci.lb = plot.vals$all.ci.lower,
       ci.ub = plot.vals$all.ci.upper,
       slab  = plot.vals$all.labels,
       psize = 1,
       efac = 0, xlim = c(-1.8, 2.5), clim = c(-1, 1),
       transf = transf.ztor, # transform z to r
       at = seq(-0.5, 1, by = 0.25),
       xlab = expression("Correlation Coefficient"~"("*italic('r')*")"),
       main = "\n\n\nSA Measures",
       ilab = c(all.pvals.rounded, ""), ilab.xpos = 2.45, ilab.pos = 2.5,
       digits = 2, refline = 0, annotate = FALSE, header = FALSE)

### keep trailing zero using sprintf
output <- cbind(sprintf("%.2f", round(transf.ztor(plot.vals$all.z), 2)),
                sprintf("%.2f", round(transf.ztor(plot.vals$all.ci.lower), 2)),
                sprintf("%.2f", round(transf.ztor(plot.vals$all.ci.upper), 2)))

### alignment kludge
annotext <- apply(output, 1, function(x) {paste0("  ", x[1], " [", x[2],", ", x[3], "]")})
text( 1.05, 12:1, annotext, pos = 4, cex = 1.05)
text(-1.475, 14.00, "SA Measure", cex = 1.05)
text( 2.30,  14.00, substitute(paste(italic('p-value'))), cex = 1.05)
text( 1.55,  14.00, "Correlation [95% CI]", cex = 1.05)
abline(h = 2.5)

### black polygon for overall mean CIs
addpoly(all.z[11], ci.lb = all.ci.lower[11], ci.ub = all.ci.upper[11],
```

```
        rows = 2, annotate = FALSE, efac = 1.5, transf = transf.ztor)

### white polygon for PI
addpoly(all.z[12], ci.lb = all.ci.lower[12], ci.ub = all.ci.upper[12],
        rows = 1, col = "white", border = "black",
        annotate = FALSE, efac = 1.5, transf = transf.ztor)

par(mfrow=c(1,1), cex = 1) # reset graph parameters to default

### confidence intervals for the variance components
re.CI.variances <- confint(res.overall)
re.CI.variances

sigma1.z <- data.frame(re.CI.variances[[1]]["random"])
sigma2.z <- data.frame(re.CI.variances[[2]]["random"])

### fit model using alternative multivariate parameterization
res.overall.alt <- rma.mv(es.z, vi.z, mods = ~ 1,
                          random = ~ factor(Outcome) | factor(SampleID),
                          data = dat,
                          test = "t")

### confidence intervals for the total amount of heterogeneity variance component
res.overall.alt.tau <- confint(res.overall.alt, tau2=1)$random

### I^2: http://www.metafor-project.org/doku.php/tips:i2_multilevel_multivariate
W <- diag(1/dat$vi.z)
X <- model.matrix(res.overall)
P <- W - W %*% X %*% solve(t(X) %*% W %*% X) %*% t(X) %*% W

### I^2 (variance due to heterogeneity): 61%
I2 <- 100 * res.overall.alt$tau2 /
      (res.overall.alt$tau2 + (res.overall$k-res.overall$p)/sum(diag(P)))
I2

### 95% CI for I^2 using uncertainty around tau^2
I2.CI.lb <- 100 * res.overall.alt.tau[1,2] /
            (res.overall.alt.tau[1,2] + (res.overall$k-res.overall$p)/sum(diag(P)))
I2.CI.lb

I2.CI.ub <- 100 * res.overall.alt.tau[1,3] /
            (res.overall.alt.tau[1,3] + (res.overall$k-res.overall$p)/sum(diag(P)))
I2.CI.ub

### total amount of heterogeneity (tau)
sqrt(res.overall.alt$tau2)

### heterogeneity table
table.heterogeneity <- data.frame(matrix(ncol = 3, nrow = 4))
colnames(table.heterogeneity) <- c("Parameter Value",
                                   "Lower 95% CI",
                                   "Upper 95% CI")
rownames(table.heterogeneity) <- c("Tau (Total)",
```

```
                                  "Tau1 (Between paper)",
                                  "Tau2 (Within paper)",
                                  "I2 (%)")

table.heterogeneity[1,] <- res.overall.alt.tau[2,]
table.heterogeneity[2,] <- sigma1.z[2,]
table.heterogeneity[3,] <- sigma2.z[2,]
table.heterogeneity[4,] <- c(I2, I2.CI.lb, I2.CI.ub)

round(table.heterogeneity, 2)

#end.time <- Sys.time()
#end.time - start.time

## End(Not run)
```

`dat.baker2009` *Studies on Pharmacologic Treatments for Chronic Obstructive Pulmonary Disease*

Description

Results from 39 trials examining pharmacologic treatments for chronic obstructive pulmonary disease (COPD).

Usage

```
dat.baker2009
```

Format

The data frame contains the following columns:

study	character	study label
year	numeric	year of publication
id	numeric	study ID
treatment	character	treatment
exac	numeric	number of individuals with one or more COPD exacerbations
total	numeric	number of individuals

Details

This dataset comes from a systematic review of randomized controlled trials on pharmacologic treatments for chronic obstructive pulmonary disease (COPD) (Baker et al., 2009).

The primary outcome, occurrence of one or more episodes of COPD exacerbation, is binary (yes / no). For this outcome, five drug treatments (fluticasone, budesonide, salmeterol, formoterol, tiotropium) and two combinations (fluticasone + salmeterol, budesonide + formoterol) were compared to placebo. The authors considered the two combinations as separate treatments instead of evaluating the individual components.

Concepts

medicine, pulmonology, odds ratios, network meta-analysis, component network meta-analysis

Author(s)

Guido Schwarzer, <guido.schwarzer@uniklinik-freiburg.de>, https://github.com/guido-s/

Source

Baker, W. L., Baker, E. L., & Coleman, C. I. (2009). Pharmacologic treatments for chronic obstructive pulmonary disease: A mixed-treatment comparison meta-analysis. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy*, **29**(8), 891–905. https://doi.org/10.1592/phco.29.8.891

Examples

```
### Show first 6 rows of the dataset
head(dat.baker2009)

## Not run:
### Load netmeta package
suppressPackageStartupMessages(library(netmeta))

### Print odds ratios and confidence limits with two digits
oldset <- settings.meta(digits = 2)

### Transform data from long arm-based format to contrast-based
### format. Argument 'sm' has to be used for odds ratio as summary
### measure; by default the risk ratio is used in the metabin function
### called internally.
pw <- pairwise(treatment, exac, total, studlab = paste(study, year),
  data = dat.baker2009, sm = "OR")

### Conduct random effects network meta-analysis (NMA)
### with placebo as reference
net <- netmeta(pw, common = FALSE, ref = "plac")

### Show network graph
netgraph(net, seq = "optimal", start = "prcomp",
  labels = gsub("+", " +\n", trts, fixed = TRUE),
  plastic = TRUE, thickness = "se.fixed", number = TRUE,
  points = TRUE, cex.points = 5, col.points = "red",
  offset = 0.025)

### Print and plot results for network meta-analysis
net
forest(net)

### Conduct component network meta-analysis (CNMA)
cnet <- netcomb(net)
cnet

### Compare results of NMA and additive CNMA
```

```
nb <- netbind(net, cnet, name = c("Standard NMA", "Additive CNMA"))
forest(nb)

### Use previous settings
settings.meta(oldset)

## End(Not run)
```

`dat.bangertdrowns2004` *Studies on the Effectiveness of Writing-to-Learn Interventions*

Description

Results from 48 studies on the effectiveness of school-based writing-to-learn interventions on academic achievement.

Usage

```
dat.bangertdrowns2004
```

Format

The data frame contains the following columns:

id	`numeric`	study number
author	`character`	study author(s)
year	`numeric`	publication year
grade	`numeric`	grade level (1 = elementary; 2 = middle; 3 = high-school; 4 = college)
length	`numeric`	treatment length (in weeks)
minutes	`numeric`	minutes per assignment
wic	`numeric`	writing tasks were completed in class (0 = no; 1 = yes)
feedback	`numeric`	feedback on writing was provided (0 = no; 1 = yes)
info	`numeric`	writing contained informational components (0 = no; 1 = yes)
pers	`numeric`	writing contained personal components (0 = no; 1 = yes)
imag	`numeric`	writing contained imaginative components (0 = no; 1 = yes)
meta	`numeric`	prompts for metacognitive reflection (0 = no; 1 = yes)
subject	`character`	subject matter
ni	`numeric`	total sample size of the study
yi	`numeric`	standardized mean difference
vi	`numeric`	corresponding sampling variance

Details

In each of the studies included in this meta-analysis, an experimental group (i.e., a group of students that received instruction with increased emphasis on writing tasks) was compared against a control group (i.e., a group of students that received conventional instruction) with respect to some content-related measure of academic achievement (e.g., final grade, an exam/quiz/test score). The outcome

measure for this meta-analysis was the standardized mean difference (with positive values indicating a higher mean level of academic achievement in the intervention group).

The standardized mean differences given here are bias-corrected and therefore differ slightly from the values reported in the article. Also, since only the total sample size is given in the article, the sampling variances were computed under the assumption that $n_{i1} = n_{i2} = n_i/2$.

Concepts

education, standardized mean differences, meta-regression

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Bangert-Drowns, R. L., Hurley, M. M., & Wilkinson, B. (2004). The effects of school-based writing-to-learn interventions on academic achievement: A meta-analysis. *Review of Educational Research*, **74**(1), 29–58. https://doi.org/10.3102/00346543074001029

Examples

```
### copy data into 'dat' and examine data
dat <- dat.bangertdrowns2004
dat[1:10,-13]

## Not run:
### load metafor package
library(metafor)

### fit random-effects model
res <- rma(yi, vi, data=dat)
res

### some examples of mixed-effects meta-regression models
res <- rma(yi, vi, mods = ~ factor(grade), data=dat)
res
res <- rma(yi, vi, mods = ~ length, data=dat)
res
res <- rma(yi, vi, mods = ~ info + pers + imag + meta, data=dat)
res

## End(Not run)
```

`dat.bartos2023` *Results of 350,757 Coin Flips to Examine Same-Side Bias*

Description

Results from 350,757 coin flips by 48 people to examine the presence of same-side bias.

Usage

```
dat.bartos2023
```

Format

The data frame contains the following columns:

person	`character`	person identifier
hsame	`numeric`	number of flips where the coin landed on heads and on the same side as where it started
hdiff	`numeric`	number of flips where the coin landed on heads and on the different side as where it started
tsame	`numeric`	number of flips where the coin landed on tails and on the same side as where it started
tdiff	`numeric`	number of flips where the coin landed on tails and on the different side as where it started
same	`numeric`	number of flips where the coin landed on the same side as where it started
flips	`numeric`	total number of flips

Details

In a landmark study by Bartoš et al. (2023), 48 people flipped a coin (of various currencies and/or denominations) a total of 350,757 times, recording on each flip whether it landed on heads or tails and whether the coin landed on the same side as where it started or on the different side. The goal of this experiment was to examine the model by Diaconis, Holmes, and Montgomery (2007), according to which flipped coins have a slightly higher than 50% chance (of around 51% according to the D-H-M model) of landing on the same side as where they started.

Concepts

physics, human factors, proportions, multivariate models

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Bartoš, F., Sarafoglou, A., Godmann, H. R., Sahrani, A., Leunk, D. K., Gui, P. Y., Voss, D., Ullah, K., Zoubek, M. J., Nippold, F., Aust, F., Vieira, F. F., Islam, C.-G., Zoubek, A. J., Shabani, S., Petter, J., Roos, I. B., Finnemann, A., Lob, A. B., Hoffstadt, M. F., Nak, J., de Ron, J., Derks, K., Huth, K., Terpstra, S., Bastelica, T., Matetovici, M., Ott, V. L., Zetea, A. S., Karnbach, K., Donzallaz, M. C., John, A., Moore, R. M., Assion, F., van Bork, R., Leidinger, T. E., Zhao, X., Motaghi, A. K., Pan, T., Armstrong, H., Peng, T., Bialas, M., Pang, J. Y.-C., Fu, B., Yang, S., Lin, X., Sleiffer, D., Bognar,

M., Aczel, B., & Wagenmakers, E.-J. (2023). Fair coins tend to land on the same side they started: Evidence from 350,757 flips. *arXiv*, 2310.04153, v2. https://arxiv.org/abs/2310.04153

References

Diaconis, P., Holmes, S., & Montgomery, R. (2007). Dynamical bias in the coin toss. *SIAM Review*, **49**(2), 211–235. https://doi.org/10.1137/s0036144504446436

Examples

```
### copy data into 'dat' and examine data
dat <- dat.bartos2023
dat

## Not run:
### load metafor package
library(metafor)

### compute proportions and the corresponding sampling variances
dat <- escalc(measure="PR", xi=same, ni=flips, data=dat, slab=person)
dat

### compute confidence intervals for the individual proportions (as in Table 1)
summary(dat, digits=3)[c(1,6:8,13,14)]

### compute a confidence interval based on the column totals
summary(escalc(measure="PR", xi=sum(dat$same), ni=sum(dat$flips)), digits=3)

### this is the same as meta-analyzing the proportions directly using an equal-effects
### model and also computing the sampling variances under the assumption that the true
### proportions are homogeneous
rma(measure="PR", xi=same, ni=flips, vtype="AV", method="EE", data=dat, digits=3)

### fit a random-effects model
res <- rma(yi, vi, data=dat)
res

### profile likelihood confidence interval for tau^2
confint(res, type="PL")

### forest plot
forest(res, refline=0.5, xlim=c(0.38,0.72), digits=c(3,2), efac=c(0,1))

### funnel plot
funnel(res, xlim=c(0.45,0.6), ylim=c(0,0.02))

### fit a random-effects model excluding those with same-side proportions larger than 0.53
res <- rma(yi, vi, data=dat, subset=yi<=0.53)
res
confint(res, type="PL")

### fit a binomial-normal model
```

```
res <- rma.glmm(measure="PLO", xi=same, ni=flips, data=dat)
res
predict(res, transf=plogis)

### conduct a meta-analysis for the proportions of heads (to examine heads-tails bias)
dat <- escalc(measure="PR", xi=hdiff+hsame, ni=flips, data=dat)
res <- rma(yi, vi, data=dat)
res
confint(res, type="PL")

### restructure the dataset for a bivariate meta-analysis of same-side and heads proportions
dat <- dat.bartos2023
dat <- dat[rep(1:nrow(dat), each=2),]
rownames(dat) <- NULL
dat$outcome <- c("heads", "same")
dat <- escalc(measure="PR", xi=hsame+hdiff, ni=flips, data=dat, include=outcome=="heads")
dat <- escalc(measure="PR", xi=hsame+tsame, ni=flips, data=dat, include=outcome=="same")
dat

### construct the 2x2 variance-covariance matrix of the proportions within persons
dat$cov <- with(dat, (hsame/flips * (1-hsame/flips) - hsame/flips * tsame/flips -
                      hsame/flips * hdiff/flips - hdiff/flips * tsame/flips) / flips)
V <- lapply(split(dat, dat$person), \(x) matrix(c(x$vi[1], x$cov, x$vi[2]), nrow=2))

### fit bivariate meta-analysis model
res <- rma.mv(yi, V, mods = ~ 0 + outcome, random = ~ outcome | person, struct="UN", data=dat)
res

### create plot with confidence ellipses ('ellipse' package must be installed)
library(ellipse)
plot(NA, xlim=c(0.45,0.62), ylim=c(0.45,0.62), bty="l", xlab="Pr(heads)", ylab="Pr(same)")
abline(h=0.5, lty="dotted")
abline(v=0.5, lty="dotted")
# add confidence ellipses for persons
invisible(tapply(dat, dat$person, \(x) {
   xy <- ellipse(matrix(c(x$vi[1],x$cov,x$vi[2]), nrow=2), centre=x$yi, level=0.95)
   lines(xy[,1],xy[,2], col="gray80")
}))
# add the points
invisible(tapply(dat, dat$person, \(x) points(x$yi[1], x$yi[2], pch=21, bg="gray80", cex=1.5)))
# add the 95% PI ellipsis based on the model
xy <- ellipse(res$G, centre=coef(res), level=0.95)
lines(xy[,1],xy[,2], col="gray30", lwd=3, lty="dotted")
# add the 95% CI ellipsis based on the model
xy <- ellipse(vcov(res), centre=coef(res), level=0.95)
lines(xy[,1],xy[,2], col="gray30", lwd=3)
# add the point for the pooled effects
points(coef(res)[1], coef(res)[2], pch=21, bg="gray40", cex=2)

## End(Not run)
```

`dat.baskerville2012` *Studies on the Effectiveness of Practice Facilitation Interventions*

Description

Results from 23 studies on the effectiveness of practice facilitation interventions within the primary care practice setting.

Usage

```
dat.baskerville2012
```

Format

The data frame contains the following columns:

author	`character`	study author(s)
year	`numeric`	publication year
score	`numeric`	quality score (0 to 12 scale)
design	`character`	study design (cct = controlled clinical trial, rct = randomized clinical trial, crct = cluster randomize
alloconc	`numeric`	allocation concealed (0 = no, 1 = yes)
blind	`numeric`	single- or double-blind study (0 = no, 1 = yes)
itt	`numeric`	intention to treat analysis (0 = no, 1 = yes)
fumonths	`numeric`	follow-up months
retention	`numeric`	retention (in percent)
country	`character`	country where study was conducted
outcomes	`numeric`	number of outcomes assessed
duration	`numeric`	duration of intervention
pperf	`numeric`	practices per facilitator
meetings	`numeric`	(average) number of meetings
hours	`numeric`	(average) hours per meeting
tailor	`numeric`	intervention tailored to the context and needs of the practice (0 = no, 1 = yes)
smd	`numeric`	standardized mean difference
se	`numeric`	corresponding standard error

Details

Baskerville et al. (2012) describe outreach or practice facilitation as a "multifaceted approach that involves skilled individuals who enable others, through a range of intervention components and approaches, to address the challenges in implementing evidence-based care guidelines within the primary care setting". The studies included in this dataset examined the effectiveness of practice facilitation interventions for improving some relevant evidence-based practice behavior. The effect was quantified in terms of a standardized mean difference, comparing the change (from pre- to post-intervention) in the intervention versus the comparison group (or the difference from baseline in prospective cohort studies).

Concepts

medicine, primary care, standardized mean differences, publication bias, meta-regression

Note

The quality score of 18 given for the study by Deitrich et al. (1992) in Table 1 of Baskerville et al. (2012) appears to be a typo. This was corrected to an 8 in the present dataset.

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Baskerville, N. B., Liddy, C., & Hogg, W. (2012). Systematic review and meta-analysis of practice facilitation within primary care settings. *Annals of Family Medicine*, **10**(1), 63–74. https://doi.org/10.1370/afm.1312

Examples

```
### copy data into 'dat' and examine data
dat <- dat.baskerville2012
dat

## Not run:
### load metafor package
library(metafor)

### random-effects model
res <- rma(smd, sei=se, data=dat, method="DL")
print(res, digits=2)

### funnel plot
funnel(res, xlab="Standardized Mean Difference", ylim=c(0,0.6))

### rank and regression tests for funnel plot asymmetry
ranktest(res)
regtest(res)

### meta-regression analyses examining various potential moderators
rma(smd, sei=se, mods = ~ score, data=dat, method="DL")
rma(smd, sei=se, mods = ~ alloconc, data=dat, method="DL")
rma(smd, sei=se, mods = ~ blind,    data=dat, method="DL")
rma(smd, sei=se, mods = ~ itt,      data=dat, method="DL")
rma(smd, sei=se, mods = ~ duration, data=dat, method="DL")
rma(smd, sei=se, mods = ~ tailor,   data=dat, method="DL")
rma(smd, sei=se, mods = ~ pperf,    data=dat, method="DL")
rma(smd, sei=se, mods = ~ I(meetings * hours), data=dat, method="DL")

## End(Not run)
```

`dat.bassler2004` *Studies on Ketotifen Alone or as Additional Medication for Long-Term Control of Asthma and Wheeze in Children*

Description

Results from 10 trials reporting the physicians' judgement on the overall efficacy of ketotifen for long-term control of asthma and wheeze in children.

Usage

```
dat.bassler2004
```

Format

The data frame contains the following columns:

study	`character`	study label
Ee	`integer`	number of children with treament success (ketotifen group)
Ne	`integer`	number of children (ketotifen group)
Ec	`integer`	number of children with treament success (control group)
Nc	`integer`	number of children (control group)
blind	`character`	blinding of clinicians

Details

Results from 10 trials reporting the physicians' judgement on the overall efficacy of Ketotifen for long-term control of asthma and wheeze in children. A prespecified subgroup analysis was conducted to evaluate whether the treatment effect is different in trials with adequate blinding compared to trials with inadequate / unclear blinding.

This data set is used as an example in Schwarzer et al. (2015).

Concepts

risk ratios, medicine, subgroup analysis

Author(s)

Guido Schwarzer, <guido.schwarzer@uniklinik-freiburg.de>, https://github.com/guido-s/

Source

Bassler D., Mitra A. A. D., Ducharme F. M., Forster J., & Schwarzer, G. (2004). Ketotifen alone or as additional medication for long-term control of asthma and wheeze in children. *Cochrane Database of Systematic Reviews*, **1**, CD001384. https://doi.org/10.1002/14651858.CD001384.pub2

References

Schwarzer, G., Carpenter, J. R., & Rücker, G. (2015). *Meta-analysis with R*. Cham, Switzerland: Springer.

Examples

```
### Show full data set
dat.bassler2004

## Not run:
### Load meta package
suppressPackageStartupMessages(library(meta))

### Use DerSimonian-Laird estimator (which was the default in meta in the year 2015).
### Furthermore, print meta-analysis results with two digits.
oldset <- settings.meta(method.tau = "DL", digits = 2)

### Calculate experimental and control event rates
with(dat.bassler2004, summary(Ee / Ne))
with(dat.bassler2004, summary(Ec / Nc))

### Conduct meta-analysis using the inverse variance method
mb3 <- metabin(Ee, Ne, Ec, Nc, method = "I",
               data = dat.bassler2004, studlab = study)
mb3

### Conduct subgroup analysis comparing trials with adequate blinding
### to trials with inadequate or unclear blinding
mb3s <- update(mb3, subgroup = blind, print.subgroup.name = FALSE)
mb3s

### Conduct subgroup analysis assuming common between-study variance in subgroups
mb3s.c <- update(mb3s, tau.common = TRUE)
mb3s.c

### Use previous settings
settings.meta(oldset)

## End(Not run)
```

---

dat.bauer2002 *Studies on OM-89 (Uro-Vaxom) in Urinary Tract Infections*

Description

Estimated Wilcoxon-Mann-Whitney (WMW) effect sizes from five studies on OM-89 (Uro-Vaxom) in patients with recurrent urinary tract infections.

Usage

```
dat.bauer2002
```

Format

The data frame contains the following columns:

study	character	study identifier
year	numeric	publication year
threshold	numeric	threshold (for bacteriuria / UTI definition)
n.treat	numeric	number of patients in treatment group
n.control	numeric	number of patients in control group
n.total	numeric	total number of patients
wmwstat	numeric	Wilcoxon-Mann-Whitney statistic
lower	numeric	lower CI bound for the WMW-statistic
upper	numeric	upper CI bound for the WMW-statistic
stderr	numeric	standard error for the WMW-statistic

Details

Bauer et al. (2002) analyzed data from five randomized, placebo-controlled studies investigating the use of OM-89 (Uro-Vaxom) in recurrent urinary tract infections (UTI). Treatment effects were quantified in terms of the *Wilcoxon-Mann-Whitney statistic* computed based on the numbers of recurrences experienced by included patients from each study.

The WMW-statistic gives an estimate of the probability that a randomly selected patient from the treatment group is superior to a randomly selected control patient, also denoted as the *common language effect size* (CLES). "Superiority" in this case relates to fewer UTI recurrences experienced. A WMW-statistic > 0.5 then suggests a beneficial treatment effect.

Concepts

medicine, common-language effect sizes, proportions

Author(s)

Christian Röver, <christian.roever@med.uni-goettingen.de>

Source

Bauer, H. W., Rahlfs, V. W., Lauener, P. A., & Bleßmann, G. S. S. (2002). Prevention of recurrent urinary tract infections with immuno-active E. coli fractions: A meta-analysis of five placebo-controlled double-blind studies. *International Journal of Antimicrobial Agents*, **19**(6), 451–456. https://doi.org/10.1016/s0924-8579(02)00106-1

See Also

dat.huber2000

Examples

```
dat.bauer2002

## Not run:
library(metafor)
library(bayesmeta)

# analyze based on plain probabilities as effect sizes
wmw.prob <- escalc(measure="CLES",
                   yi = wmwstat, sei = stderr,
                   ni = n.total, slab = study,
                   data = dat.bauer2002)

# perform a random-effects meta-analysis
ma01 <- rma.uni(wmw.prob, method="PM", test="adhoc")

# show forest plot
forest(ma01, addpred=TRUE, predstyle="bar",
       refline=0.5, main="dat.bauer2002 (probabilities)")


# analyze based on log-odds (logits) as effect sizes
wmw.logit <- escalc(measure="PLO",
                    yi   = log(wmwstat / (1-wmwstat)),
                    sei  = stderr / (wmwstat*(1-wmwstat)),
                    ni   = n.total, slab = study,
                    data = dat.bauer2002)

# perform a random-effects meta-analysis
ma02 <- rma.uni(wmw.logit, method="PM", test="adhoc")

# show forest plot (back-transformed to probabilities)
forest(ma02, addpred=TRUE, predstyle="bar",
       transf=transf.ilogit,
       header=c("study", "CLES [95 percent CI]"),
       xlab="common language effect size",
       refline=0.5, main="dat.bauer2002 (log-odds)")

# show forest plot (in terms of log-odds)
forest(ma02, addpred=TRUE, predstyle="bar",
       header=c("study", "logit(CLES) [95 percent CI]"),
       xlab="logit(common language effect size)",
       refline=0.0, main="dat.bauer2002 (log-odds)")

# perform Bayesian meta-analsis
# (using a half-normal prior for the (logit-WMW) effect heterogeneity
#  and a Normal(0.0, 1.814) prior for the overall mean logit;
#  the overall mean prior (with variance (pi/sqrt(3))^2)
#  roughly corresponds to a uniform prior in probability)
ma03 <- bayesmeta(wmw.logit,
                  tau.prior = function(t){dhalfnormal(t,scale=0.5)},
                  mu.prior = c(0.0, 1.814))
```

```
forestplot(ma03, title = "dat.bauer2002 (log-odds)",
           xlab = "logit(CLES)",
           txt_gp = fpTxtGp(ticks = gpar(cex=1), xlab = gpar(cex=1)))

## End(Not run)
```

`dat.bcg` *Studies on the Effectiveness of the BCG Vaccine Against Tuberculosis*

Description

Results from 13 studies examining the effectiveness of the Bacillus Calmette-Guerin (BCG) vaccine against tuberculosis.

Usage

```
dat.bcg
```

Format

The data frame contains the following columns:

trial	`numeric`	trial number
author	`character`	author(s)
year	`numeric`	publication year
tpos	`numeric`	number of TB positive cases in the treated (vaccinated) group
tneg	`numeric`	number of TB negative cases in the treated (vaccinated) group
cpos	`numeric`	number of TB positive cases in the control (non-vaccinated) group
cneg	`numeric`	number of TB negative cases in the control (non-vaccinated) group
ablat	`numeric`	absolute latitude of the study location (in degrees)
alloc	`character`	method of treatment allocation (random, alternate, or systematic assignment)

Details

The 13 studies provide data in terms of 2×2 tables in the form:

	TB positive	TB negative
vaccinated group	`tpos`	`tneg`
control group	`cpos`	`cneg`

The goal of the meta-analysis was to examine the overall effectiveness of the BCG vaccine for preventing tuberculosis and to examine moderators that may potentially influence the size of the effect.

The dataset has been used in several publications to illustrate meta-analytic methods (see 'References').

Concepts

medicine, risk ratios, meta-regression

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Colditz, G. A., Brewer, T. F., Berkey, C. S., Wilson, M. E., Burdick, E., Fineberg, H. V., & Mosteller, F. (1994). Efficacy of BCG vaccine in the prevention of tuberculosis: Meta-analysis of the published literature. *Journal of the American Medical Association*, **271**(9), 698–702. https://doi.org/10.1001/jama.1994.035103

References

Berkey, C. S., Hoaglin, D. C., Mosteller, F., & Colditz, G. A. (1995). A random-effects regression model for meta-analysis. *Statistics in Medicine*, **14**(4), 395–411. https://doi.org/10.1002/sim.4780140406

van Houwelingen, H. C., Arends, L. R., & Stijnen, T. (2002). Advanced methods in meta-analysis: Multivariate approach and meta-regression. *Statistics in Medicine*, **21**(4), 589–624. https://doi.org/10.1002/sim.1040

Viechtbauer, W. (2010). Conducting meta-analyses in R with the metafor package. *Journal of Statistical Software*, **36**(3), 1–48. https://doi.org/10.18637/jss.v036.i03

Examples

```
### copy data into 'dat' and examine data
dat <- dat.bcg
dat

## Not run:
### load metafor package
library(metafor)

### calculate log risk ratios and corresponding sampling variances
dat <- escalc(measure="RR", ai=tpos, bi=tneg,
                            ci=cpos, di=cneg, data=dat,
                            slab=paste0(author, ", ", year))
dat

### random-effects model
res <- rma(yi, vi, data=dat)
res

### average risk ratio with 95% CI
predict(res, transf=exp)

### mixed-effects model with absolute latitude and publication year as moderators
res <- rma(yi, vi, mods = ~ ablat + year, data=dat)
res

### predicted average risk ratios for 10-60 degrees absolute latitude
```

```
### holding the publication year constant at 1970
predict(res, newmods=cbind(seq(from=10, to=60, by=10), 1970), transf=exp)

### note: the interpretation of the results is difficult because absolute
### latitude and publication year are strongly correlated (the more recent
### studies were conducted closer to the equator)
plot(ablat ~ year, data=dat, pch=19, xlab="Publication Year", ylab="Absolute Lattitude")
cor(dat$ablat, dat$year)

## End(Not run)
```

`dat.begg1989` *Studies on Bone-Marrow Transplantation versus Chemotherapy for the Treatment of Leukemia*

Description

Results from controlled and uncontrolled studies on the effectiveness of allogeneic bone-marrow transplantation (BMT) and conventional chemotherapy (CMO) in the treatment of acute nonlymphocytic leukemia.

Usage

```
dat.begg1989
```

Format

The data frame contains the following columns:

study	`numeric`	study number
trt	`character`	treatment (BMT or CMO)
arms	`numeric`	number of arms in the study (1 = uncontrolled studies; 2 = controlled studies)
yi	`numeric`	2-year disease-free survival rates
sei	`numeric`	corresponding standard errors
vi	`numeric`	corresponding sampling variances

Details

The dataset includes the results from controlled and uncontrolled studies on the 2-year disease-free survival rate in patients with acute nonlymphocytic leukemia receiving either allogeneic bone-marrow transplantation (BMT) or conventional chemotherapy (CMO). In the controlled (two-arm) studies (studies 1-4), a cohort of patients in complete remission and potentially eligible for BMT was assembled, and those who consented and for whom a donor could be found received BMT, with the remaining patients used as controls (receiving CMO). In the uncontrolled (one-arm) studies (studies 5-16), only a single group was studied, receiving either BMT or CMO.

The data in this dataset were obtained from Table 1 in Begg and Pilote (1991, p. 902).

Concepts

medicine, oncology, single-arm studies, multilevel models

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Begg, C. B., & Pilote, L. (1991). A model for incorporating historical controls into a meta-analysis. *Biometrics*, **47**(3), 899–906. https://doi.org/10.2307/2532647

References

Begg, C. B., Pilote, L., & McGlave, P. B. (1989). Bone marrow transplantation versus chemotherapy in acute non-lymphocytic leukemia: A meta-analytic review. *European Journal of Cancer and Clinical Oncology*, **25**(11), 1519–1523. https://doi.org/10.1016/0277-5379(89)90291-5

Examples

```
### copy data into 'dat' and examine data
dat <- dat.begg1989
dat

## Not run:
### load metafor package
library(metafor)

### turn trt and arms into factors and set reference levels
dat$trt  <- relevel(factor(dat$trt), ref="CMO")
dat$arms <- relevel(factor(dat$arms), ref="2")

### create data frame with the treatment differences for the controlled studies
dat2 <- data.frame(yi = dat$yi[c(1,3,5,7)] - dat$yi[c(2,4,6,8)],
                   vi = dat$vi[c(1,3,5,7)] + dat$vi[c(2,4,6,8)])
dat2

### DerSimonian and Laird method using the treatment differences
res <- rma(yi, vi, data=dat2, method="DL", digits=2)
res

### Begg & Pilote (1991) model incorporating the uncontrolled studies
res <- rma.mv(yi, vi, mods = ~ trt, random = ~ 1 | study,
              data=dat, method="ML", digits=2)
res

### model involving bias terms for the uncontrolled studies
res <- rma.mv(yi, vi, mods = ~ trt + trt:arms, random = ~ 1 | study,
              data=dat, method="ML", digits=2)
res
```

```
### model with a random treatment effect
res <- rma.mv(yi, vi, mods = ~ trt, random = list(~ 1 | study, ~ trt | study),
              struct="UN", tau2=c(0,NA), rho=0, data=dat, method="ML", digits=2)
res

### model with a random treatment effect, but with equal variances in both arms
res <- rma.mv(yi, vi, mods = ~ trt, random = list(~ 1 | study, ~ trt | study),
              struct="CS", rho=0, data=dat, method="ML", digits=2)
res

## End(Not run)
```

`dat.berkey1998` *Studies on Treatments for Periodontal Disease*

Description

Results from 5 trials comparing surgical and non-surgical treatments for medium-severity periodontal disease one year after treatment.

Usage

```
dat.berkey1998
dat.berkey1998r
```

Format

The data frame contains the following columns:

trial	`numeric`	trial number
author	`character`	study author(s)
year	`numeric`	publication year
ni	`numeric`	number of patients
outcome	`character`	outcome (PD = probing depth; AL = attachment level)
yi	`numeric`	observed mean difference in outcome (surgical versus non-surgical)
vi	`numeric`	corresponding sampling variance
v1i	`numeric`	variances and covariances of the observed effects
v2i	`numeric`	variances and covariances of the observed effects

Details

The dataset includes the results from 5 trials that compared surgical and non-surgical methods for the treatment of medium-severity periodontal disease. Reported outcomes include the change in probing depth (PD) and attachment level (AL) one year after the treatment. The outcome measure used for this meta-analysis was the (raw) mean difference, calculated in such a way that positive values indicate that surgery was more effective than non-surgical treatment in decreasing the probing depth and increasing the attachment level (so, the results from the various trials indicate that surgery is preferable for reducing the probing depth, while non-surgical treatment is preferable for

increasing the attachment level). Since each trial provides effect size estimates for both outcomes, the estimates are correlated. A multivariate model can be used to meta-analyze the two outcomes simultaneously.

The `v1i` and `v2i` values are the variances and covariances of the observed effects. In particular, for each study, variables `v1i` and `v2i` form a 2×2 variance-covariance matrix of the observed effects, with the diagonal elements corresponding to the sampling variances of the mean differences (the first for probing depth, the second for attachment level) and the off-diagonal value corresponding to the covariance of the two mean differences. Below, the full (block diagonal) variance-covariance for all studies is constructed from these two variables.

The dataset `dat.berkey1998r` is the same as `dat.berkey1998` except that the first row of each study corresponds to outcome `AL` and the second to outcome `PD` (i.e., the rows are reversed).

Concepts

medicine, dentistry, raw mean differences, multivariate models

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Berkey, C. S., Antczak-Bouckoms, A., Hoaglin, D. C., Mosteller, F., & Pihlstrom, B. L. (1995). Multiple-outcomes meta-analysis of treatments for periodontal disease. *Journal of Dental Research*, **74**(4), 1030–1039. https://doi.org/10.1177/00220345950740040201

Berkey, C. S., Hoaglin, D. C., Antczak-Bouckoms, A., Mosteller, F., & Colditz, G. A. (1998). Meta-analysis of multiple outcomes by regression with random effects. *Statistics in Medicine*, **17**(22), 2537–2550. https://doi.org/10.1002/(sici)1097-0258(19981130)17:22<2537::aid-sim953>3.0.co;2-c

Examples

```
### copy data into 'dat' and examine data
dat <- dat.berkey1998
dat

## Not run:
### load metafor package
library(metafor)

### construct block diagonal var-cov matrix of the observed outcomes based on variables v1i and v2i
V <- vcalc(vi=1, cluster=author, rvars=c(v1i, v2i), data=dat)

### fit multiple outcomes (meta-regression) model (with REML estimation)
res <- rma.mv(yi, V, mods = ~ 0 + outcome, random = ~ outcome | trial, struct="UN", data=dat)
print(res, digits=3)

### test/estimate difference between the two outcomes
anova(res, X=c(1,-1))

### fit model including publication year as moderator for both outcomes (with ML estimation)
```

```
res <- rma.mv(yi, V, mods = ~ 0 + outcome + outcome:I(year - 1983),
              random = ~ outcome | trial, struct="UN", data=dat, method="ML")
print(res, digits=3)

## End(Not run)
```

`dat.besson2016` *Dataset on How Maternal Diet Impacts Copying Styles in Rodents*

Description

Results from 46 studies synthesising maternal nutritional effects on coping styles in rodents.

Usage

```
dat.besson2016
```

Format

The data frame contains the following columns:

comp_ID	`character`	effect-size unique identifier
study_ID	`character`	study unique identifier
dam_ID	`character`	dam unique identifier (group of dams subjected to the same treatment)
animal_ID	`character`	offspring unique identifier (group of offspring from the same dam group s
Reference	`character`	author's names and date
species	`character`	species [rats or mice]
strain	`character`	strain
manip_type	`character`	maternal nutritional manipulation type [protein or calorie]
manip_direction	`character`	direction of maternal nutritional manipulation [- = restriction, + = overfee
nom_manip_val	`character`	degree of maternal nutritional manipulation as described in the original pu
exp	`character`	percentage of caloric or protein maternal restriction or increase in caloric i
control	`character`	percentage of caloric or protein maternal restriction or increase in caloric i
manip_parameter	`character`	protein content, percentage fat or intake
vitmin_eql	`character`	were vitamins equalized across maternal diets? [yes or no]
adlib_con	`character`	were maternal control groups fed ad libitum? [yes or no]
adlib_exp	`character`	were maternal experimental groups fed ad libitum? [yes or no]
diet_con	`character`	name of maternal control diet?
diet_exp	`character`	name of maternal experimental diet?
dam_diet_start_dPC	`numeric`	start of the dam diet [in days post-conception]
dam_diet_end_dPC	`numeric`	end of the dam diet [in days post-conception]
diet_label	`character`	period of maternal diet manipulation [pregestation = pre-gestation, pre = p
age_mating	`numeric`	dam age at mating if known
n_con_dam	`integer`	sample size of the control dam groups
n_exp_dam	`integer`	sample size of the experimental dam groups
multi_use_con	`character`	were control groups used multiple time? [yes or no]
dam_housing	`character`	how were dams housed? [pair, group, or single]

temperature	numeric	temperature during the experiment [°C]
photoperiod	integer	photoperiod during the experiment [number of hours of light]
litter_size	integer	size of the litter [number of pups per dam]
litter_size_equalized	character	has litter size been equalized? [yes or no]
crossfostered	character	have pups been cross-fostered? [yes or no]
sex	character	sex of the offspring that were tested [m = male, f = female, both = mixed s
housing	character	offspring housing during the test period [dam, pair, single, or group]
bodymass_mean_contr	numeric	mean body mass of control offspring close to or during the testing period [
bodymass_SE_contr	numeric	S.E. for body mass of control offspring close to or during the testing perio
bodymass_mean_exp	numeric	mean body mass of experimental offspring close to or during the testing p
bodymass_SE_exp	numeric	S.E. for body mass of experimental offspring close to or during the testing
bm_N_contr	integer	sample size for body mass of control offspring close to or during the testir
bm_N_exp	integer	sample size for body mass of experimental offspring close to or during the
bm_dPP	integer	age of offspring when body mass was measured [in days post-parturition]
offspring_diet	character	offspring diet after weaning [type of control diet]
offspring_con_adlib	character	were control offspring fed ad libitum after weaning? [yes or no]
offspring_diet_level	character	name of offspring diet after weaning
offspring_diet_end_dPP	integer	end of the offspring diet [in days post-parturition]
post_diet_adlib	character	were experimental offspring fed ad libitum after weaning? [yes or no]
response_age_dPP	numeric	offspring age when behavioural testing started [in days post-parturition]
authors_behaviour_classification	character	author's classification of offspring behaviour [anxiety, exploration, or activ
our_behaviour_classification	character	our classification of offspring behaviour [anxiety, exploration, or activity]
response_test	character	type of test used [elevated T-maze (ETM), open field, etc.] to measure offs
time_trial	integer	duration of the testing [min]
measure	character	measures taken during testing [total distance moved, time spent in open ar
unit	character	unit of the behavioural measure taken [min, s, m, number (#), etc.]
high_better	character	for activity and exploration, a higher number is assumed to be better (i.e.,
night.day	character	time of day when behaviours were measured [night or day]
comparison	character	for a given control-treatment group comparison, animal group codes as us
exp_mean	numeric	mean of the offspring behaviour measured for the experimental group
exp_se	numeric	S.E. of the offspring behaviour measured for the experimental group
exp_n	integer	sample size for the offspring experimental group
con_mean	numeric	mean of offspring behaviour measured for the control group
con_se	numeric	S.E. of the offspring behaviour measured for the control group
con_n	integer	sample size for the offspring control group
con_ID	character	identifier for shared control groups within experiment
percentage	character	is the offspring behaviour measure a percentage? [yes or no]
Data_source	character	figure or table number in the original paper from which the data were extr
measure_comments	character	any comments on the offspring behaviour measures
SE_imputed	character	was S.E. imputed for the offspring behaviour measure? [yes or no]
Comments	character	any comments on the data

Details

Data from experiments where dams were subject to caloric or protein restriction or were overfed around gestation were included. Offspring activity, exploration, or anxiety were measured outcomes variables from maternal experimental treatments. Multilevel meta-analysis and meta-regression models were used to analyze the meta-analytic data.

Concepts

ecology, evolution, standardized mean differences

Author(s)

Daniel Noble, <daniel.noble@anu.edu.au>

Source

Besson, A. A., Lagisz, M., Senior, A. M., Hector, K. L., & Nakagawa, S. (2016). Effect of maternal diet on offspring coping styles in rodents: A systematic review and meta-analysis. *Biological Reviews*, **91**(4), 1065–1080. https://doi.org/10.1111/brv.12210

Examples

```
### copy data into 'dat' and examine data
dat <- dat.besson2016
head(dat)

## Not run:
### load metafor
library(metafor)

### compute SD from SE
dat$sd_c <- with(dat, con_se * sqrt(con_n))
dat$sd_e <- with(dat, exp_se * sqrt(exp_n))

### compute standardized mean differences and corresponding sampling variances
dat <- escalc(measure="SMD", m1i=exp_mean, m2i=con_mean, sd1i=sd_e, sd2i=sd_c,
              n1i=exp_n, n2i=con_n, data=dat, add.measure=TRUE)

### fit model
mod1 <- rma.mv(yi ~ 1, V = vi, random = list(~ 1 | study_ID, ~ 1 | comp_ID), data = dat)
mod1

## End(Not run)
```

---

dat.bonett2010 *Studies on the Reliability of the CES-D Scale*

Description

Results from 9 studies on the reliability of the Center for Epidemiologic Studies Depression (CES-D) Scale administered to children providing care to an elderly parent.

Usage

```
dat.bonett2010
```

Format

The data frame contains the following columns:

study	numeric	study number
source	character	source of data
ni	numeric	sample size
mi	numeric	number of items in the scale
ai	numeric	observed value of Cronbach's alpha
caregivers	character	gender of the children in the sample

Details

The Center for Epidemiologic Studies Depression (CES-D) Scale is a 20-item questionnaire assessing various symptoms of depression, with each item scored on a 4-point scale. The scale has been used in several studies to examine depressive symptoms in children providing care to an elderly parent. The dataset includes information on the reliability of the scale as measured with Cronbach's alpha in 9 such studies. Also, the gender composition of the children in each sample is indicated.

Concepts

psychology, Cronbach's alpha, reliability generalization, meta-regression

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Bonett, D. G. (2010). Varying coefficient meta-analytic methods for alpha reliability. *Psychological Methods*, **15**(4), 368–385. https://doi.org/10.1037/a0020142

References

Bonett, D. G. (2002). Sample size requirements for testing and estimating coefficient alpha. *Journal of Educational and Behavioral Statistics*, **27**(4), 335–340. https://doi.org/10.3102/10769986027004335

Hakstian, A. R., & Whalen, T. E. (1976). A k-sample significance test for independent alpha coefficients. *Psychometrika*, **41**(2), 219–231. https://doi.org/10.1007/BF02291840

Examples

```
### copy data into 'dat' and examine data
dat <- dat.bonett2010
dat

## Not run:
### load metafor package
library(metafor)

### meta-analysis using the raw alpha values
res <- rma(measure="ARAW", ai=ai, mi=mi, ni=ni, data=dat)
```

```
res

### meta-analysis using transformed alpha values (using the
### transformation suggested by Hakstian & Whalen, 1976)
res <- rma(measure="AHW", ai=ai, mi=mi, ni=ni, data=dat)
res
predict(res, transf=transf.iahw)

### meta-analysis using transformed alpha values (using the
### transformation suggested by Bonett, 2002)
res <- rma(measure="ABT", ai=ai, mi=mi, ni=ni, data=dat)
res
predict(res, transf=transf.iabt)

### forest plot
forest(res, slab=source, xlim=c(0,4.5),
       atransf=transf.iabt, refline=coef(res))

### examine whether female/mixed samples yield different alphas (with raw alphas)
res <- rma(measure="ARAW", ai=ai, mi=mi, ni=ni, mods = ~ caregivers, data=dat)
res
predict(res, newmods=c(0,1), digits=2)

## End(Not run)
```

`dat.bornmann2007` *Studies on Gender Differences in Grant and Fellowship Awards*

Description

Results from 21 studies on gender differences in grant and fellowship awards.

Usage

```
dat.bornmann2007
```

Format

The data frame contains the following columns:

study	character	study reference
obs	numeric	observation within study
doctype	character	document type
gender	character	gender of the study authors
year	numeric	(average) cohort year
org	character	funding organization / program
country	character	country of the funding organization / program
type	character	fellowship or grant application
discipline	character	discipline / field

waward	numeric	number of women who received a grant/fellowship award
wtotal	numeric	number of women who applied for an award
maward	numeric	number of men who received a grant/fellowship award
mtotal	numeric	number of men who applied for an award

Details

The studies in this dataset examine whether the chances of receiving a grant or fellowship award differs for men and women. Note that many studies provide multiple comparisons (e.g., for different years / cohorts / disciplines). A multilevel meta-analysis model can be used to account for the multilevel structure in these data.

Concepts

sociology, odds ratios, multilevel models

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Bornmann, L., Mutz, R., & Daniel, H. (2007). Gender differences in grant peer review: A meta-analysis. *Journal of Informetrics*, **1**(3), 226–238. https://doi.org/10.1016/j.joi.2007.03.001

References

Marsh, H. W., Bornmann, L., Mutz, R., Daniel, H.-D., & O'Mara, A. (2009). Gender effects in the peer reviews of grant proposals: A comprehensive meta-analysis comparing traditional and multilevel approaches. *Review of Educational Research*, **79**(3), 1290–1326. https://doi.org/10.3102/0034654309334143

Examples

```
### copy data into 'dat' and examine data
dat <- dat.bornmann2007
head(dat, 16)

## Not run:
### load metafor package
library(metafor)

### calculate log odds ratios and corresponding sampling variances
dat <- escalc(measure="OR", ai=waward, n1i=wtotal, ci=maward, n2i=mtotal, data=dat)

### fit multilevel meta-analysis model
res <- rma.mv(yi, vi, random = ~ 1 | study/obs, data=dat)
res

### estimated average odds ratio (with 95% CI/PI)
predict(res, transf=exp, digits=2)
```

```
### test for a difference between fellowship and grant applications
res <- rma.mv(yi, vi, mods = ~ type, random = ~ 1 | study/obs, data=dat)
res
predict(res, newmods=0:1, transf=exp, digits=2)

## End(Not run)
```

`dat.bourassa1996` *Studies on the Association between Handedness and Eye-Dominance*

Description

Results from 47 studies on the association between handedness and eye-dominance.

Usage

```
dat.bourassa1996
```

Format

The data frame contains the following columns:

study	`numeric`	study number
sample	`numeric`	sample number
author	`character`	(first) author
year	`numeric`	publication year
selection	`character`	selection of subjects on the basis of eyedness or handedness
investigator	`character`	investigator (psychologist, educationalist, or other)
hand_assess	`character`	method to assess handedness (questionnaire or performance based)
eye_assess	`character`	method to assess eyedness (see 'Details')
mage	`numeric`	mean age of sample
lh.le	`numeric`	number of left-handed left-eyed individuals
lh.re	`numeric`	number of left-handed right-eyed individuals
rh.le	`numeric`	number of right-handed left-eyed individuals
rh.re	`numeric`	number of right-handed right-eyed individuals
sex	`character`	sex of the sample (combined, male, or female)

Details

The 47 studies included in this meta-analysis examined the association between handedness and eye-dominance (ocular dominance or eyedness). Results are given in terms of 2×2 tables, indicating the number of left-handed left-eyed, left-handed right-eyed, right-handed left-eyed, and right-handed right-eyed individuals in each sample. Note that some studies included multiple (independent) samples, so that the meta-analysis included 54 samples in total. Also, for some studies, the combined data of the males and females are further broken down into the two subgroups.

In some studies, there was indication that the selection of subjects was not random with respect to handedness and/or eyedness. While this should not influence the size of the association as measured

with the odds ratio, this invalidates those studies for assessing the overall percentage of left-eyed and left-handed individuals.

Handedness was assessed in the individual studies either based on a questionnaire or based on task performance. Eyedness was assessed based on various methods: `E.1` methods are based on task performance, while `E.2.a` denotes assessment based on a questionnaire. The performance based methods could be further broken down into: `E.1.a.i` (monocular procedure with object/instrument held in one hand), `E.1.a.ii` (monocular procedure with object/instrument held in both hands), `E.1.b` (binocular procedure), `E.1.c` (a combination of the previous methods), and `E.1.d` (some other method).

Concepts

psychology, odds ratios, multilevel models

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Bourassa, D. C., McManus, I. C., & Bryden, M. P. (1996). Handedness and eye-dominance: A meta-analysis of their relationship. *Laterality*, **1**(1), 5–34. https://doi.org/10.1080/713754206

Examples

```
### copy data into 'dat' and examine data
dat <- dat.bourassa1996
head(dat, 10)

## Not run:
### load metafor package
library(metafor)

### calculate log(OR) and corresponding sampling variance with 1/2 correction
dat <- escalc(measure="OR", ai=lh.le, bi=lh.re, ci=rh.le, di=rh.re, data=dat, add=1/2, to="all")
head(dat, 10)

### overall association between handedness and eyedness
res <- rma(yi, vi, data=dat, subset=sex=="combined")
res
predict(res, transf=exp, digits=2)

### multilevel model to account for heterogeneity at the study and sample levels
res <- rma.mv(yi, vi, random = ~ 1 | study/sample, data=dat, subset=sex=="combined")
res
predict(res, transf=exp, digits=2)

### restructure the dataset to keep only the male/female data when it is reported
### separately and the combined data when this is the only data reported
dat <- lapply(split(dat, dat$sample), function(x) {
   if (nrow(x) == 3L) {
```

```
      x[-which(x$sex == "combined"),]
   } else {
      x
   }
})
dat <- do.call(rbind, dat)
rownames(dat) <- NULL
dat

### multilevel model to account for heterogeneity at the study, sample, and subgroup levels
res <- rma.mv(yi, vi, random = ~ 1 | study/sample/sex, data=dat)
res
predict(res, transf=exp, digits=2)

## End(Not run)
```

`dat.cannon2006` *Studies on the Effectiveness of Intensive Versus Moderate Statin Therapy for Preventing Coronary Death or Myocardial Infarction*

Description

Results from 4 trials examining the effectiveness of intensive (high dose) versus moderate (standard dose) statin therapy for preventing coronary death or myocardial infarction.

Usage

```
dat.cannon2006
```

Format

The data frame contains the following columns:

trial	`character`	trial name
pop	`character`	study population (post-ACS: post acute coronary syndrome; stable CAD: stable coronary artery disease)
nt	`numeric`	number of patients in the high dose group
nc	`numeric`	number of patients in the standard dose group
ep1t	`numeric`	number of events in the high dose group for end point 1: coronary death or non-fatal myocardial infarcti
ep1c	`numeric`	number of events in the standard dose group for end point 1: coronary death or non-fatal myocardial infa
ep2t	`numeric`	number of events in the high dose group for end point 2: coronary death or any cardiovascular event (MI
ep2c	`numeric`	number of events in the standard dose group for end point 2: coronary death or any cardiovascular event
ep3t	`numeric`	number of events in the high dose group for end point 3: cardiovascular death
ep3c	`numeric`	number of events in the standard dose group for end point 3: cardiovascular death
ep4t	`numeric`	number of events in the high dose group for end point 4: non-cardiovascular death
ep4c	`numeric`	number of events in the standard dose group for end point 4: non-cardiovascular death
ep5t	`numeric`	number of events in the high dose group for end point 5: deaths (all-cause mortality)
ep5c	`numeric`	number of events in the standard dose group for end point 5: deaths (all-cause mortality)
ep6t	`numeric`	number of events in the high dose group for end point 6: stroke

ep6c numeric number of events in the standard dose group for end point 6: stroke

Details

The data were obtained from Figures 2, 3, 4, and 5 in Cannon et al. (2006). The authors used the Mantel-Haenszel method for combining the results from the 4 trials. This approach is implemented in the rma.mh function.

Concepts

medicine, cardiology, odds ratios, Mantel-Haenszel method

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Cannon, C. P., Steinberg, B. A., Murphy, S. A., Mega, J. L., & Braunwald, E. (2006). Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. *Journal of the American College of Cardiology*, **48**(3), 438–445. https://doi.org/10.1016/j.jacc.2006.04.070

Examples

```
### copy data into 'dat' and examine data
dat <- dat.cannon2006
dat

## Not run:
### load metafor package
library(metafor)

### meta-analysis of log odds ratios using the MH method for endpoint 1
res <- rma.mh(measure="OR", ai=ep1t, n1i=nt, ci=ep1c, n2i=nc, data=dat, slab=trial)
print(res, digits=2)

### forest plot
forest(res, xlim=c(-.8,0.8), atransf=exp, at=log(c(2/3, 1, 3/2)),
       cex=1.2, xlab="Odds Ratio")
mtext("(high dose better)", side=1, line=par("mgp")[1]-0.5, at=log(2/3), cex=1.2, font=3)
mtext("(standard dose better)", side=1, line=par("mgp")[1]-0.5, at=log(3/2), cex=1.2, font=3)

## End(Not run)
```

dat.chiarito2020 *Studies Investigating the Efficacy of P2Y12-Inhibitors in Atherosclerosis*

Description

Data on baseline parameters, efficacy endpoints and risk-of-bias from nine studies.

Usage

```
dat.chiarito2020
```

Format

The data frame contains the following columns:

study	character	study identifier
year	numeric	publication year
p2y12	character	type of P2Y12 inhibitor
duration.months	numeric	study duration
p2y12.daily.dosage	character	daily dosage of P2Y12 inhibitor
aspirin.daily.dosage	character	daily dosage of aspirin
p2y12.daily.mg	numeric	daily dose of P2Y12 inhibitor (mg)
aspirin.daily.mg	numeric	daily dose of aspirin (mg)
baseline.age	numeric	mean age at baseline
baseline.males	numeric	proportion of males in study population
baseline.diabetes	numeric	proportion of diabetic patients in study population
baseline.hypertension	numeric	proportion of patients with hypertension in study population
baseline.dyslipidaemia	numeric	proportion of patients with dyslipidaemia in study population
p2y12.mi	numeric	number of patients with myocardial infarction in experimental group
p2y12.stroke	numeric	number of patients with stroke in experimental group
p2y12.death	numeric	number of deaths in experimental group
p2y12.vdeath	numeric	number of vascular deaths in experimental group
p2y12.total	numeric	total number of patients experimental group
aspirin.mi	numeric	number of patients with myocardial infarction in control group
aspirin.stroke	numeric	number of patients with stroke in control group
aspirin.death	numeric	number of deaths in control group
aspirin.vdeath	numeric	number of vascular deaths in control group
aspirin.total	numeric	total number of patients in control group
rob.R	factor	risk of bias arising from the randomization process (R)
rob.D	factor	risk of bias due to deviations from intended interventions (D)
rob.Mi	factor	risk of bias due to missing outcome data (Mi)
rob.Me	factor	risk of bias in measurement of the outcome (Me)
rob.S	factor	risk of bias in selection of the reported result (S)
rob.overall	factor	overall risk of bias

Details

Chiarito et al. (2020) reviewed studies investigating the efficacy of P2Y12-inhibitors (compared to aspirin) for the secondary prevention of myocardial infarction in patients with established atherosclerosis.

A diagnosis of atherosclerosis, the development of lesions in arteries, is a risk factor for myocardial infarction or stroke, and a range of therapies (including aspirin, other drugs, or surgery) are available. P2Y12-inhibitors are antiplatelet drugs and as such might serve as an alternative to the commonly used aspirin; it was of interest to review and summarize the current scientific evidence on the efficacy of this type of drug in comparison to aspirin. To this end, Chiarito et al. (2020) performed a systematic review and meta-analysis; the systematic review had been pre-registered (PROSPERO CRD42018115037), and the investigation included a risk-of-bias assessment of the nine studies included. Co-primary endpoints were myocardial infarction and stroke, secondary endpoints were death and vascular death.

Concepts

medicine, cardiology, odds ratios, risk-of-bias

Author(s)

Christian Röver, <christian.roever@med.uni-goettingen.de>

Source

Chiarito, M., Sanz-Sánchez, J., Cannata, F., Cao, D., Sturla, M., Panico, C., Godino, C., Regazzoli, D., Reimers, B., De Caterina, R., Condorelli, G., Ferrante, G., & Stefanini, G. G. (2020). Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: A systematic review and meta-analysis. *The Lancet*, **395**(10235), 1487–1495. https://doi.org/10.1016/s0140-6736(20)30315-9

References

Zapf, A., Röver, C. (2023). Metaanalyse. In J. Gertheiss, M. Schmid, & M. Spindler (Eds.), *Moderne Verfahren der Angewandten Statistik*. Berlin, Germany: Springer Spektrum. https://doi.org/10.1007/978-3-662-6

Examples

```
dat.chiarito2020

## Not run:
library(metafor)
library(meta)
library(bayesmeta)

# show plain data on stroke
dat.chiarito2020[-5, c("study","p2y12.stroke","p2y12.total","aspirin.stroke","aspirin.total")]

# show event rates in both treatment groups
cbind.data.frame("study"   = dat.chiarito2020$study,
                 "p2y12"   = dat.chiarito2020$p2y12.stroke / dat.chiarito2020$p2y12.total,
```

```
            "aspirin" = dat.chiarito2020$aspirin.stroke / dat.chiarito2020$aspirin.total)

# compute effect measures (log-ORs)
# (using the "escalc()" function from the "metafor" package)
es.stroke <- escalc(measure="OR",
                    ai=p2y12.stroke,   n1i=p2y12.total,
                    ci=aspirin.stroke, n2i=aspirin.total,
                    slab=study, subset=is.finite(p2y12.stroke),
                    data=dat.chiarito2020)

# show effect measures (log-ORs)
summary(es.stroke)

# show effect measures (ORs und 95 percent CI)
cbind("study" = es.stroke$study,
      exp(summary(es.stroke)[,c("yi","ci.lb","ci.ub")]))

# show data in a forest plot
forestplot(es.stroke, xlab="log-OR")
forestplot(es.stroke, expo=TRUE, xlog=TRUE, xlab="odds ratio (OR)")

############################################################
#  meta-analysis (frequentist, "metafor" package)

# using default settings (random-effects model, REML-estimator)
rma.uni(es.stroke)

# analysis using Paule-Mandel estimator and HKSJ intervals
rma01 <- rma.uni(es.stroke, method="PM", test="knha")

# show results
rma01

# illustrate in a forest plot
forest(rma01)
forest(rma01, atransf=exp)

############################################################
#  meta-analysis (frequentist, "meta" package)

# analogous analysis to above, using the "meta" package
meta01 <- metabin(event.e=p2y12.stroke,   n.e=p2y12.total,
                  event.c=aspirin.stroke, n.c=aspirin.total,
                  studlab=study, data=dat.chiarito2020,
                  subset=is.finite(p2y12.stroke),
                  sm="OR",
                  method.tau="PM",
                  method.random.ci="HK", method="Inverse")

meta01
summary(meta01)
forest(meta01)
```

```
############################################################
#  meta-analysis (Bayesian, "bayesmeta" package)

# analysis using default settings (uniform prior for mu und tau)
bma01 <- bayesmeta(es.stroke)

# show results
bma01

# show forest plots (for log-OR and OR)
forestplot(bma01, xlab="log-OR")
forestplot(bma01, exponentiate=TRUE, xlog=TRUE, xlab="OR")

## End(Not run)
```

`dat.cohen1981` *Studies on the Relationship between Course Instructor Ratings and Student Achievement*

Description

Results from 20 studies on the correlation between course instructor ratings and student achievement.

Usage

```
dat.cohen1981
```

Format

The data frame contains the following columns:

study	`character`	study author(s) and year
sample	`character`	course type
control	`character`	ability control
ni	`numeric`	sample size of the study (number of sections)
ri	`numeric`	observed correlation

Details

The studies included in this dataset examined to what extent students' ratings of a course instructor correlated with their achievement in the course. Instead of correlating individual ratings and achievement scores, the studies were carried out in multisection courses, in which the sections had different instructors but all sections used a common achievement measure (e.g., a final exam). The correlation coefficients reflect the correlation between the mean instructor rating and the mean achievement score of each section. Hence, the unit of analysis are the sections, not the individuals.

Note that this dataset (extracted from Table A.3 in Cooper & Hedges, 1994) only contains studies with at least 10 sections.

Concepts

education, correlation coefficients

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Cooper, H., & Hedges, L. V. (1994). Appendix A: Data Sets. In H. Cooper & L. V. Hedges (Eds.), *The handbook of research synthesis* (pp. 543–547). New York: Russell Sage Foundation.

References

Cohen, P. A. (1981). Student ratings of instruction and student achievement: A meta-analysis of multisection validity studies. *Review of Educational Research*, **51**(3), 281–309. https://doi.org/10.3102/003465430510

Examples

```
### copy data into 'dat' and examine data
dat <- dat.cohen1981
dat[c(1,4,5)]

## Not run:
### load metafor package
library(metafor)

### calculate r-to-z transformed correlations and corresponding sampling variances
dat <- escalc(measure="ZCOR", ri=ri, ni=ni, data=dat[c(1,4,5)])
dat

### meta-analysis of the transformed correlations using a random-effects model
res <- rma(yi, vi, data=dat, digits=2)
res

### predicted average correlation with 95% CI
predict(res, transf=transf.ztor)

## End(Not run)
```

---

dat.colditz1994 *Studies on the Effectiveness of the BCG Vaccine Against Tuberculosis*

Description

Results from 13 studies examining the effectiveness of the Bacillus Calmette-Guerin (BCG) vaccine against tuberculosis.

Usage

```
dat.colditz1994
```

Format

The data frame contains the following columns:

trial	numeric	trial number
author	character	author(s)
year	numeric	publication year
tpos	numeric	number of TB positive cases in the treated (vaccinated) group
tneg	numeric	number of TB negative cases in the treated (vaccinated) group
cpos	numeric	number of TB positive cases in the control (non-vaccinated) group
cneg	numeric	number of TB negative cases in the control (non-vaccinated) group
ablat	numeric	absolute latitude of the study location (in degrees)
alloc	character	method of treatment allocation (random, alternate, or systematic assignment)

Details

The 13 studies provide data in terms of 2×2 tables in the form:

	TB positive	TB negative
vaccinated group	tpos	tneg
control group	cpos	cneg

The goal of the meta-analysis was to examine the overall effectiveness of the BCG vaccine for preventing tuberculosis and to examine moderators that may potentially influence the size of the effect.

The dataset has been used in several publications to illustrate meta-analytic methods (see 'References').

Concepts

medicine, risk ratios, meta-regression

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Colditz, G. A., Brewer, T. F., Berkey, C. S., Wilson, M. E., Burdick, E., Fineberg, H. V., & Mosteller, F. (1994). Efficacy of BCG vaccine in the prevention of tuberculosis: Meta-analysis of the published literature. *Journal of the American Medical Association*, **271**(9), 698–702. https://doi.org/10.1001/jama.1994.035103

References

Berkey, C. S., Hoaglin, D. C., Mosteller, F., & Colditz, G. A. (1995). A random-effects regression model for meta-analysis. *Statistics in Medicine*, **14**(4), 395–411. https://doi.org/10.1002/sim.4780140406

van Houwelingen, H. C., Arends, L. R., & Stijnen, T. (2002). Advanced methods in meta-analysis: Multivariate approach and meta-regression. *Statistics in Medicine*, **21**(4), 589–624. https://doi.org/10.1002/sim.1040

Viechtbauer, W. (2010). Conducting meta-analyses in R with the metafor package. *Journal of Statistical Software*, **36**(3), 1–48. https://doi.org/10.18637/jss.v036.i03

Examples

```
### copy data into 'dat' and examine data
dat <- dat.colditz1994
dat

## Not run:
### load metafor package
library(metafor)

### calculate log risk ratios and corresponding sampling variances
dat <- escalc(measure="RR", ai=tpos, bi=tneg,
                            ci=cpos, di=cneg, data=dat,
                            slab=paste0(author, ", ", year))
dat

### random-effects model
res <- rma(yi, vi, data=dat)
res

### average risk ratio with 95% CI
predict(res, transf=exp)

### mixed-effects model with absolute latitude and publication year as moderators
res <- rma(yi, vi, mods = ~ ablat + year, data=dat)
res

### predicted average risk ratios for 10-60 degrees absolute latitude
### holding the publication year constant at 1970
predict(res, newmods=cbind(seq(from=10, to=60, by=10), 1970), transf=exp)

### note: the interpretation of the results is difficult because absolute
### latitude and publication year are strongly correlated (the more recent
### studies were conducted closer to the equator)
plot(ablat ~ year, data=dat, pch=19, xlab="Publication Year", ylab="Absolute Lattitude")
cor(dat$ablat, dat$year)

## End(Not run)
```

`dat.collins1985a` *Studies on the Treatment of Upper Gastrointestinal Bleeding by a Histamine H2 Antagonist*

Description

Results from studies examining the effectiveness of histamine H2 antagonists (cimetidine or ranitidine) in treating patients with acute upper gastrointestinal hemorrhage.

Usage

```
dat.collins1985a
```

Format

The data frame contains the following columns:

id	`numeric`	study number
trial	`character`	first author of trial
year	`numeric`	year of publication
ref	`numeric`	reference number
trt	`character`	C = cimetidine, R = ranitidine
ctrl	`character`	P = placebo, AA = antacids, UT = usual treatment
nti	`numeric`	number of patients in treatment group
b.xti	`numeric`	number of patients in treatment group with persistent or recurrent bleedings
o.xti	`numeric`	number of patients in treatment group in need of operation
d.xti	`numeric`	number of patients in treatment group that died
nci	`numeric`	number of patients in control group
b.xci	`numeric`	number of patients in control group with persistent or recurrent bleedings
o.xci	`numeric`	number of patients in control group in need of operation
d.xci	`numeric`	number of patients in control group that died

Details

The data were obtained from Tables 1 and 2 in Collins and Langman (1985). The authors used Peto's (one-step) method for meta-analyzing the 27 trials. This approach is implemented in the `rma.peto` function. Using the same dataset, van Houwelingen, Zwinderman, and Stijnen (1993) describe some alternative approaches for analyzing these data, including fixed- and random-effects conditional logistic models. Those are implemented in the `rma.glmm` function.

Concepts

medicine, odds ratios, Peto's method, generalized linear models

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Collins, R., & Langman, M. (1985). Treatment with histamine H2 antagonists in acute upper gastrointestinal hemorrhage. *New England Journal of Medicine*, **313**(11), 660–666. https://doi.org/10.1056/NEJM1985091

References

van Houwelingen, H. C., Zwinderman, K. H., & Stijnen, T. (1993). A bivariate approach to meta-analysis. *Statistics in Medicine*, **12**(24), 2273–2284. https://doi.org/10.1002/sim.4780122405

Examples

```
### copy data into 'dat' and examine data
dat <- dat.collins1985a
dat

## Not run:
### load metafor package
library(metafor)

### meta-analysis of log ORs using Peto's method (outcome: persistent or recurrent bleedings)
res <- rma.peto(ai=b.xti, n1i=nti, ci=b.xci, n2i=nci, data=dat)
print(res, digits=2)

### meta-analysis of log ORs using a conditional logistic regression model (FE model)
res <- rma.glmm(measure="OR", ai=b.xti, n1i=nti, ci=b.xci, n2i=nci, data=dat,
                model="CM.EL", method="FE")
summary(res)
predict(res, transf=exp, digits=2)

### plot the likelihoods of the odds ratios
llplot(measure="OR", ai=b.xti, n1i=nti, ci=b.xci, n2i=nci, data=dat,
       lwd=1, refline=NA, xlim=c(-4,4), drop00=FALSE)

### meta-analysis of log odds ratios using a conditional logistic regression model (RE model)
res <- rma.glmm(measure="OR", ai=b.xti, n1i=nti, ci=b.xci, n2i=nci, data=dat,
                model="CM.EL", method="ML")
summary(res)
predict(res, transf=exp, digits=2)

### meta-analysis of log ORs using Peto's method (outcome: need for surgery)
res <- rma.peto(ai=o.xti, n1i=nti, ci=o.xci, n2i=nci, data=dat)
print(res, digits=2)

### meta-analysis of log ORs using Peto's method (outcome: death)
res <- rma.peto(ai=d.xti, n1i=nti, ci=d.xci, n2i=nci, data=dat)
print(res, digits=2)

## End(Not run)
```

`dat.collins1985b` *Studies on the Effects of Diuretics in Pregnancy*

Description

Results from 9 studies examining the effects of diuretics in pregnancy on various outcomes.

Usage

```
dat.collins1985b
```

Format

The data frame contains the following columns:

id	`numeric`	study number
author	`character`	study author(s)
year	`numeric`	publication year
pre.nti	`numeric`	number of women in treatment group followed up for pre-eclampsia outcome
pre.nci	`numeric`	number of women in control/placebo group followed up for pre-eclampsia outcome
pre.xti	`numeric`	number of women in treatment group with any form of pre-eclampsia
pre.xci	`numeric`	number of women in control/placebo group with any form of pre-eclampsia
oedema	`numeric`	dummy variable indicating whether oedema was a diagnostic criterion
fup.nti	`numeric`	number of women in treatment group followed up for mortality outcomes
fup.nci	`numeric`	number of women in control/placebo group followed up for mortality outcomes
ped.xti	`numeric`	number of perinatal deaths in treatment group
ped.xci	`numeric`	number of perinatal deaths in control/placebo group
stb.xti	`numeric`	number of stillbirths in treatment group
stb.xci	`numeric`	number of stillbirths in control/placebo group
ned.xti	`numeric`	number of neonatal deaths in treatment group
ned.xci	`numeric`	number of neonatal deaths in control/placebo group

Details

The 9 studies in this dataset examined the effects of diuretics in pregnancy on various outcomes, including the presence of any form of pre-eclampsia, perinatal death, stillbirth, and neonatal death.

Concepts

medicine, obstetrics, odds ratios, Peto's method

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Collins, R., Yusuf, S., & Peto, R. (1985). Overview of randomised trials of diuretics in pregnancy. *British Medical Journal*, **290**(6461), 17–23. https://doi.org/10.1136/bmj.290.6461.17

Examples

```
### copy data into 'dat' and examine data
dat <- dat.collins1985b
dat

## Not run:
### load metafor package
library(metafor)

### calculate (log) odds ratio and sampling variance
dat <- escalc(measure="OR", n1i=pre.nti, n2i=pre.nci, ai=pre.xti, ci=pre.xci, data=dat)
summary(dat, digits=2, transf=exp)

### meta-analysis using Peto's method for any form of pre-eclampsia
rma.peto(n1i=pre.nti, n2i=pre.nci, ai=pre.xti, ci=pre.xci, data=dat, digits=2)

### meta-analysis including only studies where oedema was not a diagnostic criterion
rma.peto(n1i=pre.nti, n2i=pre.nci, ai=pre.xti, ci=pre.xci, data=dat, digits=2, subset=(oedema==0))

### meta-analyses of mortality outcomes (perinatal deaths, stillbirths, and neonatal deaths)
rma.peto(n1i=fup.nti, n2i=fup.nci, ai=ped.xti, ci=ped.xci, data=dat, digits=2)
rma.peto(n1i=fup.nti, n2i=fup.nci, ai=stb.xti, ci=stb.xci, data=dat, digits=2)
rma.peto(n1i=fup.nti, n2i=fup.nci, ai=ned.xti, ci=ned.xci, data=dat, digits=2)

## End(Not run)
```

---

dat.craft2003 *Studies on the Relationship between the Competitive State Anxiety Inventory-2 and Sport Performance*

Description

Results from 10 studies on the relationship between the Competitive State Anxiety Inventory-2 (CSAI-2) and sport performance.

Usage

```
dat.craft2003
```

Format

The data frame contains the following columns:

study	numeric	study number
ni	numeric	sample size
sport	character	type of sport (T = team sport, I = individual sport)
ri	numeric	correlation coefficient
var1	character	variable 1 of the correlation coefficient (see 'Details')

var2 `character` variable 2 of the correlation coefficient (see 'Details')

Details

The 10 studies included in this dataset are a subset of the studies included in the meta-analysis by Craft et al. (2003) on the relationship between the Competitive State Anxiety Inventory-2 (CSAI-2) and sport performance.

The CSAI-2 has three subscales: cognitive anxiety (`acog`), somatic anxiety (`asom`), and self-confidence (`conf`). The studies included in this dataset administered the CSAI-2 prior to some sport competition and then measured sport performance based on the competition. Most studies provided all 6 correlations (3 for the correlations among the 3 subscales and 3 for the correlations between the subscales and sport performance), but 2 studies (with study numbers 6 and 17) only provided a subset.

Concepts

psychology, correlation coefficients, multivariate models

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Becker, B. J., & Aloe, A. M. (2019). Model-based meta-analysis and related approaches. In H. Cooper, L. V. Hedges, & J. C. Valentine (Eds.), *The handbook of research synthesis and meta-analysis* (3nd ed., pp. 339–363). New York: Russell Sage Foundation.

References

Craft, L. L., Magyar, T. M., Becker, B. J., & Feltz, D. L. (2003). The relationship between the Competitive State Anxiety Inventory-2 and sport performance: A meta-analysis. *Journal of Sport and Exercise Psychology*, **25**(1), 44–65. https://doi.org/10.1123/jsep.25.1.44

Examples

```
### copy data into 'dat' and examine data
dat <- dat.craft2003
head(dat, 18)

## Not run:
### load metafor package
library(metafor)

### construct dataset and var-cov matrix of the correlations
tmp <- rcalc(ri ~ var1 + var2 | study, ni=ni, data=dat)
V <- tmp$V
dat <- tmp$dat

### examine data for study 1
dat[dat$study == 1,]
```

```
V[dat$study == 1, dat$study == 1]

### examine data for study 6
dat[dat$study == 6,]
V[dat$study == 6, dat$study == 6]

### examine data for study 17
dat[dat$study == 17,]
V[dat$study == 17, dat$study == 17]

### multivariate random-effects model
res <- rma.mv(yi, V, mods = ~ 0 + var1.var2, random = ~ var1.var2 | study, struct="UN", data=dat)
res

## End(Not run)
```

`dat.crede2010` *Studies on the Relationship between Class Attendance and Grades in College Students*

Description

Results from 68 studies on the relationship between class attendence and class performance and/or grade point average in college students.

Usage

```
dat.crede2010
```

Format

The data frame contains the following columns:

studyid	`numeric`	study number
year	`numeric`	publication year
source	`character`	study source (journal, dissertation, other)
sampleid	`numeric`	sample within study number
criterion	`character`	criterion variable (grade, gpa)
class	`character`	class type (science, nonscience)
ni	`numeric`	sample size
ri	`numeric`	observed correlation

Details

The 68 studies included in this dataset provide information about the relationship between class attendance of college students and their performance (i.e., grade) in the class and/or their overall grade point average. Some studies included multiple samples and hence the dataset actually contains 97 correlation coefficients.

The dataset was obtained via personal communication. Note that this dataset differs just slightly from the one used by Credé et al. (2010).

Concepts

education, correlation coefficients, multilevel models

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Personal communication.

References

Credé, M., Roch, S. G., & Kieszczynka, U. M. (2010). Class attendance in college: A meta-analytic review of the relationship of class attendance with grades and student characteristics. *Review of Educational Research*, **80**(2), 272–295. https://doi.org/10.3102/0034654310362998

Examples

```
### copy data into 'dat' and examine data
dat <- dat.crede2010
head(dat, 18)

## Not run:
### load metafor package
library(metafor)

### calculate r-to-z transformed correlations and corresponding sampling variances
dat <- escalc(measure="ZCOR", ri=ri, ni=ni, data=dat)

############################################################################

### meta-analysis for the relationship between attendance and grades
res <- rma(yi, vi, data=dat, subset=criterion=="grade")
res

### estimated average correlation with 95% CI/PI
predict(res, transf=transf.ztor, digits=2)

### examine if relationship between attendance and grades differs for nonscience/science classes
res <- rma(yi, vi, mods = ~ class, data=dat, subset=criterion=="grade")
res

### estimated average correlations for nonscience and science classes
predict(res, newmods=c(0,1), transf=transf.ztor, digits=2)

### examine if relationship between attendance and grades has changed over time
res <- rma(yi, vi, mods = ~ year, data=dat, subset=criterion=="grade")
res

############################################################################
```

```
### meta-analysis for the relationship between attendance and GPA
res <- rma(yi, vi, data=dat, subset=criterion=="gpa")
res

### estimated average correlation with 95% CI/PI
predict(res, transf=transf.ztor, digits=2)

### examine if relationship between attendance and GPA has changed over time
res <- rma(yi, vi, mods = ~ year, data=dat, subset=criterion=="gpa")
res

################################################################################

### use a multilevel model to examine the relationship between attendance and grades
res <- rma.mv(yi, vi, random = ~ 1 | studyid/sampleid, data=dat, subset=criterion=="grade")
res
predict(res, transf=transf.ztor, digits=2)

### use a multilevel model to examine the relationship between attendance and gpa
res <- rma.mv(yi, vi, random = ~ 1 | studyid/sampleid, data=dat, subset=criterion=="gpa")
res
predict(res, transf=transf.ztor, digits=2)

## End(Not run)
```

`dat.crisafulli2020` *Duchenne Muscular Dystrophy (DMD) Prevalence Data*

Description

26 studies reporting estimates of the birth prevalence of Duchenne muscular dystrophy.

Usage

```
dat.crisafulli2020
```

Format

The data frame contains the following columns:

study	`character`	study label (first author, year)
pubyear	`integer`	publication year
country	`factor`	origin of investigated population
from, **to**	`integer`	time span of investigation (years)
cases	`integer`	number of DMD cases
total	`integer`	corresponding total population

Details

Duchenne muscular dystrophy (DMD) is a rare disease that is caused by a genetic mutation and is characterized by impairment through muscle weakness and a reduced life expectancy.

Crisafulli et al. (2020) reported on a systematic review of data on the epidemiology of DMD, including estimates of the *birth prevalence* (which is of the order of a few per ten thousand). One of the originally reported studies (Koenig, 2019) is omitted here, as it constitutes an obvious outlier, and the reliability of the reported data is doubtful; Crisafulli et al. (2020) pointed out that "*Concerning birth prevalence, Koenig et al. were found to be outliers. This study had problems with data collection in the last study year, as due to privacy issues, DMD cases were under-reported.*"

Concepts

medicine, epidemiology, proportions

Author(s)

Christian Röver, <christian.roever@med.uni-goettingen.de>

Source

Crisafulli, S., Sultana, J., Fontana, A., Salvo, F., Messina, S., & Trifiro, G. (2020). Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis. *Orphanet Journal of Rare Diseases*, **15**, 141. https://doi.org/10.1186/s13023-020-01430-8

Examples

```
# show (some) data
head(dat.crisafulli2020)

## Not run:
# compute logarithmic proportions and associated standard errors
library(metafor)
logp <- escalc(measure="PLN",
               xi=cases, ni=total, slab=study,
               data=dat.crisafulli2020)

# perform meta-analysis
rma01 <- rma.uni(logp)

# show results
rma01

# illustrate in a forest plot
forest(rma01, xlim=c(-12,-5))

## End(Not run)
```

dat.curtin2002 *Studies on Potassium Supplementation to Reduce Diastolic Blood Pressure*

Description

Results from 21 cross-over studies evaluating the effect of potassium supplementation to reduce diastolic blood pressure.

Usage

```
dat.curtin2002
```

Format

The data frame contains the following columns:

author	character	first author
year	character	year of publication
N	integer	total sample size
mean	numeric	mean difference in diastolic blood pressure
SE	numeric	standard error
corr	numeric	within-patient correlation

Details

Results from 21 cross-over studies evaluating the effect of potassium supplementation to reduce diastolic blood pressure (Curtin et al., 2002, Table II).

This data set is used as an example in Schwarzer et al. (2015), Chapter 2.

Concepts

raw mean differences

Author(s)

Guido Schwarzer, <guido.schwarzer@uniklinik-freiburg.de>, https://github.com/guido-s/

Source

Curtin, F., Altman, D. G., & Elbourne, D. (2002). Meta-analysis combining parallel and cross-over clinical trials. I: Continuous outcomes. *Statistics in Medicine*, **21**(15), 2131–2144. https://doi.org/10.1002/sim.1205

References

Schwarzer, G., Carpenter, J. R., & Rücker, G. (2015). *Meta-analysis with R*. Cham, Switzerland: Springer.

Examples

```
### Show first five studies
head(dat.curtin2002, 5)

## Not run:
### Load meta package
suppressPackageStartupMessages(library(meta))

### Use DerSimonian-Laird estimator (which was the default in meta in the year 2015).
### Furthermore, print meta-analysis results with two digits.
oldset <- settings.meta(method.tau = "DL", digits = 2)

### Conduct meta-analysis
mg2 <- metagen(mean, SE, studlab = paste(author, year),
               data = dat.curtin2002, sm = "MD")
mg2

### Use previous settings
settings.meta(oldset)

## End(Not run)
```

---

dat.curtis1998 *Studies on the Effects of Elevated CO2 Levels on Woody Plant Mass*

Description

Results from studies examining the effects of elevated CO2 levels on woody plant mass.

Usage

```
dat.curtis1998
```

Format

The data frame contains the following columns:

id	numeric	observation number
paper	numeric	paper number
genus	character	genus name
species	character	species name
fungrp	character	plant functional group
co2.ambi	numeric	ambient CO2 level (control group)
co2.elev	numeric	elevated CO2 level (treatment group)
units	character	units for CO2 exposure levels
time	numeric	maximum length of time (days) of CO2 exposure
pot	character	growing method (see 'Details')
method	character	CO2 exposure facility (see 'Details')

stock	character	planting stock code
xtrt	character	interacting treatment code (see 'Details')
level	character	interacting treatment level codes (see 'Details')
m1i	numeric	mean plant mass under elevated CO2 level (treatment group)
sd1i	numeric	standard deviation of plant mass underelevated CO2 level (treatment group)
n1i	numeric	number of observations under elevated CO2 level (treatment group)
m2i	numeric	mean plant mass under ambient CO2 level (control group)
sd2i	numeric	standard deviation of plant mass under ambient CO2 level (control group)
n2i	numeric	number of observations under ambient CO2 level (control group)

Details

The studies included in this dataset compared the total above- plus below-ground biomass (in grams) for plants that were either exposed to ambient (around 35 Pa) and elevated CO2 levels (around twice the ambient level). The `co2.ambi` and `co2.elev` variables indicate the CO2 levels in the control and treatment groups, respectively (with the `units` variable specifying the units for the CO2 exposure levels). Many of the studies also varied one or more additional environmental variables (defined by the `xtrt` and `level` variables):

- NONE = no additional treatment factor
- FERT = soil fertility (either a `CONTROL`, `HIGH`, or `LOW` level)
- LIGHT = light treatment (always a `LOW` light level)
- FERT+L = soil fertility and light (a `LOW` light and soil fertility level)
- H2O = well watered vs drought (either a `WW` or `DRT` level)
- TEMP = temperature treatment (either a `HIGH` or `LOW` level)
- OZONE = ozone exposure (either a `HIGH` or `LOW` level)
- UVB = ultraviolet-B radiation exposure (either a `HIGH` or `LOW` level)

In addition, the studies differed with respect to various design variables, including CO2 exposure duration (`time`), growing method (`pot`: number = pot size in liters; `GRND` = plants rooted in ground; `HYDRO` = solution or aeroponic culture), CO2 exposure facility (`method`: `GC` = growth chamber; `GH` = greenhouse; `OTC` = field-based open-top chamber), and planting stock (`stock`: `SEED` = plants started from seeds; `SAP` = plants started from cuttings). The goal of the meta-analysis was to examine the effects of elevated CO2 levels on plant physiology and growth and the interacting effects of the environmental (and design) variables.

Concepts

ecology, ratios of means

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Hedges, L. V., Gurevitch, J., & Curtis, P. S. (1999). The meta-analysis of response ratios in experimental ecology. *Ecology*, **80**(4), 1150–1156. https://doi.org/10.1890/0012-9658(1999)080[1150:TMAORR]2.0.CO;2 (data obtained from *Ecological Archives*, E080-008-S1, at: https://doi.org/10.6084/m9.figshare.c.3297278)

References

Curtis, P. S., & Wang, X. (1998). A meta-analysis of elevated CO2 effects on woody plant mass, form, and physiology. *Oecologia*, **113**(3), 299–313. https://doi.org/10.1007/s004420050381

Examples

```
### copy data into 'dat' and examine data
dat <- dat.curtis1998
head(dat)

## Not run:
### load metafor package
library(metafor)

### calculate (log transformed) ratios of means and corresponding sampling variances
dat <- escalc(measure="ROM", m1i=m1i, sd1i=sd1i, n1i=n1i,
                             m2i=m2i, sd2i=sd2i, n2i=n2i, data=dat)
head(dat)

### meta-analysis using a random-effects model
res <- rma(yi, vi, method="DL", data=dat)
res

### average ratio of means with 95% CI
predict(res, transf=exp, digits=2)

### meta-analysis for plants grown under nutrient stress
res <- rma(yi, vi, method="DL", data=dat, subset=(xtrt=="FERT" & level=="LOW"))
predict(res, transf=exp, digits=2)

### meta-analysis for plants grown under low light conditions
res <- rma(yi, vi, method="DL", data=dat, subset=(xtrt=="LIGHT" & level=="LOW"))
predict(res, transf=exp, digits=2)

## End(Not run)
```

---

dat.dagostino1998 *Studies on the Effectiveness of Antihistamines in Reducing Symptoms of the Common Cold*

Description

Results from 9 studies on the effectiveness of antihistamines in reducing the severity of runny nose and sneezing in the common cold.

Usage

```
dat.dagostino1998
```

Format

The data frame contains the following columns:

study	numeric	study id
cold	character	natural or induced cold study
scale.rn	character	scale for measuring runny nose severity
scale.sn	character	scale for measuring sneezing severity
drug	character	type of antihistamine studied
tnt	numeric	total sample size of the treatment group
tnc	numeric	total sample size of the control (placebo) group
outcome	character	outcome variable (see 'Details')
mt	numeric	mean in the treatment group
sdt	numeric	SD in the treatment group
mc	numeric	mean in the control group
sdc	numeric	SD in the control group
xt	numeric	number of patients reaching the therapy goal in the treatment group
xc	numeric	number of patients reaching the therapy goal in the control (placebo) group
nt	numeric	sample size of the treatment group for measuring the outcome
nc	numeric	sample size of the control group for measuring the outcome

Details

The studies for this meta-analysis were assembled to examine the effectiveness of antihistamines in reducing the severity of runny nose and sneezing in the common cold. Effectiveness was measured after one and two days of treatment in terms of 4 different outcome variables:

1. `rnic1` and `rnic2` (continuous): incremental change (improvement) in runny nose severity at day 1 and day 2,
2. `rngoal1` and `rngoal2` (dichotomous): reaching the goal of therapy (of at least a 50% reduction in runny nose severity) at day 1 and day 2,
3. `snic1` and `snic2` (continuous): incremental change (improvement) in sneezing severity at day 1 and day 2, and
4. `rngoal1` and `rngoal2` (dichotomous): reaching the goal of therapy (of at least a 50% reduction in sneezing severity) at day 1 and day 2.

For the continuous outcomes, standardized mean differences can be computed to quantify the difference between the treatment and control groups. For the dichotomous outcomes, one can compute (log) odds ratios to quantify the difference between the treatment and control groups.

Concepts

medicine, standardized mean differences, odds ratios, multivariate models

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

D'Agostino, R. B., Sr., Weintraub, M., Russell, H. K., Stepanians, M., D'Agostino, R. B., Jr., Cantilena, L. R., Jr., Graumlich, J. F., Maldonado, S., Honig, P., & Anello, C. (1998). The effectiveness of antihistamines in reducing the severity of runny nose and sneezing: A meta-analysis. *Clinical Pharmacology & Therapeutics*, **64**(6), 579–596. https://doi.org/10.1016/S0009-9236(98)90049-2

Examples

```
### copy data into 'dat' and examine data
dat <- dat.dagostino1998
head(dat, 16)

## Not run:
### load metafor package
library(metafor)

### compute standardized mean differences and corresponding sampling variances
dat <- escalc(measure="SMD", m1i=mt, m2i=mc, sd1i=sdt, sd2i=sdc, n1i=nt, n2i=nc, data=dat,
              add.measure=TRUE)

### compute log odds ratios and corresponding sampling variances
dat <- escalc(measure="OR",  ai=xt, ci=xc, n1i=nt, n2i=nc, data=dat,
              replace=FALSE, add.measure=TRUE, add=1/2, to="all")

### inspect data for the first study
head(dat, 8)

### fit a random-effects model for incremental change in runny nose severity at day 1
res <- rma(yi, vi, data=dat, subset=outcome=="rnic1")
res

### fit a random-effects model for reaching the goal of therapy for runny nose severity at day 1
res <- rma(yi, vi, data=dat, subset=outcome=="rngoal1")
res
predict(res, transf=exp)

### construct approximate V matrix assuming a correlation of 0.7 for sampling errors within studies
dat$esid <- ave(dat$study, dat$study, FUN=seq)
V <- vcalc(vi, cluster=study, obs=esid, rho=0.7, data=dat)

### fit a model for incremental change in runny nose severity at day 1 and at day 2, allowing for
### correlated sampling errors (no random effects added, since there does not appear to be any
### noteworthy heterogeneity in these data)
res <- rma.mv(yi, V, mods = ~ 0 + outcome, data=dat, subset=outcome %in% c("rnic1","rnic2"))
res

### test if there is a difference in effects at day 1 and day 2
anova(res, X=c(1,-1))

## End(Not run)
```

dat.damico2009 *Studies on Topical plus Systemic Antibiotics to Prevent Respiratory Tract Infections*

Description

Results from 16 studies examining the effectiveness of topical plus systemic antibiotics to prevent respiratory tract infections (RTIs).

Usage

```
dat.damico2009
```

Format

The data frame contains the following columns:

study	character	first author
year	numeric	publication year
xt	numeric	number of RTIs in the treatment group
nt	numeric	number of patients in the treatment group
xc	numeric	number of RTIs in the control group
nc	numeric	number of patients in the control group
conceal	numeric	allocation concealment (0 = not adequate, 1 = adequate)
blind	numeric	blinding (0 = open, 1 = double-blind)

Details

The dataset includes the results from 16 studies that examined the effectiveness of topical plus systemic antibiotics versus no prophylaxis to prevent respiratory tract infections (RTIs).

Concepts

medicine, pulmonology, odds ratios

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

D'Amico, R., Pifferi, S., Torri, V., Brazzi, L., Parmelli, E., & Liberati, A. (2009). Antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving intensive care. *Cochrane Database of Systematic Reviews*, **4**, CD000022. https://doi.org/10.1002/14651858.CD000022.pub3

Examples

```
### copy data into 'dat' and examine data
dat <- dat.damico2009
dat

## Not run:
### load metafor package
library(metafor)

### meta-analysis of the (log) odds ratios using the Mantel-Haenszel method
rma.mh(measure="OR", ai=xt, n1i=nt, ci=xc, n2i=nc, data=dat, digits=2)

### calculate log odds ratios and corresponding sampling variances
dat <- escalc(measure="OR", ai=xt, n1i=nt, ci=xc, n2i=nc, data=dat)

### meta-analysis using a random-effects model
res <- rma(yi, vi, data=dat, method="DL")
res
predict(res, transf=exp, digits=2)

## End(Not run)
```

---

dat.debruin2009 *Studies on Standard Care Quality and HAART-Adherence*

Description

Results from 13 trials providing information about standard care quality and HAART-adherence in control groups.

Usage

```
dat.debruin2009
```

Format

The data frame contains the following columns:

author	character	(first) author of study
year	numeric	publication year
scq	numeric	standard care quality
ni	numeric	number of patients in the standard care group
xi	numeric	number of patients with an undetectable viral load in standard care group
mi	numeric	number of patients with a detectable viral load in standard care group
ethnicity	character	dominant ethnicity of the patients in the standard care group
patients	character	inclusion of patients continuing or starting (a new) treatment
select	character	baseline selection of patients with adherence problems or no selection
sens	character	sensitivity of viral load assessments (<400 vs. >=400 copies/ml)

Details

Highly active antiretroviral therapy (HAART) refers to a combination of multiple antiretroviral drugs that can effectively suppress the HIV virus. However, achieving viral suppression (to the point that the virus becomes essentially undetectable in a blood sample) requires high levels of adherence to an often complicated medication regimen. A number of trials have examined various interventions that aim to increase adherence levels. In each trial, patients receiving the intervention are compared to patients in a control group receiving standard care (often referred to as 'care as usual'). However, the quality of standard care can vary substantially between these studies. de Bruin et al. (2009) assessed the quality of standard care provided (based on a quantification of the number of behavior change techniques applied) and examined to what extent the quality of standard care was related to the proportion of patients achieving effective viral suppression in the control groups.

Concepts

psychology, medicine, proportions, single-arm studies, meta-regression

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

de Bruin, M., Viechtbauer, W., Hospers, H. J., Schaalma, H. P., & Kok, G. (2009). Standard care quality determines treatment outcomes in control groups of HAART-adherence intervention studies: Implications for the interpretation and comparison of intervention effects. *Health Psychology*, **28**(6), 668–674. https://doi.org/10.1037/a0015989

Examples

```
### copy data into 'dat' and examine data
dat <- dat.debruin2009
dat

## Not run:
### load metafor package
library(metafor)

### calculate proportions and corresponding sampling variances
dat <- escalc(measure="PR", xi=xi, ni=ni, data=dat)
dat

### random-effects model
res <- rma(yi, vi, data=dat)
print(res, digits=2)

### mixed-effects meta-regression model with all predictors/covariates
res <- rma(yi, vi, mods = ~ scq + ethnicity + patients + select + sens, data=dat)
print(res, digits=3)

### mixed-effects meta-regression model with scq and ethnicity as predictors/covariates
```

```
res <- rma(yi, vi, mods = ~ scq + ethnicity, data=dat)
print(res, digits=3)

## End(Not run)
```

`dat.demir2022` *Studies on the Reliability of the MIBS Scale*

Description

Results from 26 studies on the reliability of the Mother-to-Infant Bonding Scale (MIBS).

Usage

```
dat.demir2022
```

Format

The data frame contains the following columns:

studyid	`numeric`	study ID
esid	`numeric`	effect size ID
author	`character`	author(s) of the study
year	`numeric`	publication year
pubtype	`character`	publication type (Article or Thesis)
country	`character`	country
participants	`character`	participant characteristics
n	`numeric`	sample size
alpha	`numeric`	Cronbach's alpha
items	`numeric`	number of items in the scale

Details

The Mother-to-Infant Bonding Scale (MIBS) is an 8-item Likert-type questionnaire to evaluate caregiver-infant attachment. Demir et al. (2022) carried out a meta-analysis of 26 studies (reporting 33 Cronbach's alpha values) to assess the reliability of the scale.

Concepts

psychology, Cronbach's alpha, reliability generalization

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Demir, E., Öz, S., Aral, N., & Gürsoy, F. (2022). A reliability generalization meta-analysis of the Mother-to-Infant Bonding Scale. *Psychological Reports*, **127**(1), 447–464. https://doi.org/10.1177/003329412211144

Examples

```
### copy data into 'dat' and examine data
dat <- dat.demir2022
dat

## Not run:
### load metafor package
library(metafor)

### transform the alpha values using the Bonett (2022) transformation
dat <- escalc(measure="ABT", ai=alpha, ni=n, mi=items, data=dat)
dat

### meta-analysis using a random-effects model
res <- rma(yi, vi, data=dat)
res

### back-transform the results
predict(res, transf=transf.iabt, digits=2)

## End(Not run)
```

---

dat.dogliotti2014 *Studies on Antithrombotic Treatments to Prevent Strokes*

Description

Results from 20 trials examining the effectiveness of antithrombotic treatments to prevent strokes in patients with non-valvular atrial fibrillation.

Usage

```
dat.dogliotti2014
```

Format

The data frame contains the following columns:

study	character	study label
id	numeric	study ID
treatment	character	treatment
stroke	numeric	number of strokes
total	numeric	number of individuals

Details

This dataset comes from a systematic review aiming to estimate the effects of eight antithrombotic treatments including placebo in reducing the incidence of major thrombotic events in patients with non-valvular atrial fibrillation (Dogliotti et al., 2014).

The review included 20 studies with 79,808 participants, four studies are three-arm studies. The primary outcome is stroke reduction (yes / no).

Concepts

medicine, odds ratios, network meta-analysis, Mantel-Haenszel method

Author(s)

Guido Schwarzer, <guido.schwarzer@uniklinik-freiburg.de>, https://github.com/guido-s/

Source

Dogliotti, A., Paolasso, E., & Giugliano, R. P. (2014). Current and new oral antithrombotics in non-valvular atrial fibrillation: A network meta-analysis of 79808 patients. *Heart*, **100**(5), 396–405. https://doi.org/10.1136/heartjnl-2013-304347

Examples

```
### Show first 7 rows / 3 studies of the dataset
head(dat.dogliotti2014, 7)

## Not run:
### Load netmeta package
suppressPackageStartupMessages(library(netmeta))

### Print odds ratios and confidence limits with two digits
oldset <- settings.meta(digits = 2)

### Change appearance of confidence intervals
cilayout("(", "-")

### Transform data from long arm-based format to contrast-based
### format. Argument 'sm' has to be used for odds ratio as summary
### measure; by default the risk ratio is used in the metabin function
### called internally.
pw <- pairwise(treat = treatment, n = total, event = stroke,
  studlab = study, data = dat.dogliotti2014, sm = "OR")

### Print log odds ratios (TE) and standard errors (seTE)
head(pw, 5)[, 1:5]

### Conduct network meta-analysis (NMA) with placebo as reference
net <- netmeta(pw, ref = "plac")

### Details on excluded study
selvars <- c("studlab", "event1", "n1", "event2", "n2")
```

```
subset(pw, studlab == "WASPO, 2007")[, selvars]

### Show network graph
netgraph(net, seq = "optimal", number = TRUE)

### Conduct Mantel-Haenszel NMA
net.mh <- netmetabin(pw, ref = "plac")

### Compare results of inverse variance and Mantel-Haenszel NMA
nb <- netbind(net, net.mh, random = FALSE,
  name = c("Inverse variance", "Mantel-Haenszel"))
forest(nb, xlim = c(0.15, 2), at = c(0.2, 0.5, 1, 2))

### Print and plot results for inverse variance NMA
net
forest(net)

### Use previous settings
settings.meta(oldset)

## End(Not run)
```

`dat.dong2013` *Studies on Safety of Inhaled Medications for Chronic Obstructive Pulmonary Disease*

Description

Results from 41 trials examining the safety of inhaled medications in patients with chronic obstructive pulmonary disease.

Usage

```
dat.dong2013
```

Format

The data frame contains the following columns:

id	`integer`	study ID
treatment	`character`	treatment
death	`integer`	mortality
randomized	`integer`	number of individuals

Details

This network meta-analysis compared the safety of inhaled medications in patients with chronic obstructive pulmonary disease (Dong et al., 2013).

Mortality was reported in 41 randomized trials, with a total of 52 462 patients. Mortality was low, with 2 408 deaths (4.6%) reported across all studies. There were nine studies that reported zero events in at least one of the treatment arms and three additional studies had zero events in all treatment arms.

This dataset was used in Efthimiou et al. (2019) to illustrate the Mantel-Haenszel method for network meta-analysis.

Concepts

medicine, odds ratios, network meta-analysis, Mantel-Haenszel method

Author(s)

Guido Schwarzer, <guido.schwarzer@uniklinik-freiburg.de>, https://github.com/guido-s/

Source

Dong, Y.-H., Lin, H.-H., Shau, W.-Y., Wu, Y.-C., Chang, C.-H., & Lai, M.-S. (2013). Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: Systematic review and mixed treatment comparison meta-analysis of randomised controlled trials. *Thorax*, **68**(1), 48–56. https://doi.org/10.1136/thoraxjnl-2012-201926

References

Efthimiou, O., Rücker, G., Schwarzer, G., Higgins, J., Egger, M., & Salanti, G. (2019). A Mantel-Haenszel model for network meta-analysis of rare events. *Statistics in Medicine*, **38**(16), 2992–3012. https://doi.org/10.1002/sim.8158

Examples

```
### Show first 6 rows / 3 studies of the dataset
head(dat.dong2013)

## Not run:
### Load netmeta package
suppressPackageStartupMessages(library(netmeta))

### Print odds ratios and confidence limits with two digits
oldset <- settings.meta(digits = 2)

### Change appearance of confidence intervals
cilayout("(", "-")

### Transform data from long arm-based format to contrast-based
### format. Argument 'sm' has to be used for odds ratio as summary
### measure; by default the risk ratio is used in the metabin function
### called internally.
pw <- pairwise(treatment, death, randomized, studlab = id,
  data = dat.dong2013, sm = "OR")

### Calculated log odds ratios (TE) and standard errors (seTE)
```

```
pw[1:3, 1:9]

### Conduct Mantel-Haenszel network meta-analysis (NMA)
net <- netmetabin(pw, ref = "plac")

### Network graph
netgraph(net, seq = "optimal", col = "black", plastic = FALSE,
  points = TRUE, pch = 21, cex.points = 3, col.points = "black",
  bg.points = "gray", thickness = "se.fixed",
  number.of.studies = TRUE)

### Show results for Mantel-Haenszel NMA
net
forest(net)

### League table with network estimates in lower triangle and direct
### estimates in upper triangle
netleague(net)

### Assess inconsistency
print(netsplit(net), show = "both", ci = TRUE, overall = FALSE,
  nchar.trts = 6)

### Use previous settings
settings.meta(oldset)

## End(Not run)
```

`dat.dorn2007` *Studies on Complementary and Alternative Medicine for Irritable Bowel Syndrome*

Description

Results from 19 trials examining complementary and alternative medicine (CAM) for irritable bowel syndrome (IBS).

Usage

```
dat.dorn2007
```

Format

The data frame contains the following columns:

id	`numeric`	trial id number
study	`character`	(first) author
year	`numeric`	publication year
country	`character`	country where trial was conducted

ibs.crit	`character`	IBS diagnostic criteria (Manning, Rome I, Rome II, or Other)
days	`numeric`	number of treatment days
visits	`numeric`	number of practitioner visits
jada	`numeric`	Jadad score
x.a	`numeric`	number of responders in the active treatment group
n.a	`numeric`	number of participants in the active treatment group
x.p	`numeric`	number of responders in the placebo group
n.p	`numeric`	number of participants in the placebo group

Details

The dataset includes the results from 19 randomized clinical trials that examined the effectiveness of complementary and alternative medicine (CAM) for irritable bowel syndrome (IBS).

Concepts

medicine, alternative medicine, risk ratios

Note

The data were extracted from Table I in Dorn et al. (2009). Comparing the funnel plot in Figure 1 with the one obtained below indicates that the data for study 5 (Davis et al., 2006) in the table were not the ones that were used in the actual analyses.

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Dorn, S. D., Kaptchuk, T. J., Park, J. B., Nguyen, L. T., Canenguez, K., Nam, B. H., Woods, K. B., Conboy, L. A., Stason, W. B., & Lembo, A. J. (2007). A meta-analysis of the placebo response in complementary and alternative medicine trials of irritable bowel syndrome. *Neurogastroenterology & Motility*, **19**(8), 630–637. https://doi.org/10.1111/j.1365-2982.2007.00937.x

Examples

```
### copy data into 'dat' and examine data
dat <- dat.dorn2007
dat

## Not run:
### load metafor package
library(metafor)

### calculate log risk ratios and corresponding sampling variances
dat <- escalc(measure="RR", ai=x.a, n1i=n.a, ci=x.p, n2i=n.p, data=dat)

### random-effects model
res <- rma(yi, vi, data=dat, digits=2, method="DL")
res
```

```
### estimated average risk ratio
predict(res, transf=exp)

### funnel plot with study 5 highlighted in red
funnel(res, atransf=exp, at=log(c(0.1, 0.2, 0.5, 1, 2, 5, 10)),
       ylim=c(0,1), steps=6, las=1, col=ifelse(id == 5, "red", "black"))

### change log risk ratio for study 5
dat$yi[5] <- -0.44

### results are now more in line with what is reported in the paper
### (although the CI in the paper is not wide enough)
res <- rma(yi, vi, data=dat, digits=2, method="DL")
predict(res, transf=exp)

### funnel plot with study 5 highlighted in red
funnel(res, atransf=exp, at=log(c(0.1, 0.2, 0.5, 1, 2, 5, 10)),
       ylim=c(0,1), steps=6, las=1, col=ifelse(id == 5, "red", "black"))

## End(Not run)
```

`dat.dumouchel1994` *Nitrogen dioxide data set*

Description

Nine studies investigating the effect of NO2 exposure on respiratory illness in children.

Usage

```
dat.dumouchel1994
```

Format

The data frame contains the following columns:

study	`character`	study label
smoke	`factor`	adjustment for smoking (y/n)
no2	`factor`	direct measurement of NO2 concentration (y/n)
gender	`factor`	adjustment for gender (y/n)
or	`numeric`	odds ratio for childhood respiratory illness
lower	`numeric`	lower bound of 95 percent CI
upper	`numeric`	upper bound of 95 percent CI

Details

Hasselblad et al. (1992) investigated the effects of nitrogen dioxide (NO2) exposure on the occurrence of respiratory illness in children. Their data were picked up by DuMouchel (1994) as an illustrative example in his article on Bayesian meta-analysis, and were also part of his "hblm" S-Plus software package. DuMouchel's dataset differs slightly from the figures quoted by Hasselblad et al. (1992), apparently because he had additional, more detailed data available.

The data set features three study-level covariables reflecting characteristics of the study designs, namely, whether the quoted estimate had been adjusted for parents' smoking status, whether NO2 exposure had been measured directly (or presence of a gas stove in the household had been used as a proxy instead), and whether the quoted effect had been adjusted for gender. Inclusion of the covariables allows to account for the studies' design features, quantify their effects, and adjust for these.

Concepts

medicine, pulmonology, odds ratios, meta-regression

Author(s)

Christian Röver, <christian.roever@med.uni-goettingen.de>

Source

DuMouchel, W. H. (1994). Hierarchical Bayes linear models for meta-analysis. Technical Report 27, National Institute of Statistical Sciences (NISS); Research Triangle Park, NC, USA. https://www.niss.org/research/

References

Hasselblad, V., Eddy, D. M., & Kotchmar, D. J. (1992). Synthesis of environmental evidence: Nitrogen dioxide epidemiology studies. *Journal of the Air and Waste Management Association*, **42**(5), 662–671. https://doi.org/10.1080/10473289.1992.10467018

Examples

```
# show data:
dat.dumouchel1994

## Not run:
# derive effect sizes (log-ORs):
library(metafor)
no2 <- escalc(measure="OR", yi=log(or),
              sei=(log(upper)-log(lower))/(2*qnorm(0.975)),
              slab=study, data=dat.dumouchel1994)
summary(no2)

# compute overall meta-analysis:
library(bayesmeta)
bm01 <- bayesmeta(no2, tau.prior="DuMouchel")

# show results:
```

```
bm01
forestplot(bm01)
traceplot(bm01)

# perform meta-regression;
# specify regressor matrix:
X <- model.matrix( ~ smoke + no2 + gender, data=no2)
colnames(X) <- c("intercept", "smoke", "no2", "gender")

# perform regression:
bm02 <- bmr(no2, X=X, tau.prior="DuMouchel")

# show results:
bm02
forestplot(bm02)
#forestplot(bm02, xlab="log-OR",
#           X.mean=rbind("none"      = c(1,0,0,0),
#                        "smoke"     = c(1,1,0,0),
#                        "no2"       = c(1,0,1,0),
#                        "gender"    = c(1,0,0,1),
#                        "all three" = c(1,1,1,1)))
traceplot(bm02)

## End(Not run)
```

`dat.egger2001` *Studies on the Effectiveness of Intravenous Magnesium in Acute Myocardial Infarction*

Description

Results from 16 trials examining the effectiveness of intravenous magnesium in the prevention of death following acute myocardial infarction.

Usage

```
dat.egger2001
```

Format

The data frame contains the following columns:

id	`numeric`	trial id number
study	`character`	first author or trial name
year	`numeric`	publication year
ai	`numeric`	number of deaths in the magnesium group
n1i	`numeric`	number of patients in the magnesium group
ci	`numeric`	number of deaths in the control group
n2i	`numeric`	number of patients in the control group

Details

The dataset includes the results from 16 randomized clinical trials that examined the effectiveness of intravenous magnesium in the prevention of death following acute myocardial infarction. Studies 1-7 were included in the meta-analyses by Teo et al. (1991) and Horner (1992) and were combined with the results from the LIMIT-2 trial (Woods et al., 1992) in Yusuf et al. (1993), suggesting that magnesium is an effective treatment for reducing mortality. However, the results from the ISIS-4 mega trial (ISIS-4 Collaborative Group, 1995) indicated no reduction in mortality with magnesium treatment. Publication bias has been suggested as one possible explanation for the conflicting findings (Egger & Davey Smith, 1995).

The present dataset includes some additional trials and are based on Table 18.2 from Egger, Davey Smith, and Altman (2001).

Concepts

medicine, cardiology, Peto's method, publication bias

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Egger, M., Davey Smith, G., & Altman, D. G. (Eds.) (2001). *Systematic reviews in health care: Meta-analysis in context* (2nd ed.). London: BMJ Books.

References

Egger, M., & Davey Smith, G. (1995). Misleading meta-analysis: Lessons from "an effective, safe, simple" intervention that wasn't. *British Medical Journal*, **310**(6982), 752–754. https://doi.org/10.1136/bmj.310.6982

Horner, S. M. (1992). Efficacy of intravenous magnesium in acute myocardial infarction in reducing arrhythmias and mortality: Meta-analysis of magnesium in acute myocardial infarction. *Circulation*, **86**(3), 774–779. https://doi.org/10.1161/01.cir.86.3.774

ISIS-4 Collaborative Group (1995). ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. *Lancet*, **345**(8951), 669–685. https://doi.org/10.1016/S0140-6736(95)90865-X

Teo, K. K., Yusuf, S., Collins, R., Held, P. H., & Peto, R. (1991). Effects of intravenous magnesium in suspected acute myocardial infarction: Overview of randomised trials. *British Medical Journal*, **303**(6816), 1499–1503. https://doi.org/10.1136/bmj.303.6816.1499

Woods, K. L., Fletcher, S., Roffe, C., & Haider, Y. (1992). Intravenous magnesium sulphate in suspected acute myocardial infarction: Results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). *Lancet*, **339**(8809), 1553–1558. https://doi.org/10.1016/0140-6736(92)91828-v

Yusuf, S., Teo, K., & Woods, K. (1993). Intravenous magnesium in acute myocardial infarction: An effective, safe, simple, and inexpensive treatment. *Circulation*, **87**(6), 2043–2046. https://doi.org/10.1161/01.cir.87.

See Also

dat.li2007

Examples

```
### copy data into 'dat' and examine data
dat <- dat.egger2001
dat

## Not run:
### load metafor package
library(metafor)

### meta-analysis of trials 1-7 using Peto's method (as in Teo et al., 1991)
res <- rma.peto(ai=ai, n1i=n1i, ci=ci, n2i=n2i, data=dat, subset=1:7)
print(res, digits=2)

### meta-analysis of trials 1-7 and LIMIT-2 (as in Yusuf et al., 1993)
res <- rma.peto(ai=ai, n1i=n1i, ci=ci, n2i=n2i, data=dat, subset=c(1:7,14))
print(res, digits=2)

### meta-analysis of all trials except ISIS-4
res <- rma.peto(ai=ai, n1i=n1i, ci=ci, n2i=n2i, data=dat, subset=-16)
print(res, digits=2)
predict(res, transf=exp, digits=2)

### meta-analysis of all trials including ISIS-4
res <- rma.peto(ai=ai, n1i=n1i, ci=ci, n2i=n2i, data=dat)
print(res, digits=2)
predict(res, transf=exp, digits=2)

### contour-enhanced funnel plot centered at 0
funnel(res, refline=0, level=c(90, 95, 99), shade=c("white", "gray", "darkgray"))

## End(Not run)
```

---

dat.feng2019 *Studies on the Prevalence of Depression After Myocardial Infarction*

Description

Results from 19 studies assessing the prevalence of depression after myocardial infarction

Usage

```
dat.feng2019
```

Format

The data frame contains the following columns:

author	character	first author
year	integer	publication year

region	character	country
design	character	study design
source	character	sample source
age	numeric	mean age
males	numeric	percentage of males
first	numeric	percentage of first-time MI
questionnaire	character	self-report questionnaire
interview	character	structured interview
timing	character	timing of depression assessment
depr	integer	subjects with depression
n	integer	sample size

Details

This data set comes from a meta-analysis with 19 studies to estimate the prevalence of depression after a myocardial infarction. The variables `depr` and `n` contain the number of depressive patients and the total number of patients.

Concepts

psychology, cardiology, prevalence

Author(s)

Guido Schwarzer, <guido.schwarzer@uniklinik-freiburg.de>, https://github.com/guido-s/

Source

Feng, L., Li, L., Liu, W., Yang, J., Wang, Q., Shi, L., & Luo, M. (2019). Prevalence of depression in myocardial infarction: A PRISMA-compliant meta-analysis. *Medicine*, **98**(8), e14596. https://doi.org/10.1097/md.0000000000014596

Examples

```
### Show results of first six studies
head(dat.feng2019)

## Not run:
### Load meta package
suppressPackageStartupMessages(library(meta))

### Conduct random effects meta-analysis
mp1 <- metaprop(depr, n, data = dat.feng2019,
  studlab = paste(author, year),
  common = FALSE, prediction = TRUE)

### Create forest plot
forest(mp1, digits = 3, xlim = c(0, 1),
  print.pval.Q = FALSE, details = TRUE)

## End(Not run)
```

dat.fine1993 *Studies on Radiation Therapy with or without Adjuvant Chemotherapy in Patients with Malignant Gliomas*

Description

Results from 17 trials comparing post-operative radiation therapy with and without adjuvant chemotherapy in patients with malignant gliomas.

Usage

```
dat.fine1993
```

Format

The data frame contains the following columns:

study	numeric	study number
nei	numeric	sample size in the experimental group receiving radiotherapy plus adjuvant chemotherapy
nci	numeric	sample size in the control group receiving radiotherapy alone
e1i	numeric	number of survivors at 6 months in the experimental group
c1i	numeric	number of survivors at 6 months in the control group
e2i	numeric	number of survivors at 12 months in the experimental group
c2i	numeric	number of survivors at 12 months in the control group
e3i	numeric	number of survivors at 18 months in the experimental group
c3i	numeric	number of survivors at 18 months in the control group
e4i	numeric	number of survivors at 24 months in the experimental group
c4i	numeric	number of survivors at 24 months in the control group

Details

The 17 trials report the post-operative survival of patients with malignant gliomas receiving either radiation therapy with adjuvant chemotherapy or radiation therapy alone. Survival was assessed at 6, 12, 18, and 24 months in all but one study (which assessed survival only at 12 and at 24 months).

The data were reconstructed by Trikalinos and Olkin (2012) based on Table 2 in Fine et al. (1993) and Table 3 in Dear (1994). The data can be used to illustrate how a meta-analysis can be conducted of effect sizes reported at multiple time points using a multivariate model.

Concepts

medicine, oncology, odds ratios, longitudinal models

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Dear, K. B. G. (1994). Iterative generalized least squares for meta-analysis of survival data at multiple times. *Biometrics*, **50**(4), 989–1002. https://doi.org/10.2307/2533438

Trikalinos, T. A., & Olkin, I. (2012). Meta-analysis of effect sizes reported at multiple time points: A multivariate approach. *Clinical Trials*, **9**(5), 610–620. https://doi.org/10.1177/1740774512453218

References

Fine, H. A., Dear, K. B., Loeffler, J. S., Black, P. M., & Canellos, G. P. (1993). Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. *Cancer*, **71**(8), 2585–2597. https://doi.org/10.1002/1097-0142(19930415)71:8<2585::aid-cncr2820710825>3.0.co;2-s

Examples

```
### copy data into 'dat' and examine data
dat <- dat.fine1993
dat

## Not run:
### load metafor package
library(metafor)

### calculate log(ORs) and sampling variances for each time point
dat <- escalc(measure="OR", ai=e1i, n1i=nei, ci=c1i, n2i=nci, data=dat, var.names=c("y1i","v1i"))
dat <- escalc(measure="OR", ai=e2i, n1i=nei, ci=c2i, n2i=nci, data=dat, var.names=c("y2i","v2i"))
dat <- escalc(measure="OR", ai=e3i, n1i=nei, ci=c3i, n2i=nci, data=dat, var.names=c("y3i","v3i"))
dat <- escalc(measure="OR", ai=e4i, n1i=nei, ci=c4i, n2i=nci, data=dat, var.names=c("y4i","v4i"))

### calculate the covariances (equations in Appendix of Trikalinos & Olkin, 2012)
dat$v12i <- with(dat, nei / (e1i * (nei - e2i)) + nci / (c1i * (nci - c2i)))
dat$v13i <- with(dat, nei / (e1i * (nei - e3i)) + nci / (c1i * (nci - c3i)))
dat$v14i <- with(dat, nei / (e1i * (nei - e4i)) + nci / (c1i * (nci - c4i)))
dat$v23i <- with(dat, nei / (e2i * (nei - e3i)) + nci / (c2i * (nci - c3i)))
dat$v24i <- with(dat, nei / (e2i * (nei - e4i)) + nci / (c2i * (nci - c4i)))
dat$v34i <- with(dat, nei / (e3i * (nei - e4i)) + nci / (c3i * (nci - c4i)))

### create dataset in long format
dat.long <- data.frame(study=rep(1:nrow(dat), each=4), time=1:4,
                       yi=c(t(dat[c("y1i","y2i","y3i","y4i")])),
                       vi=c(t(dat[c("v1i","v2i","v3i","v4i")])))

### var-cov matrices of the studies
V <- lapply(split(dat, dat$study),
            function(x) matrix(c( x$v1i, x$v12i, x$v13i, x$v14i,
                                  x$v12i,  x$v2i, x$v23i, x$v24i,
                                  x$v13i, x$v23i,  x$v3i, x$v34i,
                                x$v14i, x$v24i, x$v34i,  x$v4i), nrow=4, ncol=4, byrow=TRUE))

### remove rows for the missing time points in study 17
dat.long <- na.omit(dat.long)
```

```
### remove corresponding rows/columns from var-cov matrix
V[[17]] <- V[[17]][c(2,4),c(2,4)]

### make a copy of V
Vc <- V

### replace any (near) singular var-cov matrices with ridge corrected versions
repl.Vi <- function(Vi) {
   res <- eigen(Vi)
   if (any(res$values <= 0.08)) {
      round(res$vectors %*% diag(res$values + 0.08) %*% t(res$vectors), 12)
   } else {
      Vi
   }
}
Vc <- lapply(Vc, repl.Vi)

### do not correct var-cov matrix of study 17
Vc[[17]] <- V[[17]]

### construct block diagonal matrix
Vc <- bldiag(Vc)

### multivariate fixed-effects model
res <- rma.mv(yi, Vc, mods = ~ 0 + factor(time), method="FE", data=dat.long)
print(res, digits=3)

### multivariate random-effects model with heteroscedastic AR(1) structure for the true effects
res <- rma.mv(yi, Vc, mods = ~ 0 + factor(time), random = ~ time | study,
              struct="HAR", data=dat.long, control=list(optimizer="hjk"))
print(res, digits=3)

### profile the variance components
par(mfrow=c(2,2))
profile(res, tau2=1, xlim=c(  0, 0.2))
profile(res, tau2=2, xlim=c(  0, 0.2))
profile(res, tau2=3, xlim=c(  0, 0.2))
profile(res, tau2=4, xlim=c(0.1, 0.3))

### profile the autocorrelation coefficient
par(mfrow=c(1,1))
profile(res, rho=1)

## End(Not run)
```

`dat.franchini2012` *Studies on Dopamine Agonists to Reduce "Off-Time" in Patients with Advanced Parkinson Disease*

Description

Results from 7 trials examining the effectiveness of four dopamine agonists and placebo to reduce "off-time" in patients with advanced Parkinson disease.

Usage

```
dat.franchini2012
```

Format

The data frame contains the following columns:

Study	`character`	study label
Treatment1	`character`	treatment 1
y1	`numeric`	treatment effect arm 1
sd1	`numeric`	standard deviation arm 2
n1	`integer`	sample size arm 1
Treatment2	`character`	treatment 2
y2	`numeric`	treatment effect arm 2
sd2	`numeric`	standard deviation arm 2
n2	`integer`	sample size arm 1
Treatment3	`character`	treatment 3
y3	`numeric`	treatment effect arm 3
sd3	`numeric`	standard deviation arm 2
n3	`integer`	sample size arm 1

Details

This network meta-analysis compared the effectiveness of four active treatments and placebo in patients with advanced Parkinson disease (Franchini et al., 2012). The outcome is mean lost work-time reduction in patients given dopamine agonists as adjunct therapy. The data are given as sample size, mean, and standard deviation in each trial arm.

This dataset was used as an example in the supplemental material of Dias et al. (2013) where placebo is coded as 1 and the four active drugs as 2 to 5.

Concepts

medicine, raw mean differences, network meta-analysis

Author(s)

Guido Schwarzer, <guido.schwarzer@uniklinik-freiburg.de>, https://github.com/guido-s/

Source

Dias, S., Sutton, A. J., Ades, A. E., & Welton, N. J. (2013). Evidence synthesis for decision making 2: A generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. *Medical Decision Making*, **33**(5), 607–617. https://doi.org/10.1177/0272989X12458724

Franchini, A. J., Dias, S., Ades, A. E., Jansen, J. P., & Welton, N. J. (2012). Accounting for correlation in network meta-analysis with multi-arm trials. *Research Synthesis Methods*, **3**(2), 142–160. https://doi.org/10.1002/jrsm.1049

Examples

```
### Show results from first three studies; third study is a three-arm
### study
head(dat.franchini2012, 3)

## Not run:
### Load netmeta package
suppressPackageStartupMessages(library(netmeta))

### Print mean differences with two digits
oldset <- settings.meta(digits = 2)

### Transform data from wide arm-based format to contrast-based
### format. Argument 'sm' must not be provided as the mean difference
### is the default in R function metacont() called internally.
pw <- pairwise(list(Treatment1, Treatment2, Treatment3),
  n = list(n1, n2, n3),
  mean = list(y1, y2, y3),
  sd = list(sd1, sd2, sd3),
  data = dat.franchini2012, studlab = Study, sm = "MD")

### Show calculated mean differences (TE) for first three studies
pw[1:5, c(3:7, 10, 1)]

### Conduct network meta-analysis
net <- netmeta(pw)
net

### Draw network graph
netgraph(net, points = TRUE, cex.points = 3, cex = 1.5,
  plastic = TRUE, thickness = "se.fixed",
  iterate = TRUE, start = "eigen")

### Use previous settings
settings.meta(oldset)

## End(Not run)
```

---

dat.frank2008 *Studies on the Association Between the CASP8 -652 6N del Promoter Polymorphism and Breast Cancer Risk*

Description

Results from 4 case-control studies examining the association between the CASP8 -652 6N del promoter polymorphism and breast cancer risk.

Usage

```
dat.frank2008
```

Format

The data frame contains the following columns:

study	character	study identifier
bc.ins.ins	numeric	number of cases who have a homozygous insertion polymorphism
bc.ins.del	numeric	number of cases who have a heterozygous insertion/deletion polymorphism
bc.del.del	numeric	number of cases who have a homozygous deletion polymorphism
ct.ins.ins	numeric	number of controls who have a homozygous insertion polymorphism
ct.ins.del	numeric	number of controls who are heterozygous insertion/deletion polymorphism
ct.del.del	numeric	number of controls who have a homozygous deletion polymorphism

Details

The 4 studies included in this dataset are case-control studies that have examined the association between the CASP8 -652 6N del promoter polymorphism and breast cancer risk. Breast cancer cases and controls were genotyped and either had a homozygous insertion, a heterozygous insertion/deletion, or a homozygous deletion polymorphism.

Ziegler et al. (2011) used the same dataset to illustrate the use of meta-analytic methods to examine deviations from Hardy-Weinberg equilibrium across multiple studies. The relative excess heterozygosity (REH) is the proposed measure for such a meta-analysis, which can be computed by setting `measure="REH"`.

Concepts

medicine, oncology, genetics, odds ratios

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Frank, B., Rigas, S. H., Bermejo, J. L., Wiestler, M., Wagner, K., Hemminki, K., Reed, M. W., Sutter, C., Wappenschmidt, B., Balasubramanian, S. P., Meindl, A., Kiechle, M., Bugert, P., Schmutzler, R. K., Bartram, C. R., Justenhoven, C., Ko, Y.-D., Brüning, T., Brauch, H., Hamann, U., Pharoah, P. P. D., Dunning, A. M., Pooley, K. A., Easton, D. F., Cox, A. & Burwinkel, B. (2008). The CASP8 -652 6N del promoter polymorphism and breast cancer risk: A multicenter study. *Breast Cancer Research and Treatment*, **111**(1), 139–144. https://doi.org/10.1007/s10549-007-9752-z

References

Ziegler, A., Steen, K. V. & Wellek, S. (2011). Investigating Hardy-Weinberg equilibrium in case-control or cohort studies or meta-analysis. *Breast Cancer Research and Treatment*, **128**(1), 197–201. https://doi.org/10.1007/s10549-010-1295-z

Examples

```
### copy data into 'dat' and examine data
dat <- dat.frank2008
dat

## Not run:
### load metafor package
library(metafor)

### calculate log odds ratios comparing ins/del versus ins/ins
dat <- escalc(measure="OR", ai=bc.ins.del, bi=bc.ins.ins,
                            ci=ct.ins.del, di=ct.ins.ins, data=dat)

### fit random-effects model and get the pooled odds ratio (with 95% CI)
res <- rma(yi, vi, data=dat)
res
predict(res, transf=exp, digits=2)

### calculate log odds ratios comparing del/del versus ins/ins
dat <- escalc(measure="OR", ai=bc.del.del, bi=bc.ins.ins,
                            ci=ct.del.del, di=ct.ins.ins, data=dat)

### fit random-effects model and get the pooled odds ratio (with 95% CI)
res <- rma(yi, vi, data=dat)
res
predict(res, transf=exp, digits=2)

### calculate log odds ratios comparing ins/del+del/del versus ins/ins
dat <- escalc(measure="OR", ai=bc.ins.del+bc.del.del, bi=bc.ins.ins,
                            ci=ct.ins.del+ct.del.del, di=ct.ins.ins, data=dat)

### fit random-effects model and get the pooled odds ratio (with 95% CI)
res <- rma(yi, vi, data=dat)
res
predict(res, transf=exp, digits=2)

#############################################################################

### compute the relative excess heterozygosity in the controls
dat <- escalc(measure="REH", ai=ct.ins.ins, bi=ct.ins.del, ci=ct.del.del,
              slab=study, data=dat)

### fit random-effects model and get the pooled REH value (with 90% CI)
res <- rma(yi, vi, data=dat, level=90)
res
predict(res, transf=exp, digits=2)

### draw forest plot
forest(res, atransf=exp, xlim=c(-1.4,1.4), at=log(c(0.5,5/7,1,7/5,2)))
segments(log(5/7), -2, log(5/7), res$k+1, lty="dotted")
segments(log(7/5), -2, log(7/5), res$k+1, lty="dotted")
```

```
## End(Not run)
```

`dat.furukawa2003` *Studies on Low Dosage Tricyclic Antidepressants for the Treatment of Depression*

Description

Results on depression severity from 17 studies comparing low dosage tricyclic antidepressants (TCA) and placebo for the treatment of depression.

Usage

```
dat.furukawa2003
```

Format

The data frame contains the following columns:

author	`character`	First author with information on dosage in parentheses
Ne	`integer`	number of patients in the low TCA group
Me	`numeric`	depression severity (low TCA)
Se	`numeric`	standard deviation (low TCA)
Nc	`integer`	number of patients in the placebo group
Mc	`numeric`	depression severity (placebo)
Sc	`numeric`	standard deviation (placebo)
measure	`character`	depression scale

Details

Furukawa et al. (2003) carried out a systematic review comparing low dosage tricyclic antidepressants (TCA) with placebo for the treatment of depression. They reported the effect on presence/absence of depression and on depression severity at various time points. Here we focus on depression severity at four weeks (Analysis 1.2.3). Most studies used some version of the Hamilton Depression Rating Scale, however, some studies used the Montgomery-Asberg Depression Rating Scale. Accordingly, it is not possible to pool the estimated effects in terms of mean differences. Instead, standardized mean differences can be used to make the effects comparable across studies using different scales.

This data set is used as an example in Schwarzer et al. (2015).

Concepts

psychology, psychiatry, standardized mean differences

Author(s)

Guido Schwarzer, <guido.schwarzer@uniklinik-freiburg.de>, https://github.com/guido-s/

Source

Furukawa, T. A., McGuire, H., & Barbui, C. (2003). Low dosage tricyclic antidepressants for depression. *Cochrane Database of Systematic Reviews*, **3**, CD003197. https://doi.org/10.1002/14651858.CD003197

References

Schwarzer, G., Carpenter, J. R., & Rücker, G. (2015). *Meta-analysis with R*. Cham, Switzerland: Springer.

Examples

```
### Show first five studies
head(dat.furukawa2003, 5)

## Not run:
### Load meta package
suppressPackageStartupMessages(library(meta))

### Use RevMan5 settings
oldset <- settings.meta("RevMan5", digits = 2)

### Conduct random effects meta-analysis with Hedges' g as effect measure
mc2 <- metacont(Ne, Me, Se, Nc, Mc, Sc, common = FALSE,
                data = dat.furukawa2003, sm = "SMD")
mc2

### Use previous settings
settings.meta(oldset)

## End(Not run)
```

---

dat.gibson2002 *Studies on the Effectiveness of Self-Management Education and Regular Medical Review for Adults with Asthma*

Description

Results from 15 trials examining the effectiveness of self-management education and regular medical review for adults with asthma.

Usage

```
dat.gibson2002
```

Format

The data frame contains the following columns:

author	`character`	first author of study
year	`numeric`	publication year
n1i	`numeric`	number of participants in the intervention group
m1i	`numeric`	mean number of days off work/school in the intervention group
sd1i	`numeric`	standard deviation of the number of days off work/school in the intervention group
n2i	`numeric`	number of participants in the control/comparison group
m2i	`numeric`	mean number of days off work/school in the control/comparison group
sd2i	`numeric`	standard deviation of the number of days off work/school in the control/comparison group
ai	`numeric`	number of participants who had one or more days off work/school in the intervention group
bi	`numeric`	number of participants who no days off work/school in the intervention group
ci	`numeric`	number of participants who had one or more days off work/school in the control/comparison group
di	`numeric`	number of participants who no days off work/school in the control/comparison group
type	`numeric`	numeric code for the intervention type (see 'Details')

Details

Asthma management guidelines typically recommend for patients to receive education and regular medical review. While self-management programs have been shown to increase patient knowledge, it is less clear to what extent they actually impact health outcomes. The systematic review by Gibson et al. (2002) examined the effectiveness of self-management education and regular medical review for adults with asthma. In each study, participants receiving a certain management intervention were compared against those in a control/comparison group with respect to a variety of health outcomes. One of the outcomes examined in a number of studies was the number of days off work/school.

The majority of studies reporting this outcome provided means and standard deviations allowing a meta-analysis of standardized mean differences. Seven studies also reported the number of participants who had one or more days off work/school in each group. These studies could be meta-analyzed using, for example, (log) risk ratios. Finally, one could also consider a combined analysis based on standardized mean differences computed from the means and standard deviations where available and using probit transformed risk differences (which also provide estimates of the standardized mean difference) for the remaining studies.

Some degree of patient education was provided in all studies. In addition, the `type` variable indicates what additional intervention components were included in each study:

1. optimal self-management (writing action plan, self-monitoring, regular medical review),
2. self-monitoring and regular medical review,
3. self-monitoring only,
4. regular medical review only,
5. written action plan only.

Concepts

medicine, primary care, risk ratios, standardized mean differences

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Gibson, P. G., Powell, H., Wilson, A., Abramson, M. J., Haywood, P., Bauman, A., Hensley, M. J., Walters, E. H., & Roberts, J. J. L. (2002). Self-management education and regular practitioner review for adults with asthma. *Cochrane Database of Systematic Reviews*, **3**, CD001117. https://doi.org/10.1002/14651858.CD001117

Examples

```
### copy data into 'dat' and examine data
dat <- dat.gibson2002
dat

## Not run:
### load metafor package
library(metafor)

### compute standardized mean differences and corresponding sampling variances
dat <- escalc(measure="SMD", m1i=m1i, sd1i=sd1i, n1i=n1i, m2i=m2i, sd2i=sd2i, n2i=n2i, data=dat)
dat

### fit an equal-effects model to the standardized mean differences (as in Gibson et al., 2002)
res <- rma(yi, vi, data=dat, method="EE")
print(res, digits=2)

### compute log risk ratios and corresponding sampling variances
dat <- escalc(measure="RR", ai=ai, bi=bi, ci=ci, di=di, data=dat)
dat

### fit an equal-effects model to the log risk ratios
res <- rma(yi, vi, data=dat, method="EE")
print(res, digits=2)
predict(res, transf=exp, digits=2)

### note: Gibson et al. (2002) used the Mantel-Haenszel method for their analysis
rma.mh(measure="RR", ai=ai, bi=bi, ci=ci, di=di, data=dat, digits=2)

### compute standardized mean differences where possible and otherwise probit transformed
### risk differences (which also provide estimates of the standardized mean differences)
dat <- escalc(measure="SMD", m1i=m1i, sd1i=sd1i, n1i=n1i,
                             m2i=m2i, sd2i=sd2i, n2i=n2i, data=dat, add.measure=TRUE)
dat <- escalc(measure="PBIT", ai=ai, bi=bi, ci=ci, di=di, data=dat, replace=FALSE, add.measure=TRUE)
dat

### fit a random-effects model to these estimates
res <- rma(yi, vi, data=dat)
print(res, digits=2)

### meta-regression model examining if there are systematic differences based on the
### type of measure used (there are only 2 studies where measure="PBIT", so this isn't
### very conclusive here, but shown for illustration purposes)
res <- rma(yi, vi, mods = ~ measure, data=dat)
print(res, digits=2)
```

```
predict(res, newmods=1, digits=2)

## End(Not run)
```

`dat.graves2010` *Studies on the Effectiveness of Injected Cholera Vaccines*

Description

Results from 17 studies on the effectiveness of injected vaccines against cholera.

Usage

```
dat.graves2010
```

Format

The data frame contains the following columns:

study	`character`	author/study name and publication year
ai	`numeric`	number of cholera cases in the vaccinated group
n1i	`numeric`	number of individuals in the vaccinated group
ci	`numeric`	number of cholera cases in the placebo group
n2i	`numeric`	number of individuals in the placebo group

Details

Cholera is an infection caused by certain strains of the bacterium *Vibrio cholerae*. When untreated, mortality rates can be as high as 50-60%. Proper sanitation practices are usually effective in preventing outbreaks, but a number of oral and injectable vaccines have also been developed. The Cochrane review by Graves et al. (2010) examined the effectiveness of injectable vaccines for preventing cholera cases and death. The present dataset includes results from 17 studies that reported the number of cholera cases in vaccinated and placebo/comparison groups up to 7 months after the treatment.

Concepts

medicine, risk ratios, Mantel-Haenszel method

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Graves, P. M., Deeks, J. J., Demicheli, V., & Jefferson, T. (2010). Vaccines for preventing cholera: Killed whole cell or other subunit vaccines (injected). *Cochrane Database of Systematic Reviews*, **8**, CD000974. https://doi.org/10.1002/14651858.CD000974.pub2

Examples

```
### copy data into 'dat' and examine data
dat <- dat.graves2010
dat

## Not run:
### load metafor package
library(metafor)

### analysis using the Mantel-Haenszel method
rma.mh(measure="RR", ai=ai, n1i=n1i, ci=ci, n2i=n2i, data=dat, digits=2)

## End(Not run)
```

`dat.greb2008` *Trials on High-Dose Chemotherapy with Autologous Stem Cell Transplantation in Aggressive Non-Hodgkin Lymphoma*

Description

Results on complete response from 14 trials evaluating high-dose chemotherapy with autologous stem cell transplantation in patients with aggressive non-Hodgkin lymphoma.

Usage

```
dat.greb2008
```

Format

The data frame contains the following columns:

study	`character`	study label
Ee	`integer`	complete responses (high-dose chemotherapy)
Ne	`integer`	number of patients (high-dose chemotherapy)
Ec	`integer`	complete responses (standard chemotherapy)
Nc	`integer`	number of patients (standard chemotherapy)

Details

Greb et al. (2008) conducted a Cochrane Review to assess the effects of high-dose chemotherapy with autologous stem cell transplantation as part of the first-line treatment of adult patients with aggressive non-Hodgkin lymphoma. The primary outcome was survival time; the binary outcome 'complete response' was one of several secondary outcomes. For binary outcomes, the Cochrane review used the risk ratio and the common effect model.

This data set is used as an example in Schwarzer et al. (2015).

Concepts

medicine, oncology, risk ratios

Author(s)

Guido Schwarzer, <guido.schwarzer@uniklinik-freiburg.de>, https://github.com/guido-s/

Source

Greb, A., Bohlius, J., Schiefer, D., Schwarzer, G., Schulz, H., & Engert, A. (2008). High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive Non-Hodgkin Lymphoma (NHL) in adults. *Cochrane Database of Systematic Reviews*, **1**, CD004024. https://doi.org/10.1002/14651858.cd004024.pub2

References

Schwarzer, G., Carpenter, J. R., & Rücker, G. (2015). *Meta-analysis with R*. Cham, Switzerland: Springer.

Examples

```
### Show first five studies
head(dat.greb2008, 5)

## Not run:
### Load meta package
suppressPackageStartupMessages(library(meta))

### Use RevMan 5 settings
oldset <- settings.meta("RevMan5")

### Conduct common effect meta-analysis with risk ratio as effect measure
mb1 <- metabin(Ee, Ne, Ec, Nc,
  data = dat.greb2008, studlab = study,
  label.e = "High dose", label.c = "Standard",
  label.left = "Favours standard chemotherapy",
  label.right = "Favours high dose chemotherapy",
  col.label.left = "red", col.label.right = "green")
mb1

### Create forest plot
forest(mb1)

### Use previous settings
settings.meta(oldset)

## End(Not run)
```

---

dat.greenland1992 *Case-Control Studies on the Impact of Alcohol Consumption on Breast Cancer Risk*

Description

Results from 16 case-control studies evaluating the impact of alcohol consumption on breast cancer risk.

Usage

```
dat.greenland1992
```

Format

The data frame contains the following columns:

author	character	first author
year	integer	publication year
b	numeric	adjusted log risk ratio
SE	numeric	standard error

Details

Greenland and Longecker (1992) describe a method to combine trend estimates from summarized dose-response data. A meta-analysis of 16 case-control studies evaluating the impact of alcohol consumption on breast cancer risk was used as an illustrative example. The estimates are the increase in the log relative risk of breast cancer associated with an average daily alcohol consumption of 1g.

Data are provided in Greenland and Longecker (1992), Table 3.

Concepts

epidemiology, risk ratios

Author(s)

Guido Schwarzer, <guido.schwarzer@uniklinik-freiburg.de>, https://github.com/guido-s/

Source

Greenland, S., & Longnecker, M. P. (1992). Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. *American Journal of Epidemiology*, **135**(11), 1301–1309. https://doi.org/10.1093/oxfordjournals.aje.a116237

Examples

```
### Show first 6 rows of the dataset
head(dat.greenland1992)

## Not run:
### Load meta package
suppressPackageStartupMessages(library(meta))

### Inverse variance method
```

```
mg <- metagen(b, SE, data = dat.greenland1992,
  studlab = paste(author, year), sm = "RR",
  random = FALSE, overall.hetstat = FALSE,
  backtransf = FALSE)

### Overall result
print(mg, digits = 5)

### Standard error for common effect estimate
round(mg$seTE.common, 5)

## End(Not run)
```

`dat.gurusamy2011` *Studies on Interventions to Reduce Mortality after Liver Transplantation*

Description

Results from 14 trials examining the mortality risk of interventions for decreasing blood loss and blood transfusion requirements during liver transplantation.

Usage

```
dat.gurusamy2011
```

Format

The data frame contains the following columns:

study	`character`	study information
treatment	`character`	treatment
death	`integer`	mortality at 60 days post-transplantation
n	`integer`	number of individuals

Details

This network meta-analysis compared the effectiveness of seven interventions for decreasing blood loss and blood transfusion requirements during liver transplantation (Gurusamy et al., 2011).

Fourteen studies reported mortality at 60 days, in 1,002 patients. Forty-five deaths were reported across all studies (4.5%). Six studies observed deaths in all treatment arms while three studies did not observe any deaths.

This dataset was used in Efthimiou et al. (2019) to introduce the Mantel-Haenszel method for network meta-analysis.

One of the treatments (solvent detergent plasma) was only included in one study with zero events in both treatment arms; this study was excluded from all network meta-analyses. In addition, no death was observed in the antithrombin III arm of the only study evaluating this treatment which was excluded from the Mantel-Haenszel network meta-analysis.

Concepts

medicine, odds ratios, network meta-analysis, Mantel-Haenszel method

Author(s)

Guido Schwarzer, <guido.schwarzer@uniklinik-freiburg.de>, https://github.com/guido-s/

Source

Gurusamy, K. S., Pissanou, T., Pikhart, H., Vaughan, J., Burroughs, A. K., & Davidson, B. R. (2011). Methods to decrease blood loss and transfusion requirements for liver transplantation. *Cochrane Database of Systematic Reviews*, **12**, CD009052. https://doi.org/10.1002/14651858.CD009052.pub2

References

Efthimiou, O., Rücker, G., Schwarzer, G., Higgins, J., Egger, M., & Salanti, G. (2019). A Mantel-Haenszel model for network meta-analysis of rare events. *Statistics in Medicine*, **38**(16), 2992–3012. https://doi.org/10.1002/sim.8158

Examples

```
### Show first 6 rows of the dataset
head(dat.gurusamy2011)

### Only study evaluating solvent detergent plasma
subset(dat.gurusamy2011, study == "Williamson 1999")

### Only study evaluating antithrombin III
subset(dat.gurusamy2011, study == "Baudo 1992")

## Not run:
### Load netmeta package
suppressPackageStartupMessages(library(netmeta))

### Print odds ratios and confidence limits with two digits
oldset <- settings.meta(digits = 2)

### Change appearance of confidence intervals
cilayout("(", "-")

### Transform data from long arm-based format to contrast-based
### format. Argument 'sm' has to be used for odds ratio as summary
### measure; by default the risk ratio is used in the metabin function
### called internally.
pw <- pairwise(treatment, death, n, studlab = study,
  data = dat.gurusamy2011, sm = "OR")

### Conduct Mantel-Haenszel network meta-analysis (NMA)
net.MH <- netmetabin(pw, ref = "cont")

### Conduct inverse variance (IV) network meta-analysis
```

```
net.IV <- netmeta(pw, ref = "cont")

### Network graph (Mantel-Haenszel NMA)
netgraph(net.MH, seq = "optimal", col = "black", plastic = FALSE,
  points = TRUE, pch = 21, cex.points = 3, col.points = "black",
  bg.points = "gray", thickness = "se.fixed",
  number.of.studies = TRUE)

### Full network graph (based on inverse variance method, including
### study comparing Antithrombin III with Control/Placebo)
netgraph(net.IV,
  seq = "optimal", col = "black", plastic = FALSE,
  points = TRUE, pch = 21, cex.points = 3, col.points = "black",
  bg.points = "gray", thickness = "se.fixed",
  number.of.studies = TRUE)

### Compare results for Mantel-Haenszel and IV NMA
forest(netbind(net.MH, net.IV,
  random = FALSE, name = c("MH NMA", "IV NMA")))

### Show results for Mantel-Haenszel NMA
net.MH
forest(net.MH)

### League table with network estimates in lower triangle and direct
### estimates in upper triangle
netleague(net.MH)

### Assess inconsistency
print(netsplit(net.MH), show = "both", ci = TRUE, overall = FALSE,
  nchar.trts = 6)

### Use previous settings
settings.meta(oldset)

## End(Not run)
```

`dat.hackshaw1998` *Studies on the Risk of Lung Cancer in Women Exposed to Environmental Tobacco Smoke*

Description

Results from 37 studies on the risk of lung cancer in women exposed to environmental tobacco smoke (ETS) from their smoking spouse.

Usage

```
dat.hackshaw1998
```

Format

The data frame contains the following columns:

study	numeric	study number
author	character	first author of study
year	numeric	publication year
country	character	country where study was conducted
design	character	study design (either cohort or case-control)
cases	numeric	number of lung cancer cases
or	numeric	odds ratio
or.lb	numeric	lower bound of 95% CI for the odds ratio
or.ub	numeric	upper bound of 95% CI for the odds ratio
yi	numeric	log odds ratio
vi	numeric	corresponding sampling variance

Details

The dataset includes the results from 37 studies (4 cohort, 33 case-control) examining if women (who are lifelong nonsmokers) have an elevated risk for lung cancer due to exposure to environmental tobacco smoke (ETS) from their smoking spouse. Values of the log odds ratio greater than 0 indicate an increased risk of cancer in exposed women compared to women not exposed to ETS from their spouse.

Note that the log odds ratios and corresponding sampling variances were back-calculated from the reported odds ratios and confidence interval (CI) bounds (see 'Examples'). Since the reported values were rounded to some extent, this introduces some minor inaccuracies into the back-calculations. The overall estimate reported in Hackshaw et al. (1997) and Hackshaw (1998) can be fully reproduced though.

Concepts

medicine, oncology, epidemiology, smoking, odds ratios

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Hackshaw, A. K., Law, M. R., & Wald, N. J. (1997). The accumulated evidence on lung cancer and environmental tobacco smoke. *British Medical Journal*, **315**(7114), 980–988. https://doi.org/10.1136/bmj.315.7114.

Hackshaw, A. K. (1998). Lung cancer and passive smoking. *Statistical Methods in Medical Research*, **7**(2), 119–136. https://doi.org/10.1177/096228029800700203

Examples

```
### copy data into 'dat' and examine data
dat <- dat.hackshaw1998
head(dat, 10)
```

```
## Not run:
### load metafor package
library(metafor)

### random-effects model using the log odds ratios
res <- rma(yi, vi, data=dat, method="DL")
res

### estimated average odds ratio with CI (and prediction interval)
predict(res, transf=exp, digits=2)

### illustrate how the log odds ratios and corresponding sampling variances
### can be back-calculated based on the reported odds ratios and CI bounds
dat$yi <- NULL
dat$vi <- NULL
dat <- data.frame(dat)
head(dat, 10)
dat <- conv.wald(out=or, ci.lb=or.lb, ci.ub=or.ub, data=dat, transf=log)
head(dat, 10)

## End(Not run)
```

`dat.haeuser2009` *Studies on the Treatment of Fibromyalgia Syndrome with Antidepressants*

Description

Results from studies examining the treatment of fibromyalgia syndrome with various antidepressants.

Usage

```
dat.haeuser2009
```

Format

The data frame contains the following columns:

study	`character`	study authors
ref	`numeric`	reference number as in article
year	`numeric`	publication year
country	`character`	country where study was conducted
female	`numeric`	percent of female participants
white	`numeric`	percent of white participants
mage	`numeric`	mean age of participants
duration	`numeric`	study / treatment duration
med	`character`	antidepressant medication
jadad	`numeric`	Jadad score

vantulder	numeric	van Tulder score
tgrp	character	treatment group identifier
cgrp	character	control group identifier
outcome	character	outcome variable (pain, fatigue, sleep, mood, qol)
type	character	whether means reflect raw means of mean changes
nti	numeric	number of participants in the treatment group
mti	numeric	mean (change) in the treatment group
sdti	numeric	standard deviation in the treatment group
nci	numeric	number of participants in the control group
mci	numeric	mean (change) in the control group
sdci	numeric	standard deviation in the control group

Details

The meta-analysis by Häuser et al. (2009) examined the efficacy of antidepressants in the treatment of fibromyalgia syndrome. Several outcomes were assessed in the studies, including pain, fatigue, sleep disturbances, (depressed) mood, and health-related quality of life (variable `outcome`). For all outcomes, a higher mean reflects a more negative outcome.

Riley et al. (2011) used part of these data in their discussion of prediction intervals in the context of the random-effects model for meta-analysis.

Concepts

medicine, standardized mean differences, multilevel models, cluster-robust inference, multivariate models

Note

Some studies compared multiple treatment groups against a common control group. This induces dependency between the observed standardized mean differences, which was not accounted for in the analyses conducted in the original meta-analysis.

If a range was given in the dataset (e.g., for variable `female`), then the midpoint of the range was entered in the dataset.

Some typos were discovered and corrected during data entry. For Heymann et al. (2001), the mean in the nortiptyline group for was 48.78, not 49.78. For Hannonen et al. (1998), the sample size of the treatment group for outcome sleep was 30, not 39.

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Häuser, W., Bernardy, K., Üçeyler, N., & Sommer, C. (2009). Treatment of fibromyalgia syndrome with antidepressants: A meta-analysis. *Journal of the American Medical Association*, **301**(2), 198–209. https://doi.org/10.1001/jama.2008.944

References

Riley, R. D., Higgins, J. P. T., & Deeks, J. J. (2011). Interpretation of random effects meta-analyses. *British Medical Journal*, **342**, d549. https://doi.org/10.1136/bmj.d549

Examples

```
### copy data to 'dat' and examine the data
dat <- dat.haeuser2009
head(dat)

## Not run:
### load metafor package
library(metafor)

### compute the SMD values for the outcome pain
dat.pain <- escalc(measure="SMD", m1i=mti, sd1i=sdti, n1i=nti,
                                  m2i=mci, sd2i=sdci, n2i=nci,
                                  data=dat, subset=outcome=="pain")
dat.pain

### fit a random-effects model
res <- rma(yi, vi, data=dat.pain, method="DL", digits=2)
res
predict(res)

### calculate the prediction interval as suggested by Riley et al. (2011)
predict(res, predtype="riley")

### note: reported as -0.83 to -0.02 in Riley et al. (2011); the discrepancy is due to rounding

#############################################################################

### construct an approximate var-cov matrix of the SMD values accounting for
### the dependency in the estimates due to the use of shared control groups
V <- vcalc(vi, cluster=ref, grp1=tgrp, grp2=cgrp, data=dat.pain)
V

### fit a multilevel random-effects model
res <- rma.mv(yi, V, random = ~ 1 | ref/tgrp, data=dat.pain, digits=2)
res
predict(res)

### use cluster-robust inference methods
robust(res, cluster=ref, clubSandwich=TRUE)

#############################################################################

### frequency table for the different outcomes
table(dat$outcome)

### compute the SMD values for all outcomes
dat <- escalc(measure="SMD", m1i=mti, sd1i=sdti, n1i=nti,
```

```
                            m2i=mci, sd2i=sdci, n2i=nci,
                            data=dat)

### approximate correlation matrix for the 5 outcomes
R <- read.table(header=TRUE, text = "
outcome  fatigue  mood  pain   qol sleep
fatigue     1.00  0.60  0.65  0.70  0.60
mood        0.60  1.00  0.55  0.75  0.60
pain        0.65  0.55  1.00  0.70  0.55
qol         0.70  0.75  0.70  1.00  0.60
sleep       0.60  0.60  0.55  0.60  1.00")
R <- as.matrix(R[,-1])
rownames(R) <- colnames(R)
R

### construct an approximate var-cov matrix of the SMD values accounting for
### the dependency in the estimates due to the use of shared control groups
### and for multiple outcomes measured in the same sample
V <- vcalc(vi, cluster=ref, type=outcome, rho=R,
           grp1=tgrp, grp2=cgrp, data=dat)
dat[dat$ref == 64,]
blsplit(V, dat$ref, cov2cor)[["64"]]

### fit a multivariate random-effects model allowing for different amounts
### of heterogeneity for the different outcomes
res <- rma.mv(yi, V, mods = ~ 0 + outcome,
              random = list(~ outcome | ref, ~ outcome | tgrp),
              struct="HCS", data=dat, digits=2)
res
predict(res, newmods=diag(5), tau2.levels=1:5, gamma2.levels=1:5)

### use cluster-robust inference methods
robust(res, cluster=ref, clubSandwich=TRUE)

## End(Not run)
```

`dat.hahn2001` *Studies on the Effectiveness of Different Rehydration Solutions for the Prevention of Unscheduled Intravenous Infusion in Children with Diarrhoea*

Description

Results from 12 trials examining the effectiveness of a reduced versus standard rehydration solution for the prevention of unscheduled intravenous infusion in children with diarrhoea.

Usage

```
dat.hahn2001
```

Format

The data frame contains the following columns:

study	character	trial name and year
ai	numeric	number of children requiring unscheduled intravenous infusion in the reduced rehydration solution grou
n1i	numeric	number of children in the reduced rehydration solution group
ci	numeric	number of children requiring unscheduled intravenous infusion in the standard rehydration solution grou
n2i	numeric	number of children in the standard rehydration solution group

Details

The dataset includes the results from 12 randomized clinical trials that examined the effectiveness of a reduced osmolarity oral rehydration solution (total osmolarity <250 mmol/l with reduced sodium) with a standard WHO oral rehydration solution (sodium 90 mmol/l, glucose 111mmol/l, total osmolarity 311 mmol/l) for the prevention of unscheduled intravenous infusion in children with diarrhoea.

Concepts

medicine, odds ratios, Mantel-Haenszel method

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Hahn, S., Kim, Y., & Garner, P. (2001). Reduced osmolarity oral rehydration solution for treating dehydration due to diarrhoea in children: Systematic review. *British Medical Journal*, **323**(7304), 81–85. https://doi.org/10.1136/bmj.323.7304.81

Examples

```
### copy data into 'dat' and examine data
dat <- dat.hahn2001
dat

## Not run:
### load metafor package
library(metafor)

### meta-analysis of (log) odds rations using the Mantel-Haenszel method
res <- rma.mh(measure="OR", ai=ai, n1i=n1i, ci=ci, n2i=n2i, data=dat, digits=2, slab=study)
res

### forest plot (also show studies that were excluded from the analysis)
options(na.action="na.pass")
forest(res, atransf=exp, xlim=c(-11,9), at=log(c(0.01, 0.1, 1, 10, 100)))
options(na.action="na.omit")

## End(Not run)
```

`dat.hannum2020` *Studies Comparing Objective and Subjective Olfactory Loss in COVID-19 Patients*

Description

Results from 35 studies measuring olfactory loss in COVID-19 patients using either objective or subjective measures.

Usage

```
dat.hannum2020
```

Format

The data frame contains the following columns:

authorName	`character`	(first) author of study
DOI	`character`	article DOI number
ni	`numeric`	number of Covid-19 positive patients in the study
xi	`numeric`	number of Covid-19 positive patients in the study with olfactory loss
percentOlfactoryLoss	`numeric`	percent of the sample with olfactory loss
objectivity	`character`	objective or subjective measure used
measured	`character`	outcome measure
testType	`character`	type of test used
country	`character`	country where patients were treated
patientType	`character`	type of patient information and location where being treated

Details

One of the symptoms of COVID-19 infection is olfactory loss (loss of smell) either recently acquired anosmia (complete loss of smell) or hyposmia (partial loss of smell). One challenge to reaching this symptom is the wide range of reported prevalence for this symptom ranging from 5 percent to 98 percent. In this dataset studies were grouped into one of two groups based on the type of method used to measure smell loss (either subjective measures, such as self-reported smell loss, or objective measures using rated stimuli).

Concepts

medicine, covid-19, proportions

Author(s)

W. Kyle Hamilton <whamilton@ucmerced.edu> https://kylehamilton.com

Source

Ramirez VA , Hannum ME, Lipson SJ, Herriman RD, Toskala AK, Lin C, Joseph PV, Reed DR. 2020. COVID-19 Smell Loss Prevalence Tracker. Available from: https://vicente-ramirez.shinyapps.io/COVID19_Ol and https://github.com/vramirez4/OlfactoryLoss (accessed August 11, 2021)

References

Hannum, M. E., Ramirez, V. A., Lipson, S. J., Herriman, R. D., Toskala, A. K., Lin, C., Joseph, P. V., & Reed, D. R. (2020). Objective sensory testing methods reveal a higher prevalence of olfactory loss in COVID-19 positive patients compared to subjective methods: A systematic review and meta-analysis. *Chemical Senses*, **45**(9), 865–874. https://doi.org/10.1093/chemse/bjaa064

Examples

```
# copy data into 'dat' and examine data
dat <- dat.hannum2020
dat

## Not run:
# load metafor package
library(metafor)

# compute effect size
dat <- escalc(measure="PR", xi=xi, ni=ni, data=dat)

# split data into objective and subjective datasets
dat_split <- split(dat, dat$objectivity)
dat_objective <- dat_split[["Objective"]]
dat_subjective <- dat_split[["Subjective"]]

# random-effects model all studies
res_all <- rma(yi, vi, data=dat)
print(res_all, digits=2)

# random-effects model objective
res_objective <- rma(yi, vi, data=dat_objective)
print(res_objective, digits=2)

# random-effects model subjective
res_subjective <- rma(yi, vi, data=dat_subjective)
print(res_subjective, digits=2)

## End(Not run)
```

---

dat.hart1999 *Studies on the Effectiveness of Warfarin for Preventing Strokes*

Description

Results from 6 clinical trials examining the effectiveness of adjusted-dose warfarin for preventing strokes in patients with atrial fibrillation.

Usage

```
dat.hart1999
```

Format

The data frame contains the following columns:

trial	numeric	trial number
study	character	study name (abbreviated)
year	numeric	publication year
x1i	numeric	number of strokes in the warfarin group
n1i	numeric	number of patients in the warfarin group
t1i	numeric	total person-time (in years) in the warfarin group
x2i	numeric	number of strokes in the placebo/control group
n2i	numeric	number of patients in the placebo/control group
t2i	numeric	total person-time (in years) in the placebo/control group
compgrp	character	type of comparison group (placebo or control)
prevtype	character	type of prevention (primary or secondary)
trinr	character	target range for the international normalized ratio (INR)

Details

The 6 studies provide data with respect to the number of strokes in the warfarin and the comparison (placebo or control) group. In addition, the number of patients and the total person-time (in years) is provided for the two groups. The goal of the meta-analysis was to examine the effectiveness of adjusted-dose warfarin for preventing strokes in patients with atrial fibrillation.

Concepts

medicine, cardiology, incidence rates

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Hart, R. G., Benavente, O., McBride, R., & Pearce, L. A. (1999). Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis. *Annals of Internal Medicine*, **131**(7), 492–501. https://doi.org/10.7326/0003-4819-131-7-199910050-00003

Examples

```
### copy data into 'dat' and examine data
dat <- dat.hart1999
dat

## Not run:
### load metafor package
library(metafor)

### calculate log incidence rate ratios and corresponding sampling variances
dat <- escalc(measure="IRR", x1i=x1i, x2i=x2i, t1i=t1i, t2i=t2i, data=dat)
dat

### meta-analysis of log incidence rate ratios using a random-effects model
res <- rma(yi, vi, data=dat)
res

### average incidence rate ratio with 95% CI
predict(res, transf=exp)

### forest plot with extra annotations
par(mar=c(5,4,1,2))
forest(res, xlim=c(-11, 5), at=log(c(0.05, 0.25, 1, 4)), atransf=exp,
       slab=paste0(study, " (", year, ")"),
       ilab=cbind(paste(x1i, "/", t1i, sep=" "),
                  paste(x2i, "/", t2i, sep=" ")),
       ilab.xpos=c(-6.5,-4), cex=0.85, header="Study (Year)")
op <- par(cex=0.85, font=2)
text(c(-6.5,-4), 8.5, c("Warfarin", "Control"))
text(c(-6.5,-4), 7.5, c("Strokes / PT", "Strokes / PT"))
segments(x0=-8, y0=8, x1=-2.75, y1=8)
par(op)

### meta-analysis of incidence rate differences using a random-effects model
res <- rma(measure="IRD", x1i=x1i, x2i=x2i, t1i=t1i, t2i=t2i, data=dat)
res

## End(Not run)
```

---

dat.hartmannboyce2018 *Studies on the Effectiveness of Nicotine Replacement Therapy for Smoking Cessation*

Description

Results from 133 studies examining the effectiveness of nicotine replacement therapy (NRT) for smoking cessation at 6+ months of follow-up.

Usage

```
dat.hartmannboyce2018
```

Format

The data frame contains the following columns:

study	numeric	study identifier
x.nrt	numeric	number of participants in the NRT group who were abstinent at the follow-up
n.nrt	numeric	number of participants in the NRT group
x.ctrl	numeric	number of participants in the control group who were abstinent at the follow-up
n.ctrl	numeric	number of participants in the control group
treatment	character	type of NRT provided in the treatment group

Details

The dataset includes the results from 133 studies examining the effectiveness of nicotine replacement therapy (NRT) for smoking cessation. The results given in this dataset pertain to abstinence at 6+ months of follow-up. NRT was provided to participants in the treatment groups in various forms as indicated by the `treatment` variable (e.g., gum, patch, inhalator). Note that the dataset includes 136 rows, since a few studies included multiple treatments.

Concepts

medicine, smoking, risk ratios, Mantel-Haenszel method

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Hartmann-Boyce, J., Chepkin, S. C., Ye, W., Bullen, C. & Lancaster, T. (2018). Nicotine replacement therapy versus control for smoking cessation. *Cochrane Database of Systematic Reviews*, **5**, CD000146. https://doi.org//10.1002/14651858.CD000146.pub5

Examples

```
### copy data into 'dat' and examine data
dat <- dat.hartmannboyce2018
head(dat, 10)

## Not run:
### load metafor package
library(metafor)

### turn treatment into a factor with the desired ordering
dat$treatment <- factor(dat$treatment, levels=unique(dat$treatment))

### meta-analysis per treatment using the M-H method
lapply(split(dat, dat$treatment), function(x)
       rma.mh(measure="RR", ai=x.nrt,  n1i=n.nrt,
                            ci=x.ctrl, n2i=n.ctrl, data=x, digits=2))
```

```
### all combined
rma.mh(measure="RR", ai=x.nrt,  n1i=n.nrt,
                     ci=x.ctrl, n2i=n.ctrl, data=dat, digits=2)

## End(Not run)
```

`dat.hasselblad1998` *Studies on the Effectiveness of Counseling for Smoking Cessation*

Description

Results from 24 studies on the effectiveness of various counseling types for smoking cessation.

Usage

```
dat.hasselblad1998
```

Format

The data frame contains the following columns:

id	`numeric`	id number for each treatment arm
study	`numeric`	study id number
authors	`character`	study author(s)
year	`numeric`	publication year
trt	`character`	intervention group
xi	`numeric`	number of individuals abstinent
ni	`numeric`	number of individuals in group

Details

The dataset includes the results from 24 studies on the effectiveness of various counseling types for smoking cessation (i.e., self-help, individual counseling, group counseling, and no contact). The dataset indicates the total number of individuals within each study arm and the number that were abstinent from 6 to 12 months. The majority of the studies compared two interventions types against each other, while 2 studies compared three types against each other simultaneously.

The data can be used for a 'network meta-analysis' (also called a 'mixed treatment comparison'). The code below shows how such an analysis can be conducted using an arm-based and a contrast-based model (see Salanti et al., 2008, for more details).

Concepts

medicine, psychology, smoking, odds ratios, network meta-analysis

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Hasselblad, V. (1998). Meta-analysis of multitreatment studies. *Medical Decision Making*, **18**(1), 37–43. https://doi.org/10.1177/0272989X9801800110

References

Gleser, L. J., & Olkin, I. (2009). Stochastically dependent effect sizes. In H. Cooper, L. V. Hedges, & J. C. Valentine (Eds.), *The handbook of research synthesis and meta-analysis* (2nd ed., pp. 357–376). New York: Russell Sage Foundation.

Law, M., Jackson, D., Turner, R., Rhodes, K., & Viechtbauer, W. (2016). Two new methods to fit models for network meta-analysis with random inconsistency effects. *BMC Medical Research Methodology*, **16**, 87. https://doi.org/10.1186/s12874-016-0184-5

Salanti, G., Higgins, J. P. T., Ades, A. E., & Ioannidis, J. P. A. (2008). Evaluation of networks of randomized trials. *Statistical Methods in Medical Research*, **17**(3), 279–301. https://doi.org/10.1177/0962280207080643

Examples

```
### copy data into 'dat' and examine data
dat <- dat.hasselblad1998
dat

## Not run:
### load metafor package
library(metafor)

### create network graph ('igraph' package must be installed)
library(igraph, warn.conflicts=FALSE)
pairs <- data.frame(do.call(rbind,
   sapply(split(dat$trt, dat$study), function(x) t(combn(x,2)))), stringsAsFactors=FALSE)
lvls <- c("no_contact", "self_help", "ind_counseling", "grp_counseling")
pairs$X1 <- factor(pairs$X1, levels=lvls)
pairs$X2 <- factor(pairs$X2, levels=lvls)
tab <- table(pairs[,1], pairs[,2])
tab # adjacency matrix
g <- graph_from_adjacency_matrix(tab, mode = "plus", weighted=TRUE, diag=FALSE)
vertex_attr(g, "name") <- c("No Contact", "Self-Help",
                            "Individual\nCounseling", "Group\nCounseling")
plot(g, edge.curved=FALSE, edge.width=E(g)$weight, layout=layout_on_grid,
    vertex.size=45, vertex.color="lightgray", vertex.label.color="black", vertex.label.font=2)

### calculate log odds for each study arm
dat <- escalc(measure="PLO", xi=xi, ni=ni, add=1/2, to="all", data=dat)
dat

### convert trt variable to factor with desired ordering of levels
dat$trt <- factor(dat$trt, levels=c("no_contact", "self_help", "ind_counseling", "grp_counseling"))

### add a space before each level (this makes the output a bit more legible)
levels(dat$trt) <- paste0(" ", levels(dat$trt))

### network meta-analysis using an arm-based model with fixed study effects
```

```
### by setting rho=1/2, tau^2 reflects the amount of heterogeneity for all treatment comparisons
res <- rma.mv(yi, vi, mods = ~ 0 + factor(study) + trt,
              random = ~ trt | study, rho=1/2, data=dat, btt="trt")
res

### all pairwise odds ratios of interventions versus no contact
predict(res, newmods=cbind(matrix(0, nrow=3, ncol=24), diag(3)),
        intercept=FALSE, transf=exp, digits=2)

### all pairwise odds ratios comparing interventions (ic vs sh, gc vs sh, and gc vs ic)
predict(res, newmods=cbind(matrix(0, nrow=3, ncol=24), rbind(c(-1,1,0), c(-1,0,1), c(0,-1,1))),
        intercept=FALSE, transf=exp, digits=2)

### forest plot of ORs of interventions versus no contact
forest(c(0,res$beta[25:27]), sei=c(0,res$se[25:27]), psize=1, xlim=c(-3,4), digits=c(2,1), efac=2,
       slab=c("No Contact", "Self-Help", "Individual Counseling", "Group Counseling"),
     atransf=exp, at=log(c(0.5, 1, 2, 4, 8)), xlab="Odds Ratio for Intervention vs. No Contact",
       header=c("Intervention", "Odds Ratio [95% CI]"))

#############################################################################

### restructure dataset to a contrast-based format
dat <- to.wide(dat.hasselblad1998, study="study", grp="trt", ref="no_contact", grpvars=6:7)

### calculate log odds ratios for each treatment comparison
dat <- escalc(measure="OR", ai=xi.1, n1i=ni.1,
                            ci=xi.2, n2i=ni.2, add=1/2, to="all", data=dat)
dat

### calculate the variance-covariance matrix of the log odds ratios for multitreatment studies
### see Gleser & Olkin (2009), equation (19.11), for the covariance equation
calc.v <- function(x) {
  v <- matrix(1/(x$xi.2[1] + 1/2) + 1/(x$ni.2[1] - x$xi.2[1] + 1/2), nrow=nrow(x), ncol=nrow(x))
   diag(v) <- x$vi
   v
}
V <- bldiag(lapply(split(dat, dat$study), calc.v))

### add contrast matrix to dataset
dat <- contrmat(dat, grp1="trt.1", grp2="trt.2")
dat

### network meta-analysis using a contrast-based random-effects model
### by setting rho=1/2, tau^2 reflects the amount of heterogeneity for all treatment comparisons
res <- rma.mv(yi, V, mods = ~ 0 + self_help + ind_counseling + grp_counseling,
              random = ~ comp | study, rho=1/2, data=dat)
res

### predicted odds ratios of interventions versus no contact
predict(res, newmods=diag(3), transf=exp, digits=2)

### fit random inconsistency effects model (see Law et al., 2016)
res <- rma.mv(yi, V, mods = ~ 0 + self_help + ind_counseling + grp_counseling,
```

```
            random = list(~ comp | study, ~ comp | design), rho=1/2, phi=1/2, data=dat)
res

## End(Not run)
```

`dat.higgins2008` *Trials on Haloperidol in Schizophrenia*

Description

Results on clinical improvement after therapy from 17 trials evaluating haloperidol in patients with schizophrenia.

Usage

```
dat.higgins2008
```

Format

The data frame contains the following columns:

author	`character`	study label
resp.halo	`integer`	number of responders (haloperidol group)
fail.halo	`integer`	number of failures (haloperidol group)
miss.halo	`integer`	number of missing observations (haloperidol group)
resp.plac	`integer`	number of responders (placebo group)
fail.plac	`integer`	number of failures (placebo group)
miss.plac	`integer`	number of missing observations (placebo group)

Details

Higgins et al. (2008) suggested several imputation methods for the meta-analysis of binary outcomes with missing data. The example data set with 17 trials comes originally from a Cochrane review comparing haloperidol with placebo for the treatment of schizophrenia. While the antipsychotic benefits of haloperidol were identified in the 1950s, trials in this patient population are prone to high proportions of missing outcome data, often due to insufficient compliance with randomized controlled trial protocols.

The outcome is clinical improvement after therapy. For each study, the number of responders, failures, and missing observations are available.

Concepts

psychiatry, odds ratios, missing data

Author(s)

Guido Schwarzer, <guido.schwarzer@uniklinik-freiburg.de>, https://github.com/guido-s/

Source

Higgins, J. P. T., White, I. R., & Wood, A. M. (2008). Imputation methods for missing outcome data in meta-analysis of clinical trials. *Clinical Trials*, **5**(3), 225–239. https://doi.org/10.1177/1740774508091600

Examples

```
### Show first five studies
head(dat.higgins2008, 5)

## Not run:
### Load metasens package
suppressPackageStartupMessages(library(metasens))

### Print odds ratios and confidence limits with three digits
oldset <- settings.meta(digits = 3)

### Conduct common effect meta-analysis of available data
m <- metabin(resp.halo, resp.halo + fail.halo,
  resp.plac, resp.plac + fail.plac,
  data = dat.higgins2008, studlab = author,
  sm = "OR", method = "Inverse", random = FALSE,
  label.e = "Haloperidol", label.c = "Placebo",
  label.left = "Favours placebo",
  label.right = "Favours haloperidol")

### Best case scenario for haloperidol
m.b <- metamiss(m, miss.halo, miss.plac,
  method.miss = "b", small.values = "undesirable")

### Worst case scenario for haloperidol
m.w <- metamiss(m, miss.halo, miss.plac,
  method.miss = "w", small.values = "undesirable")

### Forest plot
m.sens <- metamerge(m, m.b, text.pooled2 = "Best case scenario")
m.sens <- metamerge(m.sens, m.w, text.pooled2 = "Worst case scenario")
forest(m.sens)

## End(Not run)
```

---

dat.hine1989 *Studies on Prophylactic Use of Lidocaine After a Heart Attack*

Description

Results from 6 studies evaluating mortality from prophylactic use of lidocaine in acute myocardial infarction.

Usage

```
dat.hine1989
```

Format

The data frame contains the following columns:

study	numeric	study number
source	character	source of data
n1i	numeric	number of patients in lidocaine group
n2i	numeric	number of patients in control group
ai	numeric	number of deaths in lidocaine group
ci	numeric	number of deaths in control group

Details

Hine et al. (1989) conducted a meta-analysis of death rates in randomized controlled trials in which prophylactic lidocaine was administered to patients with confirmed or suspected acute myocardial infarction. The dataset describes the mortality at the end of the assigned treatment period for control and intravenous lidocaine treatment groups for six studies. The question of interest is whether there is a detrimental effect of lidocaine. Because the studies were conducted to compare rates of arrhythmias following a heart attack, the studies, taken individually, are too small to detect important differences in mortality rates.

The data in this dataset were obtained from Table I in Normand (1999, p. 322).

Concepts

medicine, cardiology, risk differences

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Normand, S. T. (1999). Meta-analysis: Formulating, evaluating, combining, and reporting. *Statistics in Medicine*, **18**(3), 321–359. https://doi.org/10.1002/(sici)1097-0258(19990215)18:3<321::aid-sim28>3.0

References

Hine, L. K., Laird, N., Hewitt, P., & Chalmers, T. C. (1989). Meta-analytic evidence against prophylactic use of lidocaine in acute myocardial infarction. *Archives of Internal Medicine*, **149**(12), 2694–2698. https://doi.org/10.1001/archinte.1989.00390120056011

Examples

```
### copy data into 'dat' and examine data
dat <- dat.hine1989
dat

## Not run:
### load metafor package
library(metafor)

### calculate risk differences and corresponding sampling variances
dat <- escalc(measure="RD", n1i=n1i, n2i=n2i, ai=ai, ci=ci, data=dat)
dat

### meta-analysis of risk differences using a random-effects model
res <- rma(yi, vi, data=dat)
res

## End(Not run)
```

`dat.huber2000` *Individual Participant Data (IPD) from Five Studies on Uro-Vaxom in Urinary Tract Infections*

Description

Individual participant data (IPD) of 601 patients from 5 studies comparing Uro-Vaxom versus placebo in recurrent urinary tract infections (UTI) based on the numbers of recurrences experienced.

Usage

```
dat.huber2000
```

Format

The data frame contains the following columns (one row per patient):

study	`factor`	study identifier
treatment	`factor`	treatment (Uro-Vaxom or Placebo)
recurrences	`numeric`	number of recurrences (relapses)

Details

Huber et al. (2000) jointly analyzed data from five randomized, placebo-controlled studies investigating the use of *OM-89* (Uro-Vaxom) in recurrent urinary tract infections (UTI). Treatment efficacy was evaluated based on the numbers of recurrences experienced by study participants.

The eventual analysis was carried out based on nonparametric Wilcoxon-Mann-Whitney (WMW) tests applied for each study individually and then synthesizing the five resulting test statistic values.

The WMW test statistics may be expressed in terms of *common language effect sizes* (CLES), that is, the estimated probability that a patient in the treatment group has a better outcome than a control patient.

Concepts

medicine, proportions, individual participant data)

Author(s)

Christian Röver, <christian.roever@med.uni-goettingen.de>

Source

Huber, M., Krauter, K., Winkelmann, G., Bauer, H. W., Rahlfs, V. W., Lauener, P. A., Bleßmann, G. S. S., & Bessler, W. G. (2000). Immunostimulation by bacterial components: II. Efficacy studies and meta-analysis of the bacterial extract OM-89. *International Journal of Immunopharmacology*, **22**(12), 1103–1111. https://doi.org/10.1016/s0192-0561(00)00070-9

See Also

dat.bauer2002

Examples

```
# show data
head(dat.huber2000)
str(dat.huber2000)
summary(dat.huber2000)
table(dat.huber2000[,1:2])
table(dat.huber2000[,c(2,3,1)])

# compute WMW statistics for all 5 studies
wmw <- tapply(dat.huber2000, dat.huber2000$study,
              function(x){wilcox.test(x$recurrences[x$treatment=="Placebo"],
                                      x$recurrences[x$treatment=="Uro-Vaxom"])$statistic},
              simplify=TRUE)
wmw

# determine treatment group sizes
patients <- table(dat.huber2000[,1:2])
patients

# convert WMW statistics into estimated probability of superiority
# ("common language effect size")
prob <- wmw / (patients[,1]*patients[,2])
round(prob, 3)
```

`dat.ishak2007` *Studies on Deep-Brain Stimulation in Patients with Parkinson's disease*

Description

Results from 46 studies examining the effects of deep-brain stimulation on motor skills of patients with Parkinson's disease.

Usage

```
dat.ishak2007
```

Format

The data frame contains the following columns:

study	`character`	(first) author and year
y1i	`numeric`	observed mean difference at 3 months
v1i	`numeric`	sampling variance of the mean difference at 3 months
y2i	`numeric`	observed mean difference at 6 months
v2i	`numeric`	sampling variance of the mean difference at 6 months
y3i	`numeric`	observed mean difference at 12 months
v3i	`numeric`	sampling variance of the mean difference at 12 months
y4i	`numeric`	observed mean difference at the long-term follow-up
v4i	`numeric`	sampling variance of the mean difference at the long-term follow-up
mdur	`numeric`	mean disease duration (in years)
mbase	`numeric`	mean baseline UPDRS score

Details

Deep-brain stimulation (DBS), which is delivered through thin surgically implanted wires in specific areas of the brain and controlled by the patient, is meant to provide relief of the debilitating symptoms of Parkinson's disease. The dataset includes the results from 46 studies examining the effects of DBS of the subthalamic nucleus on motor functioning, measured with the Unified Parkinson's Disease Rating Scale (UPDRS). The effect size measure for this meta-analysis was the mean difference of the scores while the stimulator is active and the baseline scores (before implantation of the stimulator). Since lower scores on the UPDRS indicate better functioning, negative numbers indicate improvements in motor skills. Effects were generally measured at 3, 6, and 12 months after implantation of the stimulator, with some studies also including a further long-term follow-up. However, the number of measurements differed between studies - hence the missing data on some of the measurement occasions.

Since the same patients were followed over time within a study, effect size estimates from multiple measurement occasions are likely to be correlated. A multivariate model accounting for the correlation in the effects can be used to meta-analyze these data. A difficulty with this approach is the lack of information about the correlation of the measurements over time in the individual studies. The approach taken by Ishak et al. (2007) was to assume an autoregressive (AR1) structure for the

estimates within the individual studies. In addition, the correlation in the true effects was modeled, again using an autoregressive structure.

Concepts

medicine, raw mean differences, longitudinal models

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Ishak, K. J., Platt, R. W., Joseph, L., Hanley, J. A., & Caro, J. J. (2007). Meta-analysis of longitudinal studies. *Clinical Trials*, **4**(5), 525–539. https://doi.org/10.1177/1740774507083567

Examples

```
### copy data into 'dat' and examine data
dat <- dat.ishak2007
head(dat, 5)

## Not run:
### load metafor package
library(metafor)

### create long format dataset
dat <- reshape(dat, direction="long", idvar="study", v.names=c("yi","vi"),
               varying=list(c(2,4,6,8), c(3,5,7,9)))
dat <- dat[order(study, time),]

### remove missing measurement occasions from dat
dat <- dat[!is.na(yi),]
rownames(dat) <- NULL
head(dat, 8)

### construct the full (block diagonal) V matrix with an AR(1) structure
### assuming an autocorrelation of 0.97 as estimated by Ishak et al. (2007)
V <- vcalc(vi, cluster=study, time1=time, phi=0.97, data=dat)

### plot data
with(dat, interaction.plot(time, study, yi, type="b", pch=19, lty="solid", xaxt="n",
          legend=FALSE, xlab="Time Point", ylab="Mean Difference", bty="l"))
axis(side=1, at=1:4, lab=c("1 (3 months)", "2 (6 months)", "3 (12 months)", "4 (12+ months)"))

### multivariate model with heteroscedastic AR(1) structure for the true effects
res <- rma.mv(yi, V, mods = ~ 0 + factor(time), random = ~ time | study,
              struct = "HAR", data = dat)
print(res, digits=2)

## End(Not run)
```

`dat.kalaian1996` *Studies on the Effectiveness of Coaching for the SAT*

Description

Results from studies examining the effectiveness of coaching on the performance on the Scholastic Aptitude Test (SAT).

Usage

```
dat.kalaian1996
```

Format

The data frame contains the following columns:

id	`numeric`	row (effect) id
study	`character`	study identifier
year	`numeric`	publication year
n1i	`numeric`	number of participants in the coached group
n2i	`numeric`	number of participants in the uncoached group
outcome	`character`	subtest (verbal or math)
yi	`numeric`	standardized mean difference
vi	`numeric`	corresponding sampling variance
hrs	`numeric`	hours of coaching
ets	`numeric`	study conducted by the Educational Testing Service (ETS) (0 = no, 1 = yes)
homework	`numeric`	assignment of homework outside of the coaching course (0 = no, 1 = yes)
type	`numeric`	study type (1 = randomized study, 2 = matched study, 3 = nonequivalent comparison study)

Details

The effectiveness of coaching for the Scholastic Aptitude Test (SAT) has been examined in numerous studies. This dataset contains standardized mean differences comparing the performance of a coached versus uncoached group on the verbal and/or math subtest of the SAT. Studies may report a standardized mean difference for the verbal subtest, the math subtest, or both. In the latter case, the two standardized mean differences are not independent (since they were measured in the same group of subjects). The number of hours of coaching (variable `hrs`), whether the study was conducted by the Educational Testing Service (variable `ets`), whether homework was assigned outside of the coaching course (variable `homework`), and the study type (variable `type`) may be potential moderators of the treatment effect.

Concepts

education, standardized mean differences, multivariate models, meta-regression

Note

The dataset was obtained from Table 1 in Kalaian and Raudenbush (1996). However, there appear to be some inconsistencies between the data in the table and those that were actually used for the analyses (see 'Examples').

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Kalaian, H. A., & Raudenbush, S. W. (1996). A multivariate mixed linear model for meta-analysis. *Psychological Methods*, **1**(3), 227–235. https://doi.org/10.1037/1082-989X.1.3.227

Examples

```
### copy data into 'dat' and examine data
dat <- dat.kalaian1996
head(dat, 12)

## Not run:
### load metafor package
library(metafor)

### check ranges
range(dat$yi[dat$outcome == "verbal"]) # -0.35 to 0.74 according to page 230
range(dat$yi[dat$outcome == "math"])   # -0.53 to 0.60 according to page 231

### comparing this with Figure 1 in the paper reveals some discrepancies
par(mfrow=c(1,2), mar=c(5,5,1,3.4))
plot(log(dat$hrs[dat$outcome == "verbal"]), dat$yi[dat$outcome == "verbal"],
     pch=19, col=rgb(0,0,0,0.4), xlab="Log(Coaching Hours)", ylab="Effect Size (verbal)",
     xlim=c(1,6), ylim=c(-0.5,1), xaxs="i", yaxs="i")
abline(h=c(-0.5,0,0.5), lty="dotted")
abline(v=log(c(5,18)),  lty="dotted")
plot(log(dat$hrs[dat$outcome == "math"]), dat$yi[dat$outcome == "math"],
     pch=19, col=rgb(0,0,0,0.4), xlab="Log(Coaching Hours)", ylab="Effect Size (math)",
     xlim=c(1,6), ylim=c(-1.0,1), xaxs="i", yaxs="i")
abline(h=c(-0.5,0,0.5), lty="dotted")
abline(v=log(c(5,18)),  lty="dotted")

### construct variance-covariance matrix assuming rho = 0.66 for effect sizes
### corresponding to the 'verbal' and 'math' outcome types
V <- vcalc(vi, cluster=study, type=outcome, data=dat, rho=0.66)

### fit multivariate random-effects model
res <- rma.mv(yi, V, mods = ~ 0 + outcome,
              random = ~ outcome | study, struct="UN",
              data=dat, digits=3)
res

### test whether the effect differs for the math and verbal subtest
```

```
anova(res, X=c(1,-1))

### log-transform and mean center the hours of coaching variable
dat$loghrs <- log(dat$hrs) - mean(log(dat$hrs), na.rm=TRUE)

### fit multivariate model with log(hrs) as moderator
res <- rma.mv(yi, V, mods = ~ 0 + outcome + outcome:loghrs,
              random = ~ outcome | study, struct="UN",
              data=dat, digits=3)
res

### fit model with tau2 = 0 for outcome verbal (which also constrains rho = 0)
res <- rma.mv(yi, V, mods = ~ 0 + outcome + outcome:loghrs,
              random = ~ outcome | study, struct="UN", tau2=c(NA,0),
              data=dat, digits=3)
res

## End(Not run)
```

`dat.karner2014` *Studies on Tiotropium in Patients with COPD*

Description

Data on several endpoints and risk-of-bias from a systematic review of studies on tiotropium in patients with chronic obstructive pulmonary disease (COPD).

Usage

```
dat.karner2014
```

Format

The data frame contains the following columns:

study	`character`	publication identifier (first author and publication year)
year	`numeric`	publication year
duration	`factor`	study duration ($<$ 1 year vs. $\geq$ 1 year)
inhaler	`factor`	type of inhaler investigated ("dry powder" or "soft mist")
baseline.age	`numeric`	mean age at baseline
baseline.males	`numeric`	proportion of males among study participants
baseline.fev1	`numeric`	mean FEV1 at baseline (L)
baseline.fev1pp	`numeric`	mean FEV1 (percent of predicted) at baseline
baseline.pyr	`numeric`	mean number of pack-years (smoking history)
tiotropium.total	`numeric`	total number of patients in the treatment group
tiotropium.exa	`numeric`	number of patients with $\geq$ 1 exacerbation in the treatment group
tiotropium.sexa	`numeric`	number of patients with $\geq$ 1 *severe* exacerbation in the treatment group
tiotropium.hospi	`numeric`	number of patients with $\geq$ 1 hospitalization (all-cause) in the treatment group

tiotropium.deaths	numeric	number of deaths in the treatment group
tiotropium.sae	numeric	number of patients with ≥ 1 serious adverse event (non-fatal) in the treatment group
tiotropium.dropout	numeric	number of withdrawals in the treatment group
placebo.total	numeric	total number of patients in the control group
placebo.exa	numeric	number of patients with ≥ 1 exacerbation in the control group
placebo.sexa	numeric	number of patients with ≥ 1 *severe* exacerbation in the control group
placebo.hospi	numeric	number of patients with ≥ 1 hospitalization (all-cause) in the control group
placebo.deaths	numeric	number of deaths in the control group
placebo.sae	numeric	number of patients with ≥ 1 serious adverse event (non-fatal) in the control group
placebo.dropout	numeric	number of withdrawals in the control group
sgrq.md, **sgrq.se**	numeric	mean difference and associated standard error for *St. George's respiratory questionnaire*
fev1.md, **fev1.se**	numeric	mean difference and associated standard error for *forced expiratory volume in 1 second (*
rob.rand	factor	random sequence generation (selection bias)
rob.alloc	factor	allocation concealment (selection bias)
rob.perf	factor	blinding of participants and personnel (performance bias)
rob.det	factor	blinding of outcome assessment (detection bias)
rob.att	factor	incomplete outcome data (attrition bias)
rob.rep	factor	selective reporting bias (reporting bias)

Details

Chronic obstructive pulmonary disease (COPD) is a chronic and progressive condition characterized by recurrent exacerbation phases. Various treatment options are available, aimed at both providing relief during an acute exacerbation, and at delaying overall disease progression. A common drug used in the management of COPD is *tiotropium*, a long-acting muscarinic antagonist (LAMA), which is administered via an inhaler device.

Karner et al. (2014) conducted a systematic review in order to evaluate the evidence on the effects of tiotropium in comparison to placebo. 22 placebo-controlled studies were found, and a range of endpoints and subgroups were considered. The data reproduced here relate to analyses 1.1, 1.9, 1.14, 1.15, 1.19, 1.26, 1.27, and 1.28 in the original investigation. The risk-of-bias assessments were shown in Fig. 2. A number of study-level covariables are also provided.

Concepts

medicine, pulmonology, odds ratios, raw mean differences, meta-regression, risk-of-bias

Author(s)

Christian Röver, <christian.roever@med.uni-goettingen.d>

Source

Karner, C., Chong, J., & Poole, P. (2014). Tiotropium versus placebo for chronic obstructive pulmonary disease. *Cochrane Database of Systematic Reviews*, **7**, CD009285. https://doi.org/10.1002/14651858.cd00928

Examples

```
dat.karner2014
```

```
## Not run:
library(metafor)
library(bayesmeta)

# compute effect sizes (log odds ratios) from exacerbation count data
# (using the "metafor" package's "escalc()" function)
karner.exa <- escalc(measure="OR",
                     ai=tiotropium.exa, n1i=tiotropium.total,
                     ci=placebo.exa,    n2i=placebo.total,
                     slab=study, data=dat.karner2014)

# show forest plot
forestplot(karner.exa, title="exacerbation",
           exponentiate=TRUE, xlog=TRUE,
           xlab="odds ratio")

# derive St. George's Respiratory Questionnaire (SGRQ) effect sizes
# (change in SGRQ score)
karner.sgrq <- escalc(measure="MD",
                      yi=sgrq.md, sei=sgrq.se,
                      slab=study, data=dat.karner2014,
                      subset=is.finite(dat.karner2014$sgrq.md))

# show forest plot
forestplot(karner.sgrq, title="SGRQ", xlab="mean difference")

## End(Not run)
```

`dat.kearon1998` *Studies on the Accuracy of Venous Ultrasonography for the Diagnosis of Deep Venous Thrombosis*

Description

Results from diagnostic accuracy studies examining the accuracy of venous ultrasonography for the diagnosis of deep venous thrombosis.

Usage

```
dat.kearon1998
```

Format

The data frame contains the following columns:

id	`numeric`	study id
author	`character`	study author(s)
year	`numeric`	publication year
patients	`character`	patient group (either symptomatic or asymptomatic patients)

tp	numeric	number of true positives
np	numeric	number of positive patients (cases)
tn	numeric	number of true negatives
nn	numeric	number of negative patients (non-cases)

Details

The studies included in the dataset examined the accuracy of venous ultrasonography for the diagnossis of a first deep venous thrombosis in symptomatic and asymptomatic patients. Cases and non-cases were determined based on contrast venography. Venous ultrasonography was then used to make a diagnosis, leading to a given number of true positives and negatives.

A subset of this dataset (using only the studies with asymptomatic patients) was used by Deeks et al. (2005) to illustrate methods for detecting publication bias (or small-study effects) in meta-analyses of diagnostic accuracy studies.

Concepts

medicine, odds ratios, diagnostic accuracy studies, multivariate models, publication bias

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Kearon, C., Julian, J. A., Math, M., Newman, T. E., & Ginsberg, J. S. (1998). Noninvasive diagnosis of deep venous thrombosis. *Annals of Internal Medicine*, **128**(8), 663–677. https://doi.org/10.7326/0003-4819-128-8-

References

Deeks, J. J., Macaskill, P., & Irwig, L. (2005). The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. *Journal of Clinical Epidemiology*, **58**(9), 882–893. https://doi.org/10.1016/j.jclinepi.2005.01.016

Examples

```
### copy data into 'dat' and examine data
dat <- dat.kearon1998
head(dat)

## Not run:
### load metafor package
library(metafor)

### calculate diagnostic log odds ratios and corresponding sampling variances
dat <- escalc(measure="OR", ai=tp, n1i=np, ci=nn-tn, n2i=nn, data=dat, add=1/2, to="all")
head(dat)

### fit random-effects model for the symptomatic patients
res <- rma(yi, vi, data=dat, subset=patients=="symptomatic")
res
```

```
### fit random-effects model for the asymptomatic patients
res <- rma(yi, vi, data=dat, subset=patients=="asymptomatic")
res

### estimated average diagnostic odds ratio (with 95% CI)
predict(res, transf=exp, digits=2)

### regression test for funnel plot asymmetry using SE as predictor
reg <- regtest(res, model="lm")
reg

### corresponding funnel plot
funnel(res, atransf=exp, xlim=c(0,7), at=log(c(1,10,100,1000)), ylim=c(0,1.5), steps=4)
ys <- seq(0, 2, length=100)
lines(coef(reg$fit)[1] + coef(reg$fit)[2]*ys, ys, lwd=2, lty=3)

### regression test for funnel plot asymmetry using total sample size as predictor
reg <- regtest(res, model="lm", predictor="ni")
reg

### corresponding funnel plot
funnel(res, yaxis="ni", atransf=exp, xlim=c(0,7), at=log(c(1,10,100,1000)), ylim=c(0,300), steps=4)
ys <- seq(0, 300, length=100)
lines(coef(reg$fit)[1] + coef(reg$fit)[2]*ys, ys, lwd=2, lty=3)

### regression test for funnel plot asymmetry using 1/sqrt(ESS) as predictor (Deeks et al., 2005)
dat$invessi <- 1/(4*dat$np) + 1/(4*dat$nn)
tmp <- rma(yi, invessi, data=dat, subset=patients=="asymptomatic")
reg <- regtest(tmp, model="lm")
reg

### corresponding funnel plot
funnel(tmp, atransf=exp, xlim=c(0,7), at=log(c(1,10,100,1000)), ylim=c(0,0.15), steps=4,
       refline=coef(res), level=0, ylab="1/root(ess)")
ys <- seq(0, 0.2, length=100)
lines(coef(reg$fit)[1] + coef(reg$fit)[2]*ys, ys, lwd=2, lty=3)

### convert data to long format
dat <- to.long(measure="OR", ai=tp, n1i=np, ci=tn, n2i=nn,
               data=dat.kearon1998, subset=patients=="asymptomatic", append=FALSE)
dat$group <- factor(dat$group, levels=c(1,2), labels=c("sensitivity", "specificity"))
dat

### calculate logit-transformed sensitivities
dat <- escalc(measure="PLO", xi=out1, mi=out2, data=dat, add=1/2, to="all",
              include=group=="sensitivity")
dat

### calculate logit-transformed specificities
dat <- escalc(measure="PLO", xi=out1, mi=out2, data=dat, add=1/2, to="all",
              include=group=="specificity")
dat
```

```
### bivariate random-effects model for logit sensitivity and specificity
res <- rma.mv(yi, vi, mods = ~ 0 + group, random = ~ group | study, struct="UN", data=dat)
res

### estimated average sensitivity and specificity based on the model
predict(res, newmods = rbind(c(1,0),c(0,1)), transf=transf.ilogit, tau2.levels=c(1,2), digits=2)

### estimated average diagnostic odds ratio based on the model
predict(res, newmods = c(1,1), transf=exp, digits=2)

## End(Not run)
```

`dat.knapp2017` *Studies on Differences in Planning Performance in Schizophrenia Patients versus Healthy Controls*

Description

Results from 31 studies examining differences in planning performance in schizophrenia patients versus healthy controls.

Usage

```
dat.knapp2017
```

Format

The data frame contains the following columns:

author	`character`	study author(s)
year	`numeric`	publication year
study	`numeric`	study id number
task	`character`	type of task
difficulty	`numeric`	task difficulty
group1	`character`	identifier for patient group within studies
group2	`character`	identifier for control group within studies
comp	`numeric`	identifier for comparisons within studies
yi	`numeric`	standardized mean difference for planning performance
vi	`numeric`	corresponding sampling variance
n_sz	`numeric`	number of schizophrenic patients
n_hc	`numeric`	number of healthy controls
yi	`numeric`	standardized mean difference for IQ
vi	`numeric`	corresponding sampling variance

Details

The studies included in this dataset examined differences between schizophrenia patients and healthy controls with respect to their performance on the tower of London test (https://en.wikipedia.org/wiki/Tower_of_London_test) or a similar cognitive tasks measuring planning ability. The outcome measure for this meta-analysis was the standardized mean difference (with positive values indicating better performance in the healthy controls compared to the schizophrenia patients).

The dataset has a more complex structure for several reasons:

1. Studies 2, 3, 9, and 20 included more than one schizophrenia patient group and the standardized mean differences were computed by comparing these groups against a single healthy control group.
2. Studies 6, 12, 14, 15, 18, 19, 22, and 26 had the patients and controls complete different tasks of varying complexity (essentially the average number of moves required to complete a task). Study 6 also included two different task types.
3. Study 24 provides two standardized mean differences, one for men and the other for women.
4. Study 29 provides three standardized mean differences, corresponding to the three different COMT Val158Met genotypes (val/val, val/met, and met/met).

All 4 issues described above lead to a multilevel structure in the dataset, with multiple standardized mean differences nested within some of the studies. Issues 1. and 2. also lead to correlated sampling errors.

Concepts

psychology, standardized mean differences, multilevel models, multivariate models, cluster-robust inference, meta-regression

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Knapp, F., Viechtbauer, W., Leonhart, R., Nitschke, K., & Kaller, C. P. (2017). Planning performance in schizophrenia patients: A meta-analysis of the influence of task difficulty and clinical and sociodemographic variables. *Psychological Medicine*, **47**(11), 2002–2016. https://doi.org/10.1017/S00332917170004

Examples

```
### copy data into 'dat' and examine data
dat <- dat.knapp2017
dat[-c(1:2)]

## Not run:
### load metafor package
library(metafor)

### fit a standard random-effects model ignoring the issues described above
res <- rma(yi, vi, data=dat)
```

```
res

### fit a multilevel model with random effects for studies and comparisons within studies
### (but this ignored the correlation in the sampling errors)
res <- rma.mv(yi, vi, random = ~ 1 | study/comp, data=dat)
res

### create variable that indicates the task and difficulty combination as increasing integers
dat$task.diff <- unlist(lapply(split(dat, dat$study), function(x) {
   task.int <- as.integer(factor(x$task))
   diff.int <- as.integer(factor(x$difficulty))
   diff.int[is.na(diff.int)] <- 1
   paste0(task.int, ".", diff.int)}))

### construct correlation matrix for two tasks with four different difficulties where the
### correlation is 0.4 for different difficulties of the same task, 0.7 for the same
### difficulty of different tasks, and 0.28 for different difficulties of different tasks
R <- matrix(0.4, nrow=8, ncol=8)
R[5:8,1:4] <- R[1:4,5:8] <- 0.28
diag(R[1:4,5:8]) <- 0.7
diag(R[5:8,1:4]) <- 0.7
diag(R) <- 1
rownames(R) <- colnames(R) <- paste0(rep(1:2, each=4), ".", 1:4)
R

### construct an approximate V matrix accounting for the use of shared groups and
### for correlations among tasks/difficulties as specified in the R matrix above
V <- vcalc(vi, cluster=study, grp1=group1, grp2=group2, w1=n_sz, w2=n_hc,
           obs=task.diff, rho=R, data=dat)

### correlation matrix for study 3 with four patient groups and a single control group
round(cov2cor(V[dat$study == 3, dat$study == 3]), 2)

### correlation matrix for study 6 with two tasks with four difficulties
cov2cor(V[dat$study == 6, dat$study == 6])

### correlation matrix for study 24 with two independent groups
cov2cor(V[dat$study == 24, dat$study == 24])

### correlation matrix for study 29 with three independent groups
cov2cor(V[dat$study == 29, dat$study == 29])

### fit multilevel model as above, but now use this V matrix in the model
res <- rma.mv(yi, V, random = ~ 1 | study/comp, data=dat)
res
predict(res, digits=2)

### use cluster-robust inference methods based on this model
robust(res, cluster=study)

### use methods from the clubSandwich package
robust(res, cluster=study, clubSandwich=TRUE)
```

```
### examine if task difficulty is a potential moderator of the effect
res <- rma.mv(yi, V, mods = ~ difficulty, random = ~ 1 | study/comp, data=dat)
res
sav <- robust(res, cluster=study)
sav
sav <- robust(res, cluster=study, clubSandwich=TRUE)
sav

### draw bubble plot
regplot(sav, xlab="Task Difficulty", ylab="Standardized Mean Difference", las=1, digits=1, bty="l")

## End(Not run)
```

`dat.konstantopoulos2011` *Studies on the Effects of Modified School Calendars on Student Achievement*

Description

Results from 56 studies on the effects of modified school calendars on student achievement.

Usage

```
dat.konstantopoulos2011
```

Format

The data frame contains the following columns:

district	numeric	district id number
school	numeric	school id number (within district)
study	numeric	study id number
yi	numeric	standardized mean difference
vi	numeric	corresponding sampling variance
year	numeric	year of the study

Details

Instead of following the more traditional school calendar with a long summer break (in addition to a short winter and spring break), some schools have switched to a modified school calendar comprising more frequent but shorter intermittent breaks (e.g., 9 weeks of school followed by 3 weeks off), while keeping the total number of days at school approximately the same. The effects of using such a modified calendar on student achievement have been examined in a number of studies and were meta-analyzed by Cooper et al. (2003).

The dataset (taken from Konstantopoulos, 2011) contains the results from 56 studies, each comparing the level of academic achievement in a group of students following a modified school calendar

with that of a group of students following a more traditional school calendar. The difference between the two groups was quantified in terms of a standardized mean difference (with positive values indicating a higher mean level of achievement in the group following the modified school calendar).

The studies were conducted at various schools that were clustered within districts. The data therefore have a multilevel structure, with schools nested within districts. A multilevel meta-analysis of these data can be used to estimate and account for the amount of heterogeneity between districts and between schools within districts.

Concepts

education, standardized mean differences, multilevel models

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Konstantopoulos, S. (2011). Fixed effects and variance components estimation in three-level meta-analysis. *Research Synthesis Methods*, **2**(1), 61–76. https://doi.org/10.1002/jrsm.35

References

Cooper, H., Valentine, J. C., Charlton, K., & Melson, A. (2003). The effects of modified school calendars on student achievement and on school and community attitudes. *Review of Educational Research*, **73**(1), 1–52. https://doi.org/10.3102/00346543073001001

Examples

```
### copy data into 'dat' and examine data
dat <- dat.konstantopoulos2011
dat

## Not run:
### load metafor package
library(metafor)

### fit random-effects model
res <- rma(yi, vi, data=dat)
print(res, digits=3)

### fit random-effects model using rma.mv()
res <- rma.mv(yi, vi, random = ~ 1 | study, data=dat)
print(res, digits=3)

### fit multilevel random-effects model
res.ml <- rma.mv(yi, vi, random = ~ 1 | district/school, data=dat)
print(res.ml, digits=3)

### profile variance components
```

```
profile(res.ml, progbar=FALSE)

### fit multivariate parameterization of the model
res.mv <- rma.mv(yi, vi, random = ~ school | district, data=dat)
print(res.mv, digits=3)

### tau^2 = sum of the two variance components from the multilevel model
round(sum(res.ml$sigma2), digits=3)

### rho = intraclass correlation coefficient based on the multilevel model
round(res.ml$sigma2[1] / sum(res.ml$sigma2), digits=3)

## End(Not run)
```

`dat.landenberger2005` *Studies on the Effectiveness of CBT for Reducing Recidivism*

Description

Results from 58 studies on the effectiveness of cognitive-behavioral therapy (CBT) for reducing recidivism in juvenile and adult offenders.

Usage

```
dat.landenberger2005
```

Format

The data frame contains the following columns:

study	character	(first) author and year
pubtype	character	publication type (book chapter, journal article, report, or thesis)
country	character	country where study was carried out (Canada, New Zealand, UK, or USA)
design	character	study design (matched groups, nonequivalent groups, or randomized trial)
program	character	purpose of setting up the CBT program (for demonstration, practice, or research purposes)
setting	character	treatment setting (community or prison)
designprob	character	indication of study design problems (no, favors the control group, or favors the treatment gr
n.ctrl.rec	numeric	number of recidivists in the control group
n.ctrl.non	numeric	number of non-recidivists in the control group
n.cbt.rec	numeric	number of recidivists in the CBT group
n.cbt.non	numeric	number of non-recidivists in the CBT group
interval	numeric	recidivism interval (in months)
group	numeric	study group (adults or juveniles)
age	numeric	mean age of the study group
male	numeric	percentage of males in the study group
minority	numeric	percentage of minorities in the study group
length	numeric	treatment length (in weeks)
sessions	numeric	number of CBT sessions per week

hrs_week	numeric	treatment hours per week
hrs_total	numeric	total hours of treatment
cbt.cogskills	character	CBT component: cognitive skills (yes, no)
cbt.cogrestruct	character	CBT component: cognitive restructuring (yes, no)
cbt.intpprbsolv	character	CBT component: interpersonal problem solving (yes, no)
cbt.socskills	character	CBT component: social skills (yes, no)
cbt.angerctrl	character	CBT component: anger control (yes, no)
cbt.victimimpact	character	CBT component: victim impact (yes, no)
cbt.subabuse	character	CBT component: substance abuse (yes, no)
cbt.behavmod	character	CBT component: behavior modification (yes, no)
cbt.relapseprev	character	CBT component: relapse prevention (yes, no)
cbt.moralrsng	character	CBT component: moral reasoning (yes, no)
cbt.roletaking	character	CBT component: role taking (yes, no)
cbt.other	character	CBT component: other (yes, no)

Details

Landenberger and Lipsey (2005) conducted a meta-analysis of 58 experimental and quasi-experimental studies of the effects of cognitive-behavioral therapy (CBT) on the recidivism rates of adult and juvenile offenders (see also Lipsey et al., 2007). The present dataset includes the results of these studies and a range of potential moderator variables to identify factors associated with variation in treatment effects.

Concepts

psychology, criminology, odds ratios, meta-regression

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Personal communication.

References

Landenberger, N. A., & Lipsey, M. W. (2005). The positive effects of cognitive-behavioral programs for offenders: A meta-analysis of factors associated with effective treatment. *Journal of Experimental Criminology*, **1**, 451–476. https://doi.org/10.1007/s11292-005-3541-7

Lipsey, M. W., Landenberger, N. A., & Wilson, S. J. (2007). Effects of cognitive-behavioral programs for criminal offenders. *Campbell Systematic Reviews*, **3**(1), 1–27. https://doi.org/10.4073/csr.2007.6

Examples

```
### copy data into 'dat' and examine data
dat <- dat.landenberger2005
head(dat)

## Not run:
```

```
### load metafor package
library(metafor)

### calculate log odds ratios (for non-recidivism in CBT vs. control groups) and sampling variances
dat <- escalc(measure="OR", ai=n.cbt.non, bi=n.cbt.rec, ci=n.ctrl.non, di=n.ctrl.rec, data=dat)

### fit random-effects model
res <- rma(yi, vi, data=dat)
res

### estimated average OR and corresponding 95% CI/PI
predict(res, transf=exp, digits=2)

### examine if number of treatment sessions per week is a potential moderator
res <- rma(yi, vi, mods = ~ sessions, data=dat)
res

### predicted ORs for 1, 2, 5, or 10 sessions per week
predict(res, newmods=c(1,2,5,10), transf=exp, digits=2)

## End(Not run)
```

`dat.laopaiboon2015` *Studies on the Effectiveness of Azithromycin for Treating Lower Respiratory Tract Infections*

Description

Results from 15 studies on the effectiveness of azithromycin versus amoxycillin or amoxycillin/clavulanic acid (amoxyclav) in the treatment of acute lower respiratory tract infections.

Usage

```
dat.laopaiboon2015
```

Format

The data frame contains the following columns:

author	character	author(s)
year	numeric	publication year
ai	numeric	number of clinical failures in the group treated with azithromycin
n1i	numeric	number of patients in the group treated with azithromycin
ci	numeric	number of clinical failures in the group treated with amoxycillin or amoxyclav
n2i	numeric	number of patients in the group treated with amoxycillin or amoxyclav
age	character	whether the trial included adults or children
diag.ab	numeric	trial included patients with a diagnosis of acute bacterial bronchitis
diag.cb	numeric	trial included patients with a diagnosis of chronic bronchitis with acute exacerbation
diag.pn	numeric	trial included patients with a diagnosis of pneumonia

ctrl	character	antibiotic in control group (amoxycillin or amoxyclav)

Details

Azithromycin is an antibiotic useful for the treatment of a number of bacterial infections. Laopaiboon et al. (2015) conducted a meta-analysis of trials comparing the effectiveness of azithromycin versus amoxycillin or amoxycillin/clavulanic acid (amoxyclav) in the treatment of acute lower respiratory tract infections, including acute bacterial bronchitis, acute exacerbations of chronic bronchitis, and pneumonia. The results from 15 trials are included in this dataset.

Concepts

medicine, pulmonology, risk ratios

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Laopaiboon, M., Panpanich, R., & Swa Mya, K. (2015). Azithromycin for acute lower respiratory tract infections. *Cochrane Database of Systematic Reviews*, **3**, CD001954. https://doi.org/10.1002/14651858.CD00195

Examples

```
### copy data into 'dat' and examine data
dat <- dat.laopaiboon2015
dat

## Not run:
### load metafor package
library(metafor)

### analysis using the Mantel-Haenszel method
rma.mh(measure="RR", ai=ai, n1i=n1i, ci=ci, n2i=n2i, data=dat, digits=3)

### calculate log risk ratios and corresponding sampling variances
dat <- escalc(measure="RR", ai=ai, n1i=n1i, ci=ci, n2i=n2i, data=dat)

### random-effects model
res <- rma(yi, vi, data=dat)
res

### average risk ratio with 95% CI
predict(res, transf=exp)

## End(Not run)
```

dat.lau1992 *Studies on Intravenous Streptokinase for Acute Myocardial Infarction*

Description

Results from 33 trials comparing intravenous streptokinase versus placebo or no therapy in patients who had been hospitalized for acute myocardial infarction.

Usage

```
dat.lau1992
```

Format

The data frame contains the following columns:

trial	character	trial name
year	numeric	publication year
ai	numeric	number of deaths in the streptokinase group
n1i	numeric	number of patients in the streptokinase group
ci	numeric	number of deaths in the control group
n2i	numeric	number of patients in the control group

Details

In the paper by Lau et al. (1992), the data are used to illustrate the idea of a cumulative meta-analysis, where the results are updated as each trial is added to the dataset. See 'Examples' for code that replicates the results and shows corresponding forest plots.

Concepts

medicine, cardiology, odds ratios, cumulative meta-analysis

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Lau, J., Antman, E. M., Jimenez-Silva, J., Kupelnick, B., Mosteller, F., & Chalmers, T. C. (1992). Cumulative meta-analysis of therapeutic trials for myocardial infarction. *New England Journal of Medicine*, **327**(4), 248–254. https://doi.org/10.1056/NEJM199207233270406

Examples

```
### copy data into 'dat' and examine data
dat <- dat.lau1992
dat

## Not run:
### load metafor package
library(metafor)

### meta-analysis of log odds ratios using the MH method
res <- rma.mh(measure="OR", ai=ai, n1i=n1i, ci=ci, n2i=n2i, data=dat, slab=trial)
print(res, digits=2)

### forest plot
forest(res, xlim=c(-11,9), atransf=exp, at=log(c(0.01, 0.1, 1, 10, 100)),
       ilab=dat$year, ilab.xpos=-7)
text(-7, 35, "Year", font=2)

### cumulative meta-analysis
sav <- cumul(res)

### forest plot of the cumulative results
forest(sav, xlim=c(-5,4), atransf=exp, at=log(c(0.1, 0.5, 1, 2, 10)),
       ilab=dat$year, ilab.xpos=-3)
text(-3, 35, "Year", font=2)
id <- c(4, 8, 15, 33) # rows for which the z/p-values should be shown (as in Lau et al., 1992)
text(1.1, (res$k:1)[id], paste0("z = ", fmtx(sav$zval[id], digits=2),
                        fmtp(sav$pval[id], pname=", p", equal=TRUE, sep=TRUE, add0=TRUE)))

## End(Not run)
```

---

dat.lee2004 *Studies on Acupoint P6 Stimulation for Preventing Nausea*

Description

Results from studies examining the effectiveness of wrist acupuncture point P6 stimulation for preventing postoperative nausea.

Usage

```
dat.lee2004
```

Format

The data frame contains the following columns:

id	numeric	trial id number
study	character	first author

year	numeric	study year
ai	numeric	number of patients experiencing nausea in the treatment group
n1i	numeric	total number of patients in treatment group
ci	numeric	number of patients experiencing nausea in the sham group
n2i	numeric	total number of patients in the sham group

Details

Postoperative nausea and vomiting are common complications following surgery and anaesthesia. As an alternative to drug therapy, acupuncture has been studied as a potential treatment in several trials. The dataset contains the results from 16 clinical trials examining the effectiveness of wrist acupuncture point P6 stimulation for preventing postoperative nausea.

Concepts

medicine, alternative medicine, risk ratios

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Lee, A., & Done, M. L. (2004). Stimulation of the wrist acupuncture point P6 for preventing postoperative nausea and vomiting. *Cochrane Database of Systematic Reviews*, **3**, CD003281. https://doi.org/10.1002/14651858.CD003281.pub2

Examples

```
### copy data into 'dat' and examine data
dat <- dat.lee2004
dat

## Not run:
### load metafor package
library(metafor)

### meta-analysis based on log risk ratios
res <- rma(measure="RR", ai=ai, n1i=n1i, ci=ci, n2i=n2i, data=dat)
res
predict(res, transf=exp, digits=2)

## End(Not run)
```

dat.lehmann2018 *The Effect of Red on Perceived Attractiveness*

Description

Results from studies in which participants rated the attractiveness of photos that featured red or a control color. See OSF project at https://osf.io/xy47p/.

Usage

```
dat.lehmann2018
```

Format

The data frame contains the following columns:

Short_Title	character	Shortened citation formatted as: Author name(s), year of publication - Experiment n
Full_Citation	character	Full citation in APA format.
Short_Citation	character	Shortened citation of different format, exactly as it would appear in an in-text citatio
Year	numeric	Year study published (whether in journal or published online).
Study	character	Experiment number. If only one experiment presented in a paper, then 'Exp 1', other
Peer_Reviewed	character	Whether the experiment was published in a peer-reviewed journal or not. 'Yes' = pe
Source_Type	character	Location where experiment is available, including journal articles, conference proce
Preregistered	character	Whether experiment was pre-registered or not.
Moderator_Group	character	In some studies, a moderator was intentionally investigated that was meant to reduce
Gender	character	Gender of rater (male or female). In all cases, gender of stimuli will be opposite.
Color_Contrast	character	The color used as the contrast against red. In some cases, not every contrast color wa
Color_Form	character	Location of color in photo. Background = background or border color manipulated;
Photo_Type	character	Amount of body visible in photo. Head Shot = head only; Bust = head, shoulders, sc
DV_Type	character	Scale used for DV. 'Perceived attractiveness' = the perceived attractiveness scale use
DV_Items	numeric	Number of items in DV scale.
DV_Scale	character	Full length of DV scale, if clear.
DV_ScaleBottom	numeric	Lower anchor of DV scale.
DV_ScaleTop	numeric	Upper anchor of DV scale.
Location	character	Country where study took place, if clear. 'Worldwide' in some cases of online partic
Continent	character	Continent where study took place, for the sake of creating larger categories for analy
Participants	character	Basic notes about participants. Students = high school, undergraduate, or graduate st
Participant_Notes	character	A finer grained description of participant characteristics.
Design	character	Whether study was a between- or within-subjects design.
Eth_Majority	character	Basic notes about participant ethnicity for ease of analysis. This represents the ethni
Eth_Majority_Detail	character	A finer grained description of participant characteristics, including in some cases par
Eth_Stim	character	Ethnicity of the people pictured in the stimulus materials.
Eth_Match	character	Whether the ethnic majority of the participant pool matched the ethnicity of stimulus
Red_Age	numeric	Mean age of participants in red group. If not given for specific group, then mean age
Control_Age	numeric	Mean age of participants in control group. If not given for specific group, then mean
Color_Red	character	Specific values of red color, if given.
Color_Control	character	Specific values of control color, if given.

Red_Original	character	Whether the red color used in the study is within 5 units of the LCh values for red us
Color_Match	character	Whether the control color used in the study is within 5 units of the red color on the L
Presentation_Control	character	Whether the color of the stimulus viewed by each participant was consistent, as in pa
Stimuli_Presentation	character	Method for presenting stimuli. 'Paper' = stimuli printed on paper, shown in-person;
Red_N	numeric	Number of participants in red group.
Red_M	numeric	Mean rating of DV in red group.
Red_SD	numeric	Standard deviation of DV in red group.
Control_N	numeric	Number of participants in control group.
Control_M	numeric	Mean rating of DV in control group.
Control_SD	numeric	Standard deviation of DV in control group.
SD_diff	numeric	Calculated for within-subjects studies, standard deviation of difference scores.
RM_r	numeric	Calculated for within-subjects studies, correlation between participant ratings of red
Control_Attractiveness	numeric	Attractiveness of stimuli in control condition, calculated as `(Control_M - DV_Scale`
Notes	character	Any additional notes on the study.
Total.SampleSize	numeric	Total unique participants in the study.
pooled	numeric	Pooled standard deviation for within-subjects studies.
yi	numeric	Standardized mean difference.
vi	numeric	Corresponding sampling variance.

Details

This is data from a meta-analysis of studies that test the red-romance hypothesis, which is that the color red enhances heterosexual attraction in romantic contexts. Analyzing male participants only, the meta-analysis should show a small, statistically significant effect (d = 0.26 [0.12, 0.40], p = .0004, N = 2,961). Analyzing female participants only should show a very small effect (d = 0.13 [0.01, 0.25], p = .03, N = 2,739). The analyses in the published meta-analysis found clear evidence of upward bias in the estimate for female participants and equivocal evidence for male participants. Moderator analyses suggest effect sizes may have declined over time (both genders), may be largest when an original shade of red is used (men only), and may be smaller in pre-registered studies (women only).

Concepts

psychology, attraction, standardized mean differences

Author(s)

Robert Calin-Jageman, <rcalinjageman@dom.edu>, https://calin-jageman.net

Source

Lehmann, G. K., Elliot, A. J., & Calin-Jageman, R. J. (2018). Meta-analysis of the effect of red on perceived attractiveness. *Evolutionary Psychology*, **16**(4). https://doi.org/10.1177/1474704918802412
https://osf.io/xy47p/

Examples

```
### copy data into 'dat' and examine data
dat <- dat.lehmann2018
```

```
head(dat)

## Not run:
### load metafor package
library(metafor)

### meta-analyses for male and female participants
red_romance_malep   <- dat[dat$Gender == "Males", ]
red_romance_femalep <- dat[dat$Gender == "Females", ]

res_malep <- rma(yi, vi, data=red_romance_malep, test="knha")
res_malep
res_femalep <- rma(yi, vi, data=red_romance_femalep, test="knha")
res_femalep

## End(Not run)
```

`dat.li2007` *Studies on the Effectiveness of Intravenous Magnesium in Acute Myocardial Infarction*

Description

Results from 22 trials examining the effectiveness of intravenous magnesium in the prevention of death following acute myocardial infarction.

Usage

```
dat.li2007
```

Format

The data frame contains the following columns:

id	`numeric`	trial id number
study	`character`	first author or trial name
year	`numeric`	publication year
ai	`numeric`	number of deaths in the magnesium group
n1i	`numeric`	number of patients in the magnesium group
ci	`numeric`	number of deaths in the control group
n2i	`numeric`	number of patients in the control group

Details

The dataset includes the results from 22 randomized clinical trials that examined the effectiveness of intravenous magnesium in the prevention of death following acute myocardial infarction. It is similar to the dataset `dat.egger2001`, with some slight differences in the included trials and data used.

Concepts

medicine, cardiology, odds ratios, publication bias

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Li, J., Zhang, Q., Zhang, M., & Egger, M. (2007). Intravenous magnesium for acute myocardial infarction. *Cochrane Database of Systematic Reviews*, **2**, CD002755. https://doi.org/10.1002/14651858.CD002755.pub2

See Also

dat.egger2001

Examples

```
### copy data into 'dat' and examine data
dat <- dat.li2007
dat

## Not run:
### load metafor package
library(metafor)

### meta-analysis of all trials except ISIS-4
res <- rma(measure="OR", ai=ai, n1i=n1i, ci=ci, n2i=n2i, data=dat, method="EE", subset=-14)
print(res, digits=2)
predict(res, transf=exp, digits=2)

### meta-analysis of all trials including ISIS-4
res <- rma(measure="OR", ai=ai, n1i=n1i, ci=ci, n2i=n2i, data=dat, method="EE")
print(res, digits=2)
predict(res, transf=exp, digits=2)

### contour-enhanced funnel plot centered at 0
funnel(res, refline=0, level=c(90, 95, 99), shade=c("white", "gray", "darkgray"))

## End(Not run)
```

---

dat.lim2014 — *Studies on the Association Between Maternal Size, Offspring Size, and Number of Offsprings*

Description

Results from studies examining the association between maternal size, offspring size, and number of offsprings.

Usage

```
dat.lim2014
```

Format

The object is a list containing data frames `m_o_size`, `m_o_fecundity`, `o_o_unadj`, and `o_o_adj` that contain the following columns and the corresponding phylogenetic trees called `m_o_size_tree`, `m_o_fecundity_tree`, `o_o_unadj_tree`, and `o_o_adj_tree`:

article	`numeric`	article id
author	`character`	study author(s)
year	`numeric`	publication year
species	`character`	species
amniotes	`character`	whether the species was amniotic
environment	`character`	whether the species were wild or captive
reprounit	`character`	whether the data were based on lifetime reproductive output or a single reproductive event (only
ri	`numeric`	correlation coefficient
ni	`numeric`	sample size

Details

The object `dat.lim2014` includes 4 datasets:

`m_o_size`	on the correlation between maternal size and offspring size
`m_o_fecundity`	on the correlation between maternal size and number of offsprings
`o_o_unadj`	on the correlation between offspring size and number of offsprings
`o_o_adj`	on the correlation between offspring size and number of offsprings adjusted for maternal size

Objects `m_o_size_tree`, `m_o_fecundity_tree`, `o_o_unadj_tree`, and `o_o_adj_tree` are the corresponding phylogenetic trees for the species included in each of these datasets.

Concepts

ecology, evolution, correlation coefficients, multilevel models, phylogeny

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Lim, J. N., Senior, A. M., & Nakagawa, S. (2014). Heterogeneity in individual quality and reproductive trade-offs within species. *Evolution*, **68**(8), 2306–2318. https://doi.org/10.1111/evo.12446

References

Cinar, O., Nakagawa, S., & Viechtbauer, W. (in press). Phylogenetic multilevel meta-analysis: A simulation study on the importance of modelling the phylogeny. *Methods in Ecology and Evolution*. https://doi.org/10.1111/2041-210X.13760

Hadfield, J. D., & Nakagawa, S. (2010). General quantitative genetic methods for comparative biology: Phylogenies, taxonomies and multi-trait models for continuous and categorical characters. *Journal of Evolutionary Biology*, **23**(3), 494–508. https://doi.org/10.1111/j.1420-9101.2009.01915.x

Nakagawa, S., & Santos, E. S. A. (2012). Methodological issues and advances in biological meta-analysis. *Evolutionary Ecology*, **26**(5), 1253–1274. https://doi.org/10.1007/s10682-012-9555-5

Examples

```
### copy data into 'dat' and examine data
dat <- dat.lim2014$o_o_unadj
dat[1:14, -c(2:3)]

## Not run:
### load metafor package
library(metafor)

### load ape package
library(ape, warn.conflicts=FALSE)

### calculate r-to-z transformed correlations and corresponding sampling variances
dat <- escalc(measure="ZCOR", ri=ri, ni=ni, data=dat)

### copy tree to 'tree'
tree <- dat.lim2014$o_o_unadj_tree

### compute branch lengths
tree <- compute.brlen(tree)

### compute phylogenetic correlation matrix
A <- vcv(tree, corr=TRUE)

### make copy of the species variable
dat$species.phy <- dat$species

### create effect size id variable
dat$esid <- 1:nrow(dat)

### fit multilevel phylogenetic meta-analytic model
res <- rma.mv(yi, vi,
   random = list(~ 1 | article, ~ 1 | esid, ~ 1 | species, ~ 1 | species.phy),
   R=list(species.phy=A), data=dat)
res

## End(Not run)
```

dat.linde2005 *Studies on the Effectiveness of St. John's Wort for Treating Depression*

Description

Results from 26 studies on the effectiveness of Hypericum perforatum extracts (St. John's wort) for treating depression.

Usage

```
dat.linde2005
```

Format

The data frame contains the following columns:

id	numeric	study number
study	character	study author(s)
year	numeric	publication year
country	character	study location
ni	numeric	total sample size
major	numeric	sample restricted to patients who met criteria for major depression
baseline	numeric	HRSD baseline score
version	numeric	HRSD version (17 or 21 items)
duration	numeric	study duration (in weeks)
prep	character	Hypericum extract preparation
dosage	numeric	dosage (in mg)
response	numeric	definition of response (see 'Details')
ai	numeric	number of responses in treatment group
n1i	numeric	number of patients in treatment group
ci	numeric	number of responses in placebo group
n2i	numeric	number of patients in placebo group
group	numeric	stratification variable used by the authors (see 'Details')

Details

The dataset includes the results from 26 double-blind placebo-controlled trials on the effectiveness of Hypericum perforatum extracts (St. John's wort) for treating depression (note that 2 studies did not provide sufficient response information).

Data were extracted from Table 1 and Figure 3 from Linde et al. (2005). For study duration, the assessment week (instead of the total study duration) was coded for Philipp et al. (1999) and Montgomery et al. (2000). For dosage, the midpoint was coded when a range of values was given.

The definition of what constitutes a `response` differed across studies and is coded as follows:

1. HRSD score reduction of at least 50% or HRSD score after therapy <10,
2. HRSD reduction of at least 50%,

3. based on HRSD scale but exact definition not reported,
4. global patient assessment of efficacy,
5. at least 'much improved' on the Clinical Global Impression sub-scale for global improvement.

The `group` variable corresponds to the variable used by Linde et al. (2005) to stratify their analyses and is coded as follows:

1. smaller trials restricted to major depression,
2. larger trials restricted to major depression,
3. smaller trials not restricted to major depression,
4. larger trials not restricted to major depression.

Concepts

medicine, psychiatry, risk ratios

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Linde, K., Berner, M., Egger, M., & Mulrow, C. (2005). St John's wort for depression: Meta-analysis of randomised controlled trials. *British Journal of Psychiatry*, **186**(2), 99–107. https://doi.org/10.1192/bjp.18

References

Viechtbauer, W. (2007). Accounting for heterogeneity via random-effects models and moderator analyses in meta-analysis. *Zeitschrift für Psychologie / Journal of Psychology*, **215**(2), 104–121. https://doi.org/10.1027/0044-3409.215.2.104

Examples

```
### copy data into 'dat' and examine data
dat <- dat.linde2005
head(dat)

## Not run:
### load metafor package
library(metafor)

### remove studies with no response information and study with no responses in either group
dat <- dat[-c(5,6,26),]

### calculate log risk ratios and corresponding sampling variances
dat <- escalc(measure="RR", ai=ai, ci=ci, n1i=n1i, n2i=n2i, data=dat)
head(dat)

### meta-analysis of the log risk ratios using a random-effects model
res <- rma(yi, vi, data=dat, method="DL")
```

```
res

### mixed-effects meta-regression model with stratification variable
res <- rma(yi, vi, mods = ~ 0 + factor(group), data=dat, method="DL")
res

### predicted average risk ratio for each level of the stratification variable
predict(res, newmods=diag(4), transf=exp, digits=2)

## End(Not run)
```

`dat.linde2015` *Studies on Classes of Antidepressants for the Primary Care Setting*

Description

Results from 66 trials examining eight classes of antidepressants and placebo for the primary care setting.

Usage

```
dat.linde2015
```

Format

The data frame contains the following columns:

id	`integer`	study ID
author	`character`	first author
year	`integer`	year of publication
treatment1	`character`	treatment 1
treatment2	`character`	treatment 2
treatment3	`character`	treatment 3
n1	`integer`	number of patients (arm 1)
resp1	`integer`	number of early responder (arm 1)
remi1	`integer`	number of early remissions (arm 1)
loss1	`integer`	number of patients loss to follow-up (arm 1)
loss.ae1	`integer`	number of patients loss to follow-up due to adverse events (arm 1)
ae1	`integer`	number of patients with adverse events (arm 1)
n2	`integer`	number of patients (arm 2)
resp2	`integer`	number of early responder (arm 2)
remi2	`integer`	number of early remissions (arm 2)
loss2	`integer`	number of patients loss to follow-up (arm 2)
loss.ae2	`integer`	number of patients loss to follow-up due to adverse events (arm 2)
ae2	`integer`	number of patients with adverse events (arm 2)
n3	`integer`	number of patients (arm 3)
resp3	`integer`	number of early responder (arm 3)
remi3	`integer`	number of early remissions (arm 3)

loss3	integer	number of patients loss to follow-up (arm 3)
loss.ae3	integer	number of patients loss to follow-up due to adverse events (arm 3)
ae3	integer	number of patients with adverse events (arm 3)

Details

This dataset comes from a systematic review of 8 pharmacological treatments of depression and placebo in primary care with 66 studies (8 of which were 3-arm studies) including 14,785 patients.

The primary outcome is early response, defined as at least a 50% score reduction on a depression scale after completion of treatment. Secondary outcomes (also measured as dichotomous) were early remission (defined as having a symptom score below a fixed threshold after completion of treatment), lost to follow-up, lost to follow-up due to adverse events, and any adverse event. The odds ratio was used as effect measure.

This dataset was used as an example in Rücker and Schwarzer (2017) who introduced methods to resolve conflicting rankings of outcomes in network meta-analysis.

Concepts

medicine, psychiatry, odds ratios, network meta-analysis

Author(s)

Guido Schwarzer, <guido.schwarzer@uniklinik-freiburg.de>, https://github.com/guido-s/

Source

Linde, K., Kriston, L., Rücker, G., Jamil, S., Schumann, I., Meissner, K., Sigterman, K., & Schneider, A. (2015). Efficacy and acceptability of pharmacological treatments for depressive disorders in primary care: Systematic review and network meta-analysis. *Annals of Family Medicine*, **13**(1), 69–79. https://doi.org/10.1370/afm.1687

References

Rücker, G., & Schwarzer, G. (2017). Resolve conflicting rankings of outcomes in network meta-analysis: Partial ordering of treatments. *Research Synthesis Methods*, **8**(4), 526–536. https://doi.org/10.1002/jrsm.127

Examples

```
### Show results from first three studies (including three-arm study
### Lecrubier 1997)
head(dat.linde2015, 3)

## Not run:
### Load netmeta package
suppressPackageStartupMessages(library(netmeta))

### Print odds ratios and confidence limits with two digits
oldset <- settings.meta(digits = 2)

### Change appearance of confidence intervals
```

```
cilayout("(", "-")

### Define order of treatments in printouts
trts <- c("TCA", "SSRI", "SNRI", "NRI", "Low-dose SARI",
 "NaSSa", "rMAO-A", "Hypericum", "Placebo")

### Transform data from wide arm-based format to contrast-based format
### (outcome: early response). Argument 'sm' has to be used for odds
### ratio as summary measure; by default the risk ratio is used in the
### metabin function called internally.
pw1 <- pairwise(list(treatment1, treatment2, treatment3),
  event = list(resp1, resp2, resp3),
  n = list(n1, n2, n3),
  studlab = id, data = dat.linde2015, sm = "OR")

### Conduct random effects network meta-analysis for primary outcome
### (early response); small number of early responses is bad (argument
### small.values)
net1 <- netmeta(pw1, common = FALSE, reference = "Placebo", seq = trts,
  small.values = "undesirable")
net1

### Random effects NMA for early remission
pw2 <- pairwise(treat = list(treatment1, treatment2, treatment3),
  event = list(remi1, remi2, remi3),
  n = list(n1, n2, n3),
  studlab = id, data = dat.linde2015, sm = "OR")
net2 <- netmeta(pw2, common = FALSE,
   seq = trts, ref = "Placebo", small.values = "undesirable")
net2

### Ranking of treatments
nr1 <- netrank(net1)
nr2 <- netrank(net2)
nr1
nr2

### Partial order of treatment rankings (two outcomes)
outcomes <- c("Early response", "Early remission")
po12 <- netposet(nr1, nr2, outcomes = outcomes)
plot(po12)

### Use previous settings
settings.meta(oldset)

## End(Not run)
```

---

dat.linde2016 *Studies on Antidepressants for the Primary Care Setting*

Description

Results from 93 trials examining 22 interventions (including placebo and usual care) for the primary care of depression.

Usage

```
dat.linde2016
```

Format

The data frame contains the following columns:

id	`integer`	study ID
author	`character`	first author
year	`numeric`	year of publication
resp	`numeric`	number of responders
n	`numeric`	number of patients
int	`character`	intervention label
int.long	`character`	intervention label (full name)

Details

This dataset comes from a network meta-analysis of 22 treatments of depression in primary care (Linde et al., 2016), based on 93 trials (79 two-arm trials, 13 three-arm trials, and one four-arm trial). The primary outcome was response after treatment (yes/no), defined as a reduction from baseline by at least 50% on a depression scale. The dataset contains log odds ratios with standard errors for all pairwise comparisons.

The interventions comprised both medical and psychological treatments, also in combination, including placebo and usual care (UC) (Linde et al., 2016). Pharmacological interventions were tricyclic antidepressants (TCA), selective serotonin reuptake inhibitors (SSRI), serotonin-noradrenaline reuptake inhibitors (SNRI), noradrenaline reuptake inhibitors (NRI), low- dose serotonin (5-HT2) antagonists and reuptake inhibitors (low-dose SARI), noradrenergic and specific serotonergic agents (NaSSa), reversible inhibitors of monoaminoxidase A (rMAO-A), hypericum extracts, and an individualized drug. Psychological interventions were cognitive behavioral therapy (CBT; four forms: face-to-face CBT, remote therapist-led CBT, guided self-help CBT, and no or minimal contact CBT), face-to-face problem-solving therapy (PST), face-to-face interpersonal psychotherapy, face-to-face psychodynamic therapy, and "other face-to-face therapy". Combination therapies were face-to-face CBT + SSRI, face-to-face PST + SSRI, and face-to-face interpersonal psychotherapy + SSRI.

The dataset was used as an example in Rücker et al. (2020) to illustrate component network meta-analysis using frequentist methods.

Concepts

medicine, psychology, psychiatry, odds ratios, network meta-analysis, component network meta-analysis

Author(s)

Guido Schwarzer, <guido.schwarzer@uniklinik-freiburg.de>, https://github.com/guido-s/

Source

Linde, K., Rücker, G., Schneider, A., & Kriston, L. (2016). Questionable assumptions hampered interpretation of a network meta-analysis of primary care depression treatments. *Journal of Clinical Epidemiology*, **71**, 86–96. https://doi.org/10.1016/j.jclinepi.2015.10.010

References

Rücker, G., Petropoulou, M., & Schwarzer, G. (2020). Network meta-analysis of multicomponent interventions. *Biometrical Journal*, **62**(3), 808–821. https://doi.org/10.1002/bimj.201800167

Examples

```
### Show results of first three studies (first study has three treatment arms)
head(dat.linde2016, 7)

## Not run:
### Load netmeta package
suppressPackageStartupMessages(library(netmeta))

### Print odds ratios and confidence limits with two digits
oldset <- settings.meta(digits = 2)

### Define order of treatments in printouts and forest plots
trts <- c("SSRI", "Face-to-face CBT", "Face-to-face interpsy",
  "Face-to-face PST", "Face-to-face CBT + SSRI",
  "Face-to-face interpsy + SSRI", "Face-to-face PST + SSRI",
  "Face-to-face psychodyn", "Other face-to-face",
  "TCA", "SNRI", "NRI", "Low-dose SARI", "NaSSa", "rMAO-A", "Ind drug",
  "Hypericum", "Remote CBT", "Self-help CBT", "No contact CBT", "UC",
  "Placebo")

### Use pairwise() to transform data to comparison-based format
pw <- pairwise(treat = int,
  event = resp, n = n,
  studlab = paste(author, year),
  data = dat.linde2016,
  reference = "plac",
  sm = "OR")

### Conduct random effects network meta-analysis
nma <- netmeta(pw, reference.group = "placebo",
  seq = trts, common = FALSE)

### Network graph
netgraph(nma, seq = "o")

### Show results
nma
```

```
forest(nma, xlim = c(0.2, 50))

### Additive component network meta-analysis with placebo as inactive treatment
cnma <- netcomb(nma, inactive = "placebo")
cnma
forest(cnma, xlim = c(0.2, 50))

### Use previous settings
settings.meta(oldset)

## End(Not run)
```

`dat.lloyd2010` *Studies on Anti-TNF-alpha Inhibitors in Rheumatoid Arthritis*

Description

Results from 16 studies evaluating anti-TNF-alpha inhibitors in patients with rheumatoid arthritis.

Usage

```
dat.lloyd2010
```

Format

The data frame contains the following columns:

author	`character`	first author
year	`integer`	publication year
mean.das	`numeric`	mean for outcome DAS-28
lower.das	`numeric`	lower limit for outcome DAS-28
upper.das	`numeric`	upper limit for outcome DAS-28
mean.haq	`numeric`	mean for outcome HAQ
lower.haq	`numeric`	lower limit for outcome HAQ
upper.haq	`numeric`	upper limit for outcome HAQ
n	`integer`	sample size

Details

Lloyd et al. (2010) report results of a systematic review evaluating the effectiveness of anti-TNF-alpha inhibitors in the treatment of rheumatoid arthritis. The authors conducted separate meta-analyses for HAQ and DAS-28.

Concepts

medicine, rheumatology, raw mean differences

Author(s)

Guido Schwarzer, <guido.schwarzer@uniklinik-freiburg.de>, https://github.com/guido-s/

Source

Lloyd, S., Bujkiewicz, S., Wailoo, A. J., Sutton, A. J., & Scott, D. (2010). The effectiveness of anti-TNF-α therapies when used sequentially in rheumatoid arthritis patients: A systematic review and meta-analysis. *Rheumatology*, **49**(12), 2313–2321. https://doi.org/10.1093/rheumatology/keq169

Examples

```
### Show first five studies
head(dat.lloyd2010, 5)

## Not run:
### Load meta package
suppressPackageStartupMessages(library(meta))

### Only consider studies providing data for both outcomes
lloyd5 <- subset(dat.lloyd2010, !is.na(mean.haq) & !is.na(mean.das))

### Univariate meta-analysis of the DAS-28 outcome
m.das <- metagen(mean.das,
  lower = lower.das, upper = upper.das,
  data = lloyd5, sm = "MD",
  studlab = paste(author, year),
  random = FALSE)

### Univariate meta-analysis of the HAQ outcome
m.haq <- metagen(mean.haq,
  lower = lower.haq, upper = upper.haq,
  data = lloyd5, sm = "MD",
  studlab = paste(author, year),
  random = FALSE)

### Forest plots
forest(m.das, test.overall = TRUE, hetstat = FALSE,
  digits.TE = 2, digits.se = 2)
forest(m.haq, test.overall = TRUE, hetstat = FALSE,
  digits.TE = 2, digits.se = 2)

## End(Not run)
```

---

dat.lopez2019 *Studies on the Effectiveness of CBT for Depression*

Description

Results from 76 studies examining the effectiveness of cognitive behavioral therapy (CBT) for depression in adults.

Usage

```
dat.lopez2019
```

Format

The data frame contains the following columns:

study	character	(first) author and year of study
treatment	character	treatment provided (see 'Details')
scale	character	scale used to measure depression symptoms
n	numeric	group size
diff	numeric	standardized mean change
se	numeric	corresponding standard error
group	numeric	type of therapy (0 = individual, 1 = group therapy)
tailored	numeric	whether the intervention was tailored to each patient (0 = no, 1 = yes)
sessions	numeric	number of sessions
length	numeric	average session length (in minutes)
intensity	numeric	product of sessions and length
multi	numeric	intervention included multimedia elements (0 = no, 1 = yes)
cog	numeric	intervention included cognitive techniques (0 = no, 1 = yes)
ba	numeric	intervention included behavioral activation (0 = no, 1 = yes)
psed	numeric	intervention included psychoeducation (0 = no, 1 = yes)
home	numeric	intervention included homework (0 = no, 1 = yes)
prob	numeric	intervention included problem solving (0 = no, 1 = yes)
soc	numeric	intervention included social skills training (0 = no, 1 = yes)
relax	numeric	intervention included relaxation (0 = no, 1 = yes)
goal	numeric	intervention included goal setting (0 = no, 1 = yes)
final	numeric	intervention included a final session (0 = no, 1 = yes)
mind	numeric	intervention included mindfulness (0 = no, 1 = yes)
act	numeric	intervention included acceptance and commitment therapy (0 = no, 1 = yes)

Details

The dataset includes the results from 76 studies examining the effectiveness of cognitive behavioral therapy (CBT) for treating depression in adults. Studies included two or more of the following treatments/conditions:

1. treatment as usual (TAU),
2. no treatment,
3. wait list,
4. psychological or attention placebo,
5. face-to-face CBT,
6. multimedia CBT,
7. hybrid CBT (i.e., multimedia CBT with one or more face-to-face sessions).

Multimedia CBT was defined as CBT delivered via self-help books, audio/video recordings, telephone, computer programs, apps, e-mail, or text messages.

Variable `diff` is the standardized mean change within each group, with negative values indicating a decrease in depression symptoms.

Concepts

psychiatry, standardized mean changes, network meta-analysis

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Personal communication.

References

López-López, J. A., Davies, S. R., Caldwell, D. M., Churchill, R., Peters, T. J., Tallon, D., Dawson, S., Wu, Q., Li, J., Taylor, A., Lewis, G., Kessler, D. S., Wiles, N., & Welton, N. J. (2019). The process and delivery of CBT for depression in adults: A systematic review and network meta-analysis. *Psychological Medicine*, **49**(12), 1937–1947. https://doi.org/10.1017/S003329171900120X

Examples

```
### copy data into 'dat' and examine data
dat <- dat.lopez2019
dat[1:10,1:6]

## Not run:
### load metafor package
library(metafor)

### create network graph ('igraph' package must be installed)
library(igraph, warn.conflicts=FALSE)
pairs <- data.frame(do.call(rbind,
  sapply(split(dat$treatment, dat$study), function(x) t(combn(x,2)))), stringsAsFactors=FALSE)
pairs$X1 <- factor(pairs$X1, levels=sort(unique(dat$treatment)))
pairs$X2 <- factor(pairs$X2, levels=sort(unique(dat$treatment)))
tab <- table(pairs[,1], pairs[,2])
tab # adjacency matrix
g <- graph_from_adjacency_matrix(tab, mode = "plus", weighted=TRUE, diag=FALSE)
plot(g, edge.curved=FALSE, edge.width=E(g)$weight/2,
   layout=layout_in_circle(g, order=c("Wait list", "No treatment", "TAU", "Multimedia CBT",
                                      "Hybrid CBT", "F2F CBT", "Placebo")),
   vertex.size=45, vertex.color="lightgray", vertex.label.color="black", vertex.label.font=2)

### restructure data into wide format
dat <- to.wide(dat, study="study", grp="treatment", ref="TAU",
               grpvars=c("diff","se","n"), postfix=c("1","2"))

### compute contrasts between treatment pairs and corresponding sampling variances
dat$yi <- with(dat, diff1 - diff2)
dat$vi <- with(dat, se1^2 + se2^2)

### calculate the variance-covariance matrix for multitreatment studies
```

```
calc.v <- function(x) {
   v <- matrix(x$se2[1]^2, nrow=nrow(x), ncol=nrow(x))
   diag(v) <- x$vi
   v
}
V <- bldiag(lapply(split(dat, dat$study), calc.v))

### add contrast matrix to the dataset
dat <- contrmat(dat, grp1="treatment1", grp2="treatment2")

### network meta-analysis using a contrast-based random-effects model
### by setting rho=1/2, tau^2 reflects the amount of heterogeneity for all treatment comparisons
### the treatment left out (TAU) becomes the reference level for the treatment comparisons
res1 <- rma.mv(yi, V, data=dat,
      mods = ~ 0 + No.treatment + Wait.list + Placebo + F2F.CBT + Hybrid.CBT + Multimedia.CBT,
         random = ~ comp | study, rho=1/2)
res1

### forest plot of the contrast estimates (treatments versus TAU)
forest(coef(res1), diag(vcov(res1)), slab=sub(".", " ", names(coef(res1)), fixed=TRUE),
       xlim=c(-5,5), alim=c(-3,3), psize=1, header="Treatment",
       xlab="Difference in Standardized Mean Change (compared to TAU)")

### fit random inconsistency effects model (might have to switch optimizer to get convergence)
res2 <- rma.mv(yi, V, data=dat,
      mods = ~ 0 + No.treatment + Wait.list + Placebo + F2F.CBT + Hybrid.CBT + Multimedia.CBT,
         random = list(~ comp | study, ~ comp | design), rho=1/2, phi=1/2,
         control=list(optimizer="BFGS"))
res2

### likelihood ratio test comparing the two models
anova(res1, res2)

### collapse the different CBT forms into a single category
dat$CBT <- with(dat, ifelse(F2F.CBT + Hybrid.CBT + Multimedia.CBT > 0, 1, 0))

### fit the model with this treatment indicator
res3 <- rma.mv(yi, V, data=dat,
         mods = ~ 0 + No.treatment + Wait.list + Placebo + CBT,
         random = ~ comp | study, rho=1/2)
res3

### component network meta-analysis (effect of CBT may be larger/smaller depending on
### the presence of various components; leaving out 'mind' and 'act' as in the paper)
res4 <- rma.mv(yi, V, data=dat,
         mods = ~ 0 + No.treatment + Wait.list + Placebo + CBT +
         CBT:(multi + cog + ba + psed + home + prob + soc + relax + goal + final),
         random = ~ comp | study, rho=1/2)
res4

rownames <- names(coef(res4))
rownames <- sub(".", " ", rownames, fixed=TRUE)
rownames[5:14] <- c("Multimedia", "Cognitive Techniques", "Behavioral Activiation",
```

```
                "Psycheducation", "Homework", "Problem Solving", "Social Skills Training",
                    "Relaxation", "Goal Setting", "Final Session")

### forest plot of the estimates
forest(coef(res4), diag(vcov(res4)), slab=rownames,
       xlim=c(-5,5), alim=c(-3,3), psize=1, header="Treatment",
       xlab="Difference in Standardized Mean Change (compared to TAU)")
abline(h=10.5, lty="dashed")

## End(Not run)
```

`dat.maire2019` *Studies on Temporal Trends in Fish Community Structures in French Rivers*

Description

Results from studies examining changes in the abundance of fish species in French rivers.

Usage

```
dat.maire2019
```

Format

The object is a list containing a data frame called `dat` that contains the following columns and distance matrix called `dmat`:

site	`character`	study site
station	`character`	sampling station at site
site_station	`character`	site and station combined
s1	`numeric`	Mann-Kendal trend statistic for relative abundance of non-local species
vars1	`numeric`	corresponding sampling variance (corrected for temporal autocorrelation)
s2	`numeric`	Mann-Kendal trend statistic for relative abundance of northern species
vars2	`numeric`	corresponding sampling variance (corrected for temporal autocorrelation)
s3	`numeric`	Mann-Kendal trend statistic for relative abundance of non-native species
vars3	`numeric`	corresponding sampling variance (corrected for temporal autocorrelation)
const	`numeric`	constant value of 1

Details

The dataset includes the results from 35 sampling stations (at 11 sites along various French rivers) examining the abundance of various fish species over time (i.e., over 19-37 years, all until 2015). The temporal trend in these abundance data was quantified in terms of Mann-Kendal trend statistics, with positive values indicating monotonically increasing trends. The corresponding sampling variances were corrected for the temporal autocorrelation in the data (Hamed & Rao, 1998).

The distance matrix `dmat` indicates the distance of the sampling stations (1-423 river-km). For stations not connected through the river network, a high distance value of 10,000 river-km was set (effectively forcing the spatial correlation to be 0 for such stations).

The dataset can be used to illustrate a meta-analysis allowing for spatial correlation in the outcomes.

Concepts

ecology, climate change, spatial correlation

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Maire, A., Thierry, E., Viechtbauer, W., & Daufresne, M. (2019). Poleward shift in large-river fish communities detected with a novel meta-analysis framework. *Freshwater Biology*, **64**(6), 1143–1156. https://doi.org/10.1111/fwb.13291

References

Hamed, K. H., & Rao, A. R. (1998). A modified Mann-Kendall trend test for autocorrelated data. *Journal of Hydrology*, **204**(1-4), 182–196. https://doi.org/10.1016/S0022-1694(97)00125-X

Examples

```
### copy data into 'dat' and examine data
dat <- dat.maire2019$dat
dat[-10]

### copy distance matrix into 'dmat' and examine first 5 rows/columns
dmat <- dat.maire2019$dmat
dmat[1:5,1:5]

## Not run:
### load metafor package
library(metafor)

### fit a standard random-effects model ignoring spatial correlation
res1 <- rma.mv(s1, vars1, random = ~ 1 | site_station, data=dat)
res1

### fit model allowing for spatial correlation
res2 <- rma.mv(s1, vars1, random = ~ site_station | const, struct="SPGAU",
               data=dat, dist=list(dmat), control=list(rho.init=10))
res2

### add random effects for sites and stations within sites
res3 <- rma.mv(s1, vars1, random = list(~ 1 | site/station, ~ site_station | const), struct="SPGAU",
               data=dat, dist=list(dmat), control=list(rho.init=10))
res3

### likelihood ratio tests comparing the models
anova(res1, res2)
anova(res2, res3)

### profile likelihood plots for model res2
```

```
profile(res2, cline=TRUE)

### effective range (river-km for which the spatial correlation is >= 0.05)
sqrt(3) * res2$rho

### note: it was necessary to adjust the starting value for rho in models
### res2 and res3 so that the optimizer does not get stuck in a local maximum
profile(res2, rho=1, xlim=c(0,200), steps=100)

## End(Not run)
```

`dat.mccurdy2020` *Studies on the Generation Effect*

Description

Results from 126 articles that examined the so-called 'generation effect'.

Usage

```
dat.mccurdy2020
```

Format

The data frame contains the following columns:

article	numeric	article identifier
experiment	character	experiment (within article) identifier
sample	numeric	sample (within experiment) identifier
id	numeric	row identifier
pairing	numeric	identifier to indicate paired conditions within experiments
yi	numeric	mean recall rate for the condition
vi	numeric	corresponding sampling variance
ni	numeric	number of participants for the condition
stimuli	numeric	number of stimuli for the condition
condition	factor	condition ('read' or 'generate')
gen_difficulty	factor	generation difficulty ('low' or 'high')
manip_type	factor	manipulation type of the generate versus read condition (using a 'within' or 'between' subje
present_style	factor	presentation style ('mixed' or 'pure' list presentation)
word_status	factor	word status ('words', 'non-words', or 'numbers')
memory_test	factor	memory test ('recognition', 'cued recall', or 'free recall')
memory_type	factor	memory type ('item', 'source', 'font color', 'font type', 'order', 'cue word', 'background co
gen_constraint	factor	generation constraint ('low', 'medium', or 'high')
learning_type	factor	learning type ('incidental' or 'intentional')
stimuli_relation	factor	stimuli relation ('semantic', 'category', 'antonym', 'synonym', 'rhyme', 'compound words',
gen_mode	factor	generation mode ('verbal/speaking', 'covert/thinking', or 'writing/typing')
gen_task	factor	generation task ('anagram', 'letter transposition', 'word fragment', 'sentence completion', '
attention	factor	attention ('divided' or 'full')

pacing	`factor`	pacing ('self-paced' or 'timed')
filler_task	`factor`	filler task ('yes' or 'no')
age_grp	`factor`	age group ('younger' or 'older' adults)
retention_delay	`factor`	retention delay ('immediate', 'short', or 'long')

Details

The generation effect is the memory benefit for self-generated compared with read or experimenter-provided information (Jacoby, 1978; Slamecka & Graf, 1978). In a typical study, participants are presented with a list of stimuli (usually words or word pairs). For half of the stimuli, participants self-generate a target word (e.g., open–cl____), while for the other half, participants simply read an intact target word (e.g., above–below). On a later memory test for the target words, the common finding is that self-generated words are better remembered than read words (i.e., the generation effect).

Although several theories have been proposed to explain the generation effect, there is still some debate on the underlying memory mechanism(s) contributing to this phenomenon. The meta-analysis by McCurdy et al. (2020) translated various theories on the generation effect into hypotheses that could then be tested in moderator analyses based on a dataset containing 126 articles, 310 experiments, and 1653 mean recall estimates collected under various conditions.

Detailed explanations of the various variables coded (and how these can be used to test various hypotheses regarding the generation effect) can be found in the article. The most important variable is `condition`, which denotes whether a particular row of the dataset corresponds to the results of a 'read' or a 'generate' condition.

The data structure is quite complex. Articles may have reported the findings from multiple experiments involving one or multiple samples that were examined under various conditions. The `pairing` variable indicates which rows of the dataset represent a pairing of a read condition with one or multiple corresponding generate conditions within an experiment. A pairing may involve the same sample of subjects (when using a within-subjects design for comparing the conditions) or different samples (when using a between-subjects design).

Concepts

psychology, memory, proportions, raw means, multilevel models, cluster-robust inference

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

McCurdy, M. P., Viechtbauer, W., Sklenar, A. M., Frankenstein, A. N., & Leshikar, E. D. (2020). Theories of the generation effect and the impact of generation constraint: A meta-analytic review. *Psychonomic Bulletin & Review*, **27**(6), 1139–1165. https://doi.org/10.3758/s13423-020-01762-3

References

Slamecka, N. J., & Graf, P. (1978). The generation effect: Delineation of a phenomenon. *Journal of Experimental Psychology: Human Learning and Memory*, **4**(6), 592–604. https://doi.org/10.1037/0278-7393.4.6.59

Jacoby, L. L. (1978). On interpreting the effects of repetition: Solving a problem versus remembering a solution. *Journal of Verbal Learning and Verbal Behavior*, **17**(6), 649–668. https://doi.org/10.1016/S0022-5371(

Examples

```
### copy data into 'dat' and examine data
dat <- dat.mccurdy2020
head(dat)

## Not run:
### load metafor package
library(metafor)

### fit multilevel mixed-effects meta-regression model
res <- rma.mv(yi, vi, mods = ~ condition,
              random = list(~ 1 | article/experiment/sample/id, ~ 1 | pairing),
              data=dat, sparse=TRUE, digits=3)
res

### proportion of total amount of heterogeneity due to each component
data.frame(source=res$s.names, sigma2=round(res$sigma2, 3),
   prop=round(res$sigma2 / sum(res$sigma2), 2))

### apply cluster-robust inference methods
sav <- robust(res, cluster=article, clubSandwich=TRUE)
sav

### estimated average recall rate in read and generate conditions
predict(sav, newmods = c(0,1), digits=3)

## End(Not run)
```

---

dat.mcdaniel1994 *Studies on the Validity of Employment Interviews*

Description

Results from 160 studies on the correlation between employment interview assessments and job performance.

Usage

```
dat.mcdaniel1994
```

Format

The data frame contains the following columns:

study numeric study number

ni	numeric	sample size of the study
ri	numeric	observed correlation
type	character	interview type (j = job-related, s = situational, p = psychological)
struct	character	interview structure (u = unstructured, s = structured)

Details

The 160 studies provide data in terms of the correlation between employment interview performance and actual job performance. In addition, the interview type and the interview structure are indicated.

McDaniel et al. (1994) describe the interview type and structure variables as follows. "Questions in situational interviews [...] focus on the individual's ability to project what his or her behavior would be in a given situation. [...] Job-related interviews are those in which the interviewer is a personnel officer or hiring authority and the questions attempt to assess past behaviors and job-related information, but most questions are not considered situational. Psychological interviews are conducted by a psychologist, and the questions are intended to assess personal traits, such as dependability." In structured interviews, "the questions and acceptable responses were specified in advance and the responses were rated for appropriateness of content. [...] Unstructured interviews gather applicant information in a less systematic manner than do structured interviews. Although the questions may be specified in advance, they usually are not, and there is seldom a formalized scoring guide. Also, all persons being interviewed are not typically asked the same questions."

The goal of the meta-analysis was to examine the overall criterion-related validity of employment interviews and to examine whether the validity depends on the type and structure of the interview.

The data in this dataset were obtained from Table A.2 in Rothstein, Sutton, and Borenstein (2005, p. 325-329). Note that the `type` and `struct` variables contain some `NA`s.

Concepts

psychology, correlation coefficients, meta-regression

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Rothstein, H. R., Sutton, A. J., & Borenstein, M. (Eds.). (2005). *Publication bias in meta-analysis: Prevention, assessment, and adjustments*. Chichester, England: Wiley.

References

McDaniel, M. A., Whetzel, D. L., Schmidt, F. L., & Maurer, S. D. (1994). The validity of employment interviews: A comprehensive review and meta-analysis. *Journal of Applied Psychology*, **79**(4), 599–616. https://doi.org/10.1037/0021-9010.79.4.599

Examples

```
### copy data into 'dat' and examine data
dat <- dat.mcdaniel1994
head(dat)

## Not run:
### load metafor package
library(metafor)

### calculate r-to-z transformed correlations and corresponding sampling variances
dat <- escalc(measure="ZCOR", ri=ri, ni=ni, data=dat)
head(dat)

### meta-analysis of the transformed correlations using a random-effects model
res <- rma(yi, vi, data=dat)
res

### average correlation with 95% CI
predict(res, transf=transf.ztor, digits=2)

### mixed-effects model with interview type as factor
### note: job-related interviews is the reference level
res <- rma(yi, vi, mods = ~ factor(type), data=dat)
res

### estimated average correlation for each level of interview type
res <- rma(yi, vi, mods = ~ 0 + factor(type), data=dat)
predict(res, newmods=diag(3), transf=transf.ztor, digits=2)

### mixed-effects model with interview structure as factor
### note: structured interviews is the reference level
res <- rma(yi, vi, mods = ~ factor(struct), data=dat)
res

### estimated average correlation for each level of interview structure
res <- rma(yi, vi, mods = ~ 0 + factor(struct), data=dat)
predict(res, newmods=diag(2), transf=transf.ztor, digits=2)

### note: the interpretation of the results is difficult since all
### situational interviews were structured, almost all psychological
### interviews were unstructured, and actually for the majority of
### the psychological interviews it was unknown whether the interview
### was structured or unstructured
table(dat$type, dat$struct, useNA="always")

### meta-analysis of raw correlations using a random-effects model
res <- rma(measure="COR", ri=ri, ni=ni, data=dat.mcdaniel1994)
res

## End(Not run)
```

dat.meeker2017 *Baseball Batting Averages*

Description

Batting averages in 2014 for 10 baseball teams.

Usage

```
dat.meeker2017
```

Format

The data frame contains the following columns:

team	character	baseball team
division	factor	division
mean	numeric	batting average (team sample mean)
se	numeric	team standard error
batters	integer	number of batters

Details

Meeker, Hahn, and Escobar (2017) considered an example application concerning batting averages from 10 baseball teams during 2014. The data (from chapter 17) consist of sample means (batting averages) and corresponding standard errors for each team's batters who had at least 300 *at-bats*. Baseball teams are associated with one of two divisions, namely *American League Central (AL-C)* or *National League Central (NL-C)*.

Concepts

sports, raw means

Author(s)

Christian Röver, <christian.roever@med.uni-goettingen.d>

Source

Meeker, W. Q. , Hahn, G. J., & Escobar, L. A. (2017). *Statistical intervals: A guide for practitioners and researchers* (2nd ed.). Hoboken, NJ: John Wiley and Sons.

Examples

```
dat.meeker2017

## Not run:
library(metafor)
library(bayesmeta)

# convert data to an "escalc" object
es <- escalc(measure="GEN",
             yi=mean, sei=se, slab=team, ni=batters,
             data=dat.meeker2017)

# illustrate the plain data
forestplot(es, zero=NA, title="baseball batting averages (dat.meeker2017)")

# specify regressor matrix,
# distinguishing between AL-C and NL-C divisions
Xmat <- cbind("intercept" = 1,
              "offset"    = rep(c(0.5, -0.5), each=5))
rownames(Xmat) <- rownames(dat.meeker2017)
Xmat

# reproduce analysis from Sec.17.2
# (using improper uniform priors for all 3 parameters)
mreg <- bmr(es, X=Xmat)
mreg

# generate a plot similar to Fig.17.2
forestplot(mreg,
           X.mean=rbind("AL-C" = c(1, 0.5),
                        "NL-C" = c(1, -0.5),
                        "mu"   = c(1, 0)),
           xlab="batting average", zero=NA)

# show more summary stats for some estimates
summary(mreg,
        X.mean=rbind("AL-C"              = c(1, 0.5),
                     "NL-C"              = c(1, -0.5),
                     "mean (mu)"         = c(1, 0),
                     "difference (beta)" = c(0, 1)))

# show shrinkage estimates
t(mreg$theta)

# show trace plot
traceplot(mreg,
          X=rbind("AL-C" = c(1, 0.5),
                  "NL-C" = c(1, -0.5)),
          infinity=TRUE, ylab="batting average")

## End(Not run)
```

`dat.metap` *Example Data for the Meta-Analysis of Significance Values*

Description

A collection of datasets for illustrating the meta-analysis of significance values (i.e., methods for combining p-values from tests of significance).

Usage

```
dat.metap
```

Format

A list with the following elements:

`beckerp` A numeric vector with 5 hypothetical p-values

`cholest` A data frame with 34 observations on the following 5 variables:

ntreat	`numeric`	number of patients in the treated group
ncontrol	`numeric`	number of patients in the control group
dtreat	`numeric`	number of deaths in the treated group
dcontrol	`numeric`	number of deaths in the control group
p	`numeric`	one-sided p-values

`edgington` A vector of with 7 hypothetical p-values

`mourning` A data frame with 9 observations on the following 3 variables:

stance	`character`	character variable with levels `No stand`, `Opponent`, `Supporter`
grade	`character`	character variable with levels `G11-12`, `G7-8`, `G9-10`
p	`numeric`	p-values

`naep` A data frame with 34 observations on the following 2 variables:

state	`character`	character variable with two-letter US state names
p	`numeric`	p-values

`rosenthal` A data frame with 5 observations on the following 3 variables:

t	`numeric`	t-statistics
df	`numeric`	degrees of freedom
p	`numeric`	one-sided p-values

`teachexpect` A vector of 19 p-values

`validity` A data frame with 20 observations on the following 3 variables:

n	`numeric`	sample sizes
r	`numeric`	correlation coefficients
p	`numeric`	one-sided p-values

`zhang` A data frame with 22 observations on the following 11 variables:

study	`character`	study names
smd	`numeric`	standardized mean differences
lo	`numeric`	lower confidence interval limits
hi	`numeric`	upper confidence interval limits
ntreat	`numeric`	treated group sample sizes
ncont	`numeric`	control group sample sizes
n	`numeric`	total sample sizes
phase	`factor`	phase the patients were in: acute, healing, healed
sd	`numeric`	the calculated standard deviations
z	`numeric`	the calculated z-values
p	`numeric`	one-sided p-values

Details

`beckerp` Hypothetical p-values from Becker (1994).

`cholest` Trials of interventions for cholesterol lowering from Sutton et al. (2000).

`edgington` Hypothetical p-values from Edgington (1972).

`mourning` Results from a study of mourning practices of Israeli youth following the assassination of Itzakh Rabin from Benjamini and Hochberg (2000).

`naep` Results of mathematical achievement scores from the National Assessment of Educational Progress from Benjamini and Hochberg (2000).

`rosenthal` Hypothetical example from Rosenthal (1978).

`teachexpect` p-values from studies of the effect of manipulating teacher expectancy on student IQ from Becker (1994).

`validity` Data from studies of validity of student ratings of their instructors from Becker (1994) including correlations and sample sizes as well as p-values.

`zhang` Data from trials of exercise training for patients with cardiovascular disease from Zhang et al. (2016).

Concepts

combining p-values

Note

The p-values in `cholest` have been re-calculated from other data given in the book and so are of higher accuracy than the ones given in the book which are only to two decimal places.

Author(s)

Michael Dewey

References

Becker, B. J. (1994). Combining significance levels. In H. Cooper & L. V. Hedges (Eds.), *The handbook of research synthesis* (pp. 215–230). New York: Russell Sage Foundation.

Benjamini, Y., & Hochberg, Y. (2000). On the adaptive control of the false discovery rate in multiple testing with independent statistics. *Journal of Educational and Behavioral Statistics*, **25**(1), 60–83. https://doi.org/10.3102/10769986025001060

Edgington, E. S. (1972). An additive method for combining probability values from independent experiments. *Journal of Psychology*, **80**(2), 351-363. https://doi.org/10.1080/00223980.1972.9924813

Rosenthal, R. (1978). Combining results of independent studies. *Psychological Bulletin*, **85**(1), 185–193. https://doi.org/10.1037/0033-2909.85.1.185

Sutton, A. J., Abrams, K. R., Jones, D. R., Sheldon, T. A., & Song, F. (2000). *Methods for meta-analysis in medical research*. Chichester, UK: Wiley.

Zhang, Y.-M., Lu, Y., Tang, Y., Yang, D., Wu, H.-F., Bian, Z.-P., Xu, J.-D., Gu, C.-R., Wang, L.-S., & Chen, X.-J. (2016). The effects of different initiation time of exercise training on left ventricular remodeling and cardiopulmonary rehabilitation in patients with left ventricular dysfunction after myocardial infarction. *Disability and Rehabilitation*, **38**(3), 268–276. https://doi.org/10.3109/09638288.2015.103617

Examples

```
dat.metap
```

---

dat.michael2013 *The Non-Persuasive Power of a Brain Image*

Description

Results from studies exploring how a superfluous fMRI brain image influences the persuasiveness of a scientific claim.

Usage

```
dat.michael2013
```

Format

The data frame contains the following columns:

Study	character	name of the study: Citation - Experiment - Subgroup
No_brain_n	numeric	sample size for no-brain-image condition
No_brain_m	numeric	mean agreement rating for no-brain-image condition
No_brain_s	numeric	standard deviation for no-brain-image condition

Brain_n	numeric	sample size for brain-image condition
Brain_m	numeric	mean agreement rating for brain-image condition
Brain_s	numeric	standard deviation for brain-image condition
Included_Critique	character	'Critique' if article included critical commentary on conclusions, otherwise 'No_critique'
Medium	character	'Paper' if conducted in person; 'Online' if conducted online
Compensation	character	notes on compensation provided to participants
Participant_Pool	character	notes on where participants were recruited
yi	numeric	raw mean difference, calculated as `Brain_m - No_brain_m`
vi	numeric	corresponding sampling variance

Details

The dataset contains the data from the meta-analysis by Michael et al. (2013) of experiments on the persuasive power of a brain image. The meta-analysis analyzed an original study by McCabe and Castel (2008) as well as 10 replication attempts conducted by the authors of the meta-analysis.

In each study, participants read an article about using brain imaging as a lie detector. The article either included a superfluous fMRI image of a brain (brain) or not (no_brain). After reading the article, all participants responded to the statement "Do you agree or disagree with the conclusion that brain imaging can be used as a lie detector?" on a scale from 1 (strongly disagree) to 4 (strongly agree).

The original study by McCabe and Castel (2008) reported a relatively large increase in agreement due to the presence of brain images. Meta-analysis of the original study with the 10 replications suggests, however, a small, possibly null effect: an estimated average raw mean difference of 0.07 points, 95% CI [-0.00, 0.14], under a random-effects model.

In some studies, the article included a passage critiquing the primary claims made in the article; this is coded in the `Included_Critique` column for analysis as a possible moderator. Note that Experiment 3 by McCabe and Castel (2008) was a 2x2 between subjects design: brain image presence was manipulated as well as the inclusion of a critique. The two different critique conditions are recorded as separate rows in this dataset. Analysis of this dataset with metafor yields the same results (given rounding) reported in the manuscript.

Concepts

psychology, persuasion, raw mean differences

Author(s)

Robert Calin-Jageman, <rcalinjageman@dom.edu>, https://calin-jageman.net

Source

Michael, R. B., Newman, E. J., Vuorre, M., Cumming, G., & Garry, M. (2013). On the (non)persuasive power of a brain image. *Psychonomic Bulletin & Review*, **20**(4), 720—725. https://doi.org/10.3758/s13423-013-0391-

References

McCabe, D. P., & Castel, A. D. (2008). Seeing is believing: The effect of brain images on judgments of scientific reasoning. *Cognition*, **107**(1), 343–352. https://doi.org/10.1016/j.cognition.2007.07.017

Examples

```
### copy data into 'dat' and examine data
dat <- dat.michael2013
dat

## Not run:
### load metafor package
library(metafor)

### Data prep
# yi and vi are already provided, but here's how you would use escalc() to obtain
# a raw-mean difference and its variance.
# Note the measure parameter is "MD" for 'raw mean difference'
dat <- metafor::escalc(
  measure = "MD",
  m1i = Brain_m,
  m2i = No_brain_m,
  sd1i = Brain_s,
  sd2i = No_brain_s,
  n1i = Brain_n,
  n2i = No_brain_n,
  data = dat
)

### meta-analysis using a random-effects model of the raw mean differences
res <- rma(yi, vi, data=dat)
print(res, digits=2)

### examine if Included_Critique is a potential moderator
res <- rma(yi, vi, mods = ~ Included_Critique, data=dat)
print(res, digits=2)

## End(Not run)
```

---

dat.molloy2014 *Studies on the Relationship between Conscientiousness and Medication Adherence*

Description

Results from 16 studies on the correlation between conscientiousness and medication adherence.

Usage

```
dat.molloy2014
```

Format

The data frame contains the following columns:

authors	character	study authors
year	numeric	publication year
ni	numeric	sample size of the study
ri	numeric	observed correlation
controls	character	number of variables controlled for
design	character	whether a cross-sectional or prospective design was used
a_measure	character	type of adherence measure (self-report or other)
c_measure	character	type of conscientiousness measure (NEO or other)
meanage	numeric	mean age of the sample
quality	numeric	methodological quality

Details

Conscientiousness, one of the big-5 personality traits, can be defined as "socially prescribed impulse control that facilitates task- and goal-directed behaviour, such as thinking before acting, delaying gratification, following norms and rules and planning, organising and prioritising tasks" (John & Srivastava, 1999). Conscientiousness has been shown to be related to a number of health-related behaviors (e.g., tobacco/alcohol/drug use, diet and activity patterns, risky behaviors). A recent meta-analysis by Molloy et al. (2014) examined to what extent conscientiousness is related to medication adherence, that is, the extent to which (typically chronically ill) patients follow a prescribed medication regimen (e.g., taking a daily dose of a cholesterol lowering drug in patients with high LDL serum cholesterol levels). The results from the 16 studies included in this meta-analysis are provided in this dataset.

Variable `a_measure` indicates whether adherence was measured based on self-reports or a more 'objective' measure (e.g., electronic monitoring of pill bottle openings, pill counts). Variable `c_measure` indicates whether conscientiousness was measured with some version of the NEO personality inventory or some other scale. Methodological quality was scored by the authors on a 1 to 4 scale with higher scores indicating higher quality (see article for details on how this score was derived).

Concepts

psychology, medicine, correlation coefficients

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Molloy, G. J., O'Carroll, R. E., & Ferguson, E. (2014). Conscientiousness and medication adherence: A meta-analysis. *Annals of Behavioral Medicine*, **47**(1), 92–101. https://doi.org/10.1007/s12160-013-9524-4

References

John, O. P., & Srivastava, S. (1999). The Big Five Trait taxonomy: History, measurement, and theoretical perspectives. In L. A. Pervin & O. P. John (Eds.), *Handbook of personality: Theory and research* (2nd ed., pp. 102-138). New York: Guilford Press.

Examples

```
### copy data into 'dat' and examine data
dat <- dat.molloy2014
dat[-c(5:6)]

## Not run:
### load metafor package
library(metafor)

### calculate r-to-z transformed correlations and corresponding sampling variances
dat <- escalc(measure="ZCOR", ri=ri, ni=ni, data=dat, slab=paste(authors, year, sep=", "))
dat[-c(5:6)]

### meta-analysis of the transformed correlations using a random-effects model
res <- rma(yi, vi, data=dat)
res

### average correlation with 95% CI
predict(res, digits=3, transf=transf.ztor)

### forest plot
forest(res, addpred=TRUE, xlim=c(-1.6,1.6), atransf=transf.ztor,
       at=transf.rtoz(seq(-0.4, 0.6, by=0.2)), digits=c(2,1), cex=0.9,
       header="Author(s), Year")

### funnel plot
funnel(res)

## End(Not run)
```

---

dat.moore1998 *Trials on Non-Steroidal Anti-Inflammatory Drugs in Acute Pain*

Description

Results from 37 trials evaluating non-steroidal anti-inflammatory drugs (NSAIDS) in patients with acute pain.

Usage

```
dat.moore1998
```

Format

The data frame contains the following columns:

id	integer	study ID
author	character	first author
year	integer	publication year
Ee	integer	number of treatment successes (NSAIDS group)
Ne	integer	number of patients (NSAIDS group)
Ec	integer	number of treatment successes (control group)
Nc	integer	number of patients (control group)
nonenglish	integer	non-English publication
medline	integer	listed in Medline
grey	integer	grey literature
samecont	integer	same control group
journal	character	journal

Details

Moore et al. (1998) conducted a systematic review of 37 randomized placebo-controlled trials on the effectiveness and safety of topical non-steroidal anti-inflammatory drugs (NSAIDS) in acute pain. The main outcome was treatment success, defined as a reduction in pain of at least 50%.

This data set is used as an example in Schwarzer et al. (2015).

Concepts

medicine, odds ratios, publication bias

Author(s)

Guido Schwarzer, <guido.schwarzer@uniklinik-freiburg.de>, https://github.com/guido-s/

Source

Moore, R. A., Tramèr, M. R., Carroll, D., Wiffen, P. J., & McQuay, H. J. (1998). Quantitive systematic review of topically applied non-steroidal anti-inflammatory drugs. *British Medical Journal*, **316**(7128), 333–338. https://doi.org/10.1136/bmj.316.7128.333

References

Schwarzer, G., Carpenter, J. R., & Rücker, G. (2015). *Meta-analysis with R*. Cham, Switzerland: Springer.

Examples

```
### Show first five studies
head(dat.moore1998, 5)

## Not run:
### Load meta package
```

```
suppressPackageStartupMessages(library(meta))

### Conduct meta-analysis
m <- metabin(Ee, Ne, Ec, Nc, data = dat.moore1998,
  sm = "OR", studlab = id,
  label.e = "NSAIDS", label.c = "Placebo")

### Funnel plot
fun <- funnel(m, type = "contour",
  random = FALSE, pch = 16)
legend(0.25, 1.25, bty = "n",
  legend = fun$text.contour, fill = fun$col.contour)

## End(Not run)
```

`dat.moura2021` *Studies on Assortative Mating*

Description

Results from 457 studies on assortative mating in various species.

Usage

```
dat.moura2021
```

Format

The object is a list containing a data frame called `dat` that contains the following columns and a phylogenetic tree called `tree`:

study.id	`character`	study id
effect.size.id	`numeric`	effect size id
species	`character`	species
species.id	`character`	species id (as in the Open Tree of Life reference taxonomy)
subphylum	`character`	the subphyla of the species
phylum	`character`	the phyla of the species
assortment.trait	`character`	the measure of body size
trait.dimensions	`character`	dimensionality of the measure
field.collection	`character`	whether data were collected in the field
publication.year	`numeric`	publication year of the study
pooled.data	`character`	whether data were pooled either spatially and/or temporally
spatially.pooled	`character`	whether data were pooled spatially
temporally.pooled	`character`	whether data were pooled temporally
ri	`numeric`	correlation coefficient
ni	`numeric`	sample size

Details

The 457 studies included in this dataset provide 1828 correlation coefficients describing the similarity in some measure of body size in mating couples in 341 different species.

Concepts

ecology, evolution, correlation coefficients, multivariate models, phylogeny, meta-regression

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Rios Moura, R., Oliveira Gonzaga, M., Silva Pinto, N., Vasconcellos-Neto, J., & Requena, G. S. (2021). Assortative mating in space and time: Patterns and biases. *Ecology Letters*, **24**(5), 1089–1102. https://doi.org/10.1111/ele.13690

References

Cinar, O., Nakagawa, S., & Viechtbauer, W. (in press). Phylogenetic multilevel meta-analysis: A simulation study on the importance of modelling the phylogeny. *Methods in Ecology and Evolution*. https://doi.org/10.1111/2041-210X.13760

Hadfield, J. D., & Nakagawa, S. (2010). General quantitative genetic methods for comparative biology: Phylogenies, taxonomies and multi-trait models for continuous and categorical characters. *Journal of Evolutionary Biology*, **23**(3), 494–508. https://doi.org/10.1111/j.1420-9101.2009.01915.x

Nakagawa, S., & Santos, E. S. A. (2012). Methodological issues and advances in biological meta-analysis. *Evolutionary Ecology*, **26**(5), 1253–1274. https://doi.org/10.1007/s10682-012-9555-5

Examples

```
### copy data into 'dat' and examine data
dat <- dat.moura2021$dat
head(dat)

## Not run:
### load metafor package
library(metafor)

### load ape package
library(ape, warn.conflicts=FALSE)

### calculate r-to-z transformed correlations and corresponding sampling variances
dat <- escalc(measure="ZCOR", ri=ri, ni=ni, data=dat)

### copy tree to 'tree'
tree <- dat.moura2021$tree

### turn tree into an ultrametric one
tree <- compute.brlen(tree)
```

```
### compute phylogenetic correlation matrix
A <- vcv(tree, corr=TRUE)

### make copy of the species.id variable
dat$species.id.phy <- dat$species.id

### fit multilevel phylogenetic meta-analytic model
res <- rma.mv(yi, vi,
  random = list(~ 1 | study.id, ~ 1 | effect.size.id, ~ 1 | species.id, ~ 1 | species.id.phy),
   R = list(species.id.phy=A), data=dat)
res

### examine if spatial and/or temporal pooling of data tends to yield larger correlations
res <- rma.mv(yi, vi,
   mods = ~ spatially.pooled * temporally.pooled,
  random = list(~ 1 | study.id, ~ 1 | effect.size.id, ~ 1 | species.id, ~ 1 | species.id.phy),
   R = list(species.id.phy=A), data=dat)
res

### estimated average correlation without pooling, when pooling spatially,
### when pooling temporally, and when pooling spatially and temporally
predict(res, newmods = rbind(c(0,0,0),c(1,0,0),c(0,1,0),c(1,1,1)), transf=transf.ztor, digits=2)

## End(Not run)
```

`dat.nakagawa2007` *Assessing the Function of House Sparrows' Bib Size Using a Flexible Meta-Analysis Method*

Description

A meta-analysis on the association between the size of a male's bib and their social status in house sparrows (*Passer domesticus*).

Usage

```
dat.nakagawa2007
```

Format

The data frame contains the following columns:

StudyID	`character`	identity of primary study
Place	`character`	location of study population
Correlation	`numeric`	correlation coefficient
SampleSize	`integer`	sample size of population

Details

Each study measures the association between a sparrows bib size and its social status. Effects are quantified as correlation coefficients.

Concepts

ecology, correlation coefficients

Author(s)

Daniel Noble, <daniel.noble@anu.edu.au>

Source

Nakagawa, S., Ockendon, N., Gillespie, D. O. S, Hatchwell, B. J., & Burke, T. (2007). Assessing the function of house sparrows' bib size using a flexible meta-analysis method. *Behavioral Ecology*, **18**(5), 831–840. https://doi.org/10.1093/beheco/arm050

Examples

```
### copy data into 'dat' and examine data
dat <- dat.nakagawa2007
dat

## Not run:
### load metafor package
library(metafor)

### calculate Zr
dat <- escalc(measure="ZCOR", ri=Correlation, ni=SampleSize, data=dat)

### fit meta-analytic model
res <- rma.mv(yi, vi, random = ~ 1 | StudyID, data=dat)
res

## End(Not run)
```

---

dat.nielweise2007 *Studies on Anti-Infective-Treated Central Venous Catheters for Prevention of Catheter-Related Bloodstream Infections*

Description

Results from 18 studies comparing the risk of catheter-related bloodstream infection when using anti-infective-treated versus standard catheters in the acute care setting.

Usage

```
dat.nielweise2007
```

Format

The data frame contains the following columns:

study	numeric	study number
author	character	(first) author
year	numeric	publication year
ai	numeric	number of CRBSIs in patients receiving an anti-infective catheter
n1i	numeric	number of patients receiving an anti-infective catheter
ci	numeric	number of CRBSIs in patients receiving a standard catheter
n2i	numeric	number of patients receiving a standard catheter

Details

The use of a central venous catheter may lead to a catheter-related bloodstream infection (CRBSI), which in turn increases the risk of morbidity and mortality. Anti-infective-treated catheters have been developed that are meant to reduce the risk of CRBSIs. Niel-Weise et al. (2007) conducted a meta-analysis of studies comparing infection risk when using anti-infective-treated versus standard catheters in the acute care setting. The results from 18 such studies are included in this dataset.

The dataset was used in the article by Stijnen et al. (2010) to illustrate various generalized linear mixed-effects models for the meta-analysis of proportions and odds ratios (see 'References').

Concepts

medicine, odds ratios, generalized linear models

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Niel-Weise, B. S., Stijnen, T., & van den Broek, P. J. (2007). Anti-infective-treated central venous catheters: A systematic review of randomized controlled trials. *Intensive Care Medicine*, **33**(12), 2058–2068. https://doi.org/10.1007/s00134-007-0897-3

References

Stijnen, T., Hamza, T. H., & Ozdemir, P. (2010). Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data. *Statistics in Medicine*, **29**(29), 3046–3067. https://doi.org/10.1002/sim.4040

Examples

```
### copy data into 'dat' and examine data
dat <- dat.nielweise2007
dat

## Not run:
### load metafor package
```

```
library(metafor)

### standard (inverse-variance) random-effects model
res <- rma(measure="OR", ai=ai, n1i=n1i, ci=ci, n2i=n2i, data=dat, drop00=TRUE)
print(res, digits=3)
predict(res, transf=exp, digits=2)

### random-effects conditional logistic model
res <- rma.glmm(measure="OR", ai=ai, n1i=n1i, ci=ci, n2i=n2i, data=dat, model="CM.EL")
print(res, digits=3)
predict(res, transf=exp, digits=2)

## End(Not run)
```

`dat.nielweise2008` *Studies on Anti-Infective-Treated Central Venous Catheters for Prevention of Catheter-Related Bloodstream Infections*

Description

Results from 18 studies comparing the risk of catheter-related bloodstream infection when using anti-infective-treated versus standard catheters for total parenteral nutrition or chemotherapy.

Usage

```
dat.nielweise2008
```

Format

The data frame contains the following columns:

study	`numeric`	study number
authors	`character`	study authors
year	`numeric`	publication year
x1i	`numeric`	number of CRBSIs in patients receiving an anti-infective catheter
t1i	`numeric`	total number of catheter days for patients receiving an anti-infective catheter
x2i	`numeric`	number of CRBSIs in patients receiving a standard catheter
t2i	`numeric`	total number of catheter days for patients receiving a standard catheter

Details

The use of a central venous catheter may lead to a catheter-related bloodstream infection (CRBSI), which in turn increases the risk of morbidity and mortality. Anti-infective-treated catheters have been developed that are meant to reduce the risk of CRBSIs. Niel-Weise et al. (2008) conducted a meta-analysis of studies comparing infection risk when using anti-infective-treated versus standard catheters for total parenteral nutrition or chemotherapy. The results from 9 such studies are included in this dataset.

The dataset was used in the article by Stijnen et al. (2010) to illustrate various generalized linear mixed-effects models for the meta-analysis of incidence rates and incidence rate ratios (see 'References').

Concepts

medicine, incidence rates, generalized linear models

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Niel-Weise, B. S., Stijnen, T., & van den Broek, P. J. (2008). Anti-infective-treated central venous catheters for total parenteral nutrition or chemotherapy: A systematic review. *Journal of Hospital Infection*, **69**(2), 114–123. https://doi.org/10.1016/j.jhin.2008.02.020

References

Stijnen, T., Hamza, T. H., & Ozdemir, P. (2010). Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data. *Statistics in Medicine*, **29**(29), 3046–3067. https://doi.org/10.1002/sim.4040

Examples

```
### copy data into 'dat' and examine data
dat <- dat.nielweise2008
dat

## Not run:
### load metafor package
library(metafor)

### standard (inverse-variance) random-effects model
res <- rma(measure="IRR", x1i=x1i, t1i=t1i, x2i=x2i, t2i=t2i, data=dat)
print(res, digits=3)
predict(res, transf=exp, digits=2)

### random-effects conditional Poisson model
res <- rma.glmm(measure="IRR", x1i=x1i, t1i=t1i, x2i=x2i, t2i=t2i, data=dat, model="CM.EL")
print(res, digits=3)
predict(res, transf=exp, digits=2)

## End(Not run)
```

---

dat.nissen2007 — *Studies on the Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes*

Description

Results from 42 trials examining the effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

Usage

```
dat.nissen2007
```

Format

The data frame contains the following columns:

study	character	study identifier
type	factor	type of trial (as in Table 1)
phase	factor	study phase
population	character	description of the study population
start, **end**	character	study period (year-month)
treatment	character	treatment group medication
control	character	control group medication
weeks	numeric	follow-up duration (weeks)
treat.total	numeric	total number of patients in the treatment group
treat.infarction	numeric	number of patients with myocardial infarction in the treatment group
treat.death	numeric	number of deaths in the treatment group
cont.total	numeric	total number of patients in the control group
cont.infarction	numeric	number of patients with myocardial infarction in the control group
cont.death	numeric	number of deaths in the control group

Details

Nissen and Wolski (2007) performed a systematic literature review aiming for randomized controlled trials (RCTs) investigating the effects of Rosiglitazone (Avandia) in comparison to a control treatment, and with a follow-up duration of at least 24 weeks. 42 studies were included. A meta-analysis was performed to quantify the treatment effect on the risks of myocardial infarction and cardiovascular death in terms of the associated odds ratio (OR).

The data set features a number of "zero" trials (no event observed in one of the treatment groups) as well as "double-zero" trials (no event in either treatment group), which poses a challenge for some analysis methods. The original analysis was a common-effect analysis based on the *Peto method* (see the `rma.peto` help and the example code below). The data set as well as its original analysis have subsequently been discussed by other investigators (e.g., Diamond et al., 2007; Ruecker & Schumacher, 2008; Friedrich et al., 2009; Tian et al., 2009; Nissen & Wolski, 2010). Jackson et al. (2018) later surveyed a range of (random-effects) models that may be applicable in this context; see also the examples below.

See also `dat.tian2009` for the same dataset, but with 6 additional trials where no event was observed in either group for both outcomes.

Concepts

medicine, cardiology, odds ratios, Peto's method, generalized linear models

Author(s)

Christian Röver, <christian.roever@med.uni-goettingen.de>

Source

Nissen, S. E., & Wolski, K. (2007). Effect of Rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. *New England Journal of Medicine*, **356**(24), 2457-2471. https://doi.org/10.1056/NEJMoa072761

References

Diamond, G. A., Bax, L., & Kaul, S. (2007). Uncertain effects of Rosiglitazone on the risk for myocardial infarction and cardiovascular death. *Annals of Internal Medicine*, **147**(8), 578–581. https://doi.org/10.7326/0003-4819-147-8-200710160-00182

Friedrich, J. O., Beyene, J., & Adhikari, N. K. J. (2009). Rosiglitazone: Can meta-analysis accurately estimate excess cardiovascular risk given the available data? Re-analysis of randomized trials using various methodologic approaches. *BMC Research Notes*, **2**, 5. https://doi.org/10.1186/1756-0500-2-5

Jackson, D., Law, M., Stijnen, T., Viechtbauer, W., & White, I. R. (2018). A comparison of seven random-effects models for meta-analyses that estimate the summary odds ratio. *Statistics in Medicine*, **37**(7), 1059–1085. https://doi.org/10.1002/sim.7588

Nissen, S. E., & Wolski, K. (2010). Rosiglitazone revisited: An updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. *Archives of Internal Medicine*, **170**(14), 1191–1201. https://doi.org/10.1001/archinternmed.2010.207

Rücker, G., & Schumacher, M. (2008). Simpson's paradox visualized: The example of the Rosiglitazone meta-analysis. *BMC Medical Research Methodology*, **8**, 34. https://doi.org/10.1186/1471-2288-8-34

Tian, L., Cai, T., Pfeffer, M. A., Piankov, N., Cremieux, P.-Y., & Wei, L. J. (2009). Exact and efficient inference procedure for meta-analysis and its application to the analysis of independent 2 x 2 tables with all available data but without artificial continuity correction. *Biostatistics*, **10**(2), 275–281. https://doi.org/10.1093/biostatistics/kxn034

See Also

dat.tian2009

Examples

```
dat.nissen2007

## Not run:
library(metafor)

############################################################
# reproduce original "Peto" analyses

# infarction
ma01 <- rma.peto(ai=treat.infarction, ci=cont.infarction,
                 n1i=treat.total, n2i=cont.total,
                 slab=study, data=dat.nissen2007)
ma01

# mortality
ma02 <- rma.peto(ai=treat.death, ci=cont.death,
```

```
                 n1i=treat.total, n2i=cont.total,
                 slab=study, data=dat.nissen2007)
ma02

############################################################
# reproduce "Fixed, IV (CC)" analyses
# from Diamond/Bax/Kaul (2007), Table 1

# infarction
ma03 <- rma.uni(measure="OR", method="FE",
                drop00=TRUE,  # (exclude "double-zeroes")
                ai=treat.infarction, ci=cont.infarction,
                n1i=treat.total, n2i=cont.total,
                slab=study, data=dat.nissen2007)
ma03

# mortality
ma04 <- rma.uni(measure="OR", method="FE",
                drop00=TRUE,  # (exclude "double-zeroes")
                ai=treat.death, ci=cont.death,
                n1i=treat.total, n2i=cont.total,
                slab=study, data=dat.nissen2007)
ma04

############################################################
# estimate ORs based on a binomial GLMM
# (with *fixed* study effects)
# ("model 4" in Jackson et al., 2018)

# infarction
ma05 <- rma.glmm(measure="OR", model="UM.FS",
                 ai=treat.infarction, ci=cont.infarction,
                 n1i=treat.total, n2i=cont.total,
                 slab=study, data=dat.nissen2007)
ma05

# mortality
ma06 <- rma.glmm(measure="OR", model="UM.FS",
                 ai=treat.death, ci=cont.death,
                 n1i=treat.total, n2i=cont.total,
                 slab=study, data=dat.nissen2007)
ma06

############################################################
# estimate ORs based on binomial GLMM
# (with *random* study effects)
# ("model 5" in Jackson et al., 2018)

# infarction
ma07 <- rma.glmm(measure="OR", model="UM.RS", nAGQ=1,
                 ai=treat.infarction, ci=cont.infarction,
                 n1i=treat.total, n2i=cont.total,
                 slab=study, data=dat.nissen2007)
```

```
ma07

# mortality
ma08 <- rma.glmm(measure="OR", model="UM.RS", nAGQ=1,
                 ai=treat.death, ci=cont.death,
                 n1i=treat.total, n2i=cont.total,
                 slab=study, data=dat.nissen2007)
ma08

############################################################
# estimate ORs based on hypergeometric model
# (model 7 (approx.) in Jackson et al., 2018)

# infarction
ma09 <- rma.glmm(measure="OR", model="CM.AL",
                 ai=treat.infarction, ci=cont.infarction,
                 n1i=treat.total, n2i=cont.total,
                 slab=study, data=dat.nissen2007)
ma09

# mortality
ma10 <- rma.glmm(measure="OR", model="CM.AL",
                 ai=treat.death, ci=cont.death,
                 n1i=treat.total, n2i=cont.total,
                 slab=study, data=dat.nissen2007)
ma10

############################################################
# tabulate estimates and CIs

# log-OR infarction
logOR.inf <- rbind("Peto"    =c("OR"=ma01$b, "lower"=ma01$ci.lb, "upper"=ma01$ci.ub),
                   "IV-CC"   =c("OR"=ma03$b, "lower"=ma03$ci.lb, "upper"=ma03$ci.ub),
                   "M4-UM.FS"=c("OR"=ma05$b, "lower"=ma05$ci.lb, "upper"=ma05$ci.ub),
                   "M5-UM.RS"=c("OR"=ma07$b, "lower"=ma07$ci.lb, "upper"=ma07$ci.ub),
                   "M7-CM.AL"=c("OR"=ma09$b, "lower"=ma09$ci.lb, "upper"=ma09$ci.ub))

# log-OR mortality
logOR.mort <- rbind("Peto"    =c("OR"=ma02$b, "lower"=ma02$ci.lb, "upper"=ma02$ci.ub),
                    "IV-CC"   =c("OR"=ma04$b, "lower"=ma04$ci.lb, "upper"=ma04$ci.ub),
                    "M4-UM.FS"=c("OR"=ma06$b, "lower"=ma06$ci.lb, "upper"=ma06$ci.ub),
                    "M5-UM.RS"=c("OR"=ma08$b, "lower"=ma08$ci.lb, "upper"=ma08$ci.ub),
                    "M7-CM.AL"=c("OR"=ma10$b, "lower"=ma10$ci.lb, "upper"=ma10$ci.ub))

# show ORs (infarction)
round(exp(logOR.inf), 2)
# show ORs (mortality)
round(exp(logOR.mort), 2)

## End(Not run)
```

dat.normand1999 *Studies on the Length of Hospital Stay of Stroke Patients*

Description

Results from 9 studies on the length of the hospital stay of stroke patients under specialized care and under conventional/routine (non-specialist) care.

Usage

```
dat.normand1999
```

Format

The data frame contains the following columns:

study	numeric	study number
source	character	source of data
n1i	numeric	number of patients under specialized care
m1i	numeric	mean length of stay (in days) under specialized care
sd1i	numeric	standard deviation of the length of stay under specialized care
n2i	numeric	number of patients under routine care
m2i	numeric	mean length of stay (in days) under routine care
sd2i	numeric	standard deviation of the length of stay under routine care

Details

The 9 studies provide data in terms of the mean length of the hospital stay (in days) of stroke patients under specialized care and under conventional/routine (non-specialist) care. The goal of the meta-analysis was to examine the hypothesis whether specialist stroke unit care will result in a shorter length of hospitalization compared to routine management.

Concepts

medicine, raw mean differences, standardized mean differences

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Normand, S. T. (1999). Meta-analysis: Formulating, evaluating, combining, and reporting. *Statistics in Medicine*, **18**(3), 321–359. https://doi.org/10.1002/(sici)1097-0258(19990215)18:3<321::aid-sim28>3.0

Examples

```
### copy data into 'dat' and examine data
dat <- dat.normand1999
dat

## Not run:
### load metafor package
library(metafor)

### calculate mean differences and corresponding sampling variances
dat <- escalc(measure="MD", m1i=m1i, sd1i=sd1i, n1i=n1i, m2i=m2i, sd2i=sd2i, n2i=n2i, data=dat)
dat

### meta-analysis of mean differences using a random-effects model
res <- rma(yi, vi, data=dat)
res

### meta-analysis of standardized mean differences using a random-effects model
res <- rma(measure="SMD", m1i=m1i, sd1i=sd1i, n1i=n1i, m2i=m2i, sd2i=sd2i, n2i=n2i,
           data=dat, slab=source)
res

### draw forest plot
forest(res, xlim=c(-7,5), alim=c(-3,1), header="Study/Source")

### calculate (log transformed) ratios of means and corresponding sampling variances
dat <- escalc(measure="ROM", m1i=m1i, sd1i=sd1i, n1i=n1i, m2i=m2i, sd2i=sd2i, n2i=n2i, data=dat)
dat

### meta-analysis of the (log transformed) ratios of means using a random-effects model
res <- rma(yi, vi, data=dat)
res
predict(res, transf=exp, digits=2)

## End(Not run)
```

---

dat.obrien2003 *Studies on the Relationship Between BMI and Risk of Preeclampsia*

Description

Results from 13 studies on the relationship between maternal body mass index (BMI) and the risk of preeclampsia.

Usage

```
dat.obrien2003
```

Format

The data frame contains the following columns:

study	numeric	study id
author	character	(first) author of the study
year	numeric	publication year
ref	numeric	reference number
ch	character	exclusion due to chronic hypertension (yes/no)
dm	character	exclusion due to diabetes mellitus (yes/no)
mg	character	exclusion due to multiple gestation (yes/no)
bmi.lb	numeric	lower bound of the BMI interval
bmi.ub	numeric	upper bound of the BMI interval
bmi	numeric	midpoint of the BMI interval
cases	numeric	number of preeclampsia cases in the BMI group
total	numeric	number of individuals in the BMI group

Details

The dataset includes the results from 13 studies examining the relationship between maternal body mass index (BMI) and the risk of preeclampsia. For each study, results are given in terms of the number of preeclampsia cases within two or more groups defined by the lower and upper BMI bounds as shown in the dataset (NA means that the interval is either open to the left or right). The bmi variable is the interval midpoint as defined by O'Brien et al. (2003).

Concepts

medicine, obstetrics, risk ratios, proportions, multilevel models, dose-response models

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

O'Brien, T. E., Ray, J. G., & Chan, W.-S. (2003). Maternal body mass index and the risk of preeclampsia: A systematic overview. *Epidemiology*, **14**(3), 368–374. https://doi.org/10.1097/00001648-200305000-

Examples

```
### copy data into 'dat' and examine data
dat <- dat.obrien2003
dat

## Not run:
### load metafor package
library(metafor)

### restructure the data into a wide format
dat2 <- to.wide(dat, study="study", grp="grp", ref=1, grpvars=c("bmi","cases","total"),
                addid=FALSE, adddesign=FALSE, postfix=c(1,2))
```

```
dat2[1:10, -c(2:3)]

### calculate log risk ratios and corresponding sampling variances
dat2 <- escalc(measure="RR", ai=cases1, n1i=total1, ci=cases2, n2i=total2, data=dat2)
dat2[1:10, -c(2:7)]

### forest plot of the risk ratios
dd <- c(0,diff(dat2$study))
dd[dd > 0] <- 1
rows <- (1:nrow(dat2)) + cumsum(dd)
rows <- 1 + max(rows) - rows
slabs <- mapply(function(x,y,z) as.expression(bquote(.(x)^.(y)~.(z))),
                dat2$author, dat2$ref, dat2$year)
with(dat2, forest(yi, vi, slab=slabs, xlim=c(-7,5.5), cex=0.8,
   psize=1, pch=19, efac=0, rows=rows, ylim=c(0,max(rows)+3), yaxs="i",
  atransf=exp, at=log(c(0.05,0.1,0.2,0.5,1,2,5,10,20)), ilab=comp, ilab.xpos=-4, ilab.pos=4))
text(-4.4, max(rows)+2, "Comparison", font=2, cex=0.8, pos=4)

### within-study mean center the BMI variable
dat$bmicent <- with(dat, bmi - ave(bmi, study))

### compute the proportion of preeclampsia cases and corresponding sampling variances
dat <- escalc(measure="PR", xi=cases, ni=total, data=dat)

### convert the proportions to percentages (and convert the variances accordingly)
dat$yi <- dat$yi*100
dat$vi <- dat$vi*100^2
dat[1:10, -c(2:3)]

### fit multilevel meta-regression model to examine the relationship between the
### (centered) BMI variable and the risk of preeclampsia
res <- rma.mv(yi, vi, mods = ~ bmicent, random = ~ 1 | study/grp, data=dat)
res

### draw scatterplot with regression line
res$slab <- dat$ref
regplot(res, xlab=expression("Within-Study Mean Centered BMI"~(kg/m^2)),
        ylab="Preeclampsia Prevalence (%)", las=1, bty="l",
        at=seq(0,18,by=2), olim=c(0,100), psize=2, bg="gray90",
        label=TRUE, offset=0, labsize=0.6)

### fit model using a random slope for bmicent
res <- rma.mv(yi, vi, mods = ~ bmicent, random = ~ bmicent | study, struct="GEN", data=dat)
res

### load rms package
library(rms)

### fit restricted cubic spline model
res <- rma.mv(yi, vi, mods = ~ rcs(bmicent, 4), random = ~ 1 | study/grp, data=dat)
res

### get knot positions
```

```
knots <- attr(rcs(model.matrix(res)[,2], 4), "parms")

### computed predicted values based on the model
xs <- seq(-10, 10, length=1000)
sav <- predict(res, newmods=rcspline.eval(xs, knots, inclx=TRUE))

### draw scatterplot with regression line based on the model
tmp <- regplot(res, mod=2, pred=sav,
               xvals=xs, xlab=expression("Within-Study Mean Centered BMI"~(kg/m^2)),
               ylab="Preeclampsia Prevalence (%)", las=1, bty="l",
               at=seq(0,18,by=2), olim=c(0,100), psize=2, bg="gray90",
               label=TRUE, offset=0, labsize=0.6)
abline(v=knots, lty="dotted")
points(tmp)

## End(Not run)
```

`dat.pagliaro1992` *Studies on the Effectiveness of Nonsurgical Treatments in Cirrhosis*

Description

Results from 26 trials examining the effectiveness of beta-blockers and sclerotherapy for the prevention of first bleeding in patients with cirrhosis

Usage

```
dat.pagliaro1992
```

Format

The data frame contains the following columns:

study	`numeric`	study id
trt	`character`	either beta-blockers, sclerotherapy, or control
xi	`numeric`	number of patients with first bleeding
ni	`numeric`	number of patients treated

Details

The dataset includes the results from 26 randomized controlled trials examining the effectiveness of nonsurgical treatments for the prevention of first bleeding in patients with cirrhosis. Patients were either treated with beta-blockers, endoscopic sclerotherapy, or with a nonactive treatment (control). Two trials included all three treatment conditions, 7 trials compared beta-blockers against control, and 17 trials compared sclerotherapy against control. The dataset has been used in various papers to illustrate methods for conducting a network meta-analysis / mixed treatment comparison.

Concepts

medicine, odds ratios, Mantel-Haenszel method, network meta-analysis

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Pagliaro, L., D'Amico, G., Sörensen, T. I. A., Lebrec, D., Burroughs, A. K., Morabito, A., Tiné, F., Politi, F., & Traina, M. (1992). Prevention of first bleeding in cirrhosis: A meta-analysis of randomized trials of nonsurgical treatment. *Annals of Internal Medicine*, **117**(1), 59–70. https://doi.org/10.7326/0003-4819-1

Examples

```
### copy data into 'dat' and examine data
dat <- dat.pagliaro1992
dat

## Not run:
### load metafor package
library(metafor)

### restructure dataset to a contrast-based format
dat.c <- to.wide(dat, study="study", grp="trt", grpvars=3:4)
dat.c

### Mantel-Haenszel results for beta-blockers and sclerotherapy versus control, respectively
rma.mh(measure="OR", ai=xi.1, n1i=ni.1, ci=xi.2, n2i=ni.2,
       data=dat.c, subset=(trt.1=="beta-blockers"), digits=2)
rma.mh(measure="OR", ai=xi.1, n1i=ni.1, ci=xi.2, n2i=ni.2,
       data=dat.c, subset=(trt.1=="sclerotherapy"), digits=2)

### calculate log odds for each study arm
dat <- escalc(measure="PLO", xi=xi, ni=ni, data=dat)
dat

### turn treatment variable into factor and set reference level
dat$trt <- relevel(factor(dat$trt), ref="control")

### add a space before each level (this makes the output a bit more legible)
levels(dat$trt) <- paste0(" ", levels(dat$trt))

### network meta-analysis using an arm-based random-effects model with fixed study effects
### (by setting rho=1/2, tau^2 reflects the amount of heterogeneity for all treatment comparisons)
res <- rma.mv(yi, vi, mods = ~ 0 + factor(study) + trt, random = ~ trt | study, rho=1/2, data=dat)
res

### average odds ratio comparing beta-blockers and sclerotherapy versus control, respectively
predict(res, newmods=c(rep(0,26), 1, 0), transf=exp, digits=2)
predict(res, newmods=c(rep(0,26), 0, 1), transf=exp, digits=2)

### average odds ratio comparing beta-blockers versus sclerotherapy
predict(res, newmods=c(rep(0,26), 1, -1), transf=exp, digits=2)

## End(Not run)
```

dat.pignon2000 *Studies on the Effectiveness of Locoregional Treatment plus Chemotherapy for Head and Neck Squamous-Cell Carcinoma*

Description

Results from studies examining mortality risk in patients with nonmetastatic head and neck squamous-cell carcinoma receiving either locoregional treatment plus chemotherapy versus locoregional treatment alone.

Usage

```
dat.pignon2000
```

Format

The data frame contains the following columns:

id	numeric	study id number
trial	character	trial abbreviation
OmE	numeric	observed minus expected number of deaths in the locoregional treatment plus chemotherapy group
V	numeric	corresponding variance
grp	numeric	timing of chemotherapy: 1 = adjuvant, 2 = neoadjuvant, 3 = concomitant

Details

The purpose of this meta-analysis was to examine the mortality risk in patients with nonmetastatic head and neck squamous-cell carcinoma receiving either locoregional treatment plus chemotherapy versus locoregional treatment alone. For 65 trials, the dataset provides the observed minus expected number of deaths and corresponding variances in the locoregional treatment plus chemotherapy group. Based on these values, we can estimate the log hazard ratios with `OmE/V` and the corresponding sampling variance with `1/V`.

The trials were also divided according to the timing of the chomotherapy: (1) adjuvant, after the locoregional treatment, (2) neoadjuvant, before the locoregional treatment, and (3) concomitant, chemotherapy given concomitantly or alternating with radiotherapy.

Concepts

medicine, oncology, hazard ratios

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Pignon, J. P., Bourhis, J., Domenge, C., & Designe, L. (2000). Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. *Lancet*, **355**(9208), 949–955. https://doi.org/10.1016/S0140-6736(00)90011-4

Examples

```
### copy data into 'dat' and examine data
dat <- dat.pignon2000
head(dat)

## Not run:
### load metafor package
library(metafor)

### calculate log hazard ratios and sampling variances
dat$yi <- with(dat, OmE/V)
dat$vi <- with(dat, 1/V)
head(dat)

### meta-analysis based on all 65 trials
res <- rma(yi, vi, data=dat, method="EE", digits=2)
res
predict(res, transf=exp)

### only adjuvant trials
res <- rma(yi, vi, data=dat, method="EE", subset=grp==1, digits=2)
res
predict(res, transf=exp)

### only neoadjuvant trials
res <- rma(yi, vi, data=dat, method="EE", subset=grp==2, digits=2)
res
predict(res, transf=exp)

### only concomitant trials
res <- rma(yi, vi, data=dat, method="EE", subset=grp==3, digits=2)
res
predict(res, transf=exp)

## End(Not run)
```

---

dat.poole2003 *Trials on Mucolytic Agents in Chronic Bronchitis or Chronic Obstructive Pulmonary Disease*

Description

Results from 19 trials evaluating mucolytic agents in patients with chronic bronchitis or chronic obstructive pulmonary disease.

Usage

```
dat.poole2003
```

Format

The data frame contains the following columns:

author	`character`	first author
year	`integer`	publication year
Ne	`integer`	sample size (mucolytic agents)
Me	`numeric`	mean exacerbations per months (mucolytic agents)
Se	`numeric`	standard deviation (mucolytic agents)
Nc	`integer`	sample size (placebo)
Mc	`numeric`	mean exacerbations per months (placebo)
Sc	`numeric`	standard deviation (placebo)
duration	`character`	study duration

Details

Poole and Black (2003) conducted a Cochrane review to evaluate mucolytic agents versus placebo for patients with chronic bronchitis or chronic obstructive pulmonary disease. The outcome used here is the mean number of acute exacerbations per month. Acute exacerbation is defined as an increase in cough and in the volume or purulence of sputum. All 17 studies included in the meta-analysis report a mean number of exacerbations and we can work with mean differences, rather than standardised mean differences. Note, later versions of this Cochrane review no longer evaluate the mean number of exacerbations per month.

This data set is used as an example in Schwarzer et al. (2015).

Concepts

medicine, pulmonology, raw mean differences, subgroup analysis

Author(s)

Guido Schwarzer, <guido.schwarzer@uniklinik-freiburg.de>, https://github.com/guido-s/

Source

Poole, P. J., & Black, P. N. (2003). Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. *Cochrane Database of Systematic Reviews*, **1**, CD001287. https://doi.org/10.1002/14651858.cd00

References

Schwarzer, G., Carpenter, J. R., & Rücker, G. (2015). *Meta-analysis with R*. Cham, Switzerland: Springer.

Examples

```
### Show first five studies
head(dat.poole2003, 5)

## Not run:
### Load meta package
```

```
suppressPackageStartupMessages(library(meta))

### Use RevMan 5 settings
oldset <- settings.meta("RevMan5",
  digits.I2 = 2, digits.tau = 3, digits.sd = 2)

### Conduct random effects meta-analysis
m <- metacont(Ne, Me, Se, Nc, Mc, Sc, data = dat.poole2003,
  studlab = paste(author, year), common = FALSE,
  subgroup = duration,
  subgroup.name = "Duration", sep.subgroup = ": ",
  label.e = "Mucolytic agent",
  label.c = "Placebo",
  label.left = "Favours mucolytic agent",
  label.right = "Favours placebo",
  col.label.left = "green", col.label.right = "red")

### Forest plot
forest(m, xlim = c(-0.5, 0.2),
  xlab = paste0("Difference in mean number of\n",
    "acute exacerbations per month"))

### Use previous settings
settings.meta(oldset)

## End(Not run)
```

`dat.pritz1997` *Studies on the Effectiveness of Hyperdynamic Therapy for Treating Cerebral Vasospasm*

Description

Results from 14 studies on the effectiveness of hyperdynamic therapy for treating cerebral vasospasm.

Usage

```
dat.pritz1997
```

Format

The data frame contains the following columns:

study	`numeric`	study number
authors	`character`	study authors
xi	`numeric`	number of patients that improved with hyperdynamic therapy
ni	`numeric`	total number of patients treated

Details

As described in Zhou et al. (1999), "hyperdynamic therapy refers to induced hypertension and hypervolaemia (volume expansion) to treat ischaemic symptoms due to vasospasm, and the success of this therapy is defined as clinical improvement in terms of neurologic deficits." For each study that was included in the meta-analysis, the dataset includes information on the number of patients that improved under this form of therapy and the total number of patients that were treated. The goal of the meta-analysis is to estimate the true (average) success rate of hyperdynamic therapy.

Concepts

medicine, cardiology, single-arm studies, proportions

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Zhou, X.-H., Brizendine, E. J., & Pritz, M. B. (1999). Methods for combining rates from several studies. *Statistics in Medicine*, **18**(5), 557–566. https://doi.org/10.1002/(SICI)1097-0258(19990315)18:5<557::AI

References

Pritz M. B., Zhou, X.-H., & Brizendine, E. J. (1996). Hyperdynamic therapy for cerebral vasospasm: A meta-analysis of 14 studies. *Journal of Neurovascular Disease*, **1**, 6–8.

Pritz, M. B. (1997). Treatment of cerebral vasospasm due to aneurysmal subarachnoid hemorrhage: Past, present, and future of hyperdynamic therapy. *Neurosurgery Quarterly*, **7**(4), 273–285.

Examples

```
### copy data into 'dat' and examine data
dat <- dat.pritz1997
dat

## Not run:
### load metafor package
library(metafor)

### computation of "weighted average" in Zhou et al. (1999), Table IV
dat <- escalc(measure="PR", xi=xi, ni=ni, data=dat, add=0)
theta.hat    <- sum(dat$ni * dat$yi) / sum(dat$ni)
se.theta.hat <- sqrt(sum(dat$ni^2 * dat$vi) / sum(dat$ni)^2)
ci.lb        <- theta.hat - 1.96 * se.theta.hat
ci.ub        <- theta.hat + 1.96 * se.theta.hat
round(c(estimate = theta.hat, se = se.theta.hat, ci.lb = ci.lb, ci.ub = ci.ub), 4)

### this is identical to an equal-effects model with sample size weights
rma(yi, vi, weights=ni, method="EE", data=dat)

### compute sampling variances under the assumption of homogeneity
```

```
dat <- escalc(measure="PR", xi=xi, ni=ni, data=dat, add=0, vtype="AV")
dat

### fit equal-effects model (same estimate, but SE is slightly different)
rma(yi, vi, data=dat, method="EE")

### under the assumption of homogeneity, the sum of independent binomial
### counts also follows a binomial distribution; this approach yields the same
### estimate and SE as above
agg <- escalc(measure="PR", xi=sum(dat$xi), ni=sum(dat$ni))
summary(agg)

### could also compute an 'exact' CI based on the Clopper-Pearson method
binom.test(sum(dat$xi), sum(dat$ni))

### logistic regression model
res <- rma.glmm(measure="PLO", xi=xi, ni=ni, data=dat, method="EE")
res
predict(res, transf=transf.ilogit)

### the results above suggest that the true proportions may be heterogeneous

### random-effects model with raw proportions
dat <- escalc(measure="PR", xi=xi, ni=ni, data=dat)
res <- rma(yi, vi, data=dat)
predict(res)

### random-effects model with logit transformed proportions
dat <- escalc(measure="PLO", xi=xi, ni=ni, data=dat)
res <- rma(yi, vi, data=dat)
predict(res, transf=transf.ilogit)

### mixed-effects logistic regression model
res <- rma.glmm(measure="PLO", xi=xi, ni=ni, data=dat)
predict(res, transf=transf.ilogit)

## End(Not run)
```

`dat.quan2000` *Studies on Pharmacotherapy for Hypertension*

Description

Results from 11 studies evaluating pharmacotherapy in patients with hypertension.

Usage

```
dat.quan2000
```

Format

The data frame contains the following columns:

study	`character`	study label
Ee	`integer`	fatal cerebrovascular events (pharmacotherapy)
Ne	`integer`	number of patients (pharmacotherapy)
Ec	`integer`	fatal cerebrovascular events (control)
Nc	`integer`	number of patients (control)

Details

Quan et al. (2000) conducted a Cochrane Review to evaluate whether the benefit of treating hypertension in women differed between younger and older women, as well as between white and African American women. In the systematic review, the Peto method was used for pooling. The primary outcome was the occurrence of fatal cerebrovascular events, a rare event in hypertension. The dataset contains the subgroup of women older than 55 years.

This data set is used as an example in Schwarzer et al. (2015).

Concepts

medicine, cardiology, Peto's method

Author(s)

Guido Schwarzer, <guido.schwarzer@uniklinik-freiburg.de>, https://github.com/guido-s/

Source

Quan, A. P., Kerlikowske, K., Gueyffier, F., Boissel, J.-P., & INDANA Investigators (2010). Pharmacotherapy for hypertension in women of different races. *Cochrane Database of Systematic Reviews*, **2**, CD002146. https://doi.org/10.1002/14651858.cd002146

References

Schwarzer, G., Carpenter, J. R., & Rücker, G. (2015). *Meta-analysis with R*. Cham, Switzerland: Springer.

Examples

```
### Show first five studies
head(dat.quan2000, 5)

## Not run:
### Load meta package
suppressPackageStartupMessages(library(meta))

### Use RevMan 5 settings
oldset <- settings.meta("RevMan5")

### Conduct meta-analyis with Peto method
```

```
m <- metabin(Ee, Ne, Ec, Nc, sm = "OR", method = "Peto",
  data = dat.quan2000, studlab = study, random = FALSE)
m

### Use previous settings
settings.meta(oldset)

## End(Not run)
```

`dat.raudenbush1985` *Studies on Assessing the Effects of Teacher Expectations on Pupil IQ*

Description

Results from 19 studies examining how teachers' expectations about their pupils can influence actual IQ levels.

Usage

```
dat.raudenbush1985
```

Format

The data frame contains the following columns:

study	`numeric`	study number
author	`character`	study author(s)
year	`numeric`	publication year
weeks	`numeric`	weeks of contact prior to expectancy induction
setting	`character`	whether tests were group or individually administered
tester	`character`	whether test administrator was aware or blind
n1i	`numeric`	sample size of experimental group
n2i	`numeric`	sample size of control group
yi	`numeric`	standardized mean difference
vi	`numeric`	corresponding sampling variance

Details

In the so-called 'Pygmalion study' (Rosenthal & Jacobson, 1968), "all of the predominantly poor children in the so-called Oak elementary school were administered a test pretentiously labeled the 'Harvard Test of Inflected Acquisition.' After explaining that this newly designed instrument had identified those children most likely to show dramatic intellectual growth during the coming year, the experimenters gave the names of these 'bloomers' to the teachers. In truth, the test was a traditional IQ test and the 'bloomers' were a randomly selected 20% of the student population. After retesting the children 8 months later, the experimenters reported that those predicted to bloom had in fact gained significantly more in total IQ (nearly 4 points) and reasoning IQ (7 points) than the control group children. Further, at the end of the study, the teachers rated the experimental

children as intellectually more curious, happier, better adjusted, and less in need of approval than their control group peers" (Raudenbush, 1984).

In the following years, a series of studies were conducted attempting to replicate this rather controversial finding. However, the great majority of those studies were unable to demonstrate a statistically significant difference between the two experimental groups in terms of IQ scores. Raudenbush (1984) conducted a meta-analysis based on 19 such studies to further examine the evidence for the existence of the 'Pygmalion effect'. The dataset includes the results from these studies.

The outcome measure used for the meta-analysis was the standardized mean difference (`yi`), with positive values indicating that the supposed 'bloomers' had, on average, higher IQ scores than those in the control group. The `weeks` variable indicates the number of weeks of prior contact between teachers and students before the expectancy induction. Testing was done either in a group setting or individually, which is indicated by the `setting` variable. Finally, the `tester` variable indicates whether the test administrators were either aware or blind to the researcher-provided designations of the children's intellectual potential.

The data in this dataset were obtained from Raudenbush and Bryk (1985) with information on the `setting` and `tester` variables extracted from Raudenbush (1984).

Concepts

education, standardized mean differences, meta-regression

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Raudenbush, S. W. (1984). Magnitude of teacher expectancy effects on pupil IQ as a function of the credibility of expectancy induction: A synthesis of findings from 18 experiments. *Journal of Educational Psychology*, **76**(1), 85–97. https://doi.org/10.1037/0022-0663.76.1.85

Raudenbush, S. W., & Bryk, A. S. (1985). Empirical Bayes meta-analysis. *Journal of Educational Statistics*, **10**(2), 75–98. https://doi.org/10.3102/10769986010002075

Examples

```
### copy data into 'dat' and examine data
dat <- dat.raudenbush1985
dat

## Not run:
### load metafor package
library(metafor)

### random-effects model
res <- rma(yi, vi, data = dat)
res

### create weeks variable where values larger than 3 are set to 3
dat$weeks.c <- ifelse(dat$weeks > 3, 3, dat$weeks)
```

```
### mixed-effects model with weeks.c variable as moderator
res <- rma(yi, vi, mods = ~ weeks.c, data = dat, digits = 3)
res

## End(Not run)
```

`dat.riley2003` *Studies on MYC-N as a Prognostic Marker for Neuroblastoma*

Description

Results from 81 studies examining overall and disease-free survival in neuroblastoma patients with amplified versus normal MYC-N protein levels.

Usage

```
dat.riley2003
```

Format

The data frame contains the following columns:

study	`numeric`	study number
yi	`numeric`	log hazard ratio of the outcome in those with amplified versus normal MYC-N protein levels
vi	`numeric`	sampling variance of the log hazard ratio
sei	`numeric`	standard error of the log hazard ratio
outcome	`character`	outcome (OS = overall survival; DFS = disease-free survival)

Details

The meta-analysis by Riley et al. (2003) examined a variety of prognostic markers for overall and disease-free survival in patients with neuroblastoma. One of the markers examined was amplified levels of the MYC-N protein, with is associated with poorer outcomes.

The dataset given here was extracted from Riley (2011) and has been used in several other publications (e.g., Riley et al., 2004, 2007). The dataset provides the (log) hazard ratios (and corresponding standard errors) with respect to these two outcomes in 81 studies, with positive values indicating a greater risk of death (for OS) or disease recurrence/death (for DFS) for patients with high MYC-N levels compared to those with normal/low levels. Note that information on both outcomes could only be extracted from 17 studies (39 studies only provided sufficient information to extract the OS estimate, while 25 studies only allowed for extraction of the DFS estimate).

Concepts

medicine, oncology, hazard ratios

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Riley, R. D., Sutton, A. J., Abrams, K. R., & Lambert, P. C. (2004). Sensitivity analyses allowed more appropriate and reliable meta-analysis conclusions for multiple outcomes when missing data was present. *Journal of Clinical Epidemiology*, **57**(9), 911–924. https://doi.org/10.1016/j.jclinepi.2004.01.018

Riley, R. D., Abrams, K. R., Lambert, P. C., Sutton, A. J., & Thompson, J. R. (2007). An evaluation of bivariate random-effects meta-analysis for the joint synthesis of two correlated outcomes. *Statistics in Medicine*, **26**(1), 78–97. https://doi.org/10.1002/sim.2524

Riley, R. D. (2011). Erratum: An evaluation of bivariate random-effects meta-analysis for the joint synthesis of two correlated outcomes. *Statistics in Medicine*, **30**(4), 400. https://doi.org/10.1002/sim.4100

References

Riley, R. D., Burchill, S. A., Abrams, K. R., Heney, D., Lambert, P. C., Jones, D. R., Sutton, A. J., Young, B., Wailoo, A. J., & Lewis, I. J. (2003). A systematic review and evaluation of the use of tumour markers in paediatric oncology: Ewing's sarcoma and neuroblastoma. *Health Technology Assessment*, **7**(5), 1–162. https://doi.org/10.3310/hta7050

Examples

```
### copy data into 'dat' and examine data
dat <- dat.riley2003
dat

## Not run:
### load metafor package
library(metafor)

### random-effects model analysis for outcome DFS
res <- rma(yi, sei=sei, data=dat, subset=(outcome == "DFS"), method="DL")
res
predict(res, transf=exp, digits=2)

### random-effects model analysis for outcome OS
res <- rma(yi, sei=sei, data=dat, subset=(outcome == "OS"), method="DL")
res
predict(res, transf=exp, digits=2)

## End(Not run)
```

---

dat.rivera2025 *Comparison of Two Diagnostic Tests for the Detection of Temporomandibular Disorders*

Description

Studies evaluating the diagnostic accuracy of the IAF and 3Q-TMD instruments based on the reference tests RDC and DC-TMD for the diagnosis of temporomandibular disorders.

Usage

```
dat.rivera2025
```

Format

The data frame contains the following columns:

Author	character	study author(s)
Year	integer	year of the study
Title	character	title of the article
DOI	character	DOI for the article
TP	integer	number of true positives
FP	integer	number of false positives
FN	integer	number of false negatives
TN	integer	number of true negatives
Sensitivity	numeric	sensitivity
Specificity	numeric	specificity
PPV	numeric	positive predictive value
NPV	numeric	negative predictive value
Sample.size	integer	sample size
n1	integer	number of people with the disease
n2	integer	number of people without the disease
Prevalence	numeric	prevalence
AUC	numeric	area under the curve
SampleID	character	sample identifier

Details

Results of 10 studies that evaluated the diagnostic accuracy of the IAF and 3Q-TMD instruments based on the reference tests RDC and DC-TMD were included. The search period ranged from 1992 to April 2022 in six electronic databases. Two independent reviewers selected the studies. Risk of bias and applicability were assessed using the QUADAS 2 instrument.

Concepts

medicine, dentistry, diagnostic accuracy studies

Author(s)

Álvarez-Vaz, Ramón, <ramon.alvarez@fcea.edu.uy>

Source

Rivera, Hugo Daniel; Álvarez-Vaz, Ramón, 2025, "Conjunto de datos de: Comparación de dos pruebas diagnósticas para la detección de trastornos témporomandibulares. Una revisión sistemática y metaanálisis.", https://doi.org/10.60895/redata/YIEGLZ, Repositorio de datos abiertos de investigación de Uruguay, V1

References

Rivera, H. D., Rodríguez, C. I., Álvarez Vaz, R., & Kreiner, M. (2025). Comparison of two diagnostic tests for the detection of temporomandibular disorders: A systematic review and meta-analysis. Odontoestomatología, 27(45). https://doi.org/10.22592/ode2025n45e338

Examples

```
### copy data into 'dat' and examine data
dat <- dat.rivera2025
dat

## Not run:
suppressPackageStartupMessages(library(meta))

### sensitivity
round(dat$TP / dat$n1, 4)
report1 <- metaprop(TP, n1, data=dat, common=TRUE, random=TRUE, studlab=paste(Author, Year))
report1
summary(report1)
forest(report1)

### specificity
round(dat$TN / dat$n2, 4)
report2 <- metaprop(TN, n2, data=dat, common=TRUE, random=TRUE, studlab=paste(Author, Year))
summary(report2)
forest(report2)

### diagnostic odds ratio
report3 <- metabin(TP, n1, n2-TN, n2, data=dat, sm="OR",common=FALSE, random=TRUE,
                   studlab=paste(Author, Year), allstudies=TRUE)
summary(report3)

## End(Not run)
```

---

dat.roever2022 *Irinotecan / S-1 Toxicity Dataset*

Description

12 studies investigating the occurrence of dose limiting toxicities (DLTs) at different doses of a combination therapy of Irinotecan and S-1.

Usage

```
dat.roever2022
```

Format

The data frame contains the following columns:

study	`character`	study label
year	`integer`	publication year
dose	`numeric`	dose (mg/m^2)
events	`integer`	number of DLTs
total	`integer`	number of patients exposed

Details

A combination therapy of Irinotecan (a topoisomerase 1 inhibitor) and S-1 (a combination of three pharmacological compounds, namely, tegafur, gimeracil, and oteracil potassium) was tested in advanced colorectal and gastric cancer. This dataset contains data from twelve studies investigating this therapy in a Japanese population; it contains the doses investigated, the numbers of patients treated, and the number of dose-limiting toxicities (DLTs) observed. In general, each study investigated several doses according to some dose-escalation scheme.

Concepts

medicine, oncology, dose-response models

Author(s)

Christian Röver, <christian.roever@med.uni-goettingen.de>

Source

Ursino, M., Röver, C., Zohar, S., & Friede T. (2021). Random-effects meta-analysis of phase I dose-finding studies using stochastic process priors. *The Annals of Applied Statistics*, **15**(1), 174–193. https://doi.org/10.1214/20-AOAS1390

Röver, C., Ursino, M., Friede, T., & Zohar, S. (2022). A straighforward meta-analysis approach for oncology phase I dose-finding studies. *Statistics in Medicine*, **41**(20), 3915–3940. https://doi.org/10.1002/sim.9484

References

European Medicines Agency (EMA) (2021). Onivyde pegylated liposomal (irinotecan hydrochloride trihydrate) EPAR summary. https://www.ema.europa.eu/en/medicines/human/EPAR/onivyde-pegylated-lipos

European Medicines Agency (EMA) (2022). Teysuno (tegafur/gimeracil/oteracil) EPAR summary. https://www.ema.europa.eu/en/medicines/human/EPAR/teysuno

Yamada, Y., Yasui, H., Goto, A., *et al.* (2003). Phase I study of irinotecan and S-1 combination therapy in patients with metastatic gastric cancer. *International Journal of Clinical Oncology*, **8**(6), 374–380. https://doi.org/10.1007/s10147-003-0359-z

Takiuchi, H., Narahara, H., Tsujinaka, T., *et al.* (2005). Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced gastric cancer (OGSG 0002). *Japanese Journal of Clinical Oncology*, **35**(9), 520–525. https://doi.org/10.1093/jjco/hyi148

Inokuchi, M., Yamashita, T., Yamada, H., *et al.* (2006). Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer. *British Journal of Cancer*, **94**(8), 11130. https://doi.org/10.1038/sj.b

Nakafusa, Y., Tanaka, M., Ohtsuka, T., *et al.* (2008). Phase I/II study of combination therapy with S-1 and CPT-11 for metastatic colorectal cancer. *Molecular Medicine Reports*, **1**(6), 925–930. https://doi.org/10.3892/mmr_00000051

Ishimoto, O., Ishida, T., Honda, Y., Munakata, M., & Sugawara, S. (2009). Phase I study of daily S-1 combined with weekly irinotecan in patients with advanced non-small cell lung cancer. *International Journal of Clinical Oncology*, **14**(1), 43–47. https://doi.org/10.1007/s10147-008-0796-9

Ogata, Y., Sasatomi, T., Akagi, Y., Ishibashi, N., Mori, S., & Shirouzu, K. (2009). Dosage escalation study of S-1 and irinotecan in metronomic chemotherapy against advanced colorectal cancer. *The Kurume Medical Journal*, **56**(1+2), 1–7. https://doi.org/10.2739/kurumemedj.56.1

Shiozawa, M., Sugano, N., Tsuchida, K., Morinaga, S., Akaike, M., & Sugimasa, Y. (2009). A phase I study of combination therapy with S-1 and irinotecan (CPT-11) in patients with advanced colorectal cancer. *Journal of Cancer Research and Clinical Oncology*, **135**(3), 365–370. https://doi.org/10.1007/s00432-008-0480-5

Yoshioka, T., Kato, S., Gamoh, M., *et al.* (2009). Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer. *British Journal of Cancer*, **101**, 1972–1977. https://doi.org/10.1038/sj.bjc.6605432

Komatsu, Y., Yuki, S., Fuse, N., *et al.* (2010). Phase 1/2 clinical study of irinotecan and oral S-1 (IRIS) in patients with advanced gastric cancer. *Advances in Therapy*, **27**(7), 483–492. https://doi.org/10.1007/s12325-

Kusaba, H., Esaki, T., Futami, K., *et al.* (2010). Phase I/II study of a 3-week cycle of irinotecan and S-1 in patients with advanced colorectal cancer. *Cancer Science*, **101**(12), 2591–2595. https://doi.org/10.1111/j.1349-7006.2010.01728.x

Yoda, S., Soejima, K., Yasuda, H., *et al.* (2011). A phase I study of S-1 and irinotecan combination therapy in previously treated advanced non-small cell lung cancer patients. *Cancer Chemotherapy and Pharmacology*, **67**(3), 717–722. https://doi.org/10.1007/s00280-010-1539-y

Goya, H., Kuraishi, H., Koyama, S., *et al.* (2012). Phase I/II study of S-1 combined with biweekly irinotecan chemotherapy in previously treated advanced non-small cell lung cancer. *Cancer Chemotherapy and Pharmacology*, **70**(5), 691–697. https://doi.org/10.1007/s00280-012-1957-0

See Also

dat.ursino2021

Examples

```
# show (some) data
head(dat.roever2022, n=10)

## Not run:
# illustrate data
plot(NA, xlim=range(dat.roever2022$dose), ylim=0:1,
     xlab="dose (mg / m²)", ylab="proportion",
     main="dat.roever2022 (Irinotecan / S-1 data)")
studylab <- unique(dat.roever2022$study)
colvec <- rainbow(length(studylab))
for (i in 1:length(studylab)) {
```

```
  idx <- (dat.roever2022$study == studylab[i])
  lines(dat.roever2022[idx,"dose"],
        dat.roever2022[idx,"events"] / dat.roever2022[idx,"total"],
        col=colvec[i], type="b")
}
legend("topleft", studylab, col=colvec, pch=15)

## End(Not run)
```

`dat.senn2013` *Studies on the Effectiveness of Glucose-Lowering Agents*

Description

Results from 26 trials examining the effectiveness of glucose-lowering agents in patients with type 2 diabetes

Usage

```
dat.senn2013
```

Format

The data frame contains the following columns:

study	`character`	(first) author and year of study
ni	`numeric`	sample size of the study arm
treatment	`character`	treatment given
comment	`character`	whether figures given are based on raw values at outcome or on change from baseline
mi	`numeric`	raw mean or mean change
sdi	`numeric`	standard deviation

Details

The dataset includes the results from 26 randomized controlled trials examining the effectiveness of adding various oral glucose-lowering agents to a baseline sulfonylurea therapy in patients with type 2 diabetes. The outcome measured in the studies was either the mean HbA1c level at follow-up or the mean change in HbA1c level from baseline to follow-up. A total of 10 different treatment types were examined in these studies: acarbose, benfluorex, metformin, miglitol, pioglitazone, placebo, rosiglitazone, sitagliptin, sulfonylurea alone, and vildagliptin. One study included three treatment arms (Willms, 1999), while the rest of the studies included two treatment arms (hence, the dataset includes the results from 53 treatment arms).

The data can be used for a network meta-analysis, either using an arm-based or a contrast-based model. See 'Examples' below.

Concepts

medicine, raw mean differences, network meta-analysis

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Senn, S., Gavini, F., Magrez, D., & Scheen, A. (2013). Issues in performing a network meta-analysis. *Statistical Methods in Medical Research*, **22**(2), 169–189. https://doi.org/10.1177/0962280211432220

References

Law, M., Jackson, D., Turner, R., Rhodes, K., & Viechtbauer, W. (2016). Two new methods to fit models for network meta-analysis with random inconsistency effects. *BMC Medical Research Methodology*, **16**, 87. https://doi.org/10.1186/s12874-016-0184-5

Rücker, G., & Schwarzer, G. (2015). Ranking treatments in frequentist network meta-analysis works without resampling methods. *BMC Medical Research Methodology*, **15**, 58. https://doi.org/10.1186/s12874-015

Examples

```
### copy data into 'dat' and examine data
dat <- dat.senn2013
dat

## Not run:
### load metafor package
library(metafor)

### create network graph ('igraph' package must be installed)
library(igraph, warn.conflicts=FALSE)
pairs <- data.frame(do.call(rbind,
  sapply(split(dat$treatment, dat$study), function(x) t(combn(x,2)))), stringsAsFactors=FALSE)
pairs$X1 <- factor(pairs$X1, levels=sort(unique(dat$treatment)))
pairs$X2 <- factor(pairs$X2, levels=sort(unique(dat$treatment)))
tab <- table(pairs[,1], pairs[,2])
tab # adjacency matrix
g <- graph_from_adjacency_matrix(tab, mode = "plus", weighted=TRUE, diag=FALSE)
plot(g, edge.curved=FALSE, edge.width=E(g)$weight, layout=layout_as_star(g, center="placebo"),
   vertex.size=45, vertex.color="lightgray", vertex.label.color="black", vertex.label.font=2)

### table of studies versus treatments examined
print(addmargins(table(dat$study, dat$treatment)), zero.print="")

### table of frequencies with which treatment pairs were studied
print(as.table(crossprod(table(dat$study, dat$treatment))), zero.print="")

### add means and sampling variances of the means to the dataset
dat <- escalc(measure="MN", mi=mi, sdi=sdi, ni=ni, data=dat)

### turn treatment variable into factor and set reference level
dat$treatment <- relevel(factor(dat$treatment), ref="placebo")

### add a space before each level (this makes the output a bit more legible)
```

```
levels(dat$treatment) <- paste0(" ", levels(dat$treatment))

### network meta-analysis using an arm-based fixed-effects model with fixed study effects
res.fe <- rma.mv(yi, vi, mods = ~ 0 + study + treatment, data=dat, slab=paste0(study, treatment))
res.fe

### test if treatment factor as a whole is significant
anova(res.fe, btt="treatment")

### forest plot of the contrast estimates (treatments versus placebos)
forest(tail(coef(res.fe), 9), tail(diag(vcov(res.fe)), 9), slab=levels(dat$treatment)[-1],
      xlim=c(-2.5, 1.5), alim=c(-1.5, 0.5), psize=1, xlab="Estimate", header="Treatment")

### weight matrix for the estimation of the fixed effects (leaving out the study effects)
w <- t(tail(vcov(res.fe) %*% t(model.matrix(res.fe)) %*% weights(res.fe, type="matrix"), 9))
rownames(w) <- res.fe$slab

### create shade plot for the diabetes network with placebo as the reference treatment
### negative values in blue shades, positive values in red shades
cols <- colorRampPalette(c("blue", "gray95", "red"))(9)
heatmap(w, Rowv=NA, Colv=NA, scale="none", margins=c(6,11), col=cols,
        cexRow=.7, cexCol=1, labCol=levels(dat$treatment)[-1])

### network meta-analysis using an arm-based random-effects model with fixed study effects
### by setting rho=1/2, tau^2 reflects the amount of heterogeneity for all treatment comparisons
res.re <- rma.mv(yi, vi, mods = ~ 0 + study + treatment, random = ~ treatment | study, rho=1/2,
                 data=dat, slab=paste0(study, treatment))
res.re

### test if treatment factor as a whole is significant
anova(res.re, btt="treatment")

### forest plot of the contrast estimates (treatments versus placebos)
forest(tail(coef(res.re), 9), tail(diag(vcov(res.re)), 9), slab=levels(dat$treatment)[-1],
      xlim=c(-2.5, 1.5), alim=c(-1.5, 0.5), psize=1, xlab="Estimate", header="Treatment")

### compute the contribution of each study to the overall Q-test value
qi <- sort(by((resid(res.fe) / sqrt(dat$vi))^2, dat$study, sum))

### check that the values add up
sum(qi)
res.fe$QE

### plot the values
s <- length(qi)
par(mar=c(5,10,2,1))
plot(qi, 1:s, pch=19, xaxt="n", yaxt="n", xlim=c(0,40), xlab="Chi-Square Contribution", ylab="")
axis(side=1)
axis(side=2, at=1:s, labels=names(qi), las=1, tcl=0)
segments(rep(0,s), 1:s, qi, 1:s)

################################################################################
```

```
### restructure dataset to a contrast-based format
dat <- dat.senn2013[c(1,4:2,5:6)] # reorder variables first
dat <- to.wide(dat, study="study", grp="treatment", ref="placebo", grpvars=4:6)
dat

### calculate mean difference and corresponding sampling variance for each treatment comparison
dat <- escalc(measure="MD", m1i=mi.1, sd1i=sdi.1, n1i=ni.1,
                            m2i=mi.2, sd2i=sdi.2, n2i=ni.2, data=dat)
dat

### calculate the variance-covariance matrix of the mean differences for the multitreatment studies
calc.v <- function(x) {
   v <- matrix(x$sdi.2[1]^2 / x$ni.2[1], nrow=nrow(x), ncol=nrow(x))
   diag(v) <- x$vi
   v
}
V <- bldiag(lapply(split(dat, dat$study), calc.v))

### add contrast matrix to dataset
dat <- contrmat(dat, grp1="treatment.1", grp2="treatment.2")
dat

### network meta-analysis using a contrast-based random-effects model
### by setting rho=1/2, tau^2 reflects the amount of heterogeneity for all treatment comparisons
### the treatment left out (placebo) becomes the reference level for the treatment comparisons
res <- rma.mv(yi, V, mods = ~ 0 + acarbose + benfluorex + metformin + miglitol + pioglitazone +
                              rosiglitazone + sitagliptin + sulfonylurea + vildagliptin,
              random = ~ comp | study, rho=1/2, data=dat)
res

### forest plot of the contrast estimates (treatments versus placebos)
forest(coef(res), diag(vcov(res)), slab=names(coef(res)), order="obs",
      xlim=c(-3.0, 2.5), alim=c(-1.5, 0.5), psize=1, xlab="Estimate", header="Treatment")

### estimate all pairwise differences between treatments
contr <- data.frame(t(combn(names(coef(res)), 2)))
contr <- contrmat(contr, "X1", "X2", last="vildagliptin")
rownames(contr) <- paste(contr$X1, "-", contr$X2)
contr <- as.matrix(contr[-c(1:2)])
sav <- predict(res, newmods=contr)
sav[["slab"]] <- rownames(contr)
sav

### fit random inconsistency effects model (see Law et al., 2016)
inc <- rma.mv(yi, V, mods = ~ 0 + acarbose + benfluorex + metformin + miglitol + pioglitazone +
                              rosiglitazone + sitagliptin + sulfonylurea + vildagliptin,
              random = list(~ comp | study, ~ comp | design), rho=1/2, phi=1/2, data=dat)
inc

#############################################################################

### compute P-scores (see Rücker & Schwarzer, 2015)
contr <- data.frame(t(combn(c(names(coef(res)),"placebo"), 2))) # add 'placebo' to contrast matrix
```

```
contr <- contrmat(contr, "X1", "X2", last="placebo", append=FALSE)
b <- c(coef(res),0) # add 0 for 'placebo' (the reference treatment)
vb <- bldiag(vcov(res),0) # add 0 row/column for 'placebo' (the reference treatment)
pvals <- apply(contr, 1, function(x) pnorm((x%*%b) / sqrt(t(x)%*%vb%*%x)))
tab <- vec2mat(pvals, corr=FALSE)
tab[upper.tri(tab)] <- t((1 - tab)[upper.tri(tab)])
rownames(tab) <- colnames(tab) <- colnames(contr)
round(tab, 2) # like Table 2 in the article
cbind(pscore=round(sort(apply(tab, 1, mean, na.rm=TRUE), decreasing=TRUE), 3))

# note: the values are slightly different from the ones given in Table 3 of Rücker and
# Schwarzer (2015) since model 'res' above is fitted using REML estimation while the
# results shown in the article are based on the 'netmeta' package, which uses a DL-type
# estimator for the amount of heterogeneity by default

################################################################################

## End(Not run)
```

`dat.spooner2002` *Studies on Nedocromil Sodium for Preventing Exercise-Induced Bronchoconstriction*

Description

Results from 17 trials, 11 studies in children and 6 studies in adults, reporting the maximum fall in the forced expiratory volume in 1 second (FEV_1) over the course of follow-up, expressed as a percentage.

Usage

```
dat.spooner2002
```

Format

The data frame contains the following columns:

author	`character`	first author
year	`character`	year of publication
Ne	`integer`	number of participants in nedocromil sodium group
Me	`numeric`	maximum fall in the FEV_1 (nedocromil sodium)
Se	`numeric`	standard deviation (nedocromil sodium)
Nc	`integer`	number of participants in placebo group
Mc	`numeric`	maximum fall in the FEV_1 (placebo)
Sc	`numeric`	standard deviation (placebo)
agegroup	`factor`	age group (children or adults)
order	`numeric`	order of studies in Table 1.1 in the Cochrane review

Details

Spooner et al. (2002) conducted a Cochrane review comparing nedocromil sodium (experimental treatment) with placebo (control) for preventing exercise-induced bronchoconstriction. Primary outcome was the maximum fall in the forced expiratory volume in 1 second (FEV_1) over the course of follow-up, expressed as a percentage. This outcome is available for 17 studies, 11 studies in children and 6 studies in adults. For each study, the mean value, standard deviation, and sample size are reported for both the experimental and control group. The authors conducted a random-effects meta-analysis with the mean difference as effect measure, i.e.\ mean value in the nedocromil sodium group minus mean value in the placebo group.

This data set is used as an example in Schwarzer et al. (2015).

Concepts

medicine, pulmonology, raw mean differences, subgroup analysis

Author(s)

Guido Schwarzer, <guido.schwarzer@uniklinik-freiburg.de>, https://github.com/guido-s/

Source

Spooner, C., Saunders, L. D., & Rowe, B. H. (2002). Nedocromil sodium for preventing exercise-induced bronchoconstriction. *Cochrane Database of Systematic Reviews*, **1**, CD001183. https://doi.org/10.1002/14651

References

Schwarzer, G., Carpenter, J. R., & Rücker, G. (2015). *Meta-analysis with R*. Cham, Switzerland: Springer.

Examples

```
### Show first five studies
head(dat.spooner2002, 5)

## Not run:
### Load meta package
suppressPackageStartupMessages(library(meta))

### Use settings from RevMan5
oldset <- settings.meta("RevMan5")

### Conduct random effects meta-analysis with age subgroups
mc1 <- metacont(Ne, Me, Se, Nc, Mc, Sc,
                data = dat.spooner2002, studlab = paste(author, year),
                subgroup = agegroup, print.subgroup.name = FALSE,
                label.e = "Nedocromil sodium", label.c = "Placebo",
                common = FALSE)
mc1

### Use previous settings
```

```
settings.meta(oldset)

## End(Not run)
```

`dat.steurer2006` *Trials on Single-Agent Purine Analogues for the Treatment of Chronic Lymphocytic Leukaemia*

Description

Results from 4 trials evaluating single-agent purine analogues in patients with chronic lymphocytic leukaemia.

Usage

```
dat.steurer2006
```

Format

The data frame contains the following columns:

author	`character`	first author
year	`integer`	publication year
Ne	`integer`	number of patients (purine antagonists)
Nc	`integer`	number of patients (alkylator-based)
HR	`numeric`	hazard ratio
lowHR	`numeric`	lower limit
uppHR	`numeric`	upper limit
lnHR	`numeric`	log hazard ratio
selnHR	`numeric`	standard error

Details

Steurer et al. (2006) conducted a Cochrane review to evaluate the effect of single-agent purine analogues for the treatment of chronic lymphocytic leukaemia. This dataset contains data from the main outcome, overall survival. Note, the hazard ratios and confidence limits have been reported in the Cochrane review with only two significant figures and were recalculated using the reported log hazard ratios and standard errors.

This data set is used as an example in Schwarzer et al. (2015).

Concepts

medicine, oncology, hazard ratios

Author(s)

Guido Schwarzer, <guido.schwarzer@uniklinik-freiburg.de>, https://github.com/guido-s/

Source

Steurer, M., Pall, G., Richards, S., Schwarzer, G., Bohlius, J., & Greil, R. (2006). Purine antagonists for chronic lymphocytic leukaemia. *Cochrane Database of Systematic Reviews*, **3**, CD004270. https://doi.org/10.1002/14651858.cd004270.pub2

References

Schwarzer, G., Carpenter, J. R., & Rücker, G. (2015). *Meta-analysis with R*. Cham, Switzerland: Springer.

Examples

```
### Show dataset
dat.steurer2006

## Not run:
### Load meta package
suppressPackageStartupMessages(library(meta))

### Use RevMan 5 settings
oldset <- settings.meta("RevMan5")

### Conduct common effect meta-analysis
m1 <- metagen(lnHR, selnHR, data = dat.steurer2006,
  studlab = paste(author, year),
  sm = "HR", random = FALSE, n.e = Ne, n.c = Nc)
m1

### Same analysis using lower and upper confidence limits
m2 <- metagen(HR, lower = lowHR, upper = uppHR,
  data = dat.steurer2006, transf = FALSE,
  studlab = paste(author, year),
  sm = "HR", random = FALSE, n.e = Ne, n.c = Nc)
m2

### Use previous settings
settings.meta(oldset)

## End(Not run)
```

---

dat.stowe2010 *Studies on Adjuvant Treatments to Levodopa Therapy for Parkinson disease*

Description

Results from 29 trials assessing efficacy of three drug classes as adjuvant treatment to levodopa therapy in patients with Parkinson disease and motor complications.

Usage

```
dat.stowe2010
```

Format

The data frame contains the following columns:

study	character	study label
id	integer	study id
t1	character	treatment 1
y1	numeric	treatment effect arm 1
sd1	numeric	standard deviation arm 1
n1	integer	sample size arm 1
t2	character	treatment 2
y2	numeric	treatment effect arm 2
sd2	numeric	standard deviation arm 2
n2	integer	sample size arm 2
t3	character	treatment 3
y3	numeric	treatment effect arm 3
sd3	numeric	standard deviation arm 3
n3	integer	sample size arm 3

Details

This dataset contains data from a Cochrane review assessing efficacy and safety of three drug classes as adjuvant treatment to levodopa therapy in patients with Parkinson disease and motor complications (Stowe et al., 2010).

The authors conducted three pairwise meta-analyses comparing dopamine agonists, catechol-O-methyl transferase inhibitors (COMTI), and monoamine oxidase type B inhibitors (MAOBI) with placebo. The primary outcome was the mean reduction of the time spent in a relatively immobile 'off' phase (mean off-time), calculated in hours per day. Relative treatment effects were expressed as mean difference. Data on this outcome were available for 5,331 patients from 28 studies comparing an active treatment with placebo and one three-arm study comparing two active treatments with placebo.

Concepts

medicine, raw mean differences, network meta-analysis

Author(s)

Guido Schwarzer, <guido.schwarzer@uniklinik-freiburg.de>, https://github.com/guido-s/

Source

Stowe, R., Ives, N., Clarke, C. E., Deane, K., Hilten, V., Wheatley, K., Gray, R., Handley, K., & Furmston, A. (2010). Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson's disease patients with motor complications. *Cochrane Database of Systematic Reviews*, **7**, CD007166. https://doi.org/10.1002/14651858.CD007166.pub2

Examples

```
### Show results from three studies (including three-arm study LARGO)
dat.stowe2010[18:20, ]

## Not run:
### Load netmeta package
suppressPackageStartupMessages(library(netmeta))

### Print mean differences with two digits and standard errors with 3
### digits
oldset <- settings.meta(digits = 2, digits.se = 3)

### Transform data from wide arm-based format to contrast-based
### format. Argument 'sm' must not be provided as the mean difference
### is the default in R function metacont() called internally.
pw <- pairwise(treat = list(t1, t2, t3), n = list(n1, n2, n3),
  mean = list(y1, y2, y3), sd = list(sd1, sd2, sd3),
  studlab = study, data = dat.stowe2010, sm = "MD")

### Show calculated mean differences (TE) for three studies
selstudy <- c("COMTI(E) INT-OZ", "LARGO", "COMTI(E) Nomecomt")
subset(pw, studlab %in% selstudy)[, c(3:7, 10, 1)]

### Conduct random effects network meta-analysis (NMA)
### with placebo as reference
net <- netmeta(pw, common = FALSE, ref = "plac")

### Show network graph
netgraph(net, number = TRUE, multiarm = TRUE,
  cex = 1.25, offset = 0.025,
  cex.number = 1, pos.number.of.studies = 0.3)

### Print NMA results
net

### Forest plot with NMA results
forest(net)

### Forest plot showing all network estimates of active treatments
### compared with other treatments
forest(net, ref = c("C", "D", "M"), baseline = FALSE, drop = TRUE)

### Treatment ranking using P-scores
netrank(net)

### Rankogram with all ranking probabilities
set.seed(1909)
ran <- rankogram(net)
ran
plot(ran)

### Treatment ranking using SUCRAs
```

```
netrank(ran)

### League table showing network and direct estimates
netleague(net, seq = netrank(net), ci = FALSE)

### Use previous settings
settings.meta(oldset)

## End(Not run)
```

`dat.tannersmith2016` *Studies on the Relationship between School Motivation and Criminal Behavior*

Description

Results from 17 studies on the correlation between school motivation/attitudes and subsequent delinquent/criminal behavior.

Usage

```
dat.tannersmith2016
```

Format

The data frame contains the following columns:

studyid	`numeric`	study identifier
yi	`numeric`	r-to-z transformed correlation coefficient
vi	`numeric`	corresponding sampling variance
sei	`numeric`	corresponding standard error
aget1	`numeric`	age at which the school motivation/attitudes were assessed
aget2	`numeric`	age at which the delinquent/criminal behavior was assessed
propmale	`numeric`	proportion of male participants in the sample
sexmix	`character`	whether the sample consisted only of males, only of females, or a mix

Details

The dataset includes 113 r-to-z transformed correlation coefficients from 17 prospective longitudinal studies that examined the relationship between school motivation/attitudes and subsequent delinquent/criminal behavior.

Multiple coefficients could be extracted from the studies "given the numerous ways in which school motivation/attitudes variables could be operationalized (e.g., academic aspirations, academic self-efficacy) as well as the numerous ways in which crime/delinquency could be operationalized (e.g., property crime, violent crime)" (Tanner-Smith et al., 2016).

Since information to compute the covariance between multiple coefficients within studies is not available, Tanner-Smith et al. (2016) illustrate the use of cluster-robust inference methods for the analysis of this dataset.

Note that this dataset is only meant to be used for pedagogical and demonstration purposes and does not constitute a proper review or synthesis of the complete and current research evidence on the given topic.

Concepts

psychology, criminology, correlation coefficients, multilevel models, cluster-robust inference, meta-regression

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Tanner-Smith, E. E., Tipton, E. & Polanin, J. R. (2016). Handling complex meta-analytic data structures using robust variance estimates: A tutorial in R. *Journal of Developmental and Life-Course Criminology*, **2**(1), 85–112. https://doi.org/10.1007/s40865-016-0026-5

Examples

```
### copy data into 'dat' and examine data
dat <- dat.tannersmith2016
head(dat)

## Not run:
### load metafor package
library(metafor)

### compute mean age variables within studies
dat$aget1 <- ave(dat$aget1, dat$studyid)
dat$aget2 <- ave(dat$aget2, dat$studyid)

### construct an effect size identifier variable
dat$esid <- 1:nrow(dat)

### construct an approximate var-cov matrix assuming a correlation of 0.8
### for multiple coefficients arising from the same study
V <- vcalc(vi, cluster=studyid, obs=esid, rho=0.8, data=dat)

### fit a multivariate random-effects model using the approximate var-cov matrix V
res <- rma.mv(yi, V, random = ~ esid | studyid, data=dat)
res

### use cluster-robust inference methods
robust(res, cluster=studyid, clubSandwich=TRUE)

### note: the results obtained above and below are slightly different compared
### to those given by Tanner-Smith et al. (2016) since the approach illustrated
### here makes use a multivariate random-effects model for the 'working model'
### before applying the cluster-robust inference methods, while the results given
### in the paper are based on a somewhat simpler working model
```

```
### examine the main effects of the age variables
res <- rma.mv(yi, V, mods = ~ aget1 + aget2,
              random = ~ 1 | studyid/esid, data=dat)
robust(res, cluster=studyid, clubSandwich=TRUE)

### also examine their interaction
res <- rma.mv(yi, V, mods = ~ aget1 * aget2,
              random = ~ 1 | studyid/esid, data=dat)
robust(res, cluster=studyid, clubSandwich=TRUE)

### add the sexmix factor to the model
res <- rma.mv(yi, V, mods = ~ aget1 * aget2 + sexmix,
              random = ~ 1 | studyid/esid, data=dat)
robust(res, cluster=studyid, clubSandwich=TRUE)

## End(Not run)
```

`dat.thompson1999` *Trials on Serum Cholesterin Concentration Lowering and Risk of Ischaemic Heart Disease*

Description

Results from 28 trials evaluating effect of serum cholesterin concentration lowering on risk of ischaemic heart disease

Usage

```
dat.thompson1999
```

Format

The data frame contains the following columns:

studyid	integer	study ID
ihd.cont	integer	number of ischaemic heart disease (control group)
noihd.cont	integer	number of non-events (control group)
ihd.exp	integer	number of ischaemic heart disease (treated group)
noihd.exp	integer	number of non-events (treated group)
OR	numeric	odds ratio
logOR	numeric	log odds ratio
varlogOR	numeric	variance of log odds ratio
cholr	numeric	cholesterol reduction (mmol/l)

Details

Thompson and Sharp (1999) compare several meta-regression approaches to explain heterogeneity in meta-analysis. The data set used is originally from Law et al. (1994), but with minor modifications.

Concepts

medicine, cardiology, odds ratios, meta-regression

Author(s)

Guido Schwarzer, <guido.schwarzer@uniklinik-freiburg.de>, https://github.com/guido-s/

Source

Thompson, S. G., & Sharp, S. J. (1999). Explaining heterogeneity in meta-analysis: A comparison of methods. *Statistics in Medicine*, **18**(20), 2693–2708. https://doi.org/10.1002/(sici)1097-0258(19991030)18:20<

References

Law, M. R., Wald, N. J., & Thompson, S. G. (1994). By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? *British Medical Journal*, **308**(6925), 367–372. https://doi.org/10.1136/bmj.308.6925.367

Examples

```
### Show first five studies
head(dat.thompson1999, 5)

## Not run:
### Load meta package
suppressPackageStartupMessages(library(meta))

### Conduct meta-analysis
m <- metabin(ihd.exp, ihd.exp + noihd.exp, ihd.cont, ihd.cont + noihd.cont,
  data = dat.thompson1999, sm = "OR", method = "Inverse")

### Thompson & Sharp (1999), Table III
### (1) None
metareg(m, cholr, method.tau = "FE")
### (3a) Additive (MM)
metareg(m, cholr, method.tau = "DL")

## End(Not run)
```

---

dat.tian2009 *Studies on the Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes*

Description

Results from 48 trials examining the effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

Usage

```
dat.tian2009
```

Format

The data frame contains the following columns:

study	character	Study ID
group	character	Treatment group (rosiglitazone or control)
intervention	character	Intervention group, i.e., combination of drug classes
detailed.intervention	character	Intervention group with drug names instead of classes
phase	integer	Phase of clinical trial
duration	integer	Duration of the trial (in weeks)
n.all	integer	Number of patients
n	integer	Number of patients with information on outcomes
deaths	integer	Number of deaths
infarcts	integer	Number of myocardial infarctions
type	character	Study types as in Table 1 from Nissen and Wolski (2007)
population	character	Details on the trial population
period	character	Trial period
age	numeric	Mean age (in years)
male	numeric	Percentage of males
hemoglobin	numeric	Mean baseline glycated hemoglobin level

Details

Nissen and Wolski (2007) performed a meta-analysis of trials examining the effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. The present dataset by Tian et al. (2009) is based on this meta-analysis, but includes six additional trials where no event was observed in either group for both outcomes. The data set is in long arm-based format. See `dat.nissen2007` for the original dataset.

Concepts

medicine, cardiology, odds ratios, Peto's method, generalized linear models

Author(s)

Guido Schwarzer, <guido.schwarzer@uniklinik-freiburg.de>, https://github.com/guido-s/

Source

Tian, L., Cai, T., Pfeffer, M. A., Piankov, N., Cremieux, P.-Y., & Wei, L. J. (2009). Exact and efficient inference procedure for meta-analysis and its application to the analysis of independent 2 x 2 tables with all available data but without artificial continuity correction. *Biostatistics*, **10**(2), 275–281. https://doi.org/10.1093/biostatistics/kxn034

References

Nissen, S. E., & Wolski, K. (2007). Effect of Rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. *New England Journal of Medicine*, **356**(24), 2457-2471. https://doi.org/10.1056/NEJMoa072761

See Also

dat.nissen2007

Examples

```
### Show first 6 rows / 3 trials of the dataset
head(dat.tian2009)

## Not run:
### Load meta package
suppressPackageStartupMessages(library(meta))

### Print odds ratios and confidence limits with two digits and define
### labels shown in forest plots
oldset <- settings.meta(digits = 2,
  label.e = "Rosiglitazone", label.c = "Control",
  label.left = "Favors rosiglitazome",
  label.right = "Favors control")

### Transform data from long arm-based format to contrast-based
### format. Argument 'sm' has to be used for odds ratio as summary
### measure; by default the risk ratio is used in the metabin function
### called internally.
pw <- pairwise(treat = group, event = deaths, n = n, studlab = study,
  data = dat.tian2009, sm = "OR", varnames = c("lnOR", "selnOR"))

### Fit the inverse variance model
mod_iv <- metabin(pw,
  text.common = "IV method (common)",
  text.random = "IV method (random)")

### Fit the Mantel-Haenszel model
mod_mh <- update(mod_iv, method = "MH", random = FALSE,
  method.incr = gs("method.incr"),
  text.common = "MH method")

### Fit the Peto model
mod_peto <- update(mod_mh, method = "Peto",
  text.common = "Peto method")

### Fit generalized linear mixed models (GLMM)
mod_glmm <- update(mod_mh, method = "glmm", model = "CM.AL",
  random = TRUE,
  text.common = "GLMM (common)",
  text.random = "GLMM (random)")
```

```
if (requireNamespace("brglm2", quietly = TRUE)) {
### Fit the logistic regression model with penalized likelihood (LRP)
mod_plma <- update(mod_glmm, method = "LRP",
  text.common = "LRP method (common)",
  text.random = "LRP method (random)")

### Fit the logistic regression model after excluding double zero studies
mod_plma1 <- metabin(event1, n1, event2, n2, studlab = study,
  data = subset(pw, !is.na(lnOR)), sm = "OR", method = "LRP",
  text.common = "LRP method, exclude zeros (common)",
  text.random = "LRP method, exclude zeros (random)")
}

### Create forest plot with all results
mm <- metaadd(mod_iv, data = mod_mh)
mm <- metaadd(mm, data = mod_peto)
mm <- metaadd(mm, data = mod_glmm)

if (requireNamespace("brglm2", quietly = TRUE)) {
mm <- metaadd(mm, data = mod_plma)
mm <- metaadd(mm, data = mod_plma1)
}

fname <- tempfile(pattern = "forest", fileext = ".pdf")
forest(mm, hetstat = FALSE, file = fname, width = 10, rows.gr = 1)

### Use previous settings
settings.meta(oldset)

## End(Not run)
```

`dat.ursino2021` *Sorafenib Toxicity Dataset*

Description

13 studies investigating the occurrence of dose limiting toxicities (DLTs) at different doses of Sorafenib.

Usage

```
dat.ursino2021
```

Format

The data frame contains the following columns:

study	`character`	study label
year	`integer`	publication year

dose	`numeric`	dose (mg)
events	`integer`	number of DLTs
total	`integer`	number of patients exposed

Details

Sorafenib (BAY 43-9006, Nexavar) is a kinase inhibitor that is used in the treatment of advanced renal cell carcinoma, hepatocellular carcinoma, and radioactive iodine resistant advanced thyroid carcinoma. Thirteen trials with published results, described in eleven manuscripts, were identified in a literature search. This dataset contains the doses investigated, the numbers of patients treated, and the number of dose-limiting toxicities (DLTs) observed. In general, each study investigated several doses according to some dose-escalation scheme.

Concepts

medicine, oncology, dose-response models

Author(s)

Christian Röver, <christian.roever@med.uni-goettingen.de>

Source

Ursino, M., Röver, C., Zohar, S., & Friede T. (2021). Random-effects meta-analysis of phase I dose-finding studies using stochastic process priors. *The Annals of Applied Statistics*, **15**(1), 174–193. https://doi.org/10.1214/20-AOAS1390

Röver, C., Ursino, M., Friede, T., & Zohar, S. (2022). A straighforward meta-analysis approach for oncology phase I dose-finding studies. *Statistics in Medicine*, **41**(20), 3915–3940. https://doi.org/10.1002/sim.9484

References

European Medicines Agency (EMA) (2022). Nexavar (sorafenib) EPAR summary. https://www.ema.europa.eu/en/medic

Awada, A., Hendlisz, A., Gil, T., *et al.* (2005). Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on / 7 days off in patients with advanced, refractory solid tumours. *British Journal of Cancer*, **92**(10), 1855. https://doi.org/10.1038/sj.bjc.6602584

Clark, J. W., Eder, J. P., Ryan, D., Lathia, C., & Lenz, H.-J. (2005). Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. *Clinical Cancer Research*, **11**(15), 5472–5480. https://doi.org/10.1158/1078-0432.CCR-04-2658

Moore, M., Hirte, H. W., Siu, L., *et al.* (2005). Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on / 7 days off in patients with advanced, refractory solid tumors. *Annals of Oncology*, **16**(10), 1688–1694. https://doi.org/10.1093/annonc/mdi310

Strumberg, D., Richly, H., Hilger, R. A., *et al.* (2005). Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. *Journal of Clinical Oncology*, **23**(5), 965–972. https://doi.org/10.1200/JCO.2005.06.124

Furuse, J., Ishii, H., Nakachi, K., Suzuki, E., Shimizu, S., & Nakajima, K. (2008). Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. *Cancer Science*, **99**(1), 159–165. https://doi.org/10.1111/j.1349-7006.2007.00648.x

Minami, H., Kawada, K., Ebi, H., *et al.* (2008). Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. *Cancer Science*, **99**(7), 1492–1498. https://doi.org/10.1111/j.1349-7006.2008.00837.x

Miller, A. A., Murry, D. J., Owzar, K., *et al.* (2009). Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. *Journal of Clinical Oncology*, **27**(11), 1800. https://doi.org/10.1200/JCO.2008.20.0931

Crump, M., Hedley, D., Kamel-Reid, S., *et al.* (2010). A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: A NCIC (National Cancer Institute of Canada) Clinical Trials Group Study. *Leukemia and Lymphoma*, **51**(2), 252–260. https://doi.org/10.3109/10428190903585286

Borthakur, G., Kantarjian, H., Ravandi, F., *et al.* (2011). Phase I study of sorafenib in patients with refractory or relapsed acute Leukemias. *Haematologica*, **96**(1), 62–68. https://doi.org/10.3324/haematol.2010.03045

Nabors, L. B., Supko, J. G., Rosenfeld, M., *et al.* (2011). Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma. *Neuro-Oncology*, **13**(12), 1324–1330. https://doi.org/10.1093/neuonc/nor

Chen, Y.-B., Li, S., Lane, A. A., *et al.* (2014). Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for FMS-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia. *Biology of Blood and Marrow Transplantation*, **20**(12), 2042–2048. https://doi.org/10.1016/j.bbmt.2014.09.007

See Also

dat.roever2022

Examples

```
# show (some) data
head(dat.ursino2021, n=15)

## Not run:
# illustrate data
plot(NA, xlim=range(dat.ursino2021$dose), ylim=0:1,
     xlab="dose (mg)", ylab="proportion",
     main="dat.ursino2021 (Sorafenib data)")
studylab <- unique(dat.ursino2021$study)
colvec <- rainbow(length(studylab))
for (i in 1:length(studylab)) {
  idx <- (dat.ursino2021$study == studylab[i])
  lines(dat.ursino2021[idx,"dose"],
        dat.ursino2021[idx,"events"] / dat.ursino2021[idx,"total"],
        col=colvec[i], type="b")
}
legend("topleft", studylab, col=colvec, pch=15)

## End(Not run)
```

dat.vanhowe1999 *Studies on the Association between Circumcision and HIV Infection*

Description

Results from 33 studies examining the association between male circumcision and HIV infection.

Usage

```
dat.vanhowe1999
```

Format

The data frame contains the following columns:

study	character	study author
category	character	study type (high-risk group, partner study, or population survey)
non.pos	numeric	number of non-circumcised HIV positive cases
non.neg	numeric	number of non-circumcised HIV negative cases
cir.pos	numeric	number of circumcised HIV positive cases
cir.neg	numeric	number of circumcised HIV negative cases

Details

The 33 studies provide data in terms of 2×2 tables in the form:

	HIV positive	HIV negative
non-circumcised	non.pos	non.neg
circumcised	cir.pos	cir.neg

The goal of the meta-analysis was to examine if the risk of an HIV infection differs between non-circumcised versus circumcised men.

The dataset is interesting because it can be used to illustrate the difference between naively pooling results by summing up the counts across studies and then computing the odds ratio based on the aggregated table (as was done by Van Howe, 1999) and conducting a proper meta-analysis (as illustrated by O'Farrell & Egger, 2000). In fact, a proper meta-analysis shows that the HIV infection risk is on average higher in non-circumcised men, which is the opposite of what the naive pooling approach yields (which makes this an illustration of Simpson's paradox).

Concepts

medicine, epidemiology, odds ratios

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Van Howe, R. S. (1999). Circumcision and HIV infection: Review of the literature and meta-analysis. *International Journal of STD & AIDS*, **10**(1), 8–16. https://doi.org/10.1258/0956462991913015

References

O'Farrell, N., & Egger, M. (2000). Circumcision in men and the prevention of HIV infection: A 'meta-analysis' revisited. *International Journal of STD & AIDS*, **11**(3), 137–142. https://doi.org/10.1258/0956462001919

Examples

```
### copy data into 'dat' and examine data
dat <- dat.vanhowe1999
dat

## Not run:
### load metafor package
library(metafor)

### naive pooling by summing up the counts within categories and then
### computing the odds ratios and corresponding confidence intervals
cat1 <- with(dat[dat$category=="high-risk group",],
  escalc(measure="OR", ai=sum(non.pos), bi=sum(non.neg), ci=sum(cir.pos), di=sum(cir.neg)))
cat2 <- with(dat[dat$category=="partner study",],
  escalc(measure="OR", ai=sum(non.pos), bi=sum(non.neg), ci=sum(cir.pos), di=sum(cir.neg)))
cat3 <- with(dat[dat$category=="population survey",],
  escalc(measure="OR", ai=sum(non.pos), bi=sum(non.neg), ci=sum(cir.pos), di=sum(cir.neg)))
summary(cat1, transf=exp, digits=2)
summary(cat2, transf=exp, digits=2)
summary(cat3, transf=exp, digits=2)

### naive pooling across all studies
all <- escalc(measure="OR", ai=sum(dat$non.pos), bi=sum(dat$non.neg),
                            ci=sum(dat$cir.pos), di=sum(dat$cir.neg))
summary(all, transf=exp, digits=2)

### calculate log odds ratios and corresponding sampling variances
dat <- escalc(measure="OR", ai=non.pos, bi=non.neg, ci=cir.pos, di=cir.neg, data=dat)
dat

### random-effects model
res <- rma(yi, vi, data=dat, method="DL")
res
predict(res, transf=exp, digits=2)

### random-effects model within subgroups
res <- rma(yi, vi, data=dat, method="DL", subset=category=="high-risk group")
predict(res, transf=exp, digits=2)
res <- rma(yi, vi, data=dat, method="DL", subset=category=="partner study")
predict(res, transf=exp, digits=2)
res <- rma(yi, vi, data=dat, method="DL", subset=category=="population survey")
predict(res, transf=exp, digits=2)
```

```
## End(Not run)
```

`dat.viechtbauer2021` *Studies to Illustrate Model Checking Methods*

Description

Results from 20 hypothetical randomized clinical trials examining the effectiveness of a medication for treating some disease.

Usage

```
dat.viechtbauer2021
```

Format

The data frame contains the following columns:

trial	`numeric`	trial number
nTi	`numeric`	number of patients in the treatment group
nCi	`numeric`	number of patients in the control group
xTi	`numeric`	number of patients in the treatment group with remission
xCi	`numeric`	number of patients in the control group with remission
dose	`numeric`	dosage of the medication provided to patients in the treatment group (in milligrams per day)

Details

The dataset was constructed for the purposes of illustrating the model checking and diagnostic methods described in Viechtbauer (2021). The code below provides the results for many of the analyses and plots discussed in the book chapter.

Concepts

medicine, odds ratios, outliers, model checks

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Viechtbauer, W. (2021). Model checking in meta-analysis. In C. H. Schmid, T. Stijnen, & I. R. White (Eds.), *Handbook of meta-analysis* (pp. 219-254). Boca Raton, FL: CRC Press. https://doi.org/10.1201/9781315

Examples

```
### copy data into 'dat' and examine data
dat <- dat.viechtbauer2021
dat

## Not run:
### load metafor package
library(metafor)

### calculate log odds ratios and corresponding sampling variances

dat <- escalc(measure="OR", ai=xTi, n1i=nTi, ci=xCi, n2i=nCi, add=1/2, to="all", data=dat)
dat

### number of studies

k <- nrow(dat)

### fit models

res.CE <- rma(yi, vi, data=dat, method="CE") # same as method="EE"
res.CE

res.RE <- rma(yi, vi, data=dat, method="DL")
res.RE

res.MR <- rma(yi, vi, mods = ~ dose, data=dat, method="FE")
res.MR

res.ME <- rma(yi, vi, mods = ~ dose, data=dat, method="DL")
res.ME

### forest and bubble plot

par(mar=c(5,4,1,2))

forest(dat$yi, dat$vi, psize=0.8, efac=0, xlim=c(-4,6), ylim=c(-3,23),
       cex=1, width=c(5,5,5), xlab="Log Odds Ratio (LnOR)",
       header=c("Trial", "LnOR [95% CI]"))
addpoly(res.CE, row=-1, mlab="CE Model")
addpoly(res.RE, row=-2, mlab="RE Model")
abline(h=0)

tmp <- regplot(res.ME, xlim=c(0,250), ylim=c(-1,1.5), predlim=c(0,250), shade=FALSE, digits=1,
               xlab="Dosage (mg per day)", psize="seinv", plim=c(NA,5), bty="l", las=1,
               lty=c("solid", "dashed"), label=TRUE, labsize=0.8, offset=c(1,0.7))
res.sub <- rma(yi, vi, mods = ~ dose, data=dat, method="DL", subset=-6)
abline(res.sub, lty="dotted")
points(tmp$xi, tmp$yi, pch=21, cex=tmp$psize, col="black", bg="darkgray")

par(mar=c(5,4,4,2))
```

```
### number of standardized deleted residuals larger than +-1.96 in each model

sum(abs(rstudent(res.CE)$z) >= qnorm(0.975))
sum(abs(rstudent(res.MR)$z) >= qnorm(0.975))
sum(abs(rstudent(res.RE)$z) >= qnorm(0.975))
sum(abs(rstudent(res.ME)$z) >= qnorm(0.975))

### plot of the standardized deleted residuals for the RE and ME models

plot(NA, NA, xlim=c(1,20), ylim=c(-4,4), xlab="Study", ylab="Standardized (Deleted) Residual",
     xaxt="n", main="Random-Effects Model", las=1)
axis(side=1, at=1:20)
abline(h=c(-1.96,1.96), lty="dotted")
abline(h=0)
points(1:20, rstandard(res.RE)$z, type="o", pch=19, col="gray70")
points(1:20, rstudent(res.RE)$z,  type="o", pch=19)
legend("top", pch=19, col=c("gray70","black"), lty="solid",
       legend=c("Standardized Residuals","Standardized Deleted Residuals"), bty="n")

plot(NA, NA, xlim=c(1,20), ylim=c(-4,4), xlab="Study", ylab="Standardized (Deleted) Residual",
     xaxt="n", main="Mixed-Effects Model", las=1)
axis(side=1, at=1:20)
abline(h=c(-1.96,1.96), lty="dotted")
abline(h=0)
points(1:20, rstandard(res.ME)$z, type="o", pch=19, col="gray70")
points(1:20, rstudent(res.ME)$z,  type="o", pch=19)
legend("top", pch=19, col=c("gray70","black"), lty="solid",
       legend=c("Standardized Residuals","Standardized Deleted Residuals"), bty="n")

### Baujat plots

baujat(res.CE, main="Common-Effects Model", xlab="Squared Pearson Residual", ylim=c(0,5), las=1)
baujat(res.ME, main="Mixed-Effects Model", ylim=c(0,2), las=1)

### GOSH plots (skipped because this takes quite some time to run)

if (FALSE) {

res.GOSH.CE <- gosh(res.CE, subsets=10^7)
plot(res.GOSH.CE, cex=0.2, out=6, xlim=c(-0.25,1.25), breaks=c(200,100))

res.GOSH.ME <- gosh(res.ME, subsets=10^7)
plot(res.GOSH.ME, het="tau2", out=6, breaks=50, adjust=0.6, las=1)

}

### plot of treatment dosage against the standardized residuals

plot(dat$dose, rstandard(res.ME)$z, pch=19, xlab="Dosage (mg per day)",
     ylab="Standardized Residual", xlim=c(0,250), ylim=c(-2.5,2.5), las=1)
abline(h=c(-1.96,1.96), lty="dotted", lwd=2)
abline(h=0)
title("Standardized Residual Plot")
```

```
text(dat$dose[6], rstandard(res.ME)$z[6], "6", pos=4, offset=0.4)

### quadratic polynomial model

rma(yi, vi, mods = ~ dose + I(dose^2), data=dat, method="DL")

### lack-of-fit model

resLOF <- rma(yi, vi, mods = ~ dose + factor(dose), data=dat, method="DL", btt=3:9)
resLOF

### scatter plot to illustrate the lack-of-fit model

regplot(res.ME, xlim=c(0,250), ylim=c(-1.0,1.5), xlab="Dosage (mg per day)", ci=FALSE,
       predlim=c(0,250), psize=1, pch=19, col="gray60", digits=1, lwd=1, bty="l", las=1)
dosages <- sort(unique(dat$dose))
lines(dosages, fitted(resLOF)[match(dosages, dat$dose)], type="o", pch=19, cex=2, lwd=2)
points(dat$dose, dat$yi, pch=19, col="gray60")
legend("bottomright", legend=c("Linear Model", "Lack-of-Fit Model"), pch=c(NA,19), col="black",
       lty="solid", lwd=c(1,2), pt.cex=c(1,2), seg.len=4, bty="n")

### checking normality of the standardized deleted residuals

qqnorm(res.ME, type="rstudent", main="Standardized Deleted Residuals", pch=19, label="out",
       lwd=2, pos=24, ylim=c(-4,3), lty=c("solid", "dotted"), las=1)

### checking normality of the random effects

sav <- qqnorm(ranef(res.ME)$pred, main="BLUPs of the Random Effects", cex=1, pch=19,
              xlim=c(-2.2,2.2), ylim=c(-0.6,0.6), las=1)
abline(a=0, b=sd(ranef(res.ME)$pred), lwd=2)
text(sav$x[6], sav$y[6], "6", pos=4, offset=0.4)

### hat values for the CE and RE models

plot(NA, NA, xlim=c(1,20), ylim=c(0,0.21), xaxt="n", las=1, xlab="Study", ylab="Hat Value")
axis(1, 1:20, cex.axis=1)
points(hatvalues(res.CE), type="o", pch=19, col="gray70")
points(hatvalues(res.RE), type="o", pch=19)
abline(h=1/20, lty="dotted", lwd=2)
title("Hat Values for the CE/RE Models")
legend("topright", pch=19, col=c("gray70","black"), lty="solid",
       legend=c("Common-Effects Model", "Random-Effects Model"), bty="n")

### heatmap of the hat matrix for the ME model

cols <- colorRampPalette(c("blue", "white", "red"))(101)
h <- hatvalues(res.ME, type="matrix")
image(1:nrow(h), 1:ncol(h), t(h[nrow(h):1,]), axes=FALSE,
    xlab="Influence of the Observed Effect of Study ...", ylab="On the Fitted Value of Study ...",
      col=cols, zlim=c(-max(abs(h)),max(abs(h))))
axis(1, 1:20, tick=FALSE)
axis(2, 1:20, labels=20:1, las=1, tick=FALSE)
```

```
abline(h=seq(0.5,20.5,by=1), col="white")
abline(v=seq(0.5,20.5,by=1), col="white")
points(1:20, 20:1, pch=19, cex=0.4)
title("Heatmap for the Mixed-Effects Model")

### plot of leverages versus standardized residuals for the ME model

plot(hatvalues(res.ME), rstudent(res.ME)$z, pch=19, cex=0.2+3*sqrt(cooks.distance(res.ME)),
     las=1, xlab="Leverage (Hat Value)", ylab="Standardized Deleted Residual",
     xlim=c(0,0.35), ylim=c(-3.5,2.5))
abline(h=c(-1.96,1.96), lty="dotted", lwd=2)
abline(h=0, lwd=2)
ids <- c(3,6,9)
text(hatvalues(res.ME)[ids] + c(0,0.013,0.010), rstudent(res.ME)$z[ids] - c(0.18,0,0), ids)
title("Leverage vs. Standardized Deleted Residuals")

### plot of the Cook's distances for the ME model

plot(1:20, cooks.distance(res.ME), ylim=c(0,1.6), type="o", pch=19, las=1, xaxt="n", yaxt="n",
     xlab="Study", ylab="Cook's Distance")
axis(1, 1:20, cex.axis=1)
axis(2, seq(0,1.6,by=0.4), las=1)
title("Cook's Distances")

### plot of the leave-one-out estimates of tau^2 for the ME model

x <- influence(res.ME)

plot(1:20, x$inf$tau2.del,  ylim=c(0,0.15), type="o", pch=19, las=1, xaxt="n", xlab="Study",
    ylab=expression(paste("Estimate of ", tau^2, " without the ", italic(i), "th study")))
abline(h=res.ME$tau2, lty="dashed")
axis(1, 1:20)
title("Residual Heterogeneity Estimates")

### plot of the covariance ratios for the ME model

plot(1:20, x$inf$cov.r,  ylim=c(0,2.0), type="o", pch=19, las=1, xaxt="n",
     xlab="Study", ylab="Covariance Ratio")
abline(h=1, lty="dashed")
axis(1, 1:20)
title("Covariance Ratios")

### fit mixed-effects model without studies 3 and/or 6

rma(yi, vi, mods = ~ dose, data=dat, method="DL", subset=-3)
rma(yi, vi, mods = ~ dose, data=dat, method="DL", subset=-6)
rma(yi, vi, mods = ~ dose, data=dat, method="DL", subset=-c(3,6))

## End(Not run)
```

`dat.white2020` *Studies on the Relationship between Sexual Signal Expression and Individual Quality*

Description

Results from 41 studies examining the relationship between measures of individual quality and the expression of structurally coloured sexual signals.

Usage

```
dat.white2020
```

Format

The object is a data frame which contains the following columns:

study_id	`character`	study-level ID
obs	`character`	observation-level ID
exp_obs	`character`	whether the study is observational or experimental
control	`numeric`	whether the study did (1) or did not (0) include a non-sexual control trait
class	`character`	class of the study organisms
genus	`character`	class of the study organisms
species	`character`	species of the study organisms
sex	`character`	sex of the study organisms
iridescent	`numeric`	whether the colour signals were iridescent (1) or not (0)
col_var	`character`	the colour variable quantified
col_component	`character`	whether the colour variable is chromatic or achromatic
quality_measure	`character`	the measure of individual quality used
region	`character`	the body region from which colour was sampled
n	`numeric`	study sample size
r	`numeric`	Pearson's correlation coefficient

Details

The 186 rows in this dataset come from 41 experimental and observational studies reporting on the correlation between measures of individual quality (age, body condition, immune function, parasite resistance) and the expression of structurally coloured sexual signals across 28 species. The purpose of this meta-analysis was to test whether structural colour signals show heightened condition-dependent expression, as predicted by evolutionary models of 'honest' signalling.

Concepts

ecology, evolution, correlation coefficients

Author(s)

Thomas E. White, <thomas.white@sydney.edu.au>

Source

White, T. E. (2020). Structural colours reflect individual quality: A meta-analysis. *Biology Letters*, **16**(4), 20200001. https://doi.org/10.1098/rsbl.2020.0001

Examples

```
### copy data into 'dat' and examine data
dat <- dat.white2020
head(dat, 10)

## Not run:
### load metafor package
library(metafor)

### calculate r-to-z transformed correlations and corresponding sampling variances
dat <- escalc(measure="ZCOR", ri=r, ni=n, data=dat)

### fit multilevel meta-analytic model
res <- rma.mv(yi, vi, random = list(~ 1 | study_id, ~ 1 | obs), data=dat)
res

## End(Not run)
```

---

dat.woods2010 *Studies on Treatments for Chronic Obstructive Pulmonary Disease*

Description

Results from 3 trials examining the mortality risk of three treatments and placebo in patients with chronic obstructive pulmonary disease.

Usage

```
dat.woods2010
```

Format

The data frame contains the following columns:

author	character	first author / study name
treatment	character	treatment
r	integer	number of deaths
N	integer	number of patients

Details

Count mortality statistics in randomised controlled trials of treatments for chronic obstructive pulmonary disease (Woods et al., 2010, Table 1).

Concepts

medicine, odds ratios, network meta-analysis

Author(s)

Guido Schwarzer, <guido.schwarzer@uniklinik-freiburg.de>, https://github.com/guido-s/

Source

Woods, B. S., Hawkins, N., & Scott, D. A. (2010). Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: A tutorial. *BMC Medical Research Methodology*, **10**, 54. https://doi.org/10.1186/1471-2288-10-54

Examples

```
### Show full dataset
dat.woods2010

## Not run:
### Load netmeta package
suppressPackageStartupMessages(library(netmeta))

### Print odds ratios and confidence limits with two digits
oldset <- settings.meta(digits = 2)

### Change appearance of confidence intervals
cilayout("(", "-")

### Transform data from long arm-based format to contrast-based
### format. Argument 'sm' has to be used for odds ratio as summary
### measure; by default the risk ratio is used in the metabin function
### called internally.
pw <- pairwise(treatment, event = r, n = N,
  studlab = author, data = dat.woods2010, sm = "OR")
pw

### Conduct network meta-analysis
net <- netmeta(pw)
net

### Show forest plot
forest(net, ref = "Placebo", drop = TRUE,
  leftlabs = "Contrast to Placebo")

### Use previous settings
settings.meta(oldset)

## End(Not run)
```

`dat.yusuf1985` *Studies of Beta Blockers During and After Myocardial Infarction*

Description

Results from studies examining the effectiveness of beta blockers for reducing mortality and reinfarction.

Usage

```
dat.yusuf1985
```

Format

The data frame contains the following columns:

table	`character`	table number
id	`character`	trial id number
trial	`character`	trial name or first author
ai	`numeric`	number of deaths/reinfarctions in treatment group
n1i	`numeric`	number of patients in treatment group
ci	`numeric`	number of deaths/reinfarctions in control group
n2i	`numeric`	number of patients in control group

Details

The dataset contains table 6 (total mortality from short-term trials of oral beta blockers), 9 (total mortality at one week from trials with an initial IV dose of a beta blocker), 10 (total mortality from long-term trials with treatment starting late and mortality from day 8 onwards in long-term trials that began early and continued after discharge), 11 (nonfatal reinfarction from long-term trials of beta blockers), 12a (sudden death in long-term beta blocker trials), and 12b (nonsudden death in long-term beta blocker trials) from the meta-analysis by Yusuf et al. (1985) on the effectiveness of of beta blockers for reducing mortality and reinfarction.

The article also describes what is sometimes called Peto's one-step method for meta-analyzing 2×2 table data. This method is implemented in the `rma.peto` function.

Concepts

medicine, cardiology, odds ratios, Peto's method

Author(s)

Wolfgang Viechtbauer, <wvb@metafor-project.org>, https://www.metafor-project.org

Source

Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985). Beta blockade during and after myocardial infarction: An overview of the randomized trials. *Progress in Cardiovascular Disease*, **27**(5), 335–371. https://doi.org/10.1016/s0033-0620(85)80003-7

Examples

```
### copy data into 'dat'
dat <- dat.yusuf1985
dat[dat$table == 6,]

## Not run:
### load metafor package
library(metafor)

### to select a table for the analysis
tab <- "6" # either: 6, 9, 10, 11, 12a, 12b

### to double-check total counts as reported in article
apply(dat[dat$table==tab,4:7], 2, sum, na.rm=TRUE)

### meta-analysis using Peto's one-step method
res <- rma.peto(ai=ai, n1i=n1i, ci=ci, n2i=n2i, data=dat, subset=(table==tab))
res
predict(res, transf=exp, digits=2)

## End(Not run)
```

`datsearch` *Search Function for the Datasets*

Description

Function to search among the existing datasets.

Usage

```
datsearch(pattern, concept=TRUE, matchall=TRUE, fixed=TRUE, pkgdown=FALSE)
```

Arguments

`pattern`	character string or vector of strings specifying the terms to search for within the datasets. Can also be left unspecified to start the function in an interactive mode.
`concept`	logical indicating whether the search should be confined to the concept terms (`TRUE` by default) or whether a full-text search should be conducted.
`matchall`	logical indicating whether only the datasets matching all terms (if multiple are specified) are returned (`TRUE` by default) or whether datasets matching any one of the terms are returned.
`fixed`	logical indicating whether a term is a string to be matched as is (`TRUE` by default). If `FALSE`, a search term is a regular expression that `grep` will search for. Only relevant when `concept=FALSE` (i.e., when doing a full-text search).
`pkgdown`	logical indicating whether the standard help file or the pkgdown docs (at `https://wviechtb.github.io/metadat/`) should be shown for a chosen dataset (`FALSE` by default).

Details

The function can be used to search all existing datasets in the **metadat** package based on their concept terms (see below) or based on a full-text search of their corresponding help files.

When running `datsearch()` without the `pattern` argument specified, the function starts in an interactive mode and prompts for one or multiple search terms.

Alternatively, one can specify a single search term via the `pattern` argument or multiple search terms by using a string vector as the `pattern` or by separating multiple search terms in a single string with ',', ';', or 'and'.

If `matchall=TRUE` (the default), only datasets matching all search terms (if multiple are specified) are returned. If `matchall=FALSE`, datasets matching any one of the search terms are returned.

If a single match is found, the corresponding help file is directly shown. If multiple matches are found, the user is prompted to choose one of the matching datasets of interest.

Concept Terms

Each dataset is tagged with one or multiple concept terms that refer to various aspects of a dataset, such as the field/topic of research, the outcome measure used for the analysis, the model(s) used for analyzing the data, and the methods/concepts that can be illustrated with the dataset.

- In terms of 'fields/topics', the following terms have been used at least once: alternative medicine, attraction, cardiology, climate change, covid-19, criminology, dentistry, ecology, education, engineering, epidemiology, evolution, genetics, human factors, medicine, memory, obstetrics, oncology, persuasion, physics, primary care, psychiatry, psychology, pulmonology, rheumatology, smoking, social work, sociology, sports.
- In terms of 'outcome measures', the following terms have been used at least once: common language effect size, correlation coefficients, Cronbach's alpha, hazard ratios, incidence rates, raw mean differences, odds ratios, proportions, ratios of means, raw means, risk differences, risk ratios, (semi-)partial correlations, standardized mean changes, standardized mean differences.
- In terms of 'models/methods/concepts', the following terms have been used at least once: cluster-robust inference, combining p-values, component network meta-analysis, cumulative meta-analysis, diagnostic accuracy studies, dose response models, generalized linear models, individual participant data, longitudinal models, Mantel-Haenszel method, meta-regression, missing data, model checks, multilevel models, multivariate models, network meta-analysis, outliers, Peto's method, phylogeny, prevalence, publication bias, reliability generalization, risk-of-bias, single-arm studies, spatial correlation, subgroup analysis.

Author(s)

Daniel Noble, <daniel.noble@anu.edu.au>
Wolfgang Viechtbauer, <wvb@metafor-project.org>

Examples

```
# note: the examples below are not run since they require interactivity

if (FALSE) {
```

```
# start the function in the interactive mode
datsearch()

# find all datasets tagged with the concept term 'standardized mean differences'
datsearch("standardized mean differences")

# find all datasets tagged with the concept terms 'odds ratio' and 'multilevel'
datsearch("odds ratio, multilevel")

# do a full-text search for the term 'infarct'
datsearch("infarct", concept=FALSE)

# do a full-text search for 'rma.mv(' (essentially finds all datasets where
# the rma.mv() function was used in the examples section of a help file)
datsearch("rma.mv(", concept=FALSE)

}
```

Index

∗ **(semi-)partial correlations**
dat.aloe2013, 6
∗ **Cronbach's alpha**
dat.bonett2010, 45
dat.demir2022, 78
∗ **Mantel-Haenszel method**
dat.anand1999, 8
dat.cannon2006, 51
dat.dogliotti2014, 79
dat.dong2013, 81
dat.graves2010, 102
dat.gurusamy2011, 106
dat.hahn2001, 113
dat.hartmannboyce2018, 118
dat.pagliaro1992, 199
∗ **Peto's method**
dat.collins1985a, 60
dat.collins1985b, 62
dat.egger2001, 87
dat.nissen2007, 190
dat.quan2000, 206
dat.tian2009, 229
dat.yusuf1985, 245
∗ **alternative medicine**
dat.dorn2007, 83
dat.lee2004, 147
∗ **attraction**
dat.lehmann2018, 149
∗ **cardiology**
dat.anand1999, 8
dat.anker2025, 10
dat.cannon2006, 51
dat.chiarito2020, 53
dat.egger2001, 87
dat.feng2019, 89
dat.hart1999, 116
dat.hine1989, 124
dat.lau1992, 146
dat.li2007, 151
dat.nissen2007, 190
dat.pritz1997, 204
dat.quan2000, 206
dat.thompson1999, 228
dat.tian2009, 229
dat.yusuf1985, 245
∗ **climate change**
dat.maire2019, 167
∗ **cluster-robust inference**
dat.assink2016, 12
dat.bakdash2021, 19
dat.haeuser2009, 110
dat.knapp2017, 137
dat.mccurdy2020, 169
dat.tannersmith2016, 226
∗ **combining p-values**
dat.metap, 176
∗ **common language effect sizes**
dat.bauer2002, 34
∗ **component network meta-analysis**
dat.baker2009, 24
dat.linde2016, 159
∗ **correlation coefficients**
dat.bakdash2021, 19
dat.cohen1981, 56
dat.craft2003, 63
dat.crede2010, 65
dat.lim2014, 152
dat.mcdaniel1994, 171
dat.molloy2014, 180
dat.moura2021, 184
dat.nakagawa2007, 186
dat.tannersmith2016, 226
dat.white2020, 242
∗ **covid-19**
dat.axfors2021, 14
dat.hannum2020, 115
∗ **criminology**
dat.assink2016, 12

dat.landenberger2005, 142
dat.tannersmith2016, 226
∗ **cumulative meta-analysis**
dat.lau1992, 146
∗ **datasets**
dat.aloe2013, 6
dat.anand1999, 8
dat.anker2025, 10
dat.assink2016, 12
dat.axfors2021, 14
dat.bachmann2010, 16
dat.bakdash2021, 19
dat.baker2009, 24
dat.bangertdrowns2004, 26
dat.bartos2023, 28
dat.baskerville2012, 31
dat.bassler2004, 33
dat.bauer2002, 34
dat.bcg, 37
dat.begg1989, 39
dat.berkey1998, 41
dat.besson2016, 43
dat.bonett2010, 45
dat.bornmann2007, 47
dat.bourassa1996, 49
dat.cannon2006, 51
dat.chiarito2020, 53
dat.cohen1981, 56
dat.colditz1994, 57
dat.collins1985a, 60
dat.collins1985b, 62
dat.craft2003, 63
dat.crede2010, 65
dat.crisafulli2020, 67
dat.curtin2002, 69
dat.curtis1998, 70
dat.dagostino1998, 72
dat.damico2009, 75
dat.debruin2009, 76
dat.demir2022, 78
dat.dogliotti2014, 79
dat.dong2013, 81
dat.dorn2007, 83
dat.dumouchel1994, 85
dat.egger2001, 87
dat.feng2019, 89
dat.fine1993, 91
dat.franchini2012, 93
dat.frank2008, 95
dat.furukawa2003, 98
dat.gibson2002, 99
dat.graves2010, 102
dat.greb2008, 103
dat.greenland1992, 104
dat.gurusamy2011, 106
dat.hackshaw1998, 108
dat.haeuser2009, 110
dat.hahn2001, 113
dat.hannum2020, 115
dat.hart1999, 116
dat.hartmannboyce2018, 118
dat.hasselblad1998, 120
dat.higgins2008, 123
dat.hine1989, 124
dat.huber2000, 126
dat.ishak2007, 128
dat.kalaian1996, 130
dat.karner2014, 132
dat.kearon1998, 134
dat.knapp2017, 137
dat.konstantopoulos2011, 140
dat.landenberger2005, 142
dat.laopaiboon2015, 144
dat.lau1992, 146
dat.lee2004, 147
dat.lehmann2018, 149
dat.li2007, 151
dat.lim2014, 152
dat.linde2005, 155
dat.linde2015, 157
dat.linde2016, 159
dat.lloyd2010, 162
dat.lopez2019, 163
dat.maire2019, 167
dat.mccurdy2020, 169
dat.mcdaniel1994, 171
dat.meeker2017, 174
dat.metap, 176
dat.michael2013, 178
dat.molloy2014, 180
dat.moore1998, 182
dat.moura2021, 184
dat.nakagawa2007, 186
dat.nielweise2007, 187
dat.nielweise2008, 189
dat.nissen2007, 190

dat.normand1999, 195
dat.obrien2003, 196
dat.pagliaro1992, 199
dat.pignon2000, 201
dat.poole2003, 202
dat.pritz1997, 204
dat.quan2000, 206
dat.raudenbush1985, 208
dat.riley2003, 210
dat.rivera2025, 211
dat.roever2022, 213
dat.senn2013, 216
dat.spooner2002, 220
dat.steurer2006, 222
dat.stowe2010, 223
dat.tannersmith2016, 226
dat.thompson1999, 228
dat.tian2009, 229
dat.ursino2021, 232
dat.vanhowe1999, 235
dat.viechtbauer2021, 237
dat.white2020, 242
dat.woods2010, 243
dat.yusuf1985, 245
* **dentistry**
dat.berkey1998, 41
dat.rivera2025, 211
* **diagnostic accuracy studies**
dat.kearon1998, 134
dat.rivera2025, 211
* **dose-response models**
dat.obrien2003, 196
dat.roever2022, 213
dat.ursino2021, 232
* **ecology**
dat.besson2016, 43
dat.curtis1998, 70
dat.lim2014, 152
dat.maire2019, 167
dat.moura2021, 184
dat.nakagawa2007, 186
dat.white2020, 242
* **education**
dat.bangertdrowns2004, 26
dat.cohen1981, 56
dat.crede2010, 65
dat.kalaian1996, 130
dat.konstantopoulos2011, 140
dat.raudenbush1985, 208
* **engineering**
dat.bakdash2021, 19
* **epidemiology**
dat.crisafulli2020, 67
dat.greenland1992, 104
dat.hackshaw1998, 108
dat.vanhowe1999, 235
* **evolution**
dat.besson2016, 43
dat.lim2014, 152
dat.moura2021, 184
dat.white2020, 242
* **file**
datsearch, 246
* **generalized linear models**
dat.collins1985a, 60
dat.nielweise2007, 187
dat.nielweise2008, 189
dat.nissen2007, 190
dat.tian2009, 229
* **genetics**
dat.frank2008, 95
* **hazard ratios**
dat.pignon2000, 201
dat.riley2003, 210
dat.steurer2006, 222
* **human factors**
dat.bakdash2021, 19
dat.bartos2023, 28
* **incidence rates**
dat.anker2025, 10
dat.hart1999, 116
dat.nielweise2008, 189
* **individual participant data**
dat.huber2000, 126
* **longitudinal models**
dat.fine1993, 91
dat.ishak2007, 128
* **medicine**
dat.anand1999, 8
dat.anker2025, 10
dat.axfors2021, 14
dat.bachmann2010, 16
dat.baker2009, 24
dat.baskerville2012, 31
dat.bassler2004, 33
dat.bauer2002, 34

dat.bcg, 37
dat.begg1989, 39
dat.berkey1998, 41
dat.cannon2006, 51
dat.chiarito2020, 53
dat.colditz1994, 57
dat.collins1985a, 60
dat.collins1985b, 62
dat.crisafulli2020, 67
dat.dagostino1998, 72
dat.damico2009, 75
dat.debruin2009, 76
dat.dogliotti2014, 79
dat.dong2013, 81
dat.dorn2007, 83
dat.dumouchel1994, 85
dat.egger2001, 87
dat.fine1993, 91
dat.franchini2012, 93
dat.frank2008, 95
dat.gibson2002, 99
dat.graves2010, 102
dat.greb2008, 103
dat.gurusamy2011, 106
dat.hackshaw1998, 108
dat.haeuser2009, 110
dat.hahn2001, 113
dat.hannum2020, 115
dat.hart1999, 116
dat.hartmannboyce2018, 118
dat.hasselblad1998, 120
dat.hine1989, 124
dat.huber2000, 126
dat.ishak2007, 128
dat.karner2014, 132
dat.kearon1998, 134
dat.laopaiboon2015, 144
dat.lau1992, 146
dat.lee2004, 147
dat.li2007, 151
dat.linde2005, 155
dat.linde2015, 157
dat.linde2016, 159
dat.lloyd2010, 162
dat.molloy2014, 180
dat.moore1998, 182
dat.nielweise2007, 187
dat.nielweise2008, 189
dat.nissen2007, 190
dat.normand1999, 195
dat.obrien2003, 196
dat.pagliaro1992, 199
dat.pignon2000, 201
dat.poole2003, 202
dat.pritz1997, 204
dat.quan2000, 206
dat.riley2003, 210
dat.rivera2025, 211
dat.roever2022, 213
dat.senn2013, 216
dat.spooner2002, 220
dat.steurer2006, 222
dat.stowe2010, 223
dat.thompson1999, 228
dat.tian2009, 229
dat.ursino2021, 232
dat.vanhowe1999, 235
dat.viechtbauer2021, 237
dat.woods2010, 243
dat.yusuf1985, 245

∗ **memory**
dat.mccurdy2020, 169

∗ **meta-regression**
dat.aloe2013, 6
dat.bangertdrowns2004, 26
dat.baskerville2012, 31
dat.bcg, 37
dat.bonett2010, 45
dat.colditz1994, 57
dat.debruin2009, 76
dat.dumouchel1994, 85
dat.kalaian1996, 130
dat.karner2014, 132
dat.knapp2017, 137
dat.landenberger2005, 142
dat.mcdaniel1994, 171
dat.moura2021, 184
dat.raudenbush1985, 208
dat.tannersmith2016, 226
dat.thompson1999, 228

∗ **missing data**
dat.higgins2008, 123

∗ **model checks**
dat.viechtbauer2021, 237

∗ **multilevel models**
dat.assink2016, 12

dat.bakdash2021, 19
dat.begg1989, 39
dat.bornmann2007, 47
dat.bourassa1996, 49
dat.crede2010, 65
dat.haeuser2009, 110
dat.knapp2017, 137
dat.konstantopoulos2011, 140
dat.lim2014, 152
dat.mccurdy2020, 169
dat.obrien2003, 196
dat.tannersmith2016, 226
∗ **multivariate models**
dat.bakdash2021, 19
dat.bartos2023, 28
dat.berkey1998, 41
dat.craft2003, 63
dat.dagostino1998, 72
dat.haeuser2009, 110
dat.kalaian1996, 130
dat.kearon1998, 134
dat.knapp2017, 137
dat.moura2021, 184
∗ **network meta-analysis**
dat.baker2009, 24
dat.dogliotti2014, 79
dat.dong2013, 81
dat.franchini2012, 93
dat.gurusamy2011, 106
dat.hasselblad1998, 120
dat.linde2015, 157
dat.linde2016, 159
dat.lopez2019, 163
dat.pagliaro1992, 199
dat.senn2013, 216
dat.stowe2010, 223
dat.woods2010, 243
∗ **obstetrics**
dat.collins1985b, 62
dat.obrien2003, 196
∗ **odds ratios**
dat.anand1999, 8
dat.axfors2021, 14
dat.bachmann2010, 16
dat.baker2009, 24
dat.bornmann2007, 47
dat.bourassa1996, 49
dat.cannon2006, 51
dat.chiarito2020, 53
dat.collins1985a, 60
dat.collins1985b, 62
dat.dagostino1998, 72
dat.damico2009, 75
dat.dogliotti2014, 79
dat.dong2013, 81
dat.dumouchel1994, 85
dat.fine1993, 91
dat.frank2008, 95
dat.gurusamy2011, 106
dat.hackshaw1998, 108
dat.hahn2001, 113
dat.hasselblad1998, 120
dat.higgins2008, 123
dat.karner2014, 132
dat.kearon1998, 134
dat.landenberger2005, 142
dat.lau1992, 146
dat.li2007, 151
dat.linde2015, 157
dat.linde2016, 159
dat.moore1998, 182
dat.nielweise2007, 187
dat.nissen2007, 190
dat.pagliaro1992, 199
dat.thompson1999, 228
dat.tian2009, 229
dat.vanhowe1999, 235
dat.viechtbauer2021, 237
dat.woods2010, 243
dat.yusuf1985, 245
∗ **oncology**
dat.begg1989, 39
dat.fine1993, 91
dat.frank2008, 95
dat.greb2008, 103
dat.hackshaw1998, 108
dat.pignon2000, 201
dat.riley2003, 210
dat.roever2022, 213
dat.steurer2006, 222
dat.ursino2021, 232
∗ **outliers**
dat.viechtbauer2021, 237
∗ **package**
metadat-package, 4
∗ **persuasion**

dat.michael2013, 178
* **phylogeny**
dat.lim2014, 152
dat.moura2021, 184
* **physics**
dat.bartos2023, 28
* **prevalence**
dat.feng2019, 89
* **primary care**
dat.baskerville2012, 31
dat.gibson2002, 99
* **proportions**
dat.bartos2023, 28
dat.bauer2002, 34
dat.crisafulli2020, 67
dat.debruin2009, 76
dat.hannum2020, 115
dat.huber2000, 126
dat.mccurdy2020, 169
dat.obrien2003, 196
dat.pritz1997, 204
* **psychiatry**
dat.furukawa2003, 98
dat.higgins2008, 123
dat.linde2005, 155
dat.linde2015, 157
dat.linde2016, 159
dat.lopez2019, 163
* **psychology**
dat.assink2016, 12
dat.bakdash2021, 19
dat.bonett2010, 45
dat.bourassa1996, 49
dat.craft2003, 63
dat.debruin2009, 76
dat.demir2022, 78
dat.feng2019, 89
dat.furukawa2003, 98
dat.hasselblad1998, 120
dat.knapp2017, 137
dat.landenberger2005, 142
dat.lehmann2018, 149
dat.linde2016, 159
dat.mccurdy2020, 169
dat.mcdaniel1994, 171
dat.michael2013, 178
dat.molloy2014, 180
dat.tannersmith2016, 226
* **publication bias**
dat.baskerville2012, 31
dat.egger2001, 87
dat.kearon1998, 134
dat.li2007, 151
dat.moore1998, 182
* **pulmonology**
dat.baker2009, 24
dat.damico2009, 75
dat.dumouchel1994, 85
dat.karner2014, 132
dat.laopaiboon2015, 144
dat.poole2003, 202
dat.spooner2002, 220
* **ratios of means**
dat.curtis1998, 70
* **raw mean differences**
dat.berkey1998, 41
dat.curtin2002, 69
dat.franchini2012, 93
dat.ishak2007, 128
dat.karner2014, 132
dat.lloyd2010, 162
dat.michael2013, 178
dat.normand1999, 195
dat.poole2003, 202
dat.senn2013, 216
dat.spooner2002, 220
dat.stowe2010, 223
* **raw means**
dat.mccurdy2020, 169
dat.meeker2017, 174
* **reliability generalization**
dat.bonett2010, 45
dat.demir2022, 78
* **rheumatology**
dat.lloyd2010, 162
* **risk differences**
dat.hine1989, 124
* **risk ratios**
dat.bachmann2010, 16
dat.bassler2004, 33
dat.bcg, 37
dat.colditz1994, 57
dat.dorn2007, 83
dat.gibson2002, 99
dat.graves2010, 102
dat.greb2008, 103

dat.greenland1992, 104
dat.hartmannboyce2018, 118
dat.laopaiboon2015, 144
dat.lee2004, 147
dat.linde2005, 155
dat.obrien2003, 196
∗ **risk-of-bias**
dat.chiarito2020, 53
dat.karner2014, 132
∗ **single-arm studies**
dat.begg1989, 39
dat.debruin2009, 76
dat.pritz1997, 204
∗ **smoking**
dat.hackshaw1998, 108
dat.hartmannboyce2018, 118
dat.hasselblad1998, 120
∗ **social work**
dat.aloe2013, 6
∗ **sociology**
dat.bornmann2007, 47
∗ **spatial correlation**
dat.maire2019, 167
∗ **sports**
dat.meeker2017, 174
∗ **standardized mean changes**
dat.lopez2019, 163
∗ **standardized mean differences**
dat.assink2016, 12
dat.bangertdrowns2004, 26
dat.baskerville2012, 31
dat.besson2016, 43
dat.dagostino1998, 72
dat.furukawa2003, 98
dat.gibson2002, 99
dat.haeuser2009, 110
dat.kalaian1996, 130
dat.knapp2017, 137
dat.konstantopoulos2011, 140
dat.lehmann2018, 149
dat.normand1999, 195
dat.raudenbush1985, 208
∗ **subgroup analysis**
dat.bassler2004, 33
dat.poole2003, 202
dat.spooner2002, 220

dat.aloe2013, 6
dat.anand1999, 8
dat.anker2025, 10
dat.assink2016, 12
dat.axfors2021, 14
dat.bachmann2010, 16
dat.bakdash2021, 19
dat.baker2009, 24
dat.bangertdrowns2004, 26
dat.bartos2023, 28
dat.baskerville2012, 31
dat.bassler2004, 33
dat.bauer2002, 34, *127*
dat.bcg, 37
dat.begg1989, 39
dat.berkey1998, 41
dat.berkey1998r *(*dat.berkey1998*)*, 41
dat.besson2016, 43
dat.bonett2010, 45
dat.bornmann2007, 47
dat.bourassa1996, 49
dat.cannon2006, 51
dat.chiarito2020, 53
dat.cohen1981, 56
dat.colditz1994, 57
dat.collins1985a, 60
dat.collins1985b, 62
dat.craft2003, 63
dat.crede2010, 65
dat.crisafulli2020, 67
dat.curtin2002, 69
dat.curtis1998, 70
dat.dagostino1998, 72
dat.damico2009, 75
dat.debruin2009, 76
dat.demir2022, 78
dat.dogliotti2014, 79
dat.dong2013, 81
dat.dorn2007, 83
dat.dumouchel1994, 85
dat.egger2001, 87, *151, 152*
dat.feng2019, 89
dat.fine1993, 91
dat.franchini2012, 93
dat.frank2008, 95
dat.furukawa2003, 98
dat.gibson2002, 99
dat.graves2010, 102
dat.greb2008, 103
dat.greenland1992, 104

dat.gurusamy2011, 106
dat.hackshaw1998, 108
dat.haeuser2009, 110
dat.hahn2001, 113
dat.hannum2020, 115
dat.hart1999, 116
dat.hartmannboyce2018, 118
dat.hasselblad1998, 120
dat.higgins2008, 123
dat.hine1989, 124
dat.huber2000, *35*, 126
dat.ishak2007, 128
dat.kalaian1996, 130
dat.karner2014, 132
dat.kearon1998, 134
dat.knapp2017, 137
dat.konstantopoulos2011, 140
dat.landenberger2005, 142
dat.laopaiboon2015, 144
dat.lau1992, 146
dat.lee2004, 147
dat.lehmann2018, 149
dat.li2007, *88*, 151
dat.lim2014, 152
dat.linde2005, 155
dat.linde2015, 157
dat.linde2016, 159
dat.lloyd2010, 162
dat.lopez2019, 163
dat.maire2019, 167
dat.mccurdy2020, 169
dat.mcdaniel1994, 171
dat.meeker2017, 174
dat.metap, 176
dat.michael2013, 178
dat.molloy2014, 180
dat.moore1998, 182
dat.moura2021, 184
dat.nakagawa2007, 186
dat.nielweise2007, 187
dat.nielweise2008, 189
dat.nissen2007, 190, *230, 231*
dat.normand1999, 195
dat.obrien2003, 196
dat.pagliaro1992, 199
dat.pignon2000, 201
dat.poole2003, 202
dat.pritz1997, 204
dat.quan2000, 206
dat.raudenbush1985, 208
dat.riley2003, 210
dat.rivera2025, 211
dat.roever2022, 213, *234*
dat.senn2013, 216
dat.spooner2002, 220
dat.steurer2006, 222
dat.stowe2010, 223
dat.tannersmith2016, 226
dat.thompson1999, 228
dat.tian2009, *191, 192*, 229
dat.ursino2021, *215*, 232
dat.vanhowe1999, 235
dat.viechtbauer2021, 237
dat.white2020, 241
dat.woods2010, 243
dat.yusuf1985, 245
datsearch, *4*, 246

grep, *246*

metadat *(*metadat-package*)*, 4
metadat-package, 4

prep_dat, *5*

rma.glmm, *60*
rma.mh, *52*
rma.peto, *60*, *191*, *245*
robust, *20*

save, *5*